
<html lang="en"     class="pb-page"  data-request-id="f77aa105-04ac-42d6-899e-7f71defd1c23"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/jm201112g;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2012.55.issue-1;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of Kinase Spectrum Selective Macrocycle (16E)-14-Methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a Potent Inhibitor of Cyclin Dependent Kinases (CDKs), Janus Kinase 2 (JAK2), and Fms-like Tyrosine Kinase-3 (FLT3) for the Treatment of Cancer" /></meta><meta name="dc.Creator" content="Anthony D.  William" /></meta><meta name="dc.Creator" content="Angeline C.-H.  Lee" /></meta><meta name="dc.Creator" content="Kee Chuan  Goh" /></meta><meta name="dc.Creator" content="Stéphanie  Blanchard" /></meta><meta name="dc.Creator" content="Anders  Poulsen" /></meta><meta name="dc.Creator" content="Ee Ling  Teo" /></meta><meta name="dc.Creator" content="Harish  Nagaraj" /></meta><meta name="dc.Creator" content="Chai Ping  Lee" /></meta><meta name="dc.Creator" content="Haishan  Wang" /></meta><meta name="dc.Creator" content="Meredith  Williams" /></meta><meta name="dc.Creator" content="Eric T.  Sun" /></meta><meta name="dc.Creator" content="Changyong  Hu" /></meta><meta name="dc.Creator" content="Ramesh  Jayaraman" /></meta><meta name="dc.Creator" content="Mohammed Khalid  Pasha" /></meta><meta name="dc.Creator" content="Kantharaj  Ethirajulu" /></meta><meta name="dc.Creator" content="Jeanette M.  Wood" /></meta><meta name="dc.Creator" content="Brian W.  Dymock" /></meta><meta name="dc.Description" content="Herein, we describe the design, synthesis, and SAR of a series of unique small molecule macrocycles that show spectrum selective kinase inhibition of CDKs, JAK2, and FLT3. The most promising leads ..." /></meta><meta name="Description" content="Herein, we describe the design, synthesis, and SAR of a series of unique small molecule macrocycles that show spectrum selective kinase inhibition of CDKs, JAK2, and FLT3. The most promising leads ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 29, 2011" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm201112g" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2011 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm201112g" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm201112g" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm201112g" /></link>
        
    
    

<title>Discovery of Kinase Spectrum Selective Macrocycle (16E)-14-Methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a Potent Inhibitor of Cyclin Dependent Kinases (CDKs), Janus Kinase 2 (JAK2), and Fms-like Tyrosine Kinase-3 (FLT3) for the Treatment of Cancer | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm201112g" /></meta><meta property="og:title" content="Discovery of Kinase Spectrum Selective Macrocycle (16E)-14-Methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a Potent Inhibitor of Cyclin Dependent Kinases (CDKs), Janus Kinase 2 (JAK2), and Fms-like Tyrosine Kinase-3 (FLT3) for the Treatment of Cancer" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0025.jpeg" /></meta><meta property="og:description" content="Herein, we describe the design, synthesis, and SAR of a series of unique small molecule macrocycles that show spectrum selective kinase inhibition of CDKs, JAK2, and FLT3. The most promising leads were assessed in vitro for their inhibition of cancer cell proliferation, solubility, CYP450 inhibition, and microsomal stability. This screening cascade revealed 26h as a preferred compound with target IC50 of 13, 73, and 56 nM for CDK2, JAK2 and FLT3, respectively. Pharmacokinetic (PK) studies of 26h in preclinical species showed good oral exposures. Oral efficacy was observed in colon (HCT-116) and lymphoma (Ramos) xenograft studies, in line with the observed PK/PD correlation. 26h (SB1317/TG02) was progressed into development in 2010 and is currently undergoing phase 1 clinical trials in advanced leukemias and multiple myeloma." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="Herein, we describe the design, synthesis, and SAR of a series of unique small molecule macrocycles that show spectrum selective kinase inhibition of CDKs, JAK2, and FLT3. The most promising leads were assessed in vitro for their inhibition of cancer cell proliferation, solubility, CYP450 inhibition, and microsomal stability. This screening cascade revealed 26h as a preferred compound with target IC50 of 13, 73, and 56 nM for CDK2, JAK2 and FLT3, respectively. Pharmacokinetic (PK) studies of 26h in preclinical species showed good oral exposures. Oral efficacy was observed in colon (HCT-116) and lymphoma (Ramos) xenograft studies, in line with the observed PK/PD correlation. 26h (SB1317/TG02) was progressed into development in 2010 and is currently undergoing phase 1 clinical trials in advanced leukemias and multiple myeloma." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0025.jpeg" /></meta><meta name="twitter:title" content="Discovery of Kinase Spectrum Selective Macrocycle (16E)-14-Methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a Potent Inhibitor of Cyclin Dependent Kinases (CDKs), Janus Kinase 2 (JAK2), and Fms-like Tyrosine Kinase-3 (FLT3) for the Treatment of Cancer" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm201112g"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm201112g">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm201112g&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm201112g&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm201112g&amp;href=/doi/10.1021/jm201112g" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2012</span><span class="cit-fg-volume">, 55</span><span class="cit-fg-issue">, 1</span><span class="cit-fg-pageRange">, 169-196</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/55/1" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm201105a" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm2011172" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Kinase Spectrum Selective Macrocycle (16<i>E</i>)-14-Methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a Potent Inhibitor of Cyclin Dependent Kinases (CDKs), Janus Kinase 2 (JAK2), and Fms-like Tyrosine Kinase-3 (FLT3) for the Treatment of Cancer</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anthony+D.++William">Anthony D. William</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Angeline+C.-H.++Lee">Angeline C.-H. Lee</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kee+Chuan++Goh">Kee Chuan Goh</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=St%C3%A9phanie++Blanchard">Stéphanie Blanchard</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anders++Poulsen">Anders Poulsen</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ee+Ling++Teo">Ee Ling Teo</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Harish++Nagaraj">Harish Nagaraj</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chai+Ping++Lee">Chai Ping Lee</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Haishan++Wang">Haishan Wang</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Meredith++Williams">Meredith Williams</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Eric+T.++Sun">Eric T. Sun</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Changyong++Hu">Changyong Hu</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ramesh++Jayaraman">Ramesh Jayaraman</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mohammed+Khalid++Pasha">Mohammed Khalid Pasha</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kantharaj++Ethirajulu">Kantharaj Ethirajulu</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jeanette+M.++Wood">Jeanette M. Wood</a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Brian+W.++Dymock">Brian W. Dymock</a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">S*BIO Pte. Ltd., 1 Science Park Road, No. 05-09, The Capricorn, Singapore Science Park II, 117528, Singapore</span></div><div class="corresp-info"><strong>*</strong>Phone: +65 62195443. E-mail: <a href="/cdn-cgi/l/email-protection#c3b4a2adb7abacadbaf2f283baa2abacaceda0acae"><span class="__cf_email__" data-cfemail="f98e98978d91969780c8c8b98098919696d79a9694">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm201112g&amp;href=/doi/10.1021%2Fjm201112g" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2012</span></span><span class="cit-volume">, 55</span><span class="cit-issue">, 1</span><span class="cit-pageRange">, 169–196</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">December 8, 2011</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>18 August 2011</li><li><span class="item_label"><b>Published</b> online</span>29 December 2011</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 12 January 2012</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm201112g" title="DOI URL">https://doi.org/10.1021/jm201112g</a></div><div class="article_header-article-copyright"><strong>Copyright © 2011 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D169%26pageCount%3D28%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DAnthony%2BD.%2BWilliam%252C%2BAngeline%2BC.-H.%2BLee%252C%2BKee%2BChuan%2BGoh%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D55%26issueNum%3D1%26contentID%3Djm201112g%26title%3DDiscovery%2Bof%2BKinase%2BSpectrum%2BSelective%2BMacrocycle%2B%252816E%2529-14-Methyl-20-oxa-5%252C7%252C14%252C26-tetraazatetracyclo%255B19.3.1.1%25282%252C6%2529.1%25288%252C12%2529%255Dheptacosa-1%252825%2529%252C2%252826%2529%252C3%252C5%252C8%252827%2529%252C9%252C11%252C16%252C21%252C23-decaene%2B%2528SB1317%252FTG02%2529%252C%2Ba%2BPotent%2BInhibitor%2Bof%2BCyclin%2BDependent%2BKinases%2B%2528CDKs%2529%252C%2BJanus%2BKinase%2B2%2B%2528JAK2%2529%252C%2Band%2BFms-like%2BTyrosine%2BKinase-3%2B%2528FLT3%2529%2Bfor%2Bthe%2BTreatment%2Bof%2BCancer%26numPages%3D28%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D196%26publicationDate%3DJanuary%2B2012">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm201112g"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4666</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">47</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm201112g" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Kinase Spectrum Selective Macrocycle (16E)-14-Methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a Potent Inhibitor of Cyclin Dependent Kinases (CDKs), Janus Kinase 2 (JAK2), and Fms-like Tyrosine Kinase-3 (FLT3) for the Treatment of Cancer&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Anthony&quot;,&quot;last_name&quot;:&quot;D. William&quot;},{&quot;first_name&quot;:&quot;Angeline&quot;,&quot;last_name&quot;:&quot;C.-H. Lee&quot;},{&quot;first_name&quot;:&quot;Kee&quot;,&quot;last_name&quot;:&quot;Chuan Goh&quot;},{&quot;first_name&quot;:&quot;Stéphanie&quot;,&quot;last_name&quot;:&quot;Blanchard&quot;},{&quot;first_name&quot;:&quot;Anders&quot;,&quot;last_name&quot;:&quot;Poulsen&quot;},{&quot;first_name&quot;:&quot;Ee&quot;,&quot;last_name&quot;:&quot;Ling Teo&quot;},{&quot;first_name&quot;:&quot;Harish&quot;,&quot;last_name&quot;:&quot;Nagaraj&quot;},{&quot;first_name&quot;:&quot;Chai&quot;,&quot;last_name&quot;:&quot;Ping Lee&quot;},{&quot;first_name&quot;:&quot;Haishan&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Meredith&quot;,&quot;last_name&quot;:&quot;Williams&quot;},{&quot;first_name&quot;:&quot;Eric&quot;,&quot;last_name&quot;:&quot;T. Sun&quot;},{&quot;first_name&quot;:&quot;Changyong&quot;,&quot;last_name&quot;:&quot;Hu&quot;},{&quot;first_name&quot;:&quot;Ramesh&quot;,&quot;last_name&quot;:&quot;Jayaraman&quot;},{&quot;first_name&quot;:&quot;Mohammed&quot;,&quot;last_name&quot;:&quot;Khalid Pasha&quot;},{&quot;first_name&quot;:&quot;Kantharaj&quot;,&quot;last_name&quot;:&quot;Ethirajulu&quot;},{&quot;first_name&quot;:&quot;Jeanette&quot;,&quot;last_name&quot;:&quot;M. Wood&quot;},{&quot;first_name&quot;:&quot;Brian&quot;,&quot;last_name&quot;:&quot;W. Dymock&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2011&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;29&quot;,&quot;issue&quot;:&quot;1&quot;,&quot;volume&quot;:&quot;55&quot;,&quot;pages&quot;:&quot;169-196&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm201112g&quot;},&quot;abstract&quot;:&quot;Herein, we describe the design, synthesis, and SAR of a series of unique small molecule macrocycles that show spectrum selective kinase inhibition of CDKs, JAK2, and FLT3. The most promising leads were assessed in vitro for their inhibition of cancer cell proliferation, solubility, CYP450 inhibition, and microsomal stability. This screening cascade revealed 26h as a preferred compound with target IC50 of 13, 73, and 56 nM for CDK2, JAK2 and FLT3, respectively. Pharmacokinetic (PK) studies of 26h in preclinical species showed good oral exposures. Oral efficacy was observed in colon (HCT-116) and lymphoma (Ramos) xenograft studies, in line with the observed PK/PD correlation. 26h (SB1317/TG02) was progressed into development in 2010 and is currently undergoing phase 1 clinical trials in advanced leukemias and multiple myeloma.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm201112g&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm201112g" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm201112g&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm201112g" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm201112g&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm201112g" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm201112g&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm201112g&amp;href=/doi/10.1021/jm201112g" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm201112g" /></input><a href="/doi/pdf/10.1021/jm201112g" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm201112g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm201112g%26sid%3Dliteratum%253Aachs%26pmid%3D22148278%26genre%3Darticle%26aulast%3DWilliam%26date%3D2012%26atitle%3DDiscovery%2Bof%2BKinase%2BSpectrum%2BSelective%2BMacrocycle%2B%252816E%2529-14-Methyl-20-oxa-5%252C7%252C14%252C26-tetraazatetracyclo%255B19.3.1.1%25282%252C6%2529.1%25288%252C12%2529%255Dheptacosa-1%252825%2529%252C2%252826%2529%252C3%252C5%252C8%252827%2529%252C9%252C11%252C16%252C21%252C23-decaene%2B%2528SB1317%252FTG02%2529%252C%2Ba%2BPotent%2BInhibitor%2Bof%2BCyclin%2BDependent%2BKinases%2B%2528CDKs%2529%252C%2BJanus%2BKinase%2B2%2B%2528JAK2%2529%252C%2Band%2BFms-like%2BTyrosine%2BKinase-3%2B%2528FLT3%2529%2Bfor%2Bthe%2BTreatment%2Bof%2BCancer%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D55%26issue%3D1%26spage%3D169%26epage%3D196%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=291651" title="Anions">Anions</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=290676" title="Substituents">Substituents</a>,</li><li><a href="/action/doSearch?ConceptID=291163" title="Macrocycles">Macrocycles</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/55/1" title="Go to Volume 55, Issue 1"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jmcmar.2012.55.issue-1/production/jmcmar.2012.55.issue-1.largecover.jpg" alt="Go to Volume 55, Issue 1"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/medium/jm-2011-01112g_0025.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201112g&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Herein, we describe the design, synthesis, and SAR of a series of unique small molecule macrocycles that show spectrum selective kinase inhibition of CDKs, JAK2, and FLT3. The most promising leads were assessed in vitro for their inhibition of cancer cell proliferation, solubility, CYP450 inhibition, and microsomal stability. This screening cascade revealed <b>26h</b> as a preferred compound with target IC<sub>50</sub> of 13, 73, and 56 nM for CDK2, JAK2 and FLT3, respectively. Pharmacokinetic (PK) studies of <b>26h</b> in preclinical species showed good oral exposures. Oral efficacy was observed in colon (HCT-116) and lymphoma (Ramos) xenograft studies, in line with the observed PK/PD correlation. <b>26h</b> (SB1317/TG02) was progressed into development in 2010 and is currently undergoing phase 1 clinical trials in advanced leukemias and multiple myeloma.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51078" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51078" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Recent advances in the understanding of the molecular etiologies of cancer have engendered hopes of new targeted therapies, but to date, these have yielded limited success with only incremental and short-lived benefits being seen with single agent targeted therapy.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Blocking more than one aberrant pathway in cancer cells is the mainstay of current standard of care, usually with combinations of chemotherapies that increasingly include targeted agents such as kinase inhibitors.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2, 3)</a> Blockade of multiple pathways with multiple targeted therapies is one of the most rapidly developing areas in cancer therapy.<a onclick="showRef(event, 'ref1 ref4'); return false;" href="javascript:void(0);" class="ref ref1 ref4">(1, 4)</a> For example, multikinase inhibitors such as sorafenib,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> approved for renal cell (RCC) and hepatocellular carcinomas (HCC), and sunitinib,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> approved for RCC and gastrointestinal stromal tumors (GIST), are effective antiangiogenic and antitumor agents and owe their efficacy to blocking multiple signaling pathways. More recently, compounds combining inhibition of two independent pathways, one of which is a non-kinase, within a single molecular entity have entered the clinic.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a></div><div class="NLM_p">Cyclin-dependent kinases (CDKs) are serine–threonine kinases that play important roles in cell cycle control (CDKs 1, 2, 4, and 6), transcription initiation (CDKs 7 and 9) and neuronal function (CDK5).<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Aberrations in the cell cycle CDKs and their cyclin partners have been observed in various tumor types, including those of the breast, colon, liver, and brain.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> The simultaneous inhibition of CDKs 1, 2, and 9 has recently been shown to enhance apoptotic killing of lung cancer (H1299) and osteosarcoma cells (U2OS) compared with inhibition of a single CDK alone.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Small molecule CDK inhibitors have been in clinical testing for a number of years for hematological malignancies and solid tumors (for example, seliciclib/CYC202 (<b>1</b>)<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> and AT7519 (<b>2</b>),<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>) but have shown limited efficacy as single agents and often require intravenous administration because of their poor oral pharmacokinetics.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> To address the deficiencies that have hampered development of CDK inhibitors, we set out to identify an orally available inhibitor of a new structural class meeting a specific target product profile: inhibition of at least CDKs 1, 2, and 9, an acceptable safety profile, and physicochemical properties suitable for oral dosing.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/medium/jm-2011-01112g_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0018.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Advanced CDK, JAK2, and FLT3 kinase inhibitors in clinical trials.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201112g&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">JAK kinases (JAK1, JAK2, JAK3, and Tyk2) are a family of intracellular nonreceptor tyrosine kinases that transduce cytokine-mediated signals via the JAK-STAT pathway.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Mutations in JAK2 have been associated with myeloproliferative neoplasms (MPNs) including polycythemia vera, essential thrombocythemia, and myelofibrosis as well as a wide range of leukemias and lymphomas.<a onclick="showRef(event, 'ref15 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref17">(15-17)</a> JAK2 inhibitors such as ruxolitinib/INCB018424 (<b>3</b>)<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> and pacritinib/SB1518 (<b>4</b>)<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> are in advanced clinical development for the treatment of myelofibrosis.<a onclick="showRef(event, 'ref20 ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref20 ref21 ref22">(20-22)</a></div><div class="NLM_p">Class III receptor tyrosine kinase (RTK), fms-like receptor tyrosine kinase 3 (FLT3), plays an important role in the maintenance, growth, and development of hematopoietic and nonhemotopotietic cells.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Overexpression and activating mutations of the RTKs are known to be involved in the pathophysiology of diverse human cancers. Mutations of the FLT3 receptor can lead to the development of leukemia.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Internal tandem duplications of FLT3 (FLT3-ITD) are the most common mutations associated with acute myelogenous leukemia (AML) and are a prognostic indicator associated with adverse disease outcome.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Examples of FLT3 kinase inhibitors, which do not inhibit CDKs or JAKs (but do inhibit many other kinases), are the marketed compounds sunitinib/SU11248 (<b>5</b>)<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> and sorafenib/Bay 43-9006 (<b>6</b>).<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></div><div class="NLM_p">We have recently reported the discovery of pacritinib, a unique macrocyclic JAK2/FLT3 dual inhibitor, as a therapy for myelofibrosis and lymphoma.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Herein we describe the work carried out to identify and develop a separate series of macrocycles targeting CDKs, JAK2, and FLT3. Although we were aiming to develop compounds with this inhibition profile, we did not know what level of inhibition of each enzyme would ultimately be required; hence, this work describes efforts toward a target profile of isolated enzyme IC<sub>50</sub> of less than 50 nM for each target enzyme, CDK2, JAK2 and FLT3, a potentially compelling profile for the treatment of advanced cancers.</div><div class="NLM_p">Complex natural products with macrocyclic features have always served as a prime source of inspiration for the synthetic organic chemist and continue to do so to this day. Almost limitless structural variations provide diverse functionality and stereochemical complexity in a conformationally preorganized ring structure. From a medicinal chemist’s perspective, this can result in high affinity and selectivity for biological targets while preserving sufficient bioavailability to reach intracellular locations. Despite these valuable characteristics and the proven success of macrocycle drugs derived from natural products, this structural class has been historically poorly explored in small molecule drug discovery.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> This is in part due to concerns about synthetic intractability and nondruglike properties, but recently, there has been greater interest in small molecule synthetic macrocycles as not just viable but attractive druglike molecules against a wide variety of targets.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> We have demonstrated success with small macrocycles in the area of JAK2 inhibitors with the recent disclosure of the aforementioned pacritinib.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Using computational modeling, we developed CDK active macrocycles <b>9</b> bearing a basic center that “switched on” activity against CDKs (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>) while maintaining JAK2 and FLT3 inhibition. Optimization of these multiple target activities, aiming at IC<sub>50</sub> in isolated ATPase assays of less than 50 nM while achieving a balance of druglike features, will thus be described.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/medium/jm-2011-01112g_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0019.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Evolution of CDK inhibitor motif by modulating the macrocycle linking moiety.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201112g&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35122" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35122" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Synthesis of the macrocycles was achieved by coupling of the two halves of the molecules via acidic displacement between chloropyrimidines (left-hand fragment) and anilines (right-hand fragment) followed by ring-closing metathesis of the resulting dienes, employing either Grubbs second generation catalyst or Zhan-1B catalyst<a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31, 32)</a> with trifluoroacetic acid as an additive. Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a> illustrates the synthetic routes for intermediates <b>14</b> and <b>15</b> and Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a> describes compounds <b>26a</b>–<b>j</b>.</div><div class="NLM_p">The left-hand fragments were constructed by Suzuki coupling of commercially available 2,4-dichloropyrimidine (<b>10a</b>) and boronic acids <b>11a</b>–<b>e</b>, affording the corresponding biaryls <b>12a</b>–<b>f</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>). Alkylation of phenol <b>12a</b> and primary alcohol <b>12b</b> were achieved under phase transfer conditions with allyl bromide, giving allyl ethers <b>13a</b>,<b>b</b>. Nitro <b>12c</b> was reduced to free amine <b>12d</b> with SnCl<sub>2</sub>·H<sub>2</sub>O and reacted with vinylacetic acid to form amide <b>14a</b>. The reverse amide <b>14b</b> was acquired from <b>12e</b> using allylamine under standard amide coupling conditions. Alkylation of phenol <b>12a</b> via cesium carbonate assisted displacement with 4-bromobut-1-ene furnished homoallyl ether <b>15a</b>. Last, reductive amination of aldehyde <b>12f</b> with <i>N</i>-allylmethylamine afforded <b>14c</b> with excellent yield. Left hand fragments <b>15b</b>–<b>f</b> were obtained in the same way as <b>15a</b>, starting from the corresponding commercially available starting materials.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/medium/jm-2011-01112g_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201112g&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reactions and conditions: (a) tetrakis(triphenylphosphine)palladium(0), Na<sub>2</sub>CO<sub>3</sub>, 1,2-dimethoxyethane, water, 80 °C, 53–91%; (b) SnCl<sub>2</sub>·H<sub>2</sub>O, CH<sub>2</sub>Cl<sub>2</sub>/MeOH (1:1), room temp, 56–98%; (c) <b>12a</b> or <b>12b</b>, allyl bromide, KOH, TBAHSO<sub>4</sub>, CH<sub>2</sub>Cl<sub>2</sub>, room temp, 55–59%; (d) <b>12d</b>, vinylacetic acid, HOBt, EDCI, CH<sub>2</sub>Cl<sub>2</sub>, room temp, 77%; (e) <b>12e</b>, allylamine, HOBt, EDCI, CH<sub>2</sub>Cl<sub>2</sub>, room temp, 59%. (f) <b>12a</b>, 4-bromobut-1-ene, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 40 °C, 75%; (g) <b>12f</b>, <i>N</i>-allylmethylamine or allylamine, Na(OAc)<sub>3</sub>BH, CH<sub>2</sub>Cl<sub>2</sub>, room temp, 88–95%.</p></p></figure><div class="NLM_p">Because of their diversity, right-hand fragments were prepared using a wide variety of methods, as illustrated in Schemes <a class="ref internalNav" href="#sch2" aria-label="2">2</a> and <a class="ref internalNav" href="#sch3" aria-label="3">3</a>. Amidation proceeded with good yield between commercially available aniline <b>16a</b> and pentenoic acid to give <b>18a</b> (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>). Benzaldehyde <b>16b</b> reacted with the corresponding allylamines via reductive amination, affording <b>18b</b>–<b>c</b> in excellent yields. Secondary amine <b>18c</b> was capped with trifluoroacetic anhydride to give <b>18d</b> in quantitative yield. Aniline <b>16a</b> was alkylated with allyl bromide, producing <b>18e</b>, which was then capped with a Boc group to give <b>18f</b>. Last, the nitro groups of all the above-described intermediates were reduced by the aforementioned SnCl<sub>2</sub>·H<sub>2</sub>O conditions, giving key anilines <b>21a</b>–<b>e</b> in moderate to excellent yields.</div><div class="NLM_p">Couping of the left- and right-hand fragments proceeded efficiently in hot butanol to afford <b>26a</b>–<b>j</b> in moderate to good yields. The resulting dienes were macrocyclized as described above with Grubb’s second generation catalyst. RCM of compounds with basic centers proceeds best in the presence of an acid as an additive; hence, we attempted the reaction with TFA (4–5 equiv) and were delighted to find that the desired products had formed with good yield.<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33, 34)</a> Deprotection of <b>26d</b> was achieved with hydrochloric acid in methanol.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/medium/jm-2011-01112g_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201112g&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reactions and conditions: (a) <b>16a</b>, 4-pentenoic acid, HOBt, EDCI, CH<sub>2</sub>Cl<sub>2</sub>, room temp, 58%; (b) SnCl<sub>2</sub>·H<sub>2</sub>O, CH<sub>2</sub>Cl<sub>2</sub>/MeOH (1:1), room temp, 56–98%; (c) <b>16b</b>, <i>N</i>-allylmethylamine or allylamine, Na(OAc)<sub>3</sub>BH, CH<sub>2</sub>Cl<sub>2</sub>, room temp, 88–95%; (d) (CF<sub>3</sub>CO)<sub>2</sub>O, Et<sub>3</sub>N, THF, room temp, 99%; (e) <b>16a</b>, allyl bromide, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, room temp, 66%; (f) (Boc)<sub>2</sub>O, NaOH, THF, room temp, 86%; (g)<b>16c</b>, allyl bromide, KOH, TBAHSO<sub>4</sub>, CH<sub>2</sub>Cl<sub>2</sub>, room temp, 78%; (h) 4 M HCl, <i>n</i>-butanol, 80–100 °C, 59–92%; (i) Grubbs second generation catalyst, TFA, CH<sub>2</sub>Cl<sub>2</sub>, 40–45 °C, 64–89%; (j) 4 M HCl, MeOH/CH<sub>2</sub>Cl<sub>2</sub>, 40 °C, 79%.</p></p></figure><div class="NLM_p">Schemes <a class="ref internalNav" href="#sch3" aria-label="3">3</a> and <a class="ref internalNav" href="#sch4" aria-label="4">4</a> illustrate the synthetic routes employed to obtain the diverse right-hand fragments <b>21f</b>–<b>o</b> and <b>22a</b>–<b>n</b>. Similar to the synthesis of aniline <b>21b</b>, anilines <b>21f</b>–<b>h</b> were obtained via reductive amination and nitro group reduction, starting from commercially available <b>16d</b>–<b>f</b>. Nitro <b>16g</b> was prepared from <b>16f</b> via standard nitration conditions.</div><div class="NLM_p">Diversity at the R<sub>1</sub> position was installed by reductive amination of <b>16b</b> and <b>16i</b> with the desired primary amines giving the corresponding secondary amines <b>17a</b>–<b>i</b>. Alkylation with allyl bromide followed by nitro group reduction gave anilines <b>21i</b>–<b>o</b>. Trisubstituted anilines <b>22a</b>,<b>b</b>, with a side chain at the R<sub>2</sub> position, were formed via a two-step procedure first by displacement of the terminal chloride with amine followed by the nitro reduction. The R<sub>2</sub> substituent can be further diversified from <b>16e</b> to give morpholine <b>22c</b> and ethylsulfonylaniline <b>22d</b>. More examples of anilines with group R<sub>12</sub> were prepared as <b>22h</b>–<b>m</b>. The nitrophenol aldehydes <b>16h</b> and <b>16o</b> were alkylated cleanly with 1,2-dichloroethane in the presence of base to afford <b>16i</b> and <b>16u</b> in moderate to good yields. The displacement of the chloride of <b>16i</b> with ethanethiol under basic conditions furnished <b>16t</b>, which along with <b>16i</b> and <b>16u</b> was subjected to reductive amination followed by displacement of the terminal chloride with secondary and cyclic amines. Finally, the reduction of the aromatic nitro functions afforded anilines <b>22h</b>–<b>m</b> in good yields. The aniline <b>22e</b> was obtained from <b>16t</b> as described previously. The anilines <b>22f</b> and <b>22g</b> were derived from <b>16h</b> as follows. The alkylation of phenol <b>16h</b> with 2-bromoethyl methyl ether followed by reductive amination with <i>N</i>-methylamine and subsequent reduction of the aromatic nitro function afforded <b>22f</b>, while the aniline <b>22g</b> was obtained by alkylation with methyl bromoacetate to afford <b>16q</b>, which on lithium hydroxide hydrolysis furnished acid <b>16r</b>. Finally, the amide formation was accomplished with pyrrolidine to <b>16s</b> under standard amide coupling conditions. Scheme <a class="ref internalNav" href="#sch4" aria-label="4">4</a> describes the synthesis to obtain a 1,3,5-trisubstituted right-hand aniline. Starting with trifluoroacetylation of aniline <b>16v</b> to give <b>16w</b> followed by ester reduction using DIBAL gave the aldehyde which was reductively aminated with <i>N</i>-allylmethylamine followed by nitro group reduction, affording aniline <b>22n</b>.</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/medium/jm-2011-01112g_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201112g&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reactions and conditions: (a) <i>N</i>-allylmethylamine, Na(OAc)<sub>3</sub>BH, CH<sub>2</sub>Cl<sub>2</sub>, room temp, 75%, quantitative; (b) Fe powder, NH<sub>4</sub>Cl, EtOH, water, 80 °C, 81–93% or SnCl<sub>2</sub>·H<sub>2</sub>O, CH<sub>2</sub>Cl<sub>2</sub>/MeOH (1:1), room temp, 52–97%; (c) <b>16h</b> or <b>16c</b>, 1,2-dichloroethane, K<sub>2</sub>CO<sub>3</sub>, DMF, 100 °C, 64–72%; (d) amine, Na(OAc)<sub>3</sub>BH<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, room temp, 68–88%; (e) allyl bromide, K<sub>2</sub>CO<sub>3</sub>, DMF, 70 °C, 48–91%; (f) amine, DMA, 90 °C, 75–90%; (g) morpholine, ACN, room temp, 83%; (h) NH<sub>4</sub>Cl, MeOH, 60 °C, 95%; (i) ethanethiol, K<sub>2</sub>CO<sub>3</sub>, DMF, 70 °C, 86–97%; (j) MCPBA, CH<sub>2</sub>Cl<sub>2</sub>, room temp, 46%; (k) TFA/H<sub>2</sub>O (1:1), CH<sub>2</sub>Cl<sub>2</sub>, room temp, quantitative; (l) conc HNO<sub>3</sub>, conc H<sub>2</sub>SO<sub>4</sub>, 0 °C, 80%.</p></p></figure><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/medium/jm-2011-01112g_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201112g&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reactions and conditions: (a) <i>N</i>-allylmethylamine, Na(OAc)<sub>3</sub>BH, CH<sub>2</sub>Cl<sub>2</sub>, room temp, 75%, quantitative; (b) Fe powder, NH<sub>4</sub>Cl, EtOH, water, 80 °C, 81–93% or SnCl<sub>2</sub>·H<sub>2</sub>O, CH<sub>2</sub>Cl<sub>2</sub>/MeOH (1:1), room temp, 52–97%; (c) <b>16h</b> or <b>16c</b>, 1,2-dichloroethane, K<sub>2</sub>CO<sub>3</sub>, DMF, 100 °C, 64–72%; (d) amine, DMA, 90 °C, 75–90%; (e) 2-bromoethyl methyl ether, K<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, 86%; (f) methyl bromoacetate, K<sub>2</sub>CO<sub>3</sub>, ACN, room temp, 87%; (g) LiOH, THF/H<sub>2</sub>O (1:1), room temp, quantitative; (h) pyrrolidine, HOBt, EDCI, CH<sub>2</sub>Cl<sub>2</sub>, room temp, quantitative; (i) (CF<sub>3</sub>CO)<sub>2</sub>O, Et<sub>3</sub>N, THF, room temp, quantitative; (j) DIBAL, CH<sub>2</sub>Cl<sub>2</sub>, −78 °C, 48%.</p></p></figure><div class="NLM_p">Coupling of the left- and right-hand sides followed by RCM was carried out, as described above for Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>, to give final products <b>26k</b>–<b>q</b> and <b>27a</b>–<b>q</b> (Scheme <a class="ref internalNav" href="#sch5" aria-label="5">5</a>). Following macrocyclization, some of the macrocycles were further modified. Trifluoroacetyl, a group necessary to protect the linker amine for efficient ring closing metathesis, was deprotected under mild basic conditions to give the corresponding <b>26g</b> and <b>27s</b>. Amidation of <b>26g</b> with bromoacetyl bromide followed by displacement with isopropylamine afforded <b>26r</b> in a one-pot reaction. Macrocycle <b>27s</b> was further derivatized with ethanesulfonyl chloride and 4-morpholinecarbonyl chloride in separate reactions to produce corresponding <b>27t</b>–<b>u</b> in moderate yield. Macrocycles <b>28a</b>–<b>e</b> were synthesized from diversified left-hand fragments <b>15b</b>–<b>f</b> using Grubbs second generation catalyst as described previously.</div><figure id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/medium/jm-2011-01112g_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 5. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201112g&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reactions and conditions: (a) 4 M HCl, <i>n</i>-butanol, 80–100 °C, 49–97%; (b) Grubbs second generation catalyst, TFA, CH<sub>2</sub>Cl<sub>2</sub>, 40–45 °C, 42–89%; (c) K<sub>2</sub>CO<sub>3</sub>, H<sub>2</sub>O, MeOH, room temp, 48–58%; (d) (i) bromoacetyl bromide, CH<sub>2</sub>Cl<sub>2</sub>, room temp; (ii) isopropylamine, DIEA, CH<sub>2</sub>Cl<sub>2</sub>, room temp, two steps 39%; (e) ethanesulfonyl chloride, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, room temp, 40%; (f) 4-morpholinecarbonyl chloride, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, room temp, 48%.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34571" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34571" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Selection of the Preferred Linker</h3><div class="NLM_p">In the early stages of our kinase inhibitor research we prepared various macrocyclic linking moieties to explore the optimal choice for both our JAK2 program<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> and CDK program described herein. In conjunction with JAK2 and FLT3 we selected CDK2 as the primary biochemical ATPase assay for evaluation of compounds. Previously we have described dioxygen linkers with only moderately polar character. Given the acidic residue Asp86/Asp698 at the entrance to the CDK2/Flt3 active site, we explored nitrogen and amide containing groups in a screen for new interactions. The equivalent residue in JAK2 is Ser936. We observed less active compounds with amide containing linkers; for example, moderate activity against all enzymes was found for phenol ether amide <b>26a</b> but amides <b>26b</b> and <b>26c</b> with basic centers were quite weak (IC<sub>50</sub> > 10 μM) against the enzymes described in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>. More flexible and shorter <b>26e</b> was quite active against CDK2 but not for JAK2 or FLT3. However, the one carbon longer <b>26g</b> and its <i>N</i>-methyl analogue <b>26h</b> were potent in the 100 nM range against all enzymes. When docked into CDK2, the more constrained amides were higher in conformational energy and/or had unfavorable electrostatic interactions with the protein. Intriguingly, when the phenol ether of <b>26h</b> is modified to benzyl ether <b>26i</b>, at least 1 order of magnitude in potency is lost even though the overall length of the linker is maintained. Some recovery against CDK2 and JAK2 is seen when the linker of <b>26i</b> is reversed to give <b>26j</b>, probably through a hydrogen bond with Asp145. Hence, if the basic nitrogen is correctly orientated in the allylic/benzylic position of the linker, it confers good potency most likely through a salt bridge interaction with Asp86 (see Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). When docked into CDK2, <b>26i</b> is also forming a salt bridge to Asp86 but the benzylic ether oxygen is clashing with the backbone carbonyl of Gln131, offering a possible explanation for the 50-fold drop in potency compared to <b>26h</b>. When docked into FLT3, <b>26h</b> adopts a slightly different preferred conformation in order to achieve the key interaction with Asp698. A few low energy conformations of <b>26h</b> docked well into all three proteins, and the differences in the putative bioactive conformations seem to be due to subtle changes in the conformation of the active site rather than homology. However, JAK2 has a serine in place of aspartic acid; hence, the basic nitrogen of <b>26h</b> probably makes a hydrogen bond interaction with Ser936 (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>) when docked into JAK2. On the basis of this SAR, we prioritized the promising <b>26h</b> linker for further studies.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. SAR of Diverse Linkers</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/medium/jm-2011-01112g_0009.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/medium/jm-2011-01112g_0010.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">All compounds were isolated as 95:5 trans/cis mixtures.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">All IC<sub>50</sub> values are the mean ± SD (of at least two independent experiments).</p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last">cLogP was calculated using QikProp.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></p></div></div><div></div></div><figure id="fig3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/medium/jm-2011-01112g_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0020.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Macrocycles docked into CDK2. The CDK2 ATP-binding site is shown in thin tube with gray carbon. Inhibitors are shown in thick tube with green carbon. (A) In addition to the hydrogen bonds to the hinge residue Leu83, <b>26h</b> is forming a salt bridge to Asp86. (B) <b>26i</b> is also forming a salt bridge to Asp86, but the ether oxygen is clashing with the backbone carbonyl of Gln131, resulting in a lower IC<sub>50</sub>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201112g&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/medium/jm-2011-01112g_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0021.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) <b>26h</b> docked into FLT3. The predicted bioactive conformation of the macrocycle is different from that docked into CDK2. However, the interactions with the protein are conserved with two hydrogen bonds formed to the hinge backbone and a salt bridge to Asp698. (B) <b>26h</b> docked into JAK2. The conformation of the macrocycle is different from that docked into CDK2 and FLT3. The two hydrogen bonds formed to the hinge backbone are conserved, but instead of the salt bridge interaction there is a hydrogen bond to Ser936.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201112g&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Optimization of the Linker Nitrogen Substituent</h3><div class="NLM_p">We next turned our attention to the linker nitrogen substituent. Modeling showed that substituents of three or four atoms could be accommodated in this part of the active site. However, only the smallest lipophilic substituents (<b>26h</b>, <b>26k</b> and compare with <b>26g</b>) were potent against all enzymes (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). All enzymes are similarly sensitive to steric effects (<b>26l</b>, <b>26m</b>), with activity being completely lost with the very bulky <i>tert</i>-butyl <b>26n</b> (see Figures <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a> and <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a> where docking of <b>26h</b> against CDK2 shows little available space particularly for bulky substituents). Increases in log <i>P</i> and reduction in solubility were undesirable trends in this series. Moderate activity was regained with the more planar pyridyl <b>26o</b> and longer methoxyethyl <b>26p</b>, but these groups were still over an order of magnitude less active than <b>26h</b>. Introduction of hydrogen-bonding functionality regained some CDK2 potency as seen with <b>26q</b>, but this was not observed with <b>26r</b>, the latter being less flexible and α-branched. However, the activity of <b>26r</b> could be considered surprising when compared with electron-withdrawing trifluoroacyl <b>26f</b>. All activity is abolished with <b>26f</b>, presumably through destruction of the salt bridge interaction with Asp86 coupled with unfavorable steric clashes with the enzyme. This surprising activity of <b>26r</b> is likely due to the hydrogen bond/salt bridge interaction with Asp86 being achieved through the basic center of the isopropylaminoacyl group (see Figure S1, <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>). Despite the striking SAR, none of these compounds were close to the activity of the highly potent simpler analogues. Hence, we were persuaded by the data to avoid adding unnecessary molecular weight to this part of the molecule.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. SAR Study of the Amine Substituent</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/medium/jm-2011-01112g_0011.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/medium/jm-2011-01112g_0012.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">All compounds were isolated as 95:5 trans/cis mixtures.</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">All IC<sub>50</sub> values are the mean ± SD (of at least two independent experiments).</p></div><div class="footnote" id="t2fn3"><sup>Table c</sup><p class="last">cLogP was calculated using QikProp.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></p></div><div class="footnote" id="t2fn4"><sup>Table d</sup><p class="last">High throughput solubility in PBS buffered at pH 7.0.</p></div><div class="footnote" id="t2fn5"><sup>Table e</sup><p class="last">Denotes not tested.</p></div></div><div></div></div><figure id="fig5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/medium/jm-2011-01112g_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0022.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. <b>26h</b> docked into CDK2 which is shown with an electrostatic surface. The methyl substituent on the basic nitrogen is just the right size. A slightly larger substituent like cyclopropyl may be accommodated but will clash slightly with the protein. Larger or more bulky substituents cannot be docked without compromising the salt bridge to Asp86.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201112g&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Other examples of electron-withdrawing N-substituents were prepared but with an additional R<sub>2</sub> substituent on the phenyl ring (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>, <b>27l</b>–<b>m</b>, p<i>K</i><sub>a</sub> of the basic nitrogen of approximately 6 for both compounds). Nevertheless, a comparison between these two compounds is instructive: trifluoroethyl <b>27l</b> suffers complete loss of all CDK2 activity but a less significant impact on either JAK2 or FLT3, losing only 3- to 4-fold; cyanomethyl <b>27m</b> retains CDK2 potency (compared to <b>27k</b>) despite being similar electronically to the trifluoroethyl. Cyano is a much smaller group than trifluoromethyl, supporting the hypothesis that a small substituent is preferred for CDK2 potency. For optimum CDK2 activity in this series it is vital to preserve the strength of the Asp86 salt bridge by retaining basicity of the nitrogen center of at least p<i>K</i><sub>a</sub> = 9 (see electrostatic surface in Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>).</div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Exploration of Aromatic Substituents at R<sub>2</sub> and R<sub>3</sub></h3><div class="NLM_p">With the optimal <i>N</i>-methyl installed in the linker, various side chains were studied at the R<sub>2</sub> position. Lipophilic groups such as methoxy <b>27a</b>, chloro <b>27b</b>, trifluoromethoxy <b>27c</b>, and methoxyethoxy <b>27d</b> were slightly less active against all enzymes when compared to <b>26h</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). However, <b>27b</b> does retain a profile very similar to that of <b>26h</b>, but the cLogP is higher. In an effort to reduce cLogP and increase solubility while maintaining potency, more polar substituents were installed such as sulfones <b>27e</b> and <b>27g</b> and amide <b>27h</b>. Unfortunately these compounds all lost activity against either CDK2 or FLT3. The branched amine substituents, such as morpholine <b>27i</b>, were tolerated quite well against JAK2 and FLT3 but lost over 5-fold activity against CDK2. Efforts then turned to basic side chains installed on an ethoxy linker, which we had found to be productive in our selective JAK2 program.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Compounds <b>27j</b> and <b>27k</b> had good JAK2 and FLT3 activity, but CDK2 activity was reduced by over an order of magnitude when compared to <b>26h</b>. Unfortunately, this trend continued with analogues <b>27n</b>, <b>27o</b>, and <b>27p</b>. Furthermore, we determined the PK profile of <b>27j</b> which was only 5% bioavailable with a very high volume of distribution (see <a class="ref internalNav" href="#notes-1" aria-label="Table S1 and Figure S4">Table S1 and Figure S4</a>). It is most probable that other very close derivatives with two basic centers and a high cLogP (<b>27j</b>–<b>q</b>) would exhibit a similar undesirable profile. Our attentions then turned to the neighboring position on the aromatic ring, R<sub>3</sub>. Combination of R<sub>2</sub> and R<sub>3</sub> was explored with <b>27q</b>, which retained potency for JAK2 and FLT3 but dramatically lost activity against CDK2, probably as a result of a repulsive interaction with the carbonyl of His84 (this interaction is not seen in docking studies of JAK2 and FLT3). Hence mono-R<sub>3</sub> substitutions were explored in further detail. Very active compounds were found when aniline substituents were installed: <b>27r</b>, <b>27s</b>, and <b>27t</b> were all slightly more active than <b>26h</b> with IC<sub>50</sub> below 10 nM. Potencies for JAK2 and FLT3 were generally also good for these compounds. An additional hydrogen bond to His84 at the end of the hinge region is most likely responsible for the high CDK2 activity (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>). Compound <b>27u</b> was the exception, being over 10-fold less potent against CDK2 probably because of the inflexible urea group not being able to adopt a suitable conformation to maintain the hydrogen bond donor to His84. Despite these data, we felt that these compounds did not offer enough gains in potency for the increase in molecular weight; hence, the lower molecular weight <b>26h</b> was favored.</div><figure id="fig6" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/medium/jm-2011-01112g_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0023.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. <b>27s</b> docked into CDK2. The aniline nitrogen is forming an additional hydrogen bond to the backbone carbonyl of His84 at the end of the kinase hinge region. This is probably not a strong hydrogen bond as evident from the increase in activity of only 2-fold over <b>26h</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201112g&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. SAR Study of Amine and Aromatic Ring Substitutions</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/medium/jm-2011-01112g_0013.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/medium/jm-2011-01112g_0014.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">All compounds were isolated as 95:5 trans/cis mixtures.</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">All IC<sub>50</sub> values are the mean ± SD (of at least two independent experiments).</p></div><div class="footnote" id="t3fn3"><sup>Table c</sup><p class="last">cLogP was calculated using QikProp.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></p></div><div class="footnote" id="t3fn4"><sup>Table d</sup><p class="last">High throughput solubility in PBS buffered at pH 7.0.</p></div><div class="footnote" id="t3fn5"><sup>Table e</sup><p class="last">Denotes not tested.</p></div></div><div></div></div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Exploration of Biaryl Substitutions (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>)</h3><div class="NLM_p">A small number of compounds confirmed that substitution at R<sub>4</sub> was not tolerated by any of the target enzymes (<b>28a</b> and <b>28b</b>). Methyl substitution at R<sub>5</sub> (<b>28c</b>) was expected to boost JAK2 potency<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> but surprisingly reduced potency slightly for JAK2 and by an order of magnitude for CDK2. One possible explanation for this is the twist induced in the biaryl system, predicted by conformational analysis, reducing interactions between the phenyl ring and Phe80 (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>). On the other hand, fluoro substitution at R<sub>6</sub> (<b>28d</b>) did produce a CDK2 and FLT3 potent compound (<b>28d</b> CDK2 IC<sub>50</sub> = 9 nM and FLT3 IC<sub>50</sub> = 22 nM), with only a slight reduction in JAK2 potency. When docked into CDK2/FLT3, the fluoro of <b>28d</b> is pointing toward the backbone NH of Asp145/Asp829. In JAK2 the peptide bond involving the homologous backbone NH is rotated 180° compared to CDK2. So when docked into JAK2, the fluoro is pointing toward the backbone carbonyl of Gly993. Substitution at R<sub>7</sub> was explored with a methoxy group (<b>28e</b>), but this resulted in dramatic loss of CDK2 potency and considerable loss of JAK2 and FLT3 activity. This was not surprising because of the likely close interactions between the methoxy and Lys33 and Asp145 in that part of the binding site (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>). The phenyl ring ortho substituents were not studied because of the anticipated twist imparted to the biaryl system, which we envisioned to be unfavorable for our desired target activity in earlier analogues. Although only a cursory survey with a limited group of compounds, these data give little justification for further studies of biaryl substitutents</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. SAR Study of Aromatic Ring Substitutions</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/medium/jm-2011-01112g_0015.gif" alt="" id="fx7" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/medium/jm-2011-01112g_0016.gif" alt="" id="fx8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>Table a</sup><p class="last">All compounds were isolated as 95:5 trans/cis mixtures.</p></div><div class="footnote" id="t4fn2"><sup>Table b</sup><p class="last">All IC<sub>50</sub> values are the mean ± SD of at least two independent experiments.</p></div><div class="footnote" id="t4fn3"><sup>Table c</sup><p class="last">cLogP was calculated using QikProp.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></p></div></div><div></div></div><figure id="fig7" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/medium/jm-2011-01112g_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0024.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) <b>28c</b> docked into CDK2. In the putative bioactive conformation, the methyl group interacts favorably with Phe80. However, the methyl group induces a twist in the A and C rings, so they are less coplanar, shifting the A-ring slightly away from Phe80 and thus preventing the A-ring from interacting with Phe80. (B) <b>28e</b> docked into CDK2. The orange-black dashed lines indicate clashes between protein and ligand atoms. The methoxy substituent clashes with the side chains of Lys33 and Asp145. These are flexible residues and may move to accommodate the substituents. However, this is energetically unfavorable, as it will break the salt bridge between the two residues.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201112g&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Further in Vitro Profiling of Preferred Compounds</h3><div class="NLM_p">Selected compounds with broad spectrum potency (IC<sub>50</sub> < 100 nM) across the three target enzymes were profiled further to determine their in vitro ADME properties and cell proliferation inhibition in a range of solid and hematological cell lines (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>). HL-60 cells (acute myeloid leukemia), a cell line known to be sensitive to CDK inhibitors, were used to initially screen compounds. Most compounds were then assessed for their human liver microsomal (HLM) stability. The most potent CDK2 inhibitor, <b>27r</b>, was also the most potent in HL-60 cells with a IC<sub>50</sub> for proliferation of 6 nM. Such high cellular activity could reflect the combinatorial strategy of inhibiting several key signaling pathways at the same time. This compound was only moderately stable in HLM (<i>t</i><sub>1/2</sub> = 21 min) and did not meet our target profile for a once per day oral therapy and so was not profiled further. A similar set of data revealed <b>27i</b> and <b>27t</b> to be potent in cells but not satisfactorily stable enough in HLM. HL-60 is a FLT3-driven cell line; hence, the lower HL-60 IC<sub>50</sub> for <b>27t</b> compared to <b>27r</b> is most likely related to its reduced FLT3 activity. The least active compound in the HL-60 cell proliferation assay was the <i>N</i>-cyclopropyl derivative <b>26k</b> with an IC<sub>50</sub> of 1.38 μM, but this compound did have good stability in HLM and mouse liver microsomes (MLM); hence, it was profiled in a range of other cell lines. Unfortunately its poor cell potency was a general feature, perhaps because of its low solubility, and it was not progressed further. Potent CDK2 inhibitor <b>27b</b> was disappointing in terms of cell proliferation activity in three cell lines despite its good enzyme activity. The high cLogP of 4.5 indicates that there may be a solubility problem, but this was not studied further. The remaining compounds, <b>26g</b> and <b>26h</b>, were potent against all the cell lines tested including solid tumor cell lines such as colon (HCT-116, COLO205) and prostate (DU145). In general both compounds had a broadly similar pharmacological profile but <b>26h</b> was always more active in cells, particularly the prostate cancer cell line DU145 where there was a 5-fold difference between the compounds. Higher cellular potency of <b>26h</b> is probably due to its generally higher potency against the enzymes but could also be due to better solubility and permeability. Furthermore, <b>26g</b> was significantly less soluble than <b>26h</b>. Taken together, these data support <b>26h</b> as the preferred compound, and as such, it was selected for advanced profiling.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. In Vitro Profiling of Preferred Compounds</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center"><i>t</i><sub>1/2</sub> (min)</th><th class="rowsep1 colsep0" colspan="5" align="center">IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">CDK2</th><th class="colsep0 rowsep0" align="center">JAK2</th><th class="colsep0 rowsep0" align="center">FLT3</th><th class="colsep0 rowsep0" align="center">solubility (μg/mL)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">HLM</th><th class="colsep0 rowsep0" align="center">MLM</th><th class="colsep0 rowsep0" align="center">HL-60</th><th class="colsep0 rowsep0" align="center">HCT-116</th><th class="colsep0 rowsep0" align="center">RAMOS</th><th class="colsep0 rowsep0" align="center">COLO205</th><th class="colsep0 rowsep0" align="center">DU145</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26g</b></td><td class="colsep0 rowsep0" align="left">0.021</td><td class="colsep0 rowsep0" align="left">0.15</td><td class="colsep0 rowsep0" align="left">0.11</td><td class="colsep0 rowsep0" align="left">14.7</td><td class="colsep0 rowsep0" align="left">48</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">0.089</td><td class="colsep0 rowsep0" align="left">0.135</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">0.12</td><td class="colsep0 rowsep0" align="left">0.71</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26h</b></td><td class="colsep0 rowsep0" align="left">0.013</td><td class="colsep0 rowsep0" align="left">0.073</td><td class="colsep0 rowsep0" align="left">0.056</td><td class="colsep0 rowsep0" align="left">71.8</td><td class="colsep0 rowsep0" align="left">45</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">0.059</td><td class="colsep0 rowsep0" align="left">0.079</td><td class="colsep0 rowsep0" align="left">0.033</td><td class="colsep0 rowsep0" align="left">0.072</td><td class="colsep0 rowsep0" align="left">0.14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26k</b></td><td class="colsep0 rowsep0" align="left">0.036</td><td class="colsep0 rowsep0" align="left">0.090</td><td class="colsep0 rowsep0" align="left">0.042</td><td class="colsep0 rowsep0" align="left">16.6</td><td class="colsep0 rowsep0" align="left">>60</td><td class="colsep0 rowsep0" align="left">>60</td><td class="colsep0 rowsep0" align="left">1.38</td><td class="colsep0 rowsep0" align="left">1.6</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">3.6</td><td class="colsep0 rowsep0" align="left">3.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27b</b></td><td class="colsep0 rowsep0" align="left">0.024</td><td class="colsep0 rowsep0" align="left">0.082</td><td class="colsep0 rowsep0" align="left">0.077</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">0.34</td><td class="colsep0 rowsep0" align="left">0.49</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">0.43</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27i</b></td><td class="colsep0 rowsep0" align="left">0.074</td><td class="colsep0 rowsep0" align="left">0.049</td><td class="colsep0 rowsep0" align="left">0.071</td><td class="colsep0 rowsep0" align="left">147.0</td><td class="colsep0 rowsep0" align="left">21</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">0.076</td><td class="colsep0 rowsep0" align="left">0.41</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27t</b></td><td class="colsep0 rowsep0" align="left">0.008</td><td class="colsep0 rowsep0" align="left">0.018</td><td class="colsep0 rowsep0" align="left">0.14</td><td class="colsep0 rowsep0" align="left">82.4</td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="left">0.13</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27r</b></td><td class="colsep0 rowsep0" align="left">0.008</td><td class="colsep0 rowsep0" align="left">0.050</td><td class="colsep0 rowsep0" align="left">0.019</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">21</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">0.006</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">All IC<sub>50</sub> values are the mean of at least two independent experiments.</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">High throughput solubility in PBS at pH 7.0.</p></div><div class="footnote" id="t5fn3"><sup>c</sup><p class="last">ND denotes not tested.</p></div></div></div></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Intracellular Pharmacodynamic Marker Studies and Kinase Profiling of <b>26h</b></h3><div class="NLM_p">Intracellular pharmacodynamic marker studies showed that <b>26h</b> potently inhibited the CDK2 biomarker pRb (phospho-Rb, retinoblastoma tumor suppressor protein) in HCT-116 (Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>). Effects could be detected at the 40 nM with the protein phosphorylation being completely inhibited at 200 nM. Similar studies in leukemic cell lines<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> showed that <b>26h</b> was also potent against pRb in MV4-11 cells (IC<sub>50</sub> = 0.13 μM) and also inhibited pFLT3 and pSTAT5 in the same cell line.</div><figure id="fig8" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/medium/jm-2011-01112g_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0001.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. HCT-116 cells were treated separately with the indicated concentrations of <b>26h</b> for 24 h prior to denaturing lysis. An amount of 30 μg of lysate from each treatment was resolved on 10% SDS–PAGE, transferred onto PVDF membrane, and probed with antibodies against phospho-Rb and β-actin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201112g&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Extensive biological characterization, including kinase profiling, intracellular mechanistic studies, and antiproliferative effects on a wide range of leukemic cell lines, was reported elsewhere.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> These data show that <b>26h</b> has a highly novel kinase inhibitory spectrum inhibiting 17 kinases from a panel of 63, 11 of which are CDK/JAK/FLT family members. The others, Lck, Fyn, Fms, TYRO3, ERK5, and p38δ, are implicated in inflammatory and proliferative processes, and further biological studies are underway to better understand these activities in an in vivo setting.</div></div><div id="sec3_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Extensive ADME Profiling of <b>26h</b></h3><div class="NLM_p">In the Caco-2 bidirectional permeability assays, the permeability (<i>P</i><sub>app</sub>) of <b>26h</b> in the apical to basolateral (<i>P</i><sub>app,A→B</sub>) direction and in the basolateral to apical (<i>P</i><sub>app,B→A</sub>) direction was 28.0 × 10<sup>–6</sup> and 27.4 x10<sup>–6</sup> cm/s, respectively. The efflux ratio, defined as the ratio of <i>P</i><sub>app, B→A</sub> to <i>P</i><sub>app,A→B</sub>, was less than 3 (1.0), indicating that <b>26h</b> was not a substrate for efflux by intestinal P-gp transporters, suggestive of high intestinal absorption in humans (Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>). In human liver microsomes (HLM) <b>26h</b> was found to be stable with a half-life of 45 min, was moderately stable in DLM (<i>t</i><sub>1/2</sub> = 33 min), and was quite rapidly cleared in MLM (<i>t</i><sub>1/2</sub> = 12 min) and in RLM (<i>t</i><sub>1/2</sub> = 11 min). Human CYP1A2, 3A4, 2C9, and 2C19 isoforms were not inhibited by <b>26h</b> at the highest tested concentration of 25 μM, but the compound inhibited CYP2D6 with IC<sub>50</sub> = 0.95 μM, approximately at the plasma <i>C</i><sub>max</sub> observed at the maximum tolerated dose. Compound <b>26h</b> was highly bound to plasma proteins in human, mouse, and dog plasma with PPB ranging between 99.4% to 99.9%.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Physicochemical Properties and in Vitro ADME of <b>26h</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">property</th><th class="colsep0 rowsep0" align="center">value</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">molecular wt</td><td class="colsep0 rowsep0" align="left">372.47</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">no. of HDB</td><td class="colsep0 rowsep0" align="left">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">no. of HBA</td><td class="colsep0 rowsep0" align="left">4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cLogP <a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">4.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PSA (Å<sup>2</sup>)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">43</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">permeability<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a> (<i>P</i><sub>app,A→B</sub>, ×10<sup>–6</sup> cm/s)</td><td class="colsep0 rowsep0" align="left">28 (efflux ratio of 1.0)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">metabolic stability (<i>t</i><sub>1/2</sub>, min)</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HLM</td><td class="colsep0 rowsep0" align="left">45</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MLM</td><td class="colsep0 rowsep0" align="left">12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RLM</td><td class="colsep0 rowsep0" align="left">11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DLM</td><td class="colsep0 rowsep0" align="left">33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human CYP inhibition IC<sub>50</sub> (μM)</td><td class="colsep0 rowsep0" align="left">>25,<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a> 0.95<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">plasma protein binding (%)<a class="ref internalNav" href="#t6fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human</td><td class="colsep0 rowsep0" align="left">99.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse</td><td class="colsep0 rowsep0" align="left">99.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="left">99.9</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">cLogP and PSA were calculated using QikProp.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></p></div><div class="footnote" id="t6fn2"><sup>b</sup><p class="last">Caco-2 bidirectional permeability assay.</p></div><div class="footnote" id="t6fn3"><sup>c</sup><p class="last">CYP3A4, 1A2, 2C9, 2C19.</p></div><div class="footnote" id="t6fn4"><sup>d</sup><p class="last">CYP2D6.</p></div><div class="footnote" id="t6fn5"><sup>e</sup><p class="last">Equilibrium dialysis assay in plasma at 1000 ng/mL.</p></div></div></div></div><div id="sec3_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Pharmacokinetics of <b>26h</b> in Mice</h3><div class="NLM_p">The PK properties of <b>26h</b> in mice are summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>. <b>26h</b> showed high systemic clearance relative to liver blood flow and high volume of distribution at steady state, with a terminal half-life of ∼5.0 h. It showed rapid absorption (<i>t</i><sub>max</sub> = 0.5 h) and a mean <i>C</i><sub>max</sub> and AUC of 1029 ng/mL and 2523 ng·h/mL, respectively, with a mean terminal half-life of 6.1 h following a single oral dose of 75 mg/kg. It showed an acceptable oral bioavailability of 24%. The exposures achieved in mice at the 75 mg/kg dose far exceeded the enzyme inhibiton (CDK2 IC<sub>50</sub> = 0.013 μM, JAK2 IC<sub>50</sub> = 0.073 μM, and FLT3 IC<sub>50</sub> = 0.056 μM) and cell proliferation concentrations in HCT-116 (IC<sub>50</sub> = 0.079 μM) and HL-60 (IC<sub>50</sub> = 0.059 μM), correlating with the observed efficacy of <b>26h</b> in preclinical pharmacology models at similar doses.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Pharmacokinetics of <b>26h</b> in Mice</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" colspan="5" align="center">(A) Intravenous Administration</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center">Cl (L h<sup>–1</sup> kg<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center"><i>V</i><sub>ss</sub>(L/kg)</th><th class="colsep0 rowsep0" align="center"><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center">AUC<sub>0–∞</sub>(ng·h/mL)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5.0</td><td class="colsep0 rowsep0" align="left">6.6</td><td class="colsep0 rowsep0" align="left">23</td><td class="colsep0 rowsep0" align="left">4.6</td><td class="colsep0 rowsep0" align="left">752</td></tr></tbody></table><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" colspan="6" align="center">(B) Oral Administration<a class="ref internalNav" href="#tbl7-fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center"><i>t</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center"><i>C</i><sub>max</sub>(ng/mL)</th><th class="colsep0 rowsep0" align="center"><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center">AUC<sub>0–∞</sub>(ng·h/mL)</th><th class="colsep0 rowsep0" align="center"><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">75</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">1029</td><td class="colsep0 rowsep0" align="left">6.1</td><td class="colsep0 rowsep0" align="left">2523</td><td class="colsep0 rowsep0" align="left">24</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl7-fn1"><div class="footnote" id="tbl7-fn1"><sup>a</sup><p class="last">In preliminary PK studies, <b>26h</b> showed oral bioavailability (<i>F</i>) of 4% and 37% in rats and dogs, respectively.</p></div></div></div></div><div id="sec3_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Efficacy of <b>26h</b> in Xenograft Models</h3><div class="NLM_p">On the basis of its efficacy on a broad spectrum of tumor cell lines and good oral bioavailability, <b>26h</b> was selected for evaluation in human tumor xenograft mouse models. Two models were selected based on their relevance in cancer: HCT-116 colon cancer and Ramos B-cell lymphoma. Prior to conducting both experiments, dosing regimes in each model were explored and optimal schedules selected for each model that would be tolerated for the duration of the experiment.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div><div class="NLM_p">In the colon cancer model, HCT-116 cells were injected subcutaneously and tumors were established with mean group sizes of approximately 100 mm<sup>3</sup>. Treatment with <b>26h</b> at doses of 50 and 75 mg/kg po 3 times per week on a Monday, Wednesday, Friday schedule was started 8 days after cell inoculation for 15 days. Treatment with <b>26h</b> at 75 mg/kg po q.d. 3×/week significantly inhibited the growth of tumors with a mean TGI of 82%, while the lower dose of 50 mg/kg po 3×/week was marginally effective (Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>).</div><figure id="fig9" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/medium/jm-2011-01112g_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0002.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. <b>26h</b> is efficacious in a murine sc xenograft model of human colon cancer (HCT-116). Tumors were established in female BALB/c nude mice by sc implantation of 5 × 10<sup>6</sup> HCT-116 tumor cells. Tumor burden (volume, mm<sup>3</sup>) was measured twice a week by (<i>w</i><sup>2</sup><i>l</i>)/2, where <i>w</i> is the width and <i>l</i> is the length in mm of an HCT-116 carcinoma. Treatment started on day 1 when the group mean tumor volume reached 105 mm<sup>3</sup> and treatment ended on day 15. </p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201112g&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In the lymphoma model Ramos cells were injected subcutaneously and tumors were established with mean group sizes of approximately 200 mm<sup>3</sup>. Two different dosing regimens of <b>26h</b> were explored in this model: 75 mg/kg po q.d. on a 2 days on and 5 days off schedule and 15 mg/kg ip q.d. on a 5 days on 5 days off schedule were started 12 days after cell inoculation for 15 days. There were two vehicle control groups that received either MC/Tween or DMA/CRE (see <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a> for details). The treatment groups were compared with the corresponding vehicle control groups for assessment of percentage TGI. Treatment with <b>26h</b> using either regime significantly inhibited the growth of tumors with mean TGIs of 42% and 63% for the oral and ip delivery methods, respectively (Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>). Given the encouraging TGIs observed with both oral and ip dosing schedules in these challenging models, <b>26h</b> was selected for further preclinical development.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div><figure id="fig10" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/medium/jm-2011-01112g_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0003.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. <b>26h</b> is efficacious in a sc xenograft model of human B-cell lymphoma (Ramos). Ramos tumors were established in female BALB/c nude mice by sc implantation of 7 × 10<sup>6</sup> Ramos cells. Treatment with <b>26h</b> and vehicle (MC/Tween for po or DMA/CRE for ip) was initiated on day 1 and continued until day 15. The tumor volumes from the 15 mg/kg ip group was significantly different compared to the ip vehicle control group on day 15. Sample size, <i>n</i> = 8–10 mice per group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201112g&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70017" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70017" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">We have described the discovery of a series of small molecule macrocycles as potent inhibitors of CDKs, JAK2, and FLT3, a spectrum selective profile not previously reported. Application of a hypothesis of conformational constraint generated macrocycles that were synthesized using a RCM strategy. Screening of initial compounds in functional biochemical assays against CDK2, JAK2, and FLT3 kinases allowed selection of a preferred linker moiety containing a phenolic ether, trans double bond, and allylic/benzylic <i>N</i>-methyl group. SAR and broader in vitro profiling, particularly cellular assays, identified <b>26h</b>, a small molecule kinase inhibitor with a distinct kinase inhibitory spectrum, as the preferred lead candidate. Further evaluation revealed excellent pharmacokinetic properties of <b>26h</b> and dose-dependent efficacy in mouse models of cancer including a HCT-116 model of colon cancer and a Ramos model of lymphoma. On the basis of its favorable pharmaceutical and pharmacological profile, <b>26h</b> (SB1317/TG02) was advanced into development and is currently being evaluated in phase 1 clinical trials in leukemia patients.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76740" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76740" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Chemistry</h3><div class="NLM_p">Solvents and reagents were used directly from the suppliers without further purification and were of the highest generally available quality. Workup for chemical reactions was typically done by diluting the reaction mixture or residue with the reaction solvent or extraction solvent and then washing with the indicated aqueous solution(s). Product solutions were dried over anhydrous sodium sulfate prior to filtration, and the solvents were removed under reduced pressure using a rotary evaporator. All compounds were purified by either flash or reverse phase chromatography. Flash column chromatography was conducted using silica gel 60 (Merck KGaA, 0.040–0.063 mm, 230–400 mesh ASTM). Reverse-phase preparative high performance liquid chromatography (rpHPLC) was operated on a Phenomenex column (Luna 5 μm C18 (2) 100A 150 mm × 21.2 mm) with adjustable solvent gradients, usually 5–95% acetonitrile in water + 0.1% trifluoroacetic acid (TFA) with a run time of 18 min at a flow rate of 20 mL/min, and was used for routine purification. Fractions containing the desired product were lyophilized or evaporated to dryness under vacuum to provide the dry compound or evaporated to remove volatile organic solvents and then extracted with a suitable organic solvent (ethyl acetate or dichloromethane were commonly used; if necessary, the pH of the aqueous solution was adjusted in order to get free base, acid, or the neutral compound).</div><div class="NLM_p">The preliminary purity and identity of all compounds were assessed after purification by tandem HPLC/mass spectrometry (LC/MS) analyses on a Waters Micromass ZQ mass spectrometer in electrospray ionization (ESI) positive mode after separation on a Waters 2795 separations module. The HPLC separations were performed on a Phenomenex column (Luna 5 μm C18 (2) 100A 50 mm × 2.00 mm) with a flow rate of 0.8 mL/min and a 4 min gradient of <i>x</i> – 100% acetonitrile in water + 0.05% TFA (<i>x</i> = 5 or 30 or 50), using a Waters 2996 photodiode array detector. Purity and identity were assessed on the integrated UV chromatogram (220–400 nm) and the mass spectrum (homogeneity of the product peak and its fragmentation(s)).</div><div class="NLM_p">The final purity was determined using a Waters 2695 separations module on a Waters Xterra RP18 3.5 μm, 4.6 mm × 20 mm IS column with a flow rate of 2.0 mL/min, gradient 5–65% B over 4 min, then 65–95% B over 1 min, and 95% B for an additional 0.1 min (solvent A, H<sub>2</sub>O with 0.1% TFA; solvent B, acetonitrile with 0.1% TFA), and a Waters 2996 photodiode array detector. For compounds not suitable for the above HPLC methods either because of polarity or poor peak separation, a longer column (Phenomenex Gemini 5 μm C18, 110A, 4.6 mm × 150 mm) together with a flow rate of 1.0–1.2 mL/min and a 15 min gradient of 5–95% acetonitrile in water + 0.1% TFA was used for purity determination. Purity was >95% for all test compounds except those indicated in their respective synthesis descriptions.</div><div class="NLM_p">All the 1D and 2D NMR experiments for <sup>1</sup>H (400.13 MHz) and <sup>13</sup>C (100.61 MHz) nuclei were performed on a Bruker AVANCE-400 digital NMR spectrometer. <sup>1</sup>H–<sup>1</sup>H and <sup>1</sup>H–<sup>13</sup>C experiments (COSY, HMQC, HSQC, and HMBC) were run with Z-gradient selection. NMR spectra are reported in ppm with reference to an internal tetramethylsilane standard (0.00 ppm for <sup>1</sup>H and <sup>13</sup>C) or solvent peak(s) of CDCl<sub>3</sub> (7.26 and 77.1 ppm) or CD<sub>3</sub>OD (3.31 and 49.0 ppm) or DMSO-<i>d</i><sub>6</sub> (2.50 and 39.5 ppm). Other NMR solvents were used as needed. When peak multiplicities are reported, the following abbreviations are used: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broadened, dd = doublet of doublets, dt = doublet of triplets, and bs = broadened singlet. Coupling constants, when given, are reported in hertz.</div><div class="NLM_p last">All melting points are uncorrected. Elemental analyses of CHN were performed on a Perkin-Elmer 2400 CHN/CHNS elemental analyzer. HRMS data were obtained from a Bruker microTOF-Q II with direct injection.</div></div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> 2,4-Dichloro-6-pyrrolidin-1-ylpyrimidine (<b>10d</b>)</h3><div class="NLM_p last">To a mixture of 2,4,6-trichloropyrimidine (1.83 g, 10.0 mmol) in THF (50 mL) at −20 °C was added pyrrolidine (0.83 mL, 10.0 mmol) dropwise over a period of 30 min. The resulting mixture was allowed to warm to room temperature over 1 h. The reaction mixture was concentrated under reduced pressure, and CH<sub>2</sub>Cl<sub>2</sub> (50 mL) was added. It was washed with 1 N NaOH, water, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure to obtain the crude residue. The crude material was purified by column chromatography (EtOAc/hexane, 1:8) to afford <b>10d</b> (1.15 g, 53%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 218 ([M + H]<sup>+</sup>) C<sub>8</sub>H<sub>9</sub>Cl<sub>2</sub>N<sub>3</sub>.</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> 3-(2-Chloropyrimidine-4-yl)phenol (<b>12a</b>)</h3><div class="NLM_p last">To a degassed (argon) solution of 2,4-dichloropyrimidine (10 g, 67.1 mmol) and 3-hydroxyphenylboronic acid (11.1 g, 80.5 mmol) in 1,2-dimethoxy ethane (150 mL) were added aqueous NaHCO<sub>3</sub> (10.6 g in 15 mL H<sub>2</sub>O) and freshly prepared Pd(PPh<sub>3</sub>)<sub>4</sub> (7.7 g, 6.6 mmol). The reaction mixture was heated to 80 °C for 7 h. It was cooled to room temperature and quenched with saturated NH<sub>4</sub>Cl solution. The reaction mass was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 50 mL). The combined organic extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure to obtain the crude residue. The crude material was purified by column chromatography (EtOAc/hexane, 1:4) to afford <b>12a</b> (12.20 g, 88%) as an off white solid. LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 207 ([M + H]<sup>+</sup>) C<sub>10</sub>H<sub>7</sub>ClN<sub>2</sub>O; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 9.71 (br, 1H), 8.71 (d, 1H), 7.98 d, 1H), 7.49–7.54 (m, 2H), 7.30 (t, 1H), 6.94 (dd, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 166.7, 161.58, 160.95, 158.54, 136.30, 130.77, 119.6, 118.6, 117.5, 116.5, 114.2. Anal. Calcd for C<sub>10</sub>H<sub>7</sub>ClN<sub>2</sub>O: C, 58.13; H, 3.14; N, 13.56; Cl, 17.16. Found: C, 58.22; H, 3.33; N, 13.32; Cl, 13.45. IR (KBr pellet): 3173, 1536, 1360, 789, 625, 1082, 791 cm<sup>–1</sup>.</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> [3-(2-Chloropyrimidine-4-yl)phenyl]methanol (<b>12b</b>)</h3><div class="NLM_p">The synthesis for this intermediate was prepared using a different Suzuki coupling procedure compared to <b>12a</b>. To a degassed (nitrogen) solution of <b>10a</b> (50 g, 335 mmol) and 3-(hydroxymethyl)phenylboronic acid <b>11b</b> (48.5 g, 318 mmol) in THF (500 mL, 10 vol) were added saturated Na<sub>2</sub>CO<sub>3</sub> (88.6 g, 838 mmol), palladium acetate [Pd(OAc)<sub>2</sub>] (0.15 g, 0.67 mmol), and triphenylphosphine (0.35 g, 1.34 mmol). The resultant mixture was stirred at 70 °C for 6 h and filtered. Water was added to the filtrate, and it was extracted with EtOAc (3 × 250 mL). The combined organic extracts were washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and filtered. The filtrate was treated with activated charcoal, and the mixture was filtered. The filtrate was concentrated under reduced pressure, and the crude product was slurried in isopropyl alcohol (300 mL). The mixture was then filtered and the solid was slurried in cold <i>n</i>-heptane and was again filtered to furnish <b>12b</b> (42.8 g, 61%). This material was taken up for the next step without any purification. LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 221 ([M + H]<sup>+</sup>) C<sub>11</sub>H<sub>9</sub>ClN<sub>2</sub>O; <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 8.81 (d, 1H), 8.15 (br, 1H), 8.10 (d, 1H), 8.04 (dt, 1H), 7.57–7.54 (m, 1H), 4.63 (s, 2H); <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 166.7, 161.4, 160.8, 143.9, 134.7, 130.5, 129.4, 126.1, 125.4, 116.4, 62.9.</div><div class="NLM_p last">Following a procedure similar to that for <b>12a</b>, the following intermediates were synthesized.</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> 2-Chloro-4-(3-nitrophenyl)pyrimidine (<b>12c</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>10a</b> and 3-nitrophenylboronic acid <b>11c</b> (91%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 236 ([M + H]<sup>+</sup>) C<sub>10</sub>H<sub>6</sub>ClN<sub>3</sub>O<sub>2</sub>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.94 (t, 1H), 8.76 (d, 1H), 8.48 (qd, 1H), 8.40 (m), 7.77–7.70 (m, 2H).</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 3-(2-Chloropyrimidin-4-yl)benzoic Acid (<b>12e</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>10a</b> and 3-carboxyphenylboronic acid <b>11d</b> (63%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 235 ([M + H]<sup>+</sup>) C<sub>11</sub>H<sub>7</sub>ClN<sub>2</sub>O<sub>2</sub>; <sup>1</sup>H NMR (MeOD-<i>d</i><sub>4</sub>) δ 8.66 (s, 1H), 8.62 (d, 1H), 8.29 (d, 1H), 8.17 (d, 1H), 7.69 (d, 1H), 7.55 (t, 1H).</div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 3-(2-Chloropyrimidin-4-yl)benzaldehyde (<b>12f</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>10a</b> and 3-carbonylphenylboronic acid <b>11e</b> (60%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 219 ([M + H]<sup>+</sup>) C<sub>11</sub>H<sub>7</sub>ClN<sub>2</sub>O.</div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> 3-(2-Chloro-6-methylpyrimidin-4-yl)phenol (<b>12g</b>)</h3><div class="NLM_p last">The title compound was synthesized from 2,4-dichloro-6-methylpyrimidine <b>10b</b> and 3-hydroxyphenylboronic acid <b>11a</b> (81%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 221 ([M + H]<sup>+</sup>) C<sub>11</sub>H<sub>9</sub>ClN<sub>2</sub>O.</div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 3-(2-Chloro-6-pyrrolidin-1-ylpyrimidin-4-yl)phenol (<b>12h</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>10d</b> and 3-hydroxyphenylboronic acid <b>11a</b> (56%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 276 ([M + H]<sup>+</sup>) C<sub>14</sub>H<sub>14</sub>ClN<sub>3</sub>O.</div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 3-(2-Chloro-5-methylpyrimidin-4-yl)phenol (<b>12i</b>)</h3><div class="NLM_p last">The title compound was synthesized from 2,4-dichloro-5-methylpyrimidine <b>10e</b> and 3-hydroxyphenylboronic acid <b>11a</b> (66%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 221 ([M + H]<sup>+</sup>) C<sub>11</sub>H<sub>9</sub>ClN<sub>2</sub>O.</div></div><div id="sec5_1_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> 3-(2-Chloropyrimidin-4-yl)-5-fluorophenol (<b>12j</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>10a</b> and 3-fluoro-5-hydroxyphenylboronic acid <b>11f</b> (53%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 225 ([M + H]<sup>+</sup>) C<sub>10</sub>H<sub>6</sub>ClFN<sub>2</sub>O.</div></div><div id="sec5_1_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Acetic Acid 5-(2-Chloropyrimidin-4-yl)-2-methoxyphenyl Ester (<b>12k</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>10a</b> and 3-acetoxy-4-methoxyphenylboronic acid pinacol ester <b>11g</b> (74%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 279 ([M + H]<sup>+</sup>) C<sub>13</sub>H<sub>11</sub>ClN<sub>2</sub>O<sub>3</sub>.</div></div><div id="sec5_1_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 3-(2-Chloropyrimidin-4-yl)phenylamine (<b>12d</b>)</h3><div class="NLM_p last">To a solution of <b>12c</b> (0.3 g, 1.07 mmol) in CH<sub>2</sub>Cl<sub>2</sub>/MeOH (1:1, 10 mL), cooled to 0 °C, SnCl<sub>2</sub>·H<sub>2</sub>O (1.15 g, 5.00 mmol) was added. The reaction mixture was gradually raised to room temperature and stirred for 7 h. After completion of the reaction, the solvent from the reaction mixture was removed under reduced pressure and the residue was taken into saturated Na<sub>2</sub>CO<sub>3</sub> and CH<sub>2</sub>Cl<sub>2</sub> (20 mL). The reaction mixture was filtered through filter paper. The organic layer was separated from the filtrate, and the aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 10 mL). The combined organic extracts were dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated under reduced pressure to afford <b>12d</b> (0.2 g, 91%) as a thick syrup which was used for the next step without further purification. LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 206 ([M + H]<sup>+</sup>) C<sub>10</sub>H<sub>8</sub>ClN<sub>3</sub>.</div></div><div id="sec5_1_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> 5-(2-Chloropyrimidin-4-yl)-2-methoxyphenol (<b>12l</b>)</h3><div class="NLM_p last">To a solution of <b>12k</b> (0.27 g, 0.96 mmol) in THF (2.5 mL) was added LiOH (0.07 g, 2.88 mmol, dissolved in 2.5 mL of H<sub>2</sub>O). The reaction mixture was stirred at room temperature for 2 h. Upon completion of the reaction, 1 M HCl added to acidify the mixture and the aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 10 mL). The combined organic extracts were dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated under reduced pressure to afford <b>12l</b> (0.22 g, 97%) as a pale orange solid which was used for the next step without further purification. LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 237 ([M + H]<sup>+</sup>) C<sub>11</sub>H<sub>9</sub>ClN<sub>2</sub>O<sub>2</sub>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.56 (d, 1H), 7.71 (dd, 1H), 7.54 (d, 1H), 6.95 (d, 1H), 3.98 (s, 3H).</div></div><div id="sec5_1_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 4-(3-Allyloxymethylphenyl)-2-chloropyrimidine (<b>13b</b>)</h3><div class="NLM_p">A mixture of <b>12b</b> (20 g, 90.6 mmol), KOH (23.8 g, 172 mmol), and tetrabutylammonium hydrogen sulfate (1.5 g, 4.53 mmol) in allyl bromide (80 mL, 4 vol) was stirred at room temperature for 12 h. The reaction mixture was quenched with water and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 25 mL). The combined organic extracts were washed with water, brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated under reduced pressure to obtain the crude residue which was purified by column chromatography (using 15% EtOAc in hexane) to furnish <b>13b</b> (13 g, 55%) as a pale yellow oil. LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 261 ([M + H]<sup>+</sup>) C<sub>14</sub>H<sub>13</sub>ClN<sub>2</sub>O; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.62 (d, 1H), 8.06 (br, 1H), 8.00 (dt, 1H), 7.66 (d, 1H), 7.54–7.46 (m, 2H), 6.02–5.93 (m, 1H), 5.27 (ddq, 2H), 4.60 (s, 2H), 4.08 (dq, 2H); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 167.1, 161.9, 159.9, 139.7, 135.3, 134.6, 131.2, 129.7, 129.3, 126.6, 117.5, 115.4, 71.7, 71.6; IR (KBr pellet): 1568, 1535, 1344, 1186, 1079 cm<sup>–1</sup>.</div><div class="NLM_p last">Following a procedure similar to that of <b>13b</b>, the following intermediates were synthesized.</div></div><div id="sec5_1_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 4-(3-Allyloxyphenyl)-2-chloropyrimidine (<b>13a</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>12a</b> and allyl bromide (59%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 247 ([M + H]<sup>+</sup>) C<sub>13</sub>H<sub>11</sub>ClN<sub>2</sub>O.</div></div><div id="sec5_1_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 1-Allyloxymethyl-3-nitrobenzene (<b>18g</b>)</h3><div class="NLM_p last">The title compound was synthesized from 3-nitrobenzyl alcohol <b>16c</b> and allyl bromide (78%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 194 ([M + H]<sup>+</sup>) C<sub>10</sub>H<sub>11</sub>NO<sub>3</sub>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.27 (s, 1H), 8.18 (dd, 1H), 7.73 (dd, 1H), 7.57 (t, 1H), 6.01 (m, 1H), 5.38 (m, 1H), 5.29 (m, 1H), 4.65 (s, 2H), 4.13 (dt, 2H).</div></div><div id="sec5_1_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> But-3-enoic Acid [3-(2-Chloropyrimidin-4-yl)phenyl]amide (<b>14a</b>)</h3><div class="NLM_p">To a mixture of <b>12e</b> (0.2 g, 0.852 mmol) and vinylacetic acid (81 μL, 0.942 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (4 mL) at room temperature were added HOBt (0.184 g, 1.36 mmol) and EDCI (0.26 g, 1.36 mmol). The resulting mixture was stirred for 4 h. The reaction mixture was cooled to 0 °C and quenched with H<sub>2</sub>O. The aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> thrice, and the combined organic extracts were washed with saturated NaHCO<sub>3</sub> followed by brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure to give <b>14a</b> (0.18 g, 77%) which was taken for the next step without further purification. LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 274 ([M + H]<sup>+</sup>) C<sub>14</sub>H<sub>12</sub>ClN<sub>3</sub>O.</div><div class="NLM_p last">Following a procedure similar to that of <b>14a</b>, the following intermediates were synthesized.</div></div><div id="sec5_1_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> <i>N</i>-Allyl-3-(2-chloropyrimidin-4-yl)benzamide (<b>14b</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>12e</b> and allylamine (59%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 274 ([M + H]<sup>+</sup>) C<sub>14</sub>H<sub>12</sub>ClN<sub>3</sub>O; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.69 (d, 1H), 8.51 (t, 1H), 8.24 (m, 2H), 7.96 (m, 1H), 7.72 (d, 1H), 7.61 (t, 1H), 6.02–5.89 (m, 1H), 5.37–5.21 (m, 2H), 4.14 (m, 2H).</div></div><div id="sec5_1_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> Pent-4-enoic Acid (3-Nitrophenyl)amide (<b>18a</b>)</h3><div class="NLM_p last">The title compound was synthesized from 3-nitroaniline <b>16a</b> and pent-4-enoic acid (yield, 58%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 221 ([M + H]<sup>+</sup>) C<sub>11</sub>H<sub>12</sub>N<sub>2</sub>O<sub>3</sub>.</div></div><div id="sec5_1_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> 4-(3-Allyloxyphenyl)-2-chloropyrimidine (<b>15a</b>)</h3><div class="NLM_p">To a solution of <b>12a</b> (8 g, 38.8 mmol) in anhydrous DMF (40 mL), 4-bromo-1-butene (23.6 mL, 233 mmol) was added slowly followed by cesium carbonate (57 g, 174.7 mmol). The reaction mixture was heated to 40 °C for 12 h. The mixture was brought to room temperature and quenched with water (140 mL). The reaction mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 75 mL), and the combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The residue was purified by column chromatography (EtOAc/hexane, 1:19) to afford <b>15a</b> (7.5 g, 75%) as a white solid. LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 261 ([M + H]<sup>+</sup>) C<sub>13</sub>H<sub>11</sub>ClN<sub>2</sub>O; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.63 (d, 1H), 7.64–7.67 (m, 2H), 7.62 (d, 1H), 7.41 (dd, 1H), 5.90–5.94 (m, 1H), 5.15–5.22 (m, 1H), 4.12 (t, 1H), 2.59 (p, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 167.0, 161.8, 159.8, 159.6,136.5, 134.3, 130.2, 119.8, 118.3, 117.2, 115.3, 113.4, 67.5,33.6. Anal. Calcd for C<sub>14</sub>H<sub>13</sub>ClN<sub>2</sub>O: C, 64.49; H, 5.03; N, 10.74; Cl, 13.60. Found: C, 64.73; H, 5.07; N, 10.54; Cl, 13.34. IR (KBr pellet): 1573, 1455, 1351, 1223, 1183, 1037, 784 cm<sup>–1</sup>.</div><div class="NLM_p last">Following a procedure similar to that of <b>15a</b>, the following intermediates were synthesized.</div></div><div id="sec5_1_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> 4-(3-But-3-enyloxyphenyl)-2-chloro-6-methylpyrimidine (<b>15b</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>12g</b> and 4-bromo-1-butene (70%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 275 ([M + H]<sup>+</sup>) C<sub>15</sub>H<sub>15</sub>ClN<sub>2</sub>O.</div></div><div id="sec5_1_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> 4-(3-But-3-enyloxyphenyl)-2-chloro-6-pyrrolidin-1-ylpyrimidine (<b>15c</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>12h</b> and 4-bromo-1-butene (41%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 330 ([M + H]<sup>+</sup>) C<sub>18</sub>H<sub>20</sub>ClN<sub>3</sub>O.</div></div><div id="sec5_1_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> 4-(3-But-3-enyloxyphenyl)-2-chloro-5-methylpyrimidine (<b>15d</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>12i</b> and 4-bromo-1-butene (56%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 275 ([M + H]<sup>+</sup>) C<sub>15</sub>H<sub>15</sub>ClN<sub>2</sub>O.</div></div><div id="sec5_1_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> 4-(3-But-3-enyloxy-5-fluorophenyl)-2-chloropyrimidine (<b>15e</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>12j</b> and 4-bromo-1-butene (65%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 279 ([M + H]<sup>+</sup>) C<sub>14</sub>H<sub>12</sub>ClFN<sub>2</sub>O.</div></div><div id="sec5_1_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> 4-(3-But-3-enyloxy-4-methoxyphenyl)-2-chloropyrimidine (<b>15f</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>12l</b> and 4-bromo-1-butene (45%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 291 ([M + H]<sup>+</sup>) C1<sub>5</sub>H<sub>15</sub>ClN<sub>2</sub>O<sub>2</sub>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.55 (d, 1H), 8.13 (m, 2H), 7.60 (d, 1H), 6.97 (d, 1H), 6.04–5.97 (m, 1H), 5.38–5.22 (m, 2H), 4.60 (s, 2H), 4.14–4.12 (m, 2H), 3.91 (s, 3H).</div></div><div id="sec5_1_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> 5-Nitro-2-trifluoromethoxybenzaldehyde (<b>16g</b>)</h3><div class="NLM_p last">To a cooled solution of 2-trifluoromethoxybenzaldehyde <b>16f</b> (2.58 g, 13.6 mmol) in concentrated H<sub>2</sub>SO<sub>4</sub> (8.1 mL) at 0 °C was added concentrated HNO<sub>3</sub> (1.7 mL) dropwise, and reaction mixture was stirred for 2 h. Cold water was added, and resulting mixture was filtered. The product <b>16g</b> was obtained as an off-white solid (2.55 g, 80%) and was taken to the next step without further purification. LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 236 ([M + H]<sup>+</sup>) C<sub>8</sub>H<sub>4</sub>F<sub>3</sub>NO<sub>4</sub>.</div></div><div id="sec5_1_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> Allylmethyl-(3 nitrobenzyl)amine (<b>18b</b>)</h3><div class="NLM_p">To a solution of 3-nitrobenzaldehyde <b>16b</b> (20 g, 132.4 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (500 mL) was added <i>N</i>-allylmethylamine (18.8 mL, 198.6 mmol), and the resulting mixture was stirred at room temperature for 12 h after which Na(OAc)<sub>3</sub>BH (56.13 g, 265 mmol) was added portionwise and the mixture stirred for an additional 4 h. The reaction mixture was then quenched with saturated NH<sub>4</sub>Cl solution and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 150 mL). The combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to give the crude material which was purified by column chromatography (EtOAc/hexane, 1:19) to afford <b>18b</b> (25.9 g, 95%) as a pale yellow syrup. LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 207 ([M + H]<sup>+</sup>) C<sub>11</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.20 (s, 1H), 8.11 (dd, 1H), 7.68 (dd, 1H), 7.48 (t, 1H), 5.85–5.94 (m, 1H), 5.20 (t, 1H), 3.60 (s, 2H), 3.07 (dd, 1H), 2.22 (s, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 148.4, 141.5, 135.20, 134.9, 129.1, 123.7, 122.1, 118.1, 60.52, 60.50. Anal. Calcd for C<sub>11</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub>: C, 64.06; H, 6.84; N, 13.58. Found: C, 62.31; H, 6.69; N, 13.25. IR (KBr pellet): 2787, 1528, 1349, 924, 733 cm<sup>–1</sup>.</div><div class="NLM_p last">Following a procedure similar to that of <b>18b</b>, the following intermediates were synthesized.</div></div><div id="sec5_1_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> <i>N</i>-Allyl-3-(2-chloropyrimidin-4-yl)benzamide (<b>14c</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>12f</b> and <i>N</i>-allylmethylamine (60%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 274 ([M + H]<sup>+</sup>) C<sub>11</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub>.</div></div><div id="sec5_1_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> Allyl-(3-nitrobenzyl)amine (<b>18c</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>10b</b> and allylamine (88%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 193 ([M + H]<sup>+</sup>) C<sub>10</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.20 (s, 1H), 8.07 (d, 1H), 7.68 (d, 1H), 7.47 (t, 1H), 5.93–5.87 (m, 1H), 5.22–5.11 (m, 2H), 3.88 (s, 2H), 3.28–3.26 (m, 2H).</div></div><div id="sec5_1_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> <i>N</i>-Allyl-2,2,2-trifluoro-<i>N</i>-(3-nitrobenzyl)acetamide (<b>18d</b>)</h3><div class="NLM_p last">To a solution of <b>18c</b> (0.673 g, 3.51 mmol) and trifluoroacetic anhydride (0.98 mL, 7.00 mmol) in THF (10 mL) was added triethylamine (0.98 mL, 7.00 mmol) dropwise, and the resulting mixture was stirred at room temperature for 1 h. Aqueous NaHCO<sub>3</sub> (20 mL) was added and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 15 mL). The combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to give <b>18d</b> (1 g, 99%) as an orange liquid. This material was taken up for the next step without further purification. LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 289 ([M + H]<sup>+</sup>) C<sub>12</sub>H<sub>11</sub>F<sub>3</sub>N<sub>2</sub>O<sub>3</sub>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.19 (m, 1H), 8.09 (s, 1H), 7.62–7.55 (m, 2H), 5.81–5.75 (m, 1H), 5.38–5.26 (m, 2H), 4.70 (s, 2H), 4.01–3.96 (m, 2H).</div></div><div id="sec5_1_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> 3-Nitro-5-(2,2,2-trifluoroacetylamino)benzoic Acid Methyl Ester (<b>16w</b>)</h3><div class="NLM_p last">Following a procedure similar to that of <b>18d</b>, the title compound was synthesized from 3-amino-5-nitrobenzoic acid methyl ester <b>16v</b> (yield, quantitative). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 293 ([M + H]<sup>+</sup>) C<sub>10</sub>H<sub>7</sub>F<sub>3</sub>N<sub>2</sub>O<sub>5</sub>.</div></div><div id="sec5_1_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> Allyl-(3-nitrophenyl)amine (<b>18e</b>)</h3><div class="NLM_p last">To a solution of 3-nitroaniline <b>16a</b> (1 g, 7.24 mmol) and allyl bromide (0.86 mL, 7.60 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) was added triethylamine (2.0 mL, 14.5 mmol), and the resulting mixture was stirred at room temperature for 3 h. The reaction mixture was cooled to 0 °C and quenched with water. The product was extracted with CH<sub>2</sub>Cl<sub>2</sub> thrice, and the combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to furnish an oil, which was purified by column (EtOAc/hexane) to obtain 0.89 g of <b>18e</b> (66%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 179 ([M + H]<sup>+</sup>) C<sub>9</sub>H<sub>10</sub>N<sub>2</sub>O<sub>2</sub>.</div></div><div id="sec5_1_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> Allyl-(3-nitrophenyl)carbamic Acid <i>tert</i>-Butyl Ester (<b>18f</b>)</h3><div class="NLM_p last">To a solution of <b>18e</b> (0.3 g, 1.68 mmol), di-<i>tert</i>-butyl dicarbonate (0.55 g, 2.52 mmol), and 4-(dimethylamino)pyridine (10 mg, 0.084 mmol) in THF (5 mL) was added triethylamine (0.33 mL, 2.36 mmol), and the resulting mixture was stirred at room temperature for 4 h. Upon completion, THF was removed under reduced pressure and water (20 mL) was added. The product was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 15 mL) and the combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to give <b>18f</b> (0.4 g, 86%) as a colorless liquid. This material was taken up for the next step without further purification. LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 279 ([M + H]<sup>+</sup>) C<sub>14</sub>H<sub>18</sub>N<sub>2</sub>O<sub>4</sub>.</div></div><div id="sec5_1_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> 1-Chloro-2-dimethoxymethyl-4-nitrobenzene (<b>16j</b>)</h3><div class="NLM_p last">To a solution of 2-chloro-5-nitrobenzaldehyde <b>16e</b> (1.85 g, 1.00 mmol) in MeOH (50 mL) was added ammonium chloride (0.2 g, 3.67 mmol), and the resulting mixture was refluxed for 7 h. Upon completion, the reaction mixture was concentrated under reduced pressure to give an oil, which was dissolved in CH<sub>2</sub>Cl<sub>2</sub>. It was washed with water once, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure to furnish colorless oil <b>16j</b> (2.2 g, 95%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 232 ([M + H]<sup>+</sup>) C<sub>9</sub>H<sub>10</sub>ClNO<sub>4</sub>.</div></div><div id="sec5_1_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> 2-Dimethoxymethyl-1-ethylsulfanyl-4-nitrobenzene (<b>16k</b>)</h3><div class="NLM_p last">To a solution of <b>16j</b> (2.0 g, 8.63 mmol), K<sub>2</sub>CO<sub>3</sub> (2.39 g, 17.3 mmol) in DMF (50 mL) was added ethanethiol (0.64 mL, 8.63 mmol), and the resulting mixture was refluxed for 7 h. Upon completion, the reaction mixture was concentrated under reduced pressure to give thick syrup, which was dissolved in CH<sub>2</sub>Cl<sub>2</sub>. It was washed with water once, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure to furnish colorless oil <b>16k</b> (1.9 g, 86%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 258 ([M + H]<sup>+</sup>) C<sub>11</sub>H<sub>15</sub>NO<sub>4</sub>S.</div></div><div id="sec5_1_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> 2-Dimethoxymethyl-1-ethanesulfonyl-4-nitrobenzene (<b>16l</b>)</h3><div class="NLM_p last">To a cooled, degassed (N<sub>2</sub>) solution of <b>16k</b> (1 g, 3.88 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) at 0 °C was added 3-chloroperbenzoic acid (1.34 g, 7.76 mmol), and the resulting mixture was stirred at room temperature overnight. The reaction mixture was cooled to 0 °C and quenched with water. The product was extracted with CH<sub>2</sub>Cl<sub>2</sub> thrice, and the combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to furnish an oil, which was purified by column chromatography (EtOAc/hexane) to obtain 0.52 g of <b>16l</b> (46%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 290 ([M + H]<sup>+</sup>) C<sub>11</sub>H<sub>15</sub>NO<sub>6</sub>S.</div></div><div id="sec5_1_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> 2-Ethanesulfonyl-5-nitrobenzaldehyde (<b>16m</b>)</h3><div class="NLM_p last">To a cooled solution of <b>16l</b> (0.5 g, 1.73 mmol) in water (10 mL) at 0 °C was added 50% TFA/CH<sub>2</sub>Cl<sub>2</sub> (10 mL), and the resulting mixture was stirred at room temperature for 1 day. The organic layer was separated, and the aqueous layer was basified using saturated NaHCO<sub>3</sub> solution and extracted with CH<sub>2</sub>Cl<sub>2</sub> twice. The combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to furnish <b>16m</b> (0.42 g, quantitative) as an off-white solid. LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 244 ([M + H]<sup>+</sup>) C<sub>9</sub>H<sub>9</sub>NO<sub>5</sub>S.</div></div><div id="sec5_1_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> 2-Morpholin-4-yl-5-nitrobenzaldehyde (<b>16n</b>)</h3><div class="NLM_p last">To a mixture of 2-chloro-5-nitrobenzaldehyde <b>16e</b> (2 g, 10.8 mmol) in ACN (40 mL, 20 vol) was added morpholine (3.5 mL, 32.4 mmol), and the resulting mixture was stirred at room temperature overnight. The reaction mixture was cooled to room temperature, and water (60 mL) was added to quench the reaction. The aqueous layer was extracted thrice with EtOAc (30 mL each), and the combined organic extract was washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated under reduced pressure. Product <b>16n</b> (2.11 g, 83%) was taken forward for the next step without any purification. LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 237 ([M + H]<sup>+</sup>) C<sub>11</sub>H<sub>12</sub>N<sub>2</sub>O<sub>4</sub>.</div></div><div id="sec5_1_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> 2-(2-Chloroethoxy)-5-nitrobenzaldehyde (<b>16i</b>)</h3><div class="NLM_p last">To a mixture of 2-hydroxy-4-nitrobenzaldehyde <b>16h</b> (50 g, 299 mmol) and 1,2-dichloroethane (300 mL, 6 vol) in DMF (600 mL, 12 vol)) was added K<sub>2</sub>CO<sub>3</sub> (62.5 g, 450 mmol), and the resulting mixture was stirred at 100–105 °C for 6 h. The reaction mixture was quenched with water (500 mL), and the product was extracted four times with CH<sub>2</sub>Cl<sub>2</sub> (200 mL each). The combined organic extracts were washed with water (500 mL), brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated under reduced pressure, and hexane (500 mL) was added to the crude product. The resulting mixture was stirred for 30 min and evaporated to dryness under reduced pressure followed by hexane slurry. The slurry with cold hexane (500 mL) procedure was repeated, and the yellow solid was collected by filtration. Product <b>15e</b> (49.3 g, 72%) was taken forward to the next step without any purification. LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 230 ([M + H]<sup>+</sup>) C<sub>9</sub>H<sub>8</sub>ClNO<sub>4</sub>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 10.52 (s, 1H), 8.71 (d, 1H), 8.45 (dd, 1H), 7.14 (d, 1H), 4.51 (t, 2H), 3.96 (t, 2H); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 187.3, 164.2, 142.1, 130.6, 125.0, 124.6, 113.2, 69.4, 41.3.</div></div><div id="sec5_1_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> 2-(2-Chloroethoxy)-3-methoxy-5-nitrobenzaldehyde (<b>16u</b>)</h3><div class="NLM_p last">Following a procedure similar to that of <b>16i</b>, the title compound was synthesized from 2-hydroxy-3-methoxy-5-nitro-benzaldehyde <b>16o</b> and 1,2-dichloroethane (64%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 260 ([M + H]<sup>+</sup>) C<sub>10</sub>H<sub>10</sub>ClNO<sub>5</sub>.</div></div><div id="sec5_1_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> 2-(2-Methoxyethoxy)-5-nitrobenzaldehyde (<b>16p</b>)</h3><div class="NLM_p last">To a mixture of 2-hydroxy-5-nitrobenzaldehyde <b>16h</b> (5 g, 29.9 mmol) and 1-bromo-2-methoxyethane (5.6 mL, 59.8 mmol) in DMF (50 mL, 10 vol) was added K<sub>2</sub>CO<sub>3</sub> (6.25 g, 45.0 mmol), and the resulting mixture was stirred at 100–105 °C for 6 h. The reaction mixture was cooled to 0 °C and quenched with water. The product was extracted with CH<sub>2</sub>Cl<sub>2</sub> thrice and the combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to furnish an oil, which was purified by column (EtOAc/hexane) to obtain 5.8 g of <b>16p</b> (86%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 226 ([M + H]<sup>+</sup>) C<sub>10</sub>H<sub>11</sub>NO<sub>5</sub>.</div></div><div id="sec5_1_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> (2-Formyl-4-nitrophenoxy)acetic Acid Methyl Ester (<b>16q</b>)</h3><div class="NLM_p last">To a mixture of 2-hydroxy-5-nitrobenzaldehyde <b>16h</b> (0.5 g, 2.99 mmol) and methyl bromoacetate (1.4 mL, 14.9 mmol) in DMF (15 mL) was added K<sub>2</sub>CO<sub>3</sub> (0.83 g, 5.98 mmol), and the resulting mixture was stirred at 40 °C for 20 h. The reaction mixture was cooled to 0 °C and quenched with water. The product was extracted with CH<sub>2</sub>Cl<sub>2</sub> thrice and the combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to furnish an oil, which was purified by column (EtOAc/hexane) to obtain 0.62 g of <b>16q</b> (87%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 240 ([M + H]<sup>+</sup>) C<sub>10</sub>H<sub>9</sub>NO<sub>6</sub>.</div></div><div id="sec5_1_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> (2-Formyl-4-nitrophenoxy)acetic Acid (<b>16r</b>)</h3><div class="NLM_p last">Following a procedure similar to that of <b>12l</b>, the title compound was synthesized from <b>16q</b> (yield, quantitative). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 226 ([M + H]<sup>+</sup>) C<sub>9</sub>H<sub>7</sub>NO<sub>6</sub>.</div></div><div id="sec5_1_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> 5-Nitro-2-(2-oxo-2-pyrrolidin-1-ylethoxy)benzaldehyde (<b>16s</b>)</h3><div class="NLM_p last">Following a procedure similar to that of <b>14a</b>, the title compound was synthesized from <b>16r</b> (yield, quantitative). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 279 ([M + H]<sup>+</sup>) C<sub>13</sub>H<sub>14</sub>N<sub>2</sub>O<sub>5</sub>.</div></div><div id="sec5_1_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> 2-(2-Ethylsulfanylethoxy)-5-nitrobenzaldehyde (<b>16t</b>)</h3><div class="NLM_p last">Following a procedure similar to that of <b>16k</b>, the title compound was synthesized from <b>16i</b> and ethanethiol (97%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 256 ([M + H]<sup>+</sup>) C<sub>11</sub>H<sub>13</sub>NO<sub>4</sub>S.</div></div><div id="sec5_1_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> 2,2,2-Trifluoro-<i>N</i>-(3-formyl-5-nitrophenyl)acetamide (<b>16x</b>)</h3><div class="NLM_p last">To a cooled mixture of <b>16u</b> (1.4 g, 4.73 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (6 mL, 10 vol) at 0 °C was added 1.0 M DIBAL solution (4 mL, 4.00 mmol) dropwise. The resulting mixture was stirred for 1 h and allowed to warm to room temperature. Water was added, and product was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 10 mL). The combined organic extracts were washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated under reduced pressure to obtain the crude residue which was purified by column chromatography (using 35% EtOAc in hexane) to furnish <b>11g</b> (230 mg, 48%) as a colorless oil. LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 263 ([M + H]<sup>+</sup>) C<sub>9</sub>H<sub>5</sub>F<sub>3</sub>N<sub>2</sub>O<sub>4</sub>.</div></div><div id="sec5_1_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> Cyclopropylmethyl-(3-nitrobenzyl)amine (<b>17c</b>)</h3><div class="NLM_p">To a mixture of 3-nitrobenzaldehyde <b>16b</b> (1.2 g, 7.94 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (12 mL) was added aminomethylcyclopropane (1.35 mL, 15.6 mmol), and the resulting mixture was stirred at room temperature for 4 h after which Na(OAc)<sub>3</sub>BH (3.3 g, 15.6 mmol) was added portionwise and the mixture stirred for additional 4 h. The reaction mixture was then quenched with water (20 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 15 mL). The combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to afford <b>17c</b> (1.4 g, 86%) as a pale yellow syrup. LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 207 ([M + H]<sup>+</sup>) C<sub>11</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub>.</div><div class="NLM_p last">Following a procedure similar to that of <b>17c</b>, the following intermediates were synthesized.</div></div><div id="sec5_1_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> Cyclopropyl-(3-nitrobenzyl)amine (<b>17a</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>16b</b> and cyclopropylamine (72%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 193 ([M + H]<sup>+</sup>) C<sub>10</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 10.20 (br, 1H), 8.32 (s, 1H), 8.11 (d, 1H), 8.01 (d, 1H), 7.50 (t, 1H), 4.20 (s, 2H), 2.40–2.37 (m, 1H), 1.07 (m, 2H), 0.66 (m, 2H).</div></div><div id="sec5_1_49" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> Isobutyl-(3-nitrobenzyl)amine (<b>17b</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>16b</b> and isobutylamine (79%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 209 ([M + H]<sup>+</sup>) C<sub>11</sub>H<sub>16</sub>N<sub>2</sub>O<sub>2</sub>.</div></div><div id="sec5_1_50" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> (2,2-Dimethylpropyl)-(3-nitrobenzyl)amine (<b>17d</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>16b</b> and 2,2-dimethylpropan-1-amine (68%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 223 ([M + H]<sup>+</sup>) C<sub>12</sub>H<sub>18</sub>N<sub>2</sub>O<sub>2</sub>.</div></div><div id="sec5_1_51" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> (3-Nitrobenzyl)pyridin-2-ylmethylamine (<b>17e</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>16b</b> and 2-(aminomethyl)pyridine (83%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 244 ([M + H]<sup>+</sup>) C<sub>13</sub>H<sub>13</sub>N<sub>3</sub>O<sub>2</sub>.</div></div><div id="sec5_1_52" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> (2-Methoxyethyl)-(3-nitrobenzyl)amine (<b>17f</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>16b</b> and 2-methoxyethylamine (88%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 211 ([M + H]<sup>+</sup>) C<sub>10</sub>H<sub>14</sub>N<sub>2</sub>O<sub>3</sub>.</div></div><div id="sec5_1_53" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> 2-(3-Nitrobenzylamino)ethanol (<b>17g</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>16b</b> and 2-aminoethanol (75%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 197 ([M + H]<sup>+</sup>) C<sub>9</sub>H<sub>12</sub>N<sub>2</sub>O<sub>3</sub>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.19 (s, 1H), 8.10 (d, 1H), 7.64 (dd, 1H), 7.51–7.44 (m, 1H), 3.90 (s, 2H), 3.67 (t, 2H), 2.76 (t, 2H).</div></div><div id="sec5_1_54" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> [2-(2-Chloroethoxy)-5-nitrobenzyl]-(2,2,2-trifluoroethyl)amine (<b>17h</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>16b</b> and 2,2,2-trifluoroethylamine (79%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 313 ([M + H]<sup>+</sup>) C<sub>11</sub>H<sub>12</sub>ClF<sub>3</sub>N<sub>2</sub>O<sub>3</sub>.</div></div><div id="sec5_1_55" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> [2-(2-Chloroethoxy)-5-nitrobenzylamino]acetonitrile (<b>17i</b>)</h3><div class="NLM_p">The title compound was synthesized from <b>16b</b> and 2-aminoacetonitrile (75%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 270 ([M + H]<sup>+</sup>) C<sub>11</sub>H<sub>12</sub>ClN<sub>3</sub>O<sub>3</sub>.</div><div class="NLM_p last">Following a procedure similar to that of <b>18b</b>, the following intermediates were synthesized.</div></div><div id="sec5_1_56" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> Allyl-(2-methoxy-5-nitrobenzyl)methylamine (<b>18h</b>)</h3><div class="NLM_p last">The title compound was synthesized from 2-methoxy-5-nitrobenzaldehyde <b>16d</b> and <i>N</i>-allylmethylamine (95%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 237 ([M + H]<sup>+</sup>) C<sub>12</sub>H<sub>16</sub>N<sub>2</sub>O<sub>3</sub>.</div></div><div id="sec5_1_57" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> Allyl-(2-chloro-5-nitrobenzyl)methylamine (<b>18i</b>)</h3><div class="NLM_p last">The title compound was synthesized from 2-chloro-5-nitrobenzaldehyde <b>16e</b> and <i>N</i>-allylmethylamine (86%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 241 ([M + H]<sup>+</sup>) C<sub>11</sub>H<sub>13</sub>ClN<sub>2</sub>O<sub>2</sub>.</div></div><div id="sec5_1_58" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> Allylmethyl-(5-nitro-2-trifluoromethoxybenzyl)amine (<b>18j</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>16g</b> and <i>N</i>-allylmethylamine (91%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 291 ([M + H]<sup>+</sup>) C<sub>12</sub>H<sub>13</sub>F<sub>3</sub>N<sub>2</sub>O<sub>3</sub>.</div></div><div id="sec5_1_59" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> Allyl-[2-(2-methoxyethoxy)-5-nitrobenzyl]methylamine (<b>18k</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>16p</b> and <i>N</i>-allylmethylamine (92%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 281 ([M + H]<sup>+</sup>) C<sub>14</sub>H<sub>2</sub>0N<sub>2</sub>O<sub>4</sub>.</div></div><div id="sec5_1_60" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> Allyl-(2-ethanesulfonyl-5-nitrobenzyl)methylamine (<b>18l</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>16m</b> and <i>N</i>-allylmethylamine (78%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 299 ([M + H]<sup>+</sup>) C<sub>13</sub>H<sub>18</sub>N<sub>2</sub>O<sub>4</sub>S.</div></div><div id="sec5_1_61" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> Allylmethyl-(2-morpholin-4-yl-5-nitrobenzyl)amine (<b>18m</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>16n</b> and <i>N</i>-allylmethylamine (yield, quantitative). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 292 ([M + H]<sup>+</sup>) C<sub>15</sub>H<sub>21</sub>N<sub>3</sub>O<sub>3</sub>.</div></div><div id="sec5_1_62" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> Allyl-[2-(2-ethylsulfanylethoxy)-5-nitrobenzyl]methylamine (<b>18n</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>16t</b> and <i>N</i>-allylmethylamine (93%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 311 ([M + H]<sup>+</sup>) C<sub>15</sub>H<sub>22</sub>N<sub>2</sub>O<sub>3</sub>S.</div></div><div id="sec5_1_62_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i85" class="anchor-spacer"></div><h3 class="article-section__title" id="_i85"> 2-{2-[(Allylmethylamino)methyl]-4-nitrophenoxy}-1-pyrrolidin-1-ylethanone (<b>18o</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>16s</b> and <i>N</i>-allylmethylamine (92%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 335 ([M + H]<sup>+</sup>) C<sub>17</sub>H<sub>23</sub>N<sub>3</sub>O<sub>4</sub>.</div></div><div id="sec5_1_63" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> Allyl-[2-(2-chloroethoxy)-5-nitrobenzyl]methylamine (<b>18p</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>16i</b> and <i>N</i>-allylmethylamine (99%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 285 ([M + H]<sup>+</sup>) C<sub>13</sub>H<sub>17</sub>ClN<sub>2</sub>O<sub>3</sub>.</div></div><div id="sec5_1_64" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> Allyl-[2-(2-chloroethoxy)-3-methoxy-5-nitrobenzyl]methylamine (<b>18q</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>16u</b> and <i>N</i>-allylmethylamine (84%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 315 ([M + H]<sup>+</sup>) C<sub>14</sub>H<sub>19</sub>ClN<sub>2</sub>O<sub>4</sub>.</div></div><div id="sec5_1_65" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> <i>N</i>-{3-[(Allylmethylamino)methyl]-5-nitrophenyl}-2,2,2-trifluoroacetamide (<b>18r</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>16x</b> and <i>N</i>-allylmethylamine (96%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 318 ([M + H]<sup>+</sup>) C<sub>13</sub>H<sub>14</sub>F<sub>3</sub>N<sub>3</sub>O<sub>3</sub>.</div></div><div id="sec5_1_66" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> Allylcyclopropyl-(3-nitrobenzyl)amine (<b>19a</b>)</h3><div class="NLM_p">To a stirring solution of <b>17a</b> (0.18 g, 0.938 mmol) and K<sub>2</sub>CO<sub>3</sub> (0.39 g, 2.81 mmol) in DMF (2 mL) was added allyl bromide (0.2 mL, 2.25 mmol) dropwise, and the resulting mixture was stirred at 70 °C for 3 h. The reaction mixture was then brought to room temperature, quenched with water (15 mL), and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 20 mL). The combined organic extracts were washed with water, brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated under reduced pressure to afford the crude <b>19a</b> (0.12 g, 86%) as a yellow syrup. This intermediate was taken forward to the next step without any purification. LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 233 ([M + H]<sup>+</sup>) C<sub>13</sub>H<sub>16</sub>N<sub>2</sub>O<sub>2</sub>.</div><div class="NLM_p last">Following a procedure similar to that of <b>19a</b>, the following intermediates were synthesized.</div></div><div id="sec5_1_67" class="NLM_sec NLM_sec_level_2"><div id="ac_i90" class="anchor-spacer"></div><h3 class="article-section__title" id="_i90"> Allylisobutyl-(3-nitrobenzyl)amine (<b>19b</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>17b</b> and allyl bromide (83%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 249 ([M + H]<sup>+</sup>) C<sub>14</sub>H<sub>20</sub>N<sub>2</sub>O<sub>2</sub>.</div></div><div id="sec5_1_68" class="NLM_sec NLM_sec_level_2"><div id="ac_i91" class="anchor-spacer"></div><h3 class="article-section__title" id="_i91"> Allylcyclopropylmethyl-(3-nitrobenzyl)amine (<b>19c</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>17c</b> and allyl bromide (80%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 245 ([M + H]<sup>+</sup>) C<sub>14</sub>H<sub>18</sub>N<sub>2</sub>O<sub>2</sub>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.23 (s, 1H), 8.08 (dd, 1H), 7.72 (d, 1H), 7.47 (t, 1H), 5.94–5.84 (m, 1H), 5.22–5.15 (m, 2H), 3.76 (s, 2H), 3.22 (d, 2H), 2.37 (d, 2H), 0.88–0.85 (m, 1H), 0.51–0.47 (m, 2H), 0.09–0.06 (m, 2H).</div></div><div id="sec5_1_69" class="NLM_sec NLM_sec_level_2"><div id="ac_i92" class="anchor-spacer"></div><h3 class="article-section__title" id="_i92"> Allyl-(2,2-dimethylpropyl)-(3-nitrobenzyl)amine (<b>19d</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>17d</b> and allyl bromide (91%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 263 ([M + H]<sup>+</sup>) C<sub>15</sub>H<sub>22</sub>N<sub>2</sub>O<sub>2</sub>.</div></div><div id="sec5_1_70" class="NLM_sec NLM_sec_level_2"><div id="ac_i93" class="anchor-spacer"></div><h3 class="article-section__title" id="_i93"> Allyl-(3-nitrobenzyl)pyridin-2-ylmethylamine (<b>19e</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>17e</b> and allyl bromide (48%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 284 ([M + H]<sup>+</sup>) C<sub>16</sub>H<sub>17</sub>N<sub>3</sub>O<sub>2</sub>.</div></div><div id="sec5_1_71" class="NLM_sec NLM_sec_level_2"><div id="ac_i94" class="anchor-spacer"></div><h3 class="article-section__title" id="_i94"> Allyl-(2-methoxyethyl)-(3-nitrobenzyl)amine (<b>19f</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>17f</b> and allyl bromide (77%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 251 ([M + H]<sup>+</sup>) C<sub>13</sub>H<sub>18</sub>N<sub>2</sub>O<sub>3</sub>.</div></div><div id="sec5_1_72" class="NLM_sec NLM_sec_level_2"><div id="ac_i95" class="anchor-spacer"></div><h3 class="article-section__title" id="_i95"> 2-[Allyl-(3-nitrobenzyl)amino]ethanol (<b>19g</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>17g</b> and allyl bromide (72%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 237 ([M + H]<sup>+</sup>) C<sub>12</sub>H<sub>16</sub>N<sub>2</sub>O<sub>3</sub>.</div></div><div id="sec5_1_73" class="NLM_sec NLM_sec_level_2"><div id="ac_i96" class="anchor-spacer"></div><h3 class="article-section__title" id="_i96"> Allyl-[2-(2-chloroethoxy)-5-nitrobenzyl]-(2,2,2-trifluoroethyl)amine (<b>19h</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>17h</b> and allyl bromide (57%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 353 ([M + H]<sup>+</sup>) C<sub>14</sub>H<sub>16</sub>ClF<sub>3</sub>N<sub>2</sub>O<sub>3</sub>.</div></div><div id="sec5_1_74" class="NLM_sec NLM_sec_level_2"><div id="ac_i97" class="anchor-spacer"></div><h3 class="article-section__title" id="_i97"> {Allyl-[2-(2-chloroethoxy)-5-nitrobenzyl]amino}acetonitrile (<b>19i</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>17i</b> and allyl bromide (64%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 310 ([M + H]<sup>+</sup>) C<sub>14</sub>H<sub>16</sub>ClN<sub>3</sub>O<sub>3</sub>.</div></div><div id="sec5_1_75" class="NLM_sec NLM_sec_level_2"><div id="ac_i98" class="anchor-spacer"></div><h3 class="article-section__title" id="_i98"> Allyl-[2-(2-diethylaminoethoxy)-5-nitrobenzyl]methylamine (<b>19j</b>)</h3><div class="NLM_p">To a solution of <b>18p</b> (2 g, 7.02 mmol) in <i>N</i>,<i>N</i>-dimethylacetamide (10 mL) was added dimethylamine (4 mL, 2 vol), and the resulting mixture was stirred at 90 °C for 20 h. The reaction mixture was brought to room temperature and quenched with water (20 mL) and extracted in ethyl acetate (3 × 20 mL). The combined organic extracts were washed with water, brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated under reduced pressure to afford the crude <b>19j</b> (1.85 g, 82%) as a thick syrup. This intermediate was taken forward to the next step without any purification. LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 322 ([M + H]<sup>+</sup>) C<sub>17</sub>H<sub>27</sub>N<sub>3</sub>O<sub>3</sub>.</div><div class="NLM_p last">Following a procedure similar to that of <b>19j</b>, the following intermediates were synthesized.</div></div><div id="sec5_1_76" class="NLM_sec NLM_sec_level_2"><div id="ac_i99" class="anchor-spacer"></div><h3 class="article-section__title" id="_i99"> Allylmethyl-[5-nitro-2-(2-pyrrolidin-1-ylethoxy)benzyl]amine (<b>19k</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>18p</b> and pyrrolidine (75%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 320 ([M + H]<sup>+</sup>) C<sub>17</sub>H<sub>25</sub>N<sub>3</sub>O<sub>3</sub>.</div></div><div id="sec5_1_77" class="NLM_sec NLM_sec_level_2"><div id="ac_i100" class="anchor-spacer"></div><h3 class="article-section__title" id="_i100"> Allyl-[5-nitro-2-(2-pyrrolidin-1-ylethoxy)benzyl]-(2,2,2-trifluoroethyl)amine (<b>19l</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>19h</b> and pyrrolidine (79%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 388 ([M + H]<sup>+</sup>) C<sub>18</sub>H<sub>24</sub>F<sub>3</sub>N<sub>3</sub>O<sub>3</sub>.</div></div><div id="sec5_1_78" class="NLM_sec NLM_sec_level_2"><div id="ac_i101" class="anchor-spacer"></div><h3 class="article-section__title" id="_i101"> {Allyl-[5-nitro-2-(2-pyrrolidin-1-ylethoxy)benzyl]amino}acetonitrile (<b>19m</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>19i</b> and pyrrolidine (90%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 345 ([M + H]<sup>+</sup>) C<sub>18</sub>H<sub>24</sub>N<sub>4</sub>O<sub>3</sub>.</div></div><div id="sec5_1_79" class="NLM_sec NLM_sec_level_2"><div id="ac_i102" class="anchor-spacer"></div><h3 class="article-section__title" id="_i102"> Allylmethyl-[2-(2-morpholin-4-ylethoxy)-5-nitrobenzyl]amine (<b>19n</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>18p</b> and morpholine (84%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 336 ([M + H]<sup>+</sup>) C<sub>17</sub>H<sub>25</sub>N<sub>3</sub>O<sub>4</sub>.</div></div><div id="sec5_1_80" class="NLM_sec NLM_sec_level_2"><div id="ac_i103" class="anchor-spacer"></div><h3 class="article-section__title" id="_i103"> Allylmethyl-{2-[2-(4-methylpiperazin-1-yl)ethoxy]-5-nitrobenzyl}amine (<b>19o</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>18p</b> and <i>N</i>-methylpiperazine (88%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 349 ([M + H]<sup>+</sup>) C<sub>18</sub>H<sub>28</sub>N<sub>4</sub>O<sub>3</sub>.</div></div><div id="sec5_1_81" class="NLM_sec NLM_sec_level_2"><div id="ac_i104" class="anchor-spacer"></div><h3 class="article-section__title" id="_i104"> Allylmethyl-[5-nitro-2-(2-piperidin-1-ylethoxy)benzyl]amine (<b>19p</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>18p</b> and piperidine (78%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 334 ([M + H]<sup>+</sup>) C<sub>18</sub>H<sub>27</sub>N<sub>3</sub>O<sub>3</sub>.</div></div><div id="sec5_1_82" class="NLM_sec NLM_sec_level_2"><div id="ac_i105" class="anchor-spacer"></div><h3 class="article-section__title" id="_i105"> Allyl-[3-methoxy-5-nitro-2-(2-pyrrolidin-1-ylethoxy)benzyl]methylamine (<b>19q</b>)</h3><div class="NLM_p">The title compound was synthesized from <b>18q</b> and pyrrolidine (78%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 350 ([M + H]<sup>+</sup>) C<sub>18</sub>H<sub>27</sub>N<sub>3</sub>O<sub>4</sub>.</div><div class="NLM_p last">Following a procedure similar to that of <b>12d</b>, the following intermediates were synthesized.</div></div><div id="sec5_1_83" class="NLM_sec NLM_sec_level_2"><div id="ac_i106" class="anchor-spacer"></div><h3 class="article-section__title" id="_i106"> Pent-4-enoic Acid (3-Aminophenyl)amide (<b>21a</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>18a</b> (96%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 191 ([M + H]<sup>+</sup>) C<sub>11</sub>H<sub>14</sub>N<sub>2</sub>O.</div></div><div id="sec5_1_84" class="NLM_sec NLM_sec_level_2"><div id="ac_i107" class="anchor-spacer"></div><h3 class="article-section__title" id="_i107"> 3-[(Allylmethylamino)methyl]phenylamine (<b>21b</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>18b</b> (98%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 177 ([M + H]<sup>+</sup>) C<sub>11</sub>H<sub>16</sub>N<sub>2</sub>. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.09 (t, 1H), 6.57–6.69 (m, 2H), 6.55 (dd, 1H), 5.85–5.95 (m, 1H), 5.12–5.17 (m, 2H), 3.67 (br, 1H), 3.39 (s, 2H), 3.02 (d, 2H), 2.18 (s, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 146.4, 140.3, 136.0, 129.1, 119.4, 117.4, 115.7, 113.8, 61.7, 60.6, 42.2. Anal. Calcd for C<sub>11</sub>H<sub>16</sub>N<sub>2</sub>: C, 74.96; H, 9.15; N, 15.89. Found: C, 74.34; H, 9.04; N, 15.68. IR (KBr pellet): 3346, 3210, 2782, 1605, 1460, 1294, 921, 785, 696 cm<sup>–1</sup>.</div></div><div id="sec5_1_85" class="NLM_sec NLM_sec_level_2"><div id="ac_i108" class="anchor-spacer"></div><h3 class="article-section__title" id="_i108"> Allyl-(3-aminophenyl)carbamic Acid <i>tert</i>-Butyl Ester (<b>21c</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>18f</b> (56%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 249 ([M + H]<sup>+</sup>) C<sub>14</sub>H<sub>20</sub>N<sub>2</sub>O<sub>2</sub>.</div></div><div id="sec5_1_86" class="NLM_sec NLM_sec_level_2"><div id="ac_i109" class="anchor-spacer"></div><h3 class="article-section__title" id="_i109"> <i>N</i>-Allyl-<i>N</i>-(3-aminobenzyl)-2,2,2-trifluoroacetamide (<b>21d</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>18d</b> (78%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 259 ([M + H]<sup>+</sup>) C<sub>12</sub>H<sub>13</sub>F<sub>3</sub>N<sub>2</sub>O.</div></div><div id="sec5_1_87" class="NLM_sec NLM_sec_level_2"><div id="ac_i110" class="anchor-spacer"></div><h3 class="article-section__title" id="_i110"> 3-[(Allylmethylamino)methyl]-4-methoxyphenylamine (<b>21f</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>18h</b> (63%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 207 ([M + H]<sup>+</sup>) C<sub>12</sub>H<sub>18</sub>N<sub>2</sub>O.</div></div><div id="sec5_1_88" class="NLM_sec NLM_sec_level_2"><div id="ac_i111" class="anchor-spacer"></div><h3 class="article-section__title" id="_i111"> 3-[(Allylmethylamino)methyl]-4-chlorophenylamine (<b>21g</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>18i</b> (95%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 211 ([M + H]<sup>+</sup>) C<sub>11</sub>H<sub>15</sub>ClN<sub>2</sub>.</div></div><div id="sec5_1_89" class="NLM_sec NLM_sec_level_2"><div id="ac_i112" class="anchor-spacer"></div><h3 class="article-section__title" id="_i112"> 3-[(Allylmethylamino)methyl]-4-trifluoromethoxyphenylamine (<b>21h</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>18j</b> (77%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 261 ([M + H]<sup>+</sup>) C<sub>12</sub>H<sub>15</sub>F<sub>3</sub>N<sub>2</sub>O.</div></div><div id="sec5_1_90" class="NLM_sec NLM_sec_level_2"><div id="ac_i113" class="anchor-spacer"></div><h3 class="article-section__title" id="_i113"> 3-[(Allylcyclopropylamino)methyl]phenylamine (<b>21i</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>19a</b> (88%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 203 ([M + H]<sup>+</sup>) C<sub>13</sub>H<sub>18</sub>N<sub>2</sub>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.09 (t, 1H), 6.69 (m, 1H), 6.59 (dd, 1H), 6.04–5.87 (m, 1H), 5.22–5.13 (m, 2H), 3.73 (s, 2H), 3.25 (d, 2H), 1.90 (br s, 1H), 0.59–0.40 (m, 4H).</div></div><div id="sec5_1_91" class="NLM_sec NLM_sec_level_2"><div id="ac_i114" class="anchor-spacer"></div><h3 class="article-section__title" id="_i114"> 3-[(Allylisobutylamino)methyl]phenylamine (<b>21j</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>19b</b> (65%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 219 ([M + H]<sup>+</sup>) C<sub>14</sub>H<sub>22</sub>N<sub>2</sub>.</div></div><div id="sec5_1_92" class="NLM_sec NLM_sec_level_2"><div id="ac_i115" class="anchor-spacer"></div><h3 class="article-section__title" id="_i115"> 3-[(Allylcyclopropylmethylamino)methyl]phenylamine (<b>21k</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>19c</b> (90%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 217 ([M + H]<sup>+</sup>) C<sub>14</sub>H<sub>20</sub>N<sub>2</sub>.</div></div><div id="sec5_1_93" class="NLM_sec NLM_sec_level_2"><div id="ac_i116" class="anchor-spacer"></div><h3 class="article-section__title" id="_i116"> 3-{[Allyl-(2,2-dimethylpropyl)amino]methyl}phenylamine (<b>21l</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>19d</b> (61%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 233 ([M + H]<sup>+</sup>) C<sub>15</sub>H<sub>24</sub>N<sub>2</sub>.</div></div><div id="sec5_1_94" class="NLM_sec NLM_sec_level_2"><div id="ac_i117" class="anchor-spacer"></div><h3 class="article-section__title" id="_i117"> 3-[(Allylpyridin-2-ylmethylamino)methyl]phenylamine (<b>21m</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>19e</b> (97%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 254 ([M + H]<sup>+</sup>) C<sub>16</sub>H<sub>19</sub>N<sub>3</sub>.</div></div><div id="sec5_1_95" class="NLM_sec NLM_sec_level_2"><div id="ac_i118" class="anchor-spacer"></div><h3 class="article-section__title" id="_i118"> 3-{[Allyl-(2-methoxyethyl)amino]methyl}phenylamine (<b>21n</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>19f</b> (64%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 221 ([M + H]<sup>+</sup>) C<sub>13</sub>H<sub>20</sub>N<sub>2</sub>O.</div></div><div id="sec5_1_96" class="NLM_sec NLM_sec_level_2"><div id="ac_i119" class="anchor-spacer"></div><h3 class="article-section__title" id="_i119"> 2-[Allyl-(3-aminobenzyl)amino]ethanol (<b>21o</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>19g</b> (76%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 207 ([M + H]<sup>+</sup>) C<sub>12</sub>H<sub>18</sub>N<sub>2</sub>O.</div></div><div id="sec5_1_97" class="NLM_sec NLM_sec_level_2"><div id="ac_i120" class="anchor-spacer"></div><h3 class="article-section__title" id="_i120"> 3-[(Allylmethylamino)methyl]-4-(2-ethylsulfanylethoxy)phenylamine (<b>22e</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>18n</b> (91%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 281 ([M + H]<sup>+</sup>) C<sub>15</sub>H<sub>24</sub>N<sub>2</sub>OS; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.77 (d, 1H), 6.69 (d, 1H), 6.54 (dd, 1H), 5.98–5.88 (m, 1H), 5.24–5.12 (m, 2H), 4.05 (t, 2H), 3.48 (s, 2H), 3.07 (d, 2H), 2.87 (t, 2H), 2.62 (q, 2H), 2.22 (s, 3H), 1.25 (t, 3H).</div></div><div id="sec5_1_98" class="NLM_sec NLM_sec_level_2"><div id="ac_i121" class="anchor-spacer"></div><h3 class="article-section__title" id="_i121"> 3-[(Allylmethylamino)methyl]-4-(2-methoxyethoxy)phenylamine (<b>22f</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>18k</b> (64%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 251 ([M + H]<sup>+</sup>) C<sub>14</sub>H<sub>22</sub>N<sub>2</sub>O<sub>2</sub>.</div></div><div id="sec5_1_99" class="NLM_sec NLM_sec_level_2"><div id="ac_i122" class="anchor-spacer"></div><h3 class="article-section__title" id="_i122"> 3-[(Allylmethylamino)methyl]-4-(2-diethylaminoethoxy)phenylamine (<b>22h</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>19j</b> (59%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 292 ([M + H]<sup>+</sup>) C<sub>17</sub>H<sub>29</sub>N<sub>3</sub>O.</div></div><div id="sec5_1_100" class="NLM_sec NLM_sec_level_2"><div id="ac_i123" class="anchor-spacer"></div><h3 class="article-section__title" id="_i123"> 3-[(Allylmethylamino)methyl]-4-(2-pyrrolidin-1-ylethoxy)phenylamine (<b>22i</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>19k</b> (88%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 290 ([M + H]<sup>+</sup>) C<sub>17</sub>H<sub>27</sub>N<sub>3</sub>O.</div></div><div id="sec5_1_101" class="NLM_sec NLM_sec_level_2"><div id="ac_i124" class="anchor-spacer"></div><h3 class="article-section__title" id="_i124"> 3-[(Allylmethylamino)methyl]-4-(2-morpholin-4-ylethoxy)phenylamine (<b>22j</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>19i</b> (54%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 306 ([M + H]<sup>+</sup>) C<sub>17</sub>H<sub>27</sub>N<sub>3</sub>O<sub>2</sub>.</div></div><div id="sec5_1_102" class="NLM_sec NLM_sec_level_2"><div id="ac_i125" class="anchor-spacer"></div><h3 class="article-section__title" id="_i125"> 3-[(Allylmethylamino)methyl]-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenylamine (<b>22k</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>19i</b> (77%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 319 ([M + H]<sup>+</sup>) C<sub>18</sub>H<sub>30</sub>N<sub>4</sub>O.</div></div><div id="sec5_1_103" class="NLM_sec NLM_sec_level_2"><div id="ac_i126" class="anchor-spacer"></div><h3 class="article-section__title" id="_i126"> 3-[(Allylmethylamino)methyl]-4-(2-piperidin-1-ylethoxy)phenylamine (<b>22l</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>19p</b> (85%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 304 ([M + H]<sup>+</sup>) C<sub>18</sub>H<sub>29</sub>N<sub>3</sub>O.</div></div><div id="sec5_1_104" class="NLM_sec NLM_sec_level_2"><div id="ac_i127" class="anchor-spacer"></div><h3 class="article-section__title" id="_i127"> 3-[(Allylmethylamino)methyl]-5-methoxy-4-(2-pyrrolidin-1-ylethoxy)phenylamine (<b>22m</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>19q</b> (63%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 288 ([M + H]<sup>+</sup>) C<sub>18</sub>H<sub>29</sub>N<sub>3</sub>O<sub>2</sub>.</div></div><div id="sec5_1_105" class="NLM_sec NLM_sec_level_2"><div id="ac_i128" class="anchor-spacer"></div><h3 class="article-section__title" id="_i128"> <i>N</i>-{3-[(Allylmethylamino)methyl]-5-aminophenyl}-2,2,2-trifluoroacetamide (<b>22n</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>18r</b> (52%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 320 ([M + H]<sup>+</sup>) C<sub>13</sub>H<sub>16</sub>F<sub>3</sub>N<sub>3</sub>O; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.73 (br s, 1H), 7.10 (t, 1H), 6.67 (s, 1H), 6.53 (s, 1H), 5.93–5.86 (m, 1H), 5.30–5.15 (m, 2H), 3.86 (br s, 2H), 3.38 (s, 2H), 3.03 (d, 2H), 2.18 (s, 3H).</div></div><div id="sec5_1_106" class="NLM_sec NLM_sec_level_2"><div id="ac_i129" class="anchor-spacer"></div><h3 class="article-section__title" id="_i129"> 3-[(Allylmethylamino)methyl]-4-morpholin-4-ylphenylamine (<b>22c</b>)</h3><div class="NLM_p">Compound <b>18m</b> (2.0 g, 6.86 mmol) was taken in EtOH (20 mL, 10 vol), and fine Fe powder (1.15 g, 20.6 mmol) was added at 50–55 °C followed by NH<sub>4</sub>Cl solution (1.76 g, 32 mmol in 2 mL of water). The reaction mixture was refluxed for 4 h, and EtOH was removed from the reaction mixture under reduced pressure. The residue was basified with NaHCO<sub>3</sub> solution (pH 7–8) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 25 mL). The combined organic extracts were washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated under reduced pressure to furnish <b>22c</b> (1.67 g, 93%) as a brown oil. This material was taken up for the next step without any purification. LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 262 ([M + H]<sup>+</sup>) C<sub>15</sub>H<sub>23</sub>N<sub>3</sub>O.</div><div class="NLM_p last">Following a procedure similar to that of <b>22c</b>, the following intermediates were synthesized.</div></div><div id="sec5_1_107" class="NLM_sec NLM_sec_level_2"><div id="ac_i130" class="anchor-spacer"></div><h3 class="article-section__title" id="_i130"> 3-Allyloxymethylphenylamine (<b>21e</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>18g</b> (91%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 164 ([M + H]<sup>+</sup>) C<sub>10</sub>H<sub>13</sub>NO.</div></div><div id="sec5_1_108" class="NLM_sec NLM_sec_level_2"><div id="ac_i131" class="anchor-spacer"></div><h3 class="article-section__title" id="_i131"> 3-{[Allyl-(2,2,2-trifluoroethyl)amino]methyl}-4-(2-pyrrolidin-1-ylethoxy)phenylamine (<b>22a</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>19h</b> (87%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 358 ([M + H]<sup>+</sup>) C<sub>18</sub>H<sub>26</sub>F<sub>3</sub>N<sub>3</sub>O.</div></div><div id="sec5_1_109" class="NLM_sec NLM_sec_level_2"><div id="ac_i132" class="anchor-spacer"></div><h3 class="article-section__title" id="_i132"> {Allyl-[5-amino-2-(2-pyrrolidin-1-ylethoxy)benzyl]amino}acetonitrile (<b>22b</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>19i</b> (92%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 315 ([M + H]<sup>+</sup>) C<sub>18</sub>H<sub>26</sub>N<sub>4</sub>O.</div></div><div id="sec5_1_110" class="NLM_sec NLM_sec_level_2"><div id="ac_i133" class="anchor-spacer"></div><h3 class="article-section__title" id="_i133"> 3-[(Allylmethylamino)methyl]-4-ethanesulfonylphenylamine (<b>22d</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>18l</b> (81%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 267 ([M + H]<sup>+</sup>) C<sub>13</sub>H<sub>20</sub>N<sub>2</sub>O<sub>2</sub>S.</div></div><div id="sec5_1_111" class="NLM_sec NLM_sec_level_2"><div id="ac_i134" class="anchor-spacer"></div><h3 class="article-section__title" id="_i134"> 2-{2-[(Allylmethylamino)methyl]-4-aminophenoxy}-1-pyrrolidin-1-ylethanone (<b>22g</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>18o</b> (86%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 262 ([M + H]<sup>+</sup>) C<sub>17</sub>H<sub>25</sub>N<sub>3</sub>O<sub>2</sub>.</div></div><div id="sec5_1_112" class="NLM_sec NLM_sec_level_2"><div id="ac_i135" class="anchor-spacer"></div><h3 class="article-section__title" id="_i135"> {3-[(Alkylmethylamino)methyl]phenyl}-[4-(3-allyloxyphenyl)pyrimidine-2-yl]amine (<b>23f</b>)</h3><div class="NLM_p">To a solution of <b>15a</b> (4.22 g, 24 mmol) and <b>18b</b> (5.2 g, 20 mmol) in <i>n</i>-butanol (70 mL) was added concentrated HCl (3 mL), and the resulting mixture was heated to 90–100 °C for 12 h. The reaction mixture was brought to room temperature, and the solvent was removed under reduced pressure. The residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (50 mL). Saturated NaHCO<sub>3</sub> was added, and pH was adjusted to 7–8. The organic layer was separated, and the aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 50 mL). The combined organic extracts were dried (Na<sub>2</sub>SO<sub>4</sub>), concentrated under reduced pressure, and purified by column chromatography (1:3 EtOAc/hexane) to furnish <b>23f</b> as a white solid (7.4 g, 92%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 401 ([M + H]<sup>+</sup>); <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.46 (d, 1H), 7.69–7.60 (m, 4H), 7.49 (s, 1H), 7.37 (t, 1H), 7.29 (t, 1H), 7.13 (d, 1H), 7.04–6.99 (m, 2H), 5.95–5.87 (m, 2H), 5.22–5.13 (m, 4H), 4.10 (t, 2H), 3.51 (s, 2H), 3.05 (d, 2H), 2.57 (m, 2H), 2.22 (s, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 164.7, 160.3, 159.4, 158.6, 140.0, 139.7, 138.6, 136.0, 134.4, 129.8, 128.7, 123.2, 119.9, 119.6, 118.0, 117.5, 117.3, 117.2,113.1, 108.4, 67.4, 61.8, 60.6, 42.2, 33.7. Anal. Calcd for C<sub>25</sub>H<sub>28</sub>N<sub>4</sub>O: C, 74.97; H, 7.05; N, 13.99. Found: C, 74.80; H, 7.15; N, 13.86. IR (KBr pellet): 3271, 3070, 2776, 1572, 1433, 1295, 913, 780, 627 cm<sup>–1</sup>.</div><div class="NLM_p last">Following a procedure similar to that of <b>23f</b>, the following intermediates were synthesized.</div></div><div id="sec5_1_113" class="NLM_sec NLM_sec_level_2"><div id="ac_i136" class="anchor-spacer"></div><h3 class="article-section__title" id="_i136"> Pent-4-enoic Acid {3-[4-(3-Allyloxyphenyl)pyrimidin-2-ylamino]phenyl}amide (<b>23a</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>13a</b> and <b>21a</b> (76%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 401 ([M + H]<sup>+</sup>) C<sub>24</sub>H<sub>24</sub>N<sub>4</sub>O<sub>2</sub>.</div></div><div id="sec5_1_114" class="NLM_sec NLM_sec_level_2"><div id="ac_i137" class="anchor-spacer"></div><h3 class="article-section__title" id="_i137"> But-3-enoic Acid [3-(2-{3-[(Allylmethylamino)methyl]phenylamino}pyrimidin-4-yl)phenyl]amide (<b>23b</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>14a</b> and <b>21b</b> (83%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 414 ([M + H]<sup>+</sup>) C<sub>25</sub>H<sub>27</sub>N<sub>5</sub>O.</div></div><div id="sec5_1_115" class="NLM_sec NLM_sec_level_2"><div id="ac_i138" class="anchor-spacer"></div><h3 class="article-section__title" id="_i138"> <i>N</i>-Allyl-3-(2-{3-[(allylmethylamino)methyl]phenylamino}pyrimidin-4-yl)benzamide (<b>23c</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>14b</b> and <b>21b</b> (91%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 414 ([M + H]<sup>+</sup>) C<sub>25</sub>H<sub>27</sub>N<sub>5</sub>O.</div></div><div id="sec5_1_116" class="NLM_sec NLM_sec_level_2"><div id="ac_i139" class="anchor-spacer"></div><h3 class="article-section__title" id="_i139"> Allyl-{3-[4-(3-but-3-enyloxyphenyl)pyrimidin-2-ylamino]phenyl}carbamic Acid <i>tert</i>-Butyl Ester (<b>23d</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>15a</b> and <b>21c</b> (59%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 473 ([M + H]<sup>+</sup>) C<sub>28</sub>H<sub>32</sub>N<sub>4</sub>O<sub>3</sub>.</div></div><div id="sec5_1_117" class="NLM_sec NLM_sec_level_2"><div id="ac_i140" class="anchor-spacer"></div><h3 class="article-section__title" id="_i140"> <i>N</i>-Allyl-<i>N</i>-{3-[4-(3-but-3-enyloxyphenyl)pyrimidin-2-ylamino]benzyl}-2,2,2-trifluoroacetamide (<b>23e</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>15a</b> and <b>21d</b> (87%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 483 ([M + H]<sup>+</sup>) C<sub>26</sub>H<sub>25</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.41 (t, 1H), 7.71–7.59 (m, 4H), 7.44 (m, 1H), 7.36 (m, 1H), 7.22 (m, 1H), 7.11 (m, 1H), 6.98 (dd, 1H), 5.96–5.89 (m, 1H), 5.78–5.73 (m, 1H), 5.33–5.07 (m, 4H), 4.66 (s, 2H), 4.13 (t, 2H), 3.94 (br, 2H), 2.59 (q, 2H).</div></div><div id="sec5_1_118" class="NLM_sec NLM_sec_level_2"><div id="ac_i141" class="anchor-spacer"></div><h3 class="article-section__title" id="_i141"> {3-[(Allylmethylamino)methyl]phenyl}-[4-(3-allyloxymethylphenyl)pyrimidin-2-yl]amine (<b>23g</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>13b</b> and <b>21b</b> (87%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 401 ([M + H]<sup>+</sup>) C<sub>25</sub>H<sub>28</sub>N<sub>4</sub>O.</div></div><div id="sec5_1_119" class="NLM_sec NLM_sec_level_2"><div id="ac_i142" class="anchor-spacer"></div><h3 class="article-section__title" id="_i142"> (4-{3-[(Allylmethylamino)methyl]phenyl}pyrimidin-2-yl)-(3-allyloxymethylphenyl)amine (<b>23h</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>14c</b> and <b>21e</b> (71%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 401 ([M + H]<sup>+</sup>) C<sub>25</sub>H<sub>28</sub>N<sub>4</sub>O.</div></div><div id="sec5_1_120" class="NLM_sec NLM_sec_level_2"><div id="ac_i143" class="anchor-spacer"></div><h3 class="article-section__title" id="_i143"> {3-[(Allylcyclopropylamino)methyl]phenyl}-[4-(3-but-3-enyloxyphenyl)pyrimidin-2-yl]amine (<b>18a</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>15a</b> and <b>21i</b> (57%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 427 ([M + H]<sup>+</sup>) C<sub>27</sub>H<sub>30</sub>N<sub>4</sub>O; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 11.73 (br, 1H), 8.29 (d, 1H), 8.02 (d, 1H), 7.80 (s, 1H), 7.64 (m, 2H), 7.58–7.46 (m, 2H), 7.38 (m, 1H), 7.32 (d, 1H), 7.18 (d, 1H), 6.20–6.10 (m, 1H), 5.97–5.83 (m, 1H), 5.57–5.53 (m, 2H), 5.29–5.13 (m, 2H), 4.33 (s, 2H), 4.10 (t, 2H), 2.62–2.57 (m, 2H), 2.34–2.29 (m, 1H), 0.83 (m, 4H).</div></div><div id="sec5_1_121" class="NLM_sec NLM_sec_level_2"><div id="ac_i144" class="anchor-spacer"></div><h3 class="article-section__title" id="_i144"> {3-[(Allylisobutylamino)methyl]phenyl}-[4-(3-but-3-enyloxyphenyl)pyrimidin-2-yl]amine (<b>24b</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>15a</b> and <b>21j</b> (64%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 443 ([M + H]<sup>+</sup>) C<sub>28</sub>H<sub>34</sub>N<sub>4</sub>O.</div></div><div id="sec5_1_122" class="NLM_sec NLM_sec_level_2"><div id="ac_i145" class="anchor-spacer"></div><h3 class="article-section__title" id="_i145"> {3-[(Allylcyclopropylmethylamino)methyl]phenyl}-[4-(3-but-3-enyloxyphenyl)pyrimidin-2-yl]amine (<b>24c</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>15a</b> and <b>21k</b> (56%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 441 ([M + H]<sup>+</sup>) C<sub>28</sub>H<sub>32</sub>N<sub>4</sub>O.</div></div><div id="sec5_1_123" class="NLM_sec NLM_sec_level_2"><div id="ac_i146" class="anchor-spacer"></div><h3 class="article-section__title" id="_i146"> (3-{[Allyl-(2,2-dimethylpropyl)amino]methyl}phenyl)-[4-(3-but-3-enyloxyphenyl)pyrimidin-2-yl]amine (<b>24d</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>15a</b> and <b>21l</b> (96%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 457 ([M + H]<sup>+</sup>) C<sub>29</sub>H<sub>36</sub>N<sub>4</sub>O.</div></div><div id="sec5_1_124" class="NLM_sec NLM_sec_level_2"><div id="ac_i147" class="anchor-spacer"></div><h3 class="article-section__title" id="_i147"> {3-[(Allylpyridin-2-ylmethylamino)methyl]phenyl}-[4-(3-but-3-enyloxyphenyl)pyrimidin-2-yl]amine (<b>24e</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>15a</b> and <b>21m</b> (49%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 478 ([M + H]<sup>+</sup>) C<sub>30</sub>H<sub>31</sub>N<sub>5</sub>O.</div></div><div id="sec5_1_125" class="NLM_sec NLM_sec_level_2"><div id="ac_i148" class="anchor-spacer"></div><h3 class="article-section__title" id="_i148"> (3-{[Allyl-(2-methoxyethyl)amino]methyl}phenyl)-[4-(3-but-3-enyloxyphenyl)pyrimidin-2-yl]amine (<b>24f</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>15a</b> and <b>21n</b> (77%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 445 ([M + H]<sup>+</sup>) C<sub>27</sub>H<sub>32</sub>N<sub>4</sub>O<sub>2</sub>.</div></div><div id="sec5_1_126" class="NLM_sec NLM_sec_level_2"><div id="ac_i149" class="anchor-spacer"></div><h3 class="article-section__title" id="_i149"> 2-(Allyl-{3-[4-(3-but-3-enyloxyphenyl)pyrimidin-2-ylamino]benzyl}amino)ethanol (<b>24g</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>15a</b> and <b>21o</b> (85%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 431 ([M + H]<sup>+</sup>) C<sub>26</sub>H<sub>30</sub>N<sub>4</sub>O<sub>2</sub>.</div></div><div id="sec5_1_127" class="NLM_sec NLM_sec_level_2"><div id="ac_i150" class="anchor-spacer"></div><h3 class="article-section__title" id="_i150"> {3-[(Allylmethylamino)methyl]-4-methoxyphenyl}-[4-(3-but-3-enyloxyphenyl)pyrimidin-2-yl]amine (<b>25a</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>15a</b> and <b>21f</b> (76%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 431 ([M + H]<sup>+</sup>) C<sub>26</sub>H<sub>30</sub>N<sub>4</sub>O<sub>2</sub>.</div></div><div id="sec5_1_128" class="NLM_sec NLM_sec_level_2"><div id="ac_i151" class="anchor-spacer"></div><h3 class="article-section__title" id="_i151"> {3-[(Allylmethylamino)methyl]-4-chlorophenyl}-[4-(3-but-3-enyloxyphenyl)pyrimidin-2-yl]amine (<b>25b</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>15a</b> and <b>21g</b> (86%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 435 ([M + H]<sup>+</sup>) C<sub>25</sub>H<sub>27</sub>ClN<sub>4</sub>O.</div></div><div id="sec5_1_129" class="NLM_sec NLM_sec_level_2"><div id="ac_i152" class="anchor-spacer"></div><h3 class="article-section__title" id="_i152"> {3-[(Allylmethylamino)methyl]-4-trifluoromethoxyphenyl}-[4-(3-but-3-enyloxyphenyl)pyrimidin-2-yl]amine (<b>25c</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>15a</b> and <b>21h</b> (71%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 485 ([M + H]<sup>+</sup>) C<sub>26</sub>H<sub>27</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>.</div></div><div id="sec5_1_130" class="NLM_sec NLM_sec_level_2"><div id="ac_i153" class="anchor-spacer"></div><h3 class="article-section__title" id="_i153"> [3-[(Allylmethylamino)methyl]-4-(2-methoxyethoxy)phenyl]-[4-(3-but-3-enyloxyphenyl)pyrimidin-2-yl]amine (<b>25d</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>15a</b> and <b>22f</b> (73%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 475 ([M + H]<sup>+</sup>) C<sub>28</sub>H<sub>34</sub>N<sub>4</sub>O<sub>3</sub>.</div></div><div id="sec5_1_131" class="NLM_sec NLM_sec_level_2"><div id="ac_i154" class="anchor-spacer"></div><h3 class="article-section__title" id="_i154"> {3-[(Allylmethylamino)methyl]-4-ethanesulfonylphenyl}-[4-(3-but-3-enyloxyphenyl)pyrimidin-2-yl]amine (<b>25e</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>15a</b> and <b>22d</b> (88%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 492 ([M + H]<sup>+</sup>) C<sub>27</sub>H<sub>32</sub>N<sub>4</sub>O<sub>3</sub>S.</div></div><div id="sec5_1_132" class="NLM_sec NLM_sec_level_2"><div id="ac_i155" class="anchor-spacer"></div><h3 class="article-section__title" id="_i155"> [3-[(Allylmethylamino)methyl]-4-(2-ethylsulfanylethoxy)phenyl]-[4-(3-but-3-enyloxyphenyl)pyrimidin-2-yl]amine (<b>25f</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>15a</b> and <b>22e</b> (67%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 505 ([M + H]<sup>+</sup>) C<sub>29</sub>H<sub>36</sub>N<sub>4</sub>O<sub>2</sub>S; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.42 (d, 1H), 7.64–7.62 (m, 3H), 7.54 (d, 1H), 7.38 (t, 1H), 7.10–7.08 (m, 2H), 7.06–7.04 (m, 1H), 6.87 (d, 1H), 6.04–5.88 (m, 2H), 5.22–5.12 (m, 4H), 4.15 (t, 2H), 4.08 (t, 2H), 3.57 (s, 2H), 3.11 (d, 2H), 2.93 (t, 2H), 2.66 (t, 2H), 2.62–2.58 (m, 2H), 2.26 (s, 3H), 1.31 (t, 3H).</div></div><div id="sec5_1_133" class="NLM_sec NLM_sec_level_2"><div id="ac_i156" class="anchor-spacer"></div><h3 class="article-section__title" id="_i156"> 2-{2-[(Allylmethylamino)methyl]-4-[4-(3-but-3-enyloxyphenyl)pyrimidin-2-ylamino]phenoxy}-1-pyrrolidin-1-ylethanone (<b>25g</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>15a</b> and <b>2g</b> (82%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 528 ([M + H]<sup>+</sup>) C<sub>31</sub>H<sub>37</sub>N<sub>5</sub>O<sub>3</sub>.</div></div><div id="sec5_1_134" class="NLM_sec NLM_sec_level_2"><div id="ac_i157" class="anchor-spacer"></div><h3 class="article-section__title" id="_i157"> {3-[(Allylmethylamino)methyl]-4-morpholin-4-ylphenyl}-[4-(3-but-3-enyloxyphenyl)pyrimidin-2-yl]amine (<b>25h</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>15a</b> and <b>22c</b> (63%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 586 ([M + H]<sup>+</sup>) C<sub>29</sub>H<sub>35</sub>N<sub>5</sub>O<sub>2</sub>.</div></div><div id="sec5_1_135" class="NLM_sec NLM_sec_level_2"><div id="ac_i158" class="anchor-spacer"></div><h3 class="article-section__title" id="_i158"> [3-[(Allylmethylamino)methyl]-4-(2-diethylaminoethoxy)phenyl]-[4-(3-but-3-enyloxyphenyl)pyrimidin-2-yl]amine (<b>25i</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>15a</b> and <b>22h</b> (97%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 516 ([M + H]<sup>+</sup>) C<sub>31</sub>H<sub>41</sub>N<sub>5</sub>O<sub>2</sub>.</div></div><div id="sec5_1_136" class="NLM_sec NLM_sec_level_2"><div id="ac_i159" class="anchor-spacer"></div><h3 class="article-section__title" id="_i159"> [3-[(Allylmethylamino)methyl]-4-(2-pyrrolidin-1-ylethoxy)phenyl]-[4-(3-but-3-enyloxyphenyl)pyrimidin-2-yl]amine (<b>25j</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>15a</b> and <b>22i</b> (77%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 514 ([M + H]<sup>+</sup>) C<sub>31</sub>H<sub>39</sub>N<sub>5</sub>O<sub>2</sub>.</div></div><div id="sec5_1_137" class="NLM_sec NLM_sec_level_2"><div id="ac_i160" class="anchor-spacer"></div><h3 class="article-section__title" id="_i160"> [3-{[Allyl-(2,2,2-trifluoroethyl)amino]methyl}-4-(2-pyrrolidin-1-ylethoxy)phenyl]-[4-(3-but-3-enyloxyphenyl)pyrimidin-2-yl]amine (<b>25k</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>15a</b> and <b>22a</b> (67%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 582 ([M + H]<sup>+</sup>) C<sub>32</sub>H<sub>38</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub>.</div></div><div id="sec5_1_138" class="NLM_sec NLM_sec_level_2"><div id="ac_i161" class="anchor-spacer"></div><h3 class="article-section__title" id="_i161"> {Allyl-[5-[4-(3-but-3-enyloxyphenyl)pyrimidin-2-ylamino]-2-(2-pyrrolidin-1-ylethoxy)benzyl]amino}acetonitrile (<b>25l</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>15a</b> and <b>22b</b> (71%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 539 ([M + H]<sup>+</sup>) C<sub>32</sub>H<sub>38</sub>N<sub>6</sub>O<sub>2</sub>.</div></div><div id="sec5_1_139" class="NLM_sec NLM_sec_level_2"><div id="ac_i162" class="anchor-spacer"></div><h3 class="article-section__title" id="_i162"> [3-[(Allylmethylamino)methyl]-4-(2-morpholin-4-ylethoxy)phenyl]-[4-(3-but-3-enyloxyphenyl)pyrimidin-2-yl]amine (<b>25m</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>15a</b> and <b>22j</b> (88%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 530 ([M + H]<sup>+</sup>) C<sub>31</sub>H<sub>39</sub>N<sub>5</sub>O<sub>3</sub>.</div></div><div id="sec5_1_140" class="NLM_sec NLM_sec_level_2"><div id="ac_i163" class="anchor-spacer"></div><h3 class="article-section__title" id="_i163"> {3-[(Allylmethylamino)methyl]-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl}-[4-(3-but-3-enyloxyphenyl)pyrimidin-2-yl]amine (<b>25n</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>15a</b> and <b>22k</b> (90%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 543 ([M + H]<sup>+</sup>) C<sub>32</sub>H<sub>42</sub>N<sub>6</sub>O<sub>2</sub>.</div></div><div id="sec5_1_141" class="NLM_sec NLM_sec_level_2"><div id="ac_i164" class="anchor-spacer"></div><h3 class="article-section__title" id="_i164"> [3-[(Allylmethylamino)methyl]-4-(2-piperidin-1-ylethoxy)phenyl]-[4-(3-but-3-enyloxyphenyl)pyrimidin-2-yl]amine (<b>25o</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>15a</b> and <b>22l</b> (93%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 528 ([M + H]<sup>+</sup>) C<sub>32</sub>H<sub>41</sub>N<sub>5</sub>O<sub>2</sub>.</div></div><div id="sec5_1_142" class="NLM_sec NLM_sec_level_2"><div id="ac_i165" class="anchor-spacer"></div><h3 class="article-section__title" id="_i165"> [3-[(Allylmethylamino)methyl]-5-methoxy-4-(2-pyrrolidin-1-ylethoxy)phenyl]-[4-(3-but-3-enyloxyphenyl)pyrimidin-2-yl]amine (<b>25p</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>15a</b> and <b>22m</b> (68%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 544 ([M + H]<sup>+</sup>) C<sub>32</sub>H<sub>41</sub>N<sub>5</sub>O<sub>3</sub>.</div></div><div id="sec5_1_143" class="NLM_sec NLM_sec_level_2"><div id="ac_i166" class="anchor-spacer"></div><h3 class="article-section__title" id="_i166"> <i>N</i>-{3-[(Allylmethylamino)methyl]-5-[4-(3-but-3-enyloxyphenyl)pyrimidin-2-ylamino]phenyl}-2,2,2-trifluoroacetamide (<b>25q</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>15a</b> and <b>22n</b> (89%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 512 ([M + H]<sup>+</sup>) C<sub>27</sub>H<sub>28</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub>.</div></div><div id="sec5_1_144" class="NLM_sec NLM_sec_level_2"><div id="ac_i167" class="anchor-spacer"></div><h3 class="article-section__title" id="_i167"> {3-[(Allylmethylamino)methyl]phenyl}-[4-(3-but-3-enyloxyphenyl)-6-methylpyrimidin-2-yl]amine (<b>25r</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>15b</b> and <b>21b</b> (92%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 415 ([M + H]<sup>+</sup>) C<sub>26</sub>H<sub>30</sub>N<sub>4</sub>O.</div></div><div id="sec5_1_145" class="NLM_sec NLM_sec_level_2"><div id="ac_i168" class="anchor-spacer"></div><h3 class="article-section__title" id="_i168"> {3-[(Allylmethylamino)methyl]phenyl}-[4-(3-but-3-enyloxyphenyl)-6-pyrrolidin-1-ylpyrimidin-2-yl]amine (<b>25s</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>15c</b> and <b>21b</b> (90%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 470 ([M + H]<sup>+</sup>) C<sub>29</sub>H<sub>35</sub>N<sub>5</sub>O.</div></div><div id="sec5_1_146" class="NLM_sec NLM_sec_level_2"><div id="ac_i169" class="anchor-spacer"></div><h3 class="article-section__title" id="_i169"> {3-[(Allylmethylamino)methyl]phenyl}-[4-(3-but-3-enyloxyphenyl)-5-methylpyrimidin-2-yl]amine (<b>25t</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>15d</b> and <b>21b</b> (68%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 415 ([M + H]<sup>+</sup>) C<sub>26</sub>H<sub>30</sub>N<sub>4</sub>O.</div></div><div id="sec5_1_147" class="NLM_sec NLM_sec_level_2"><div id="ac_i170" class="anchor-spacer"></div><h3 class="article-section__title" id="_i170"> {3-[(Allylmethylamino)methyl]phenyl}-[4-(3-but-3-enyloxy-5-fluorophenyl)pyrimidin-2-yl]amine (<b>25u</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>15e</b> and <b>21b</b> (66%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 419 ([M + H]<sup>+</sup>) C<sub>25</sub>H<sub>27</sub>FN<sub>4</sub>O.</div></div><div id="sec5_1_148" class="NLM_sec NLM_sec_level_2"><div id="ac_i171" class="anchor-spacer"></div><h3 class="article-section__title" id="_i171"> {3-[(Allylmethylamino)methyl]phenyl}-[4-(3-but-3-enyloxy-4-methoxyphenyl)pyrimidin-2-yl]amine (<b>25v</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>15f</b> and <b>21b</b> (51%). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 431 ([M + H]<sup>+</sup>) C<sub>26</sub>H<sub>30</sub>N<sub>4</sub>O<sub>2</sub>.</div></div><div id="sec5_1_149" class="NLM_sec NLM_sec_level_2"><div id="ac_i172" class="anchor-spacer"></div><h3 class="article-section__title" id="_i172"> (16<i>E</i>)-14-Methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (<b>26h</b>)</h3><div class="NLM_p">Diene <b>23f</b> (1.0 g, 2.5 mmol) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (1 L). The reaction appartus was flushed with N<sub>2</sub> vigorously. The reaction mixture was heated to 45 °C for 1 h. The apparatus was flushed with N<sub>2</sub>, and TFA (1 mL) was added maintaining the temperature at 45 °C. The mixture was then flushed with nitrogen gas for an additional 15 min, and Grubbs second generation catalyst (0.21 g, 0.25 mmol), predissolved in CH<sub>2</sub>Cl<sub>2</sub> (10 mL), was added to the reaction mixture. The mixture was stirred at 45 °C for 5 h. Solvent was removed from the reaction mixture under reduced pressure. The crude residue was purified by column chromatography (EtOAc/MeOH) to furnish 1.2 g of the crude product which was recrystallized with EtOAc/hexane to give 950 mg of the desired product. This material was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) and washed with saturated NaHCO<sub>3</sub>. The organic layer was separated, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated under reduced pressure to obtain (827 mg, 86%) of <b>26h</b> as free base. The free amine was dissolved in 1 N HCl (20 mL). The resulting mixture was filtered through a filter paper and lyophilized to afford <b>26h</b> as 2HCl monohydrate salt (900 mg, 78%) as a light yellow solid. LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 373 ([M + H]<sup>+</sup>); <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 10.6 (br, 1H), 9.9 (s,1H), 8.80 (s, 1H), 8.51 (d, 1H), 7.81 (s, 1H), 7.57 (d, 1H),7.40 (m, 2H), 7.29 (d, 1H), 7.23 (m, 2H), 7.16 (d, 1H), 6.08 (m, 1H), 5.74 (m, 1H), 4.50 (m, 1H), 4.17–4.07 (m, 2H), 3.93–3.67 (m, 3H), 2.51 (m, 2H), 2.42 (s, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 163.1, 160.2, 159.2, 141.6, 140.8, 138.6, 131.1, 130.7, 129.6, 124.0, 121.0,120.4, 119.7, 116.5, 115.1,108.5, 65.3, 57.7,57.5, 37.4, 32.4. Anal. Calcd for C<sub>23</sub>H<sub>28</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>2</sub> (2HCl·H<sub>2</sub>O salt): C, 59.61; H, 6.09; N, 12.09; Cl, 15.30. Found: C, 59.87; H, 5.82; N, 12.28; Cl, 15.50. IR (KBr pellet): 3474, 3058, 1633, 1591, 1459, 1281, 1213, 1801, 1043, 793, 692 cm<sup>–1</sup>.</div><div class="NLM_p last">Following a procedure similar to that of <b>26h</b>, the following products were synthesized but isolated as free base.</div></div><div id="sec5_1_150" class="NLM_sec NLM_sec_level_2"><div id="ac_i173" class="anchor-spacer"></div><h3 class="article-section__title" id="_i173"> (17<i>E</i>)-20-Oxa-5,7,13,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,17,21,23-decaen-14-one (<b>26a</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>23a</b> (73%, >95% trans by <sup>1</sup>H NMR). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 373 ([M + H]<sup>+</sup>) C<sub>22</sub>H<sub>20</sub>N<sub>4</sub>O<sub>2</sub>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 11.23 (s, 1H), 8.34 (m, 1H), 8.13 (d, 1H), 7.71 (m, 1H), 7.50 (d, 1H), 7.41 (t, 1H), 7.24–7.34 (m, 4H), 7.14 (s, 1H), 7.02 (m, 1H), 5.75–5.87 (m, 2H), 4.61 (d, 2H), 2.45 (s, 4H).</div></div><div id="sec5_1_151" class="NLM_sec NLM_sec_level_2"><div id="ac_i174" class="anchor-spacer"></div><h3 class="article-section__title" id="_i174"> (16<i>E</i>)-14-Methyl-5,7,14,20,26-pentaazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene-19-one (<b>26b</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>23b</b> (81%, >95% trans by <sup>1</sup>H NMR). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 386 ([M + H]<sup>+</sup>) C<sub>23</sub>H<sub>23</sub>N<sub>5</sub>O; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.55–8.54 (m, 1H), 8.27 (s, 1H), 8.03–7.97 (m, 2H), 7.54–7.52 (m, 1H), 7.38–7.35 (m, 1H), 7.31 (s, 1H), 7.25–7.10 (m, 3H), 6.77–6.75 (m, 1H), 5.85–5.69 (m, 2H), 5.08 (s, 2H), 4.03–3.95 (m, 4H), 3.48 (s, 3H).</div></div><div id="sec5_1_152" class="NLM_sec NLM_sec_level_2"><div id="ac_i175" class="anchor-spacer"></div><h3 class="article-section__title" id="_i175"> (16<i>E</i>)-14-Methyl-5,7,14,19,26-pentaazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene-20-one (<b>26c</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>23c</b> (82%, >95% trans by <sup>1</sup>H NMR). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 386 ([M + H]<sup>+</sup>) C<sub>23</sub>H<sub>23</sub>N<sub>5</sub>O; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.55–8.54 (m, 1H), 8.27 (s, 1H), 8.03–7.97 (m, 2H), 7.54–7.52 (m, 1H), 7.38–7.35 (m, 1H), 7.31 (s, 1H), 7.25–7.10 (m, 3H), 6.77–6.75 (m, 1H), 5.85–5.69 (m, 2H), 5.08 (s, 2H), 4.03–3.95 (m, 4H), 3.48 (s, 3H).</div></div><div id="sec5_1_153" class="NLM_sec NLM_sec_level_2"><div id="ac_i176" class="anchor-spacer"></div><h3 class="article-section__title" id="_i176"> 1-(20-Oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaen-14-yl)-2,2,2-trifluoroethanone (<b>26f</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>23e</b> (73%, 90% trans by <sup>1</sup>H NMR). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 455 ([M + H]<sup>+</sup>) C<sub>24</sub>H<sub>21</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.85 (d, 1H), 8.38 (d, 1H), 7.99–7.94 (m, 1H), 7.52–7.34 (m, 4H), 7.27 (d, 1H), 7.03–6.92 (m, 2H), 5.79–5.46 (m, 2H), 4.80 (s, 2H), 4.20 (t, 2H), 4.09–4.02 (m, 2H), 2.54–2.50 (m, 2H).</div></div><div id="sec5_1_154" class="NLM_sec NLM_sec_level_2"><div id="ac_i177" class="anchor-spacer"></div><h3 class="article-section__title" id="_i177"> 14-Methyl-19-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (<b>26i</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>23g</b> (74%, 15:85 cis/trans ratio by <sup>1</sup>H NMR). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 373 ([M + H]<sup>+</sup>) C<sub>23</sub>H<sub>24</sub>N<sub>4</sub>O; <sup>1</sup>H NMR (MeOD-<i>d</i><sub>4</sub>) δ 8.66–8.85 (m, 1H), 8.46 (d, 1H), 8.31 (s, 1H), 7.92 (d, 1H), 7.55–7.52 (m, 1H), 7.51–7.50 (m, 1H), 7.39–7.34 (m, 2H), 7.21–7.18 (m, 1H), 7.09–7.08 (m, 1H), 6.22 (td, 1H), 5.91–5.84 (m, 1H, CH), 4.61–4.58 (m, 2H), 4.15 (s, 2H), 3.94–3.86 (m, 2H), 2.73 (s, 2H), 2.59 (s, 3H).</div></div><div id="sec5_1_155" class="NLM_sec NLM_sec_level_2"><div id="ac_i178" class="anchor-spacer"></div><h3 class="article-section__title" id="_i178"> (16<i>E</i>)-19-Methyl-14-oxa-5,7,19,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (<b>26j</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>23h</b> (64%, >95% trans by <sup>1</sup>H NMR). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 373 ([M + H]<sup>+</sup>) C<sub>23</sub>H<sub>24</sub>N<sub>4</sub>O; <sup>1</sup>H NMR (MeOD-<i>d</i><sub>4</sub>) δ 8.57–8.43 (m, 3H), 8.22 (d, 1H), 7.76–7.74 (m, 1H), 7.68 (t, 1H), 7.48 (d, 1H), 7.34 (t, 1 H), 7.16 (d, 1H), 7.08 (dt, 1H), 6.25 (dt, 1H), 6.03 (dt, 1H), 4.81 (s, 2H), 4.29–4.26 (m, 2H), 3.82–3.79 (m, 2H), 2.91 (s, 3H).</div></div><div id="sec5_1_156" class="NLM_sec NLM_sec_level_2"><div id="ac_i179" class="anchor-spacer"></div><h3 class="article-section__title" id="_i179"> (16<i>E</i>)-14-Cyclopropyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (<b>26k</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>24a</b> (49%, >95% trans by <sup>1</sup>H NMR). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 399 ([M + H]<sup>+</sup>) C<sub>25</sub>H<sub>26</sub>N<sub>4</sub>O; <sup>1</sup>H NMR (MeOD-<i>d</i><sub>4</sub>) δ 9.05 (s, 1H), 8.44 (br s, 1H), 7.90 (br s, 1H), 7.52 (d, 1H), 7.43 (t, 1H), 7.38 (t, 1H), 7.31 (d, 1H), 7.22 (dd, 1H), 7.10–7.16 (m, 2H), 6.21 (dt, 1H), 5.80 (dt, 1H), 4.60 (br s, 1H), 3.90–4.19 (5H, m), 2.80 (m, 1H), 2.65–2.66 (m, 2H), 0.51–0.60 (m, 3H), 0.58–0.55 (br s, 1H).</div></div><div id="sec5_1_157" class="NLM_sec NLM_sec_level_2"><div id="ac_i180" class="anchor-spacer"></div><h3 class="article-section__title" id="_i180"> (16<i>E</i>)-14-Isobutyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (<b>26l</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>24b</b> (53%, >95% trans by <sup>1</sup>H NMR). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 415 ([M + H]<sup>+</sup>) C<sub>26</sub>H<sub>30</sub>N<sub>4</sub>O; <sup>1</sup>H NMR (MeOD-<i>d</i><sub>4</sub>) δ 8.95 (br s, 1H), 8.42 (d, 1H), 7.99 (t, 1H), 7.47 (t, 1H), 7.38 (t, 1H), 7.35 (t, 1H), 7.28 (d, 1H), 7.16 (dd, 1H), 7.11 (d, 1H), 7.08 (dd, 2H), 6.15 (dt, 1H), 5.85 (dt, 1H), 4.58 (d, 1H), 4.22–4.26 (m, 1H), 4.11 (d, 1H), 3.86–4.05 (m, 3H), 3.86–4.05 (m, 3H), 3.02–3.07 (m, 1H), 2.60–2.73 (m, 3H), 1.78–1.98 (m, 1H), 0.60 (d, 3H), 0.51 (d, 3H).</div></div><div id="sec5_1_158" class="NLM_sec NLM_sec_level_2"><div id="ac_i181" class="anchor-spacer"></div><h3 class="article-section__title" id="_i181"> (16<i>E</i>)-14-(Cyclopropylmethyl)-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (<b>26m</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>24c</b> (52%, >95% trans by <sup>1</sup>H NMR). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 413 ([M + H]<sup>+</sup>) C<sub>26</sub>H<sub>28</sub>N<sub>4</sub>O; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 12.00 (s, 1H), 8.80 (s, 1H), 8.30 (br s, 1H), 7.93 (d, 1H), 7.38–7.59 (m, 6H), 7.17–7.21 (m, 1H), 6.12 (dt, 1H), 5.89 (dt, 1H), 4.79 (d, 1H), 4.22–4.27 (m, 3H), 3.94–4.00 (m, 1H), 3.86 (d, 1H), 2.68–2.86 (m, 4H), 1.05 (m, 1H), 0.64–0.72 (m, 2H), 0.19–0.23 (m, 2H).</div></div><div id="sec5_1_159" class="NLM_sec NLM_sec_level_2"><div id="ac_i182" class="anchor-spacer"></div><h3 class="article-section__title" id="_i182"> (16<i>E</i>)-14-(2,2-Dimethylpropyl)-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (<b>26n</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>24d</b> (75%, >95% trans by <sup>1</sup>H NMR). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 429 ([M + H]<sup>+</sup>) C<sub>27</sub>H<sub>32</sub>N<sub>4</sub>O; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.79 (s, 1H), 8.39 (d, 1H), 7.86 (d, 1H), 7.68 (d, 1H), 7.45–7.47 (m, 2H), 7.42 (t, 1H), 7.27 (d, 1H), 7.14 (d, 1H), 7.05–7.08 (m, 1H), 6.02 (dt, 1H), 5.87 (dt, 1H), 4.87–4.91 (m, 1H), 4.50–4.51 (m, 1H), 4.27–4.31 (m, 1H), 4.04–4.12 (m, 1H), 3.80–3.85 (m, 2H), 2.97 (d, 2H), 2.65–2.70 (m, 2H), 0.66 (s, 9H).</div></div><div id="sec5_1_160" class="NLM_sec NLM_sec_level_2"><div id="ac_i183" class="anchor-spacer"></div><h3 class="article-section__title" id="_i183"> 14-(Pyridin-2-ylmethyl)-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (<b>26o</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>24e</b> (42%, >95% trans by <sup>1</sup>H NMR). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 450 ([M + H]<sup>+</sup>) C<sub>28</sub>H<sub>27</sub>N<sub>5</sub>O; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 11.9 (s, 1H), 8.90 (s, 1H), 8.59 (d, 1H), 8.27 (d, 1H), 7.99 (s, 1H), 7.67 (t, 1H), 7.66 (d, 1H), 7.36–7.57 (m, 7H, m), 7.19–7.21 (m, 1H), 6.07 (dt, 1H), 5.92 (dt, 1H), 4.55 (s, 2H), 4.31 (s, 2H), 3.88–3.89 (m, 2H), 2.64 (d, 2H), 2.64 (t, 2H).</div></div><div id="sec5_1_161" class="NLM_sec NLM_sec_level_2"><div id="ac_i184" class="anchor-spacer"></div><h3 class="article-section__title" id="_i184"> (16<i>E</i>)-14-(2-Methoxyethyl)-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (<b>26p</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>24f</b> (77%, >95% trans by <sup>1</sup>H NMR). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 417 ([M + H]<sup>+</sup>) C<sub>25</sub>H<sub>28</sub>N<sub>4</sub>O<sub>2</sub>; <sup>1</sup>H NMR (MeOD-<i>d</i><sub>4</sub>) δ 8.71 (s, 1H), 8.36 (d, 1H), 7.88 (s, 1H), 7.43 (d, 1H), 7.31 (t, 1H), 7.19–7.15 (m, 2H), 7.02 (dd, 1H), 6.96 (t, 2H), 5.76–5.80 (m, 1H), 5.59–5.66 (m, 1H), 4.09 (t, 2H), 3.85 (s, 2H), 3.42 (d, 2H), 3.30–3.28 (m, 2H), 3.25, (s, 3H), 2.44, (br s, 2H), 2.43 (d, 2H).</div></div><div id="sec5_1_162" class="NLM_sec NLM_sec_level_2"><div id="ac_i185" class="anchor-spacer"></div><h3 class="article-section__title" id="_i185"> 2-(20-Oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaen-14-yl)ethanol (<b>26q</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>24g</b> (63%, >95% trans by <sup>1</sup>H NMR). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 403 ([M + H]<sup>+</sup>) C<sub>24</sub>H<sub>26</sub>N<sub>4</sub>O<sub>2</sub>; <sup>1</sup>H NMR (MeOD-<i>d</i><sub>4</sub>) δ 9.09 (s, 1H), 8.41 (d, 1H), 7.91 (s, 1H), 7.48–7.53 (m, 1H), 7.28–7.40 (m, 3H), 7.08–7.15 (m, 3H), 6.13–6.20 (m, 1H), 5.77–5.82 (m, 1H), 4.12–4.00 (m, 2H), 4.00–3.98 (m, 2H), 2.59–2.61 (m, 2H), 1.20–1.28 (m, 4H), 0.80–0.87 (m, 2H).</div></div><div id="sec5_1_163" class="NLM_sec NLM_sec_level_2"><div id="ac_i186" class="anchor-spacer"></div><h3 class="article-section__title" id="_i186"> (16<i>E</i>)-11-Methoxy-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (<b>27a</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>25a</b> (71%, >95% trans by <sup>1</sup>H NMR). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 403 ([M + H]<sup>+</sup>) C<sub>24</sub>H<sub>26</sub>N<sub>4</sub>O<sub>2</sub>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 12.19 (s, 1H), 8.72 (d, 1H), 8.33 (d, 1H), 7.93 (s, 1H), 7.56–7.60 (m, 2H), 7.51 (dd, 1H), 7.38 (d, 1H), 7.22–7.24 (m, 1H), 7.03 (d, 1H), 4.18–4.33 (m, 6H), 2.74 (q, 2H), 2.68 (s, 3H), 2.14 (s, 3H).</div></div><div id="sec5_1_164" class="NLM_sec NLM_sec_level_2"><div id="ac_i187" class="anchor-spacer"></div><h3 class="article-section__title" id="_i187"> (16<i>E</i>)-11-Chloro-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (<b>27b</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>25b</b> (48%, >95% trans by <sup>1</sup>H NMR). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 407 ([M + H]<sup>+</sup>) C<sub>23</sub>H<sub>23</sub>ClN<sub>4</sub>O; <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 10.15 (s, 1H), 9.73 (br s, 1H), 9.10 (d, 1H), 8.63 (d, 1H), 7.90 (s, 1H), 7.69 (d, 1H), 7.50–7.55 (m, 2H), 7.39 (dd, 1H), 7.27 (dd, 1H), 6.12–6.23 (m, 1H), 5.67–5.78 (m, 1H), 4.59 (s, 2H), 4.08–4.27 (m, 4H), 3.85–3.89 (m, 2H), 2.59 (s, 3H).</div></div><div id="sec5_1_165" class="NLM_sec NLM_sec_level_2"><div id="ac_i188" class="anchor-spacer"></div><h3 class="article-section__title" id="_i188"> (16<i>E</i>)-14-Methyl-11-trifluoromethoxy-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (<b>27c</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>25c</b> (53%, >95% trans by <sup>1</sup>H NMR). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 457 ([M + H]<sup>+</sup>) C<sub>24</sub>H<sub>23</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>; <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 10.18 (s, 1H), 9.85 (br s, 1H), 9.13 (m, 1H), 8.63 (d, 1H), 7.90 (s, 1H), 7.69 (d, 1H), 7.55 (d, 1H), 7.52 (t, 1H), 7.46 (br s, 1H), 7.29 (dd, 1H), 6.12–6.23 (m, 1H), 5.67–5.78 (m, 1H), 3.95–4.59 (m, 6H), 3.85–3.89 (m, 2H), 2.59 (s, 3H).</div></div><div id="sec5_1_166" class="NLM_sec NLM_sec_level_2"><div id="ac_i189" class="anchor-spacer"></div><h3 class="article-section__title" id="_i189"> (16<i>E</i>)-11-(2-Methoxyethoxy)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (<b>27d</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>25d</b> (56%, >95% trans by <sup>1</sup>H NMR). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 447 ([M + H]<sup>+</sup>) C<sub>26</sub>H<sub>30</sub>N<sub>4</sub>O<sub>3</sub>; <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 9.48 (s, 1H), 8.52 (d, 1H), 8.50 (d, 1H), 7.87 (t, 1H), 7.64 (dd, 1H), 7.47 (t, 1H), 7.35 (d, 1H), 7.24 (dd, 1H), 7.04 (dd, 1H), 6.93 (d, 1H), 5.64–5.71 (m, 1H), 5.44–5.51 (m, 1H), 4.25 (t, 2H), 4.05–4.08 (m, 2H), 3.65–3.68 (m, 2H), 3.48 (s, 2H), 3.34 (s, 3H), 3.00 (d, 2H), 2.37–2.40 (m, 2H), 1.98 (s, 3H).</div></div><div id="sec5_1_167" class="NLM_sec NLM_sec_level_2"><div id="ac_i190" class="anchor-spacer"></div><h3 class="article-section__title" id="_i190"> (16<i>E</i>)-11-Ethylsulfonyl-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (<b>27e</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>25e</b> (68%, >95% trans by <sup>1</sup>H NMR). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 465 ([M + H]<sup>+</sup>) C<sub>25</sub>H<sub>28</sub>N<sub>4</sub>O<sub>3</sub>S; <sup>1</sup>H NMR (MeOD-<i>d</i><sub>4</sub>) δ 9.51 (d, 1H), 8.62 (d, 1H), 8.05–7.97 (m, 2H), 7.65–7.63 (m, 1H), 7.54–7.52 (m, 2H), 7.52–7.49 (m, 2H), 7.23–7.21 (m, 1H), 6.31–6.24 (m, 1H), 6.02–5.94 (m, 1H), 4.43–4.04 (m, 8H), 3.38–3.32 (m, 2H), 2.74 (s, 3H), 1.33 (t, 3H).</div></div><div id="sec5_1_168" class="NLM_sec NLM_sec_level_2"><div id="ac_i191" class="anchor-spacer"></div><h3 class="article-section__title" id="_i191"> 2-(14-Methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaen-11-yl)oxy-1-(pyrrolidin-1-yl)ethanone (<b>27h</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>25g</b> (59%, >95% trans by <sup>1</sup>H NMR). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 500 ([M + H]<sup>+</sup>) C<sub>29</sub>H<sub>33</sub>N<sub>5</sub>O<sub>3</sub>; <sup>1</sup>H NMR (MeOD-<i>d</i><sub>4</sub>) δ 8.82 (d, 1H), 8.39 (d, 1H), 7.87–7.86 (m, 1H), 7.51–7.47 (m, 1H), 7.39 (t, 1H), 7.33 (d, 1H), 7.18 (dd, 1H), 7.14–7.09 (m, 2H), 6.18–6.10 (m 1H), 6.18–6.10 (m, 1H), 5.91–5.82 (m, 1H), 4.24–4.20 (m, 1H), 4.09–3.92 (m, 3H), 3.84–3.78 (m, 1H), 2.55 (s, 3H), 1.98–1.91 (m, 4H), 1.84–1.79 (m, 3H).</div></div><div id="sec5_1_169" class="NLM_sec NLM_sec_level_2"><div id="ac_i192" class="anchor-spacer"></div><h3 class="article-section__title" id="_i192"> (16<i>E</i>)-11-(4-Morpholino)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (<b>27i</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>25h</b> (88%, >95% trans by <sup>1</sup>H NMR). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 458 ([M + H]<sup>+</sup>) C<sub>27</sub>H<sub>31</sub>N<sub>5</sub>O<sub>2</sub>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 10.83 (s, 1H), 9.04 (br s, 1H), 8.34 (d, 1H), 8.06 (t, 1H), 7.56–7.59 (m, 1H), 7.53 (t, 1H), 7.35–7.38 (m, 2H), 7.25 (s, 1H), 7.19 (dd, 1H), 6.10–6.17 (m, 1H), 5.91–5.96 (m, 1H), 4.27–4.30 (m, 2H), 4.03–4.04 (m, 2H), 3.84–3.94 (m, 6H), 3.00 (m, 2H), 2.90 (m, 2H), 2.69 (m, 2H), 2.64 (s, 3H).</div></div><div id="sec5_1_170" class="NLM_sec NLM_sec_level_2"><div id="ac_i193" class="anchor-spacer"></div><h3 class="article-section__title" id="_i193"> (16<i>E</i>)-11-(2-(Diethylamino)ethoxy)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (<b>27j</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>25i</b> (50%, >95% trans by <sup>1</sup>H NMR). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 488 ([M + H]<sup>+</sup>) C<sub>29</sub>H<sub>37</sub>N<sub>5</sub>O<sub>2</sub>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 12.03 (s, 1H), 8.79 (d, 1H), 8.29 (d, 1H), 7.92–7.93 (br s, 1H), 7.56–7.60 (m, 2H), 7.49 (dd, 1H), 7.39 (d, 1H), 7.19–7.22 (m, 1H), 6.98 (d, 1H), 6.07–6.14 (m, 1H), 5.88–5.95 (m, 1H), 4.42 (br s, 2H), 4.34–4.38 (m, 2H), 3.90–4.09 (m, 2H), 3.28–3.58 (m, 6H), 2.74–2.85 (m, 2H), 2.66 (s, 3H), 1.47 (t, 3H), 1.42 (t, 3H).</div></div><div id="sec5_1_171" class="NLM_sec NLM_sec_level_2"><div id="ac_i194" class="anchor-spacer"></div><h3 class="article-section__title" id="_i194"> (16<i>E</i>)-14-Methyl-11-(2-(pyrrolidin-1-yl)ethoxy)-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (<b>27k</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>25j</b> (67%, >95% trans by <sup>1</sup>H NMR). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 486 ([M + H]<sup>+</sup>) C<sub>29</sub>H<sub>35</sub>N<sub>5</sub>O<sub>2</sub>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 11.94 (s, 1H), 8.73 (d, 1H), 8.26 (d, 1H), 7.85–7.86 (br s, 1H), 7.50–7.52 (m, 2H), 7.41 (dd, 1H), 7.34 (d, 1H), 7.13–7.16 (m, 1H), 6.92 (d, 1H), 6.04–6.09 (m, 1H), 5.82–5.89 (m, 1H), 4.28–4.37 (m, 4H), 3.92–4.06. (m, 4H), 3.05 (br s, 2H), 2.65–2.74 (m, 2H), 2.60 (s, 3H), 2.20–2.24 (m, 4H), 2.12–2.14 (m, 4H).</div></div><div id="sec5_1_172" class="NLM_sec NLM_sec_level_2"><div id="ac_i195" class="anchor-spacer"></div><h3 class="article-section__title" id="_i195"> (16<i>E</i>)-11-(2-(Pyrrolidin-1-yl)ethoxy)-14-(2,2,2-trifluoroethyl)-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (<b>27l</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>25k</b> (51%, >95% trans by <sup>1</sup>H NMR). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 554 ([M + H]<sup>+</sup>) C<sub>30</sub>H<sub>34</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.61 (s, 1H), 8.30 (d, 1H), 7.92 (s, 1H), 7.57–7.54 (m, 2H), 7.40–7.36 (m, 2H), 7.24(d, 1H), 6.95 (d, 1H), 6.03–5.89 (m, 1H), 5.83–5.74 (m, 1H), 4.43 (m, 2H), 4.28–4.25 (m, 4H), 4.01 (m, 2H), 3.77 (d, 2H), 3.70 (m, 2H), 3.38 (m, 2H), 3.15–3.07 (m, 2H), 2.63–2.61 (m, 2H), 2.24–2.20 (m, 4H).</div></div><div id="sec5_1_173" class="NLM_sec NLM_sec_level_2"><div id="ac_i196" class="anchor-spacer"></div><h3 class="article-section__title" id="_i196"> 11-(2-(Pyrrolidin-1-yl)ethoxy)-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaen-14-acetonitrile (<b>27m</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>25l</b> (62%, >95% trans by <sup>1</sup>H NMR). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 511 ([M + H]<sup>+</sup>) C<sub>30</sub>H<sub>34</sub>N<sub>6</sub>O<sub>2</sub>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.44 (d, 1H), 8.30 (d, 1H), 7.84 (s, 1H), 7.50 (d, 1H), 7.45 (t, 1H), 7.27 (d, 1H), 7.16 (d, 1H), 7.11 (d, 1H), 5.81 (dt, 1H), 5.52 (dt, 1H), 4.36 (t, 2H), 4.27 (t, 2H), 3.85–3.62 (m, 8H), 3.33 (s, 2H), 3.24 (d, 2H), 2.11–2.15 (m, 4H).</div></div><div id="sec5_1_174" class="NLM_sec NLM_sec_level_2"><div id="ac_i197" class="anchor-spacer"></div><h3 class="article-section__title" id="_i197"> 14-Methyl-11-(2-(morpholin-4-yl)ethoxy)-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (<b>27n</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>25m</b> (66%, >95% trans by <sup>1</sup>H NMR). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 502 ([M + H]<sup>+</sup>) C<sub>29</sub>H<sub>35</sub>N<sub>5</sub>O<sub>3</sub>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 12.05 (s, 1H), 8.66 (d, 1H), 8.22 (d, 1H), 7.78 (s, 1H), 7.45–7.47 (m, 2H), 6.38 (dd, 1H), 7.29 (d, 1H), 7.08–7.11 (m, 1H), 6.83 (d, 1H), 5.98–6.05 (m, 1H), 5.72–5.78 (m, 1H), 4.33–4.39 (m, 2H), 4.19–4.25 (m, 2H), 3.96–4.00 (m, 6H,), 3.54–3.81 (m, 6H), 2.99–3.01 (m, 2H), 2.63–2.68 (m, 2H), 2.53 (s, 3H).</div></div><div id="sec5_1_175" class="NLM_sec NLM_sec_level_2"><div id="ac_i198" class="anchor-spacer"></div><h3 class="article-section__title" id="_i198"> 14-Methyl-11-(2-(4-methylpiperazin-1-yl)ethoxy)-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (<b>27o</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>25n</b> (50%, >95% trans by <sup>1</sup>H NMR). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 515 ([M + H]<sup>+</sup>) C<sub>30</sub>H<sub>38</sub>N<sub>6</sub>O<sub>2</sub>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 11.99 (s, 1H), 8.73 (d, 1H), 8.27 (d, 1H), 7.86–7.87 (br s, 1H), 7.52–7.56 (m, 2H), 7.47 (dd, 1H), 7.35 (d, 1H), 7.16–7.19 (m, 1H), 6.96 (d, 1H), 6.05–6.11 (m, 1H), 5.82–5.88 (m, 1H), 4.28–4.36 (m, 4H), 3.71–4.03. (m, 12H), 3.05 (br s, 2H), 2.91 (s, 3H), 2.60 (s, 3H), 2.05 (s, 2H).</div></div><div id="sec5_1_176" class="NLM_sec NLM_sec_level_2"><div id="ac_i199" class="anchor-spacer"></div><h3 class="article-section__title" id="_i199"> 14-Methyl-11-(2-(piperidin-1-yl)ethoxy)-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (<b>27p</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>25o</b> (62%, >95% trans by <sup>1</sup>H NMR). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 500 ([M + H]<sup>+</sup>) C<sub>30</sub>H<sub>37</sub>N<sub>5</sub>O<sub>2</sub>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 12.04 (s, 1H), 8.72 (d, 1H), 8.25 (d, 1H), 7.82 (br s, 1H), 7.51–7.52 (m, 2H), 7.41 (dd, 1H), 7.34 (d, 1H), 7.14–7.18 (m, 1H), 6.94 (d, 1H), 6.03–6.10 (m, 1H), 5.80–5.87 (m, 1H), 4.95 (d, 1H), 4.22–4.33 (m, 4H), 4.02–4.06 (m, 1H), 3.59–4.06 (m, 6H), 2.93 (br s, 2H), 2.65–2.77 (m, 2H, CH2), 2.59 (s, 3H), 1.83–2.01 (m, 6H).</div></div><div id="sec5_1_177" class="NLM_sec NLM_sec_level_2"><div id="ac_i200" class="anchor-spacer"></div><h3 class="article-section__title" id="_i200"> 10-Methoxy-14-methyl-11-(2-(pyrrolidin-1-yl)ethoxy)-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (<b>27q</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>25p</b> (44%, >95% trans by <sup>1</sup>H NMR). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 516 ([M + H]<sup>+</sup>) C<sub>30</sub>H<sub>37</sub>N<sub>5</sub>O<sub>3</sub>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.59 (d, 1H), 8.49 (br s, 1H), 7.93 (s, 1H), 7.52 (d, 1H), 7.41 (t, 1H), 7.23 (d, 1H), 7.13 (dd, 1H), 6.97 (d, 1H), 6.18 (dt, 1H), 5.77 (m, 1H), 4.32–4.24 (m, 4H), 4.05 (d, 2H), 3.90 (s, 2H), 3.85–3.81 (m, 4H), 3.65 (t, 2H), 3.26–3.20 (m, 2H), 3.25 (s, 3H), 2.61 (s, 3H), 2.16–2.05 (m, 4H).</div></div><div id="sec5_1_178" class="NLM_sec NLM_sec_level_2"><div id="ac_i201" class="anchor-spacer"></div><h3 class="article-section__title" id="_i201"> <i>N</i>-(14-Methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaen-10-yl)-2,2,2-trifluoroacetamide (<b>27r</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>25q</b> (68%, >95% trans by <sup>1</sup>H NMR). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 483 ([M + H]<sup>+</sup>) C<sub>25</sub>H<sub>24</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub>; <sup>1</sup>H NMR (MeOD-<i>d</i><sub>4</sub>) δ 8.98 (s, 1H), 8.51 (d, 1H), 7.98 (s, 1H), 7.59–7.57 (m, 1H), 7.51–7.47 (m, 3H), 7.41–7.39 (m, 1H), 7.20–7.18 (m, 1H), 6.22 (dt, 1H), 5.83 (dt, 1H), 4.85–4.35 (m, 2H), 4.34–4.09 (m, 2H), 4.07–3.79 (m, 2H), 2.74–2.64 (m, 2H), 2.69 (s, 3H)</div></div><div id="sec5_1_179" class="NLM_sec NLM_sec_level_2"><div id="ac_i202" class="anchor-spacer"></div><h3 class="article-section__title" id="_i202"> (16<i>E</i>)-4,14-Dimethyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (<b>28a</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>25r</b> (56%, >95% trans by <sup>1</sup>H NMR). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 387 ([M + H]<sup>+</sup>) C<sub>24</sub>H<sub>26</sub>N<sub>4</sub>O; <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 9.62 (s, 1H), 8.60 (s, 1H), 8.42 (s, 1H), 7.92 (t, 1H), 7.64 (d, 1H), 7.46 (t, 1H), 7.34 (s, 1H), 7.16–7.22 (m, 2H), 7.05 (d, 1H), 6.86 (d, 1H, 5.48–5.74 (m, 2H), 4.20 (t, 2H), 3.48 (s, 2H), 3.06 (d, 2H), 2.45–2.46 (m, 2H), 2.42 (s, 3H), 2.01 (s, 3H).</div></div><div id="sec5_1_180" class="NLM_sec NLM_sec_level_2"><div id="ac_i203" class="anchor-spacer"></div><h3 class="article-section__title" id="_i203"> (16<i>E</i>)-14-Methyl-4-(pyrrolidin-1-yl)-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (<b>28b</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>25s</b> (49%, >95% trans by <sup>1</sup>H NMR). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 442 ([M + H]<sup>+</sup>) C<sub>27</sub>H<sub>31</sub>N<sub>5</sub>O; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 12.6 (s, 1H), 8.73 (s, 1H), 7.86–7.91 (m, 2H), 7.41–7.48 (m, 2H), 7.34–7.35 (m, 1H), 7.10 (d, 1H), 6.45 (s, 1H), 6.03–6.18 (m, 1H), 5.86–5.92 (m, 1H), 4.13–4.30 (m, 4H), 3.83–3.84 (m, 2H), 3.68 (s, 2H), 2.74 (m, 2H), 2.56 (s, 2H), 2.21 (s, 3H), 1.63 (m, 4H).</div></div><div id="sec5_1_181" class="NLM_sec NLM_sec_level_2"><div id="ac_i204" class="anchor-spacer"></div><h3 class="article-section__title" id="_i204"> (16<i>E</i>)-3,14-Dimethyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (<b>28c</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>25t</b> (54%, >95% trans by <sup>1</sup>H NMR). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 387 ([M + H]<sup>+</sup>) C<sub>24</sub>H<sub>26</sub>N<sub>4</sub>O; <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 9.52 (s, 1H), 8.63 (br s, 1H), 8.42 (s, 1H), 7.51 (t, 1H), 7.44 (t, 1H), 7.32–7.37 (m, 1H), 7.13–7.19 (m, 2H), 7.02–7.08 (m, 1H), 6.82 (d, 1H), 5.64–5.72 (m, 1H), 5.62–5.71 (m, 1H), 5.51–5.55 (m, 1H), 4.20 (t, 2H), 3.41 (s, 2H), 3.07 (d, 2H), 3.34 (s, 3H), 1.98 (s, 3H).</div></div><div id="sec5_1_182" class="NLM_sec NLM_sec_level_2"><div id="ac_i205" class="anchor-spacer"></div><h3 class="article-section__title" id="_i205"> (16<i>E</i>)-23-Fluoro-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (<b>28d</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>25u</b> (51%, >95% trans by <sup>1</sup>H NMR). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 391 ([M + H]<sup>+</sup>) C<sub>23</sub>H<sub>23</sub>FN<sub>4</sub>O; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 9.78 (s, 1H), 8.85 (s, 1H), 8.45 (m, 1H), 7.82 (s, 1H), 7.48–7.50 (m, 2H), 7.21–7.29 (m, 3H), 6.87 (td, 1H), 6.06–6.13 (m, 1H), 5.85–5.93 (m, 1H), 4.16–4.27 (m, 4H), 3.75–3.85 (m, 2H), 2.74–2.75 (m, 2H), 2.62 (s, 3H).</div></div><div id="sec5_1_183" class="NLM_sec NLM_sec_level_2"><div id="ac_i206" class="anchor-spacer"></div><h3 class="article-section__title" id="_i206"> (16<i>E</i>)-22-Methoxy-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (<b>28e</b>)</h3><div class="NLM_p last">The title compound was synthesized from <b>25v</b> (44%, >95% trans by <sup>1</sup>H NMR). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 403 ([M + H]<sup>+</sup>) C<sub>24</sub>H<sub>26</sub>N<sub>4</sub>O<sub>2</sub>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 11.8 (s, 1H), 8.41–8.44 (m, 2H), 8.26 (br s, 1H), 7.95 (d, 1H), 7.65 (br s, 1H), 7.52–7.54 (m, 1H), 7.45 (d, 1H), 7.45 (d, 1H), 7.31–7.34 (m, 1H), 7.07 (d, 1H), 6.18–6.24 (m, 2H), 4.67 (s, 2H), 4.08–4.27 (m, 4H), 3.99 (s, 3H), 3.93–4.04 (m, 1H), 3.65 (br s, 1H), 2.84 (s, 3H).</div></div><div id="sec5_1_184" class="NLM_sec NLM_sec_level_2"><div id="ac_i207" class="anchor-spacer"></div><h3 class="article-section__title" id="_i207"> 19-Oxa-5,7,13,25-tetraazatetracyclo[18.3.1.1(2,6).1(8,12)]hexacosa-1(24),2(25),3,5,8(26),9,11,15,20,22-decaene (<b>26e</b>)</h3><div class="NLM_p last">To a solution of <b>26d</b> (12 mg, 0.027 mmol) in MeOH/CH<sub>2</sub>Cl<sub>2</sub> (0.2:1, 2 mL) was added 4 M HCl (0.5 mL), and the resulting mixture was heated at 40 °C for 4 h. It was concentrated under reduced pressure and purified by preparative HPLC to furnish <b>26e</b> (7 mg, 79%, >95% trans by <sup>1</sup>H NMR) as a yellow solid. LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 346 ([M + H]<sup>+</sup>) C<sub>21</sub>H<sub>20</sub>N<sub>4</sub>O; <sup>1</sup>H NMR (MeOD-<i>d</i><sub>4</sub>) δ 8.58–8.57 (m, 2H), 8.52 (d, 1H), 8.02 (t, 1H), 7.74–7.72 (m, 1H), 7.56–7.41 (m, 3H), 7.30–7.27 (m, 2H), 7.13 (dd, 1H), 6.18 (td, 1H), 5.86 (td, 1H), 4.32–4.30 (m, 2H), 4.12 (d, 2H), 2.39–2.34 (m, 2H).</div></div><div id="sec5_1_185" class="NLM_sec NLM_sec_level_2"><div id="ac_i208" class="anchor-spacer"></div><h3 class="article-section__title" id="_i208"> 20-Oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (<b>26g</b>)</h3><div class="NLM_p last">To a mixture of <b>26f</b> (45 mg, 0.100 mmol) in 5.5% H<sub>2</sub>O/MeOH (3 mL) was added K<sub>2</sub>CO<sub>3</sub> (69 mg, 0.500 mmol), and the resulting mixture was stirred at 90 °C for 6 h. It was concentrated under reduced pressure and purified by preparative HPLC to furnish <b>26g</b> (17 mg, 48%, >95% trans by <sup>1</sup>H NMR) as a pale yellow solid. LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 360 ([M + H]<sup>+</sup>) C<sub>22</sub>H<sub>22</sub>N<sub>4</sub>O; <sup>1</sup>H NMR (MeOD-<i>d</i><sub>4</sub>) δ 8.99 (br s, 1H), 8.44 (d, 1H), 8.44 (d, 1H), 8.01 (t, 1H), 7.51 (dd, 1H), 7.42 (t, 1H), 7.24–7.31 (m, 2H), 7.24–7.31 (m, 2H), 7.13 (dd, 1H), 7.02–7.06 (m, 2H), 5.85 (dt, 1H), 5.67 (dt, 1H), 4.19 (t, 2H), 3.93 (s, 2H), 3.48 (d, 2H), 2.53–2.57 (m, 2H).</div></div><div id="sec5_1_186" class="NLM_sec NLM_sec_level_2"><div id="ac_i209" class="anchor-spacer"></div><h3 class="article-section__title" id="_i209"> (16<i>E</i>)-14-Methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaen-10-amine (<b>27s</b>)</h3><div class="NLM_p last">Following a procedure similar to that of <b>26g</b>, the title compound was synthesized from <b>27r</b> (58%, >95% trans by <sup>1</sup>H NMR). LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 388 ([M + H]<sup>+</sup>) C<sub>23</sub>H<sub>25</sub>N<sub>5</sub>O; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.41 (d, 1H), 8.17 (s, 1H), 8.10 (t, 1H), 7.48–7.43 (m, 1H), 7.38 (t, 1H), 7.16 (s, 1H), 7.04–7.01 (m, 1H), 6.50 (s, 1H), 6.16 (t, 1H), 5.78– 5.69 (m, 2H), 4.19 (t, 2H), 3.62–3.59 (m, 2H), 3.29–3.27 (m, 2H), 2.91 (q, 2H), 2.53 (q, 2H), 2.24 (s, 3H).</div></div><div id="sec5_1_187" class="NLM_sec NLM_sec_level_2"><div id="ac_i210" class="anchor-spacer"></div><h3 class="article-section__title" id="_i210"> 2-(Isopropylamino)-1-(20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaen-14-yl)ethanone (<b>26r</b>)</h3><div class="NLM_p last">To a solution of <b>26g</b> (5 mg, 0.0168 mmol) and bromoacetyl bromide (1.5 μL, 0.0168 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1 mL) was added diisopropylethylamine (3 μL, 0.0168 mmol), and the resulting solution was stirred at room temperature for 4 h. Isopropylamine (5 μL) was added, and resulting mixture was stirred for another 4 h. It was concentrated under reduced pressure and purified by preparative HPLC to furnish <b>26r</b> (3 mg, 39%, >95% trans by <sup>1</sup>H NMR) as a pale yellow solid. LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 458 ([M + H]<sup>+</sup>) C<sub>27</sub>H<sub>31</sub>N<sub>5</sub>O<sub>2</sub>; <sup>1</sup>H NMR (MeOD-<i>d</i><sub>4</sub>) δ 8.60 (s, 1H), 8.48 (d, 1H), 7.97 (d, 1H), 7.62 (m, 1H), 7.46 (t, 1H), 7.35 (m, 1H), 7.28 (t, 1H), 7.24 (dd, 1H), 7.06 (t, 1H), 6.86 (d, 1H), 5.78–5.71 (m, 1H), 5.52–5.42 (m, 1H), 4.23 (t, 2H), 4.18–4.10 (m, 5H), 3.92 (s, 2H), 2.52 (br, 2H), 1.39 (d, 6H).</div></div><div id="sec5_1_188" class="NLM_sec NLM_sec_level_2"><div id="ac_i211" class="anchor-spacer"></div><h3 class="article-section__title" id="_i211"> (16<i>E</i>)-11-(2-(Ethylsulfonyl)ethoxy)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (<b>27g</b>)</h3><div class="NLM_p last">To a solution of <b>27f</b> (20 mg, 0.042 mmol) in acetic acid (2 mL) at 0 °C was added 50% hydrogen peroxide solution (0.1 mL), and the resulting mixture was stirred at room temperature for 7 h. It was concentrated under reduced pressure and purified by preparative HPLC to furnish <b>27g</b> (4 mg, 19%, >95% trans by <sup>1</sup>H NMR) as a yellow solid. LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 509 ([M + H]<sup>+</sup>) C<sub>27</sub>H<sub>32</sub>N<sub>4</sub>O<sub>4</sub>S; <sup>1</sup>H NMR (MeOD-<i>d</i><sub>4</sub>) δ 8.66 (d, 1H), 8.41 (d, 1H), 7.97 (t, 1H), 7.52 (d, 1H), 7.42 (t, 1H), 7.26 (d, 1H,), 7.09–7.14 (m, 2H), 7.03 (d, 1H), 5.88 (dt, 1H), 5.72 (dt, 1H, CH), 4.49 (t, 2H), 4.20 (t, 2H), 3.91 (brs, 2H), 3.64 (t, 2H), 3.46–3.48 (m, 2H), 3.25–3.28 (m, 2H), 2.53–2.57 (m, 2H), 2.28 (s, 3H), 1.42 (t, 3H).</div></div><div id="sec5_1_189" class="NLM_sec NLM_sec_level_2"><div id="ac_i212" class="anchor-spacer"></div><h3 class="article-section__title" id="_i212"> <i>N</i>-(Ethylsulfonylmethyl)(14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaen-10-yl)amine (<b>27t</b>)</h3><div class="NLM_p last">To a solution of <b>27s</b> (9 mg, 0.021 mmol) and ethanesulfonyl chloride (10 μL) in CH<sub>2</sub>Cl<sub>2</sub> (1 mL) was added triethylamine (10 μL), and the resulting solution was stirred at room temperature for 4 h. It was concentrated under reduced pressure and purified by preparative HPLC to furnish <b>27t</b> (4 mg, 40%, >95% trans by <sup>1</sup>H NMR) as a pale yellow solid. LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 480 ([M + H]<sup>+</sup>) C<sub>26</sub>H<sub>31</sub>N<sub>5</sub>O<sub>3</sub>S; <sup>1</sup>H NMR (MeOD-<i>d</i><sub>4</sub>) δ 8.47 (s, 1H), 8.39 (d, 1H), 8.01 (s, 1H), 7.41–7.39 (m, 1H), 7.34 (t, 1H), 7.13 (d, 1H), 7.01–6.98 (m, 1H), 7.86–7.83 (m, 2H), 5.68–5.65 (m, 2H), 4.14 (t, 2H), 3.60–3.55 (m, 2H), 3.39 (s, 2H), 3.17–3.13 (m, 2H), 3.07 (q, 2H), 2.54–2.52 (m, 2H), 2.28 (s, 3H), 1.28 (t, 3H).</div></div><div id="sec5_1_190" class="NLM_sec NLM_sec_level_2"><div id="ac_i213" class="anchor-spacer"></div><h3 class="article-section__title" id="_i213"> <i>N</i>-(14-Methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaen-10-yl)morpholine-4-carboxamide (<b>27u</b>)</h3><div class="NLM_p last">Following a procedure similar to that of <b>27t</b>, the title compound was synthesized from <b>27s</b> and Grubbs second generation catalyst. LC/MS (ESI positive mode) <i>m</i>/<i>z</i> 501 ([M + H]<sup>+</sup>) C<sub>28</sub>H<sub>32</sub>N<sub>6</sub>O<sub>3</sub>; <sup>1</sup>H NMR (MeOD-<i>d</i><sub>4</sub>) δ 8.81 (s, 1H), 8.50 (d, 1H), 8.02 (s, 1H), 7.58–7.56 (m, 1H), 7.48 (t, 1H), 7.38 (d, 1H), 7.22–7.16 (m, 1H), 6.92 (s, 1H), 6.89–6.85 (m, 1H), 6.26–6.18 (m, 1H), 5.90–5.83 (m, 1H), 4.56 (t, 2H), 4.38–4.30 (m, 2H), 4.19–4.05 (m, 2H), 3.73–3.70 (m, 2H), 3.56–3.53 (m, 2H), 2.70 (s, 3H), 2.24–2.02 (m, 4H).</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i214" class="anchor-spacer"></div><h3 class="article-section__title" id="_i214"> Enzyme Assays</h3><div class="NLM_p last">The recombinant enzymes (CDK2/cyclin A, JAK2, and FLT3) were purchased from Invitrogen (catalog numbers PV 3267, 4210, and 3182, respectively). All assays were carried out in 384-well white microtiter plates using the PKLight assay system from Cambrex. This assay platform is a luminometric assay for the detection of ATP in the reaction using a luciferase-coupled reaction. The compounds were tested at eight concentrations prepared from 3- or 4-fold serial dilution starting at 10 μM. For CDK2/cyclin A assay, the reaction mixture consisted of the following components in 25 μL of assay buffer (50 mM Hepes, pH 7.5, 10 mM MgCl<sub>2</sub>, 5 mM MnCl<sub>2</sub>, 5 mM BGP, 1 mM DTT, 0.1 mM sodium orthovanadate), 1.4 μg/mL of CDK2/cyclin A complex, 0.5 μM RbING substrate (Invitrogen, catalog number PV2939), and 0.5 μM ATP. The mixture was incubated at room temperature for 2 h. Then 13 μL of PKLight ATP detection reagent was added and the mixture was incubated for 10 min. Luminescence signals were detected on a multilabel plate reader (Victor<sup>2</sup> V 1420, Perkin-Elmer). The other kinase assays were similar, with the following differences in reagents: For FLT3 assays, the mixture contained 2.0 μg/mL FLT3 enzyme, 5 μM poly(Glu,Tyr) substrate (Sigma, catalog number P0275), and 4 μM ATP. For JAK2 assays, the reaction contained 0.35 μg/mL JAK2 enzyme, 10 μM poly(Glu,Ala,Tyr) substrate (Sigma, catalog number P3899), and 0.15 μM ATP. The analytical software Prism 5.0 (GraphPad Software Pte Ltd.) was used to generate IC<sub>50</sub> values from the data.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i215" class="anchor-spacer"></div><h3 class="article-section__title" id="_i215"> Cell Proliferation Assays</h3><div class="NLM_p last">All cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA) and cultured according to the recommended guidelines. For proliferation assays in 96-well plates, 20 000 cells were seeded in 100 μL of medium and treated the following day with compounds (in triplicate) at concentrations up to 10 μM for 48 h. Cell viability was monitored using the CellTiter-96 Aqueous One solution cell proliferation assay (Promega, Madison, WI). Dose–response curves were plotted to determine IC<sub>50</sub> values for the compounds using the XL-fit software (IDBS Ltd., Alameda, CA).</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i216" class="anchor-spacer"></div><h3 class="article-section__title" id="_i216"> Cell Pharmacodynamic Assay</h3><div class="NLM_p last">HCT-116 cells (2 × 10<sup>5</sup> in 5 mL of McCoy’s medium supplemented with 2 mM <span class="smallcaps smallerCapital">l</span>-glutamine and 10% fetal bovine serum) were seeded in 60 mm dishes 16–24 h before drug treatment. Each dish was treated separately with different concentrations of <b>26h</b> or DMSO for 24 h prior to lysis using a modified radioimmunoprecipitation buffer (50 mM Tris-HCl, 150 mM NaCl, 1% sodium deoxycholate, 0.25 mM EDTA (pH 8.0), 1% Triton X-100, 0.2% NaF, and protease inhibitor cocktail (Sigma catalog number P8340). Proteins were measured using the Bradford assay, and 30 μg of lysate from each treatment was resolved on 10% SDS–PAGE and transferred onto PVDF membrane. Western blot analyses using antibodies against phospho-Rb (catalog number 9308, Cell Signaling Technology, Danvers, MA) and β-actin (catalog number A2066, Sigma-Aldrich, St. Louis, MO) were performed using dilutions recommended by suppliers. Signals were detected using autoradiography with Pierce ECL Western blotting substrate (Thermo Fisher Scientific, Rockford, IL).</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i217" class="anchor-spacer"></div><h3 class="article-section__title" id="_i217"> High Throughput Solubility Assay</h3><div class="NLM_p last">This assay measures the solubility of a compound in PBS in a high throughput mode. The assay was done using 96-well semitransparent PP microplates with V-shaped bottom (Greiner Bio-One) and 96-well UV transparent microplates (Greiner Bio-One). Compound solutions (250 μM) were prepared in 10 mM phosphate buffer (pH 7.0) containing 20% DMSO in a total volume of 0.2 mL. Plates were placed on a shaker set at 600 rpm for 1.5 h, following which the plates were allowed to stand for 2 h at room temperature. The plates were centrifuged at 1500<i>g</i> for 15 min. The supernatants were transferred to a UV transparent microplate and analyzed by UV spectrophotometry at the appropriate absorption maxima. The concentration of the compound in the supernatant was quantified using a calibration curve. For calculated solubilities of 250 ± 30 μM, solubilities are reported as >250 μM (>150 μg/mL).</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i218" class="anchor-spacer"></div><h3 class="article-section__title" id="_i218"> Metabolic Stability in Liver Microsomes</h3><div class="NLM_p last">Compounds (5 μM) were incubated with MLM (mouse liver microsomes), RLM (rat liver microsomes), DLM (dog liver microsomes), and HLM (human liver microsomes) (final microsomal concentration of ∼0.87 mg/mL) in a reaction mix containing 50 mM potassium phosphate buffer (pH 7.4) and NADPH regeneration system, at 37 °C, in a total reaction volume of 1 mL. Reactions were terminated at 0, 15, 30, 45, and 60 min of incubation with a chilled mixture of acetonitrile and DMSO (80:20). The mixture was vortexed for 5 min, centrifuged at 13 200 rpm for 15 min at 4 °C, and the supernatants were analyzed by LC–MS/MS. Stability was assessed by plotting the percent of parent compound remaining against time on a log–linear scale, and half-life was estimated from the linear portion of the log–linear curve using the first order equation <i>t</i><sub>1/2</sub> = 0.693/<i>k</i>, where <i>k</i> is the slope of the curve (equal to the first order elimination rate constant).</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i219" class="anchor-spacer"></div><h3 class="article-section__title" id="_i219"> Human in Vitro CYP450 Inhibition Assay</h3><div class="NLM_p last"><b>26h</b> was incubated (at concentrations of 0.05, 0.25, 0.5, 2.5, 5, 25 μM in DMSO; final DMSO concentration of 0.35%) with human liver microsomes (0.25 mg/mL for CYP1A and CYP3A4, 0.5 mg/mL for CYP2C19 and CYP2D6, 1 mg/mL for CYP2C9) and NADPH (1 mM) in the presence of the probe substrate ethoxyresorufin (0.5 μM) for 5 min (CYP1A), tolbutamide (120 μM) for 60 min (CYP2C9), mephenytoin (25 μM) for 60 min (CYP2C19), dextromethorphan (5 μM) for 30 min (CYP2D6), and midazolam (2.5 μM) for 5 min (CYP3A4) at 37 °C. The selective inhibitors α-naphthoflavone, sulfaphenazole, tranylcypromine, quinidine, and ketoconazole were used as positive controls for CYP1A, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 inhibitor, respectively. For CYP1A, the reactions were terminated by the addition of methanol, and the formation of the metabolite, resorufin, was monitored by fluorescence (excitation wavelength of 535 nm, emission wavelength of 595 nm). For the CYP2C9, CYP2C19, CYP2D6, and CYP3A4 incubations, the reactions were terminated by the addition of methanol containing an internal standard. The samples were centrifuged, and the supernatants were combined for the simultaneous analysis of 4-hydroxytolbutamide, 4-hydroxymephenytoin, dextrorphan, 1-hydroxymidazolam, and the internal standard by LC–MS/MS. Formic acid in deionized water (final concentration of 0.1%) was added to the final sample prior to analysis. A decrease in the formation of the metabolites compared to vehicle control was used to calculate an IC<sub>50</sub> value (test compound concentration that produces 50% inhibition).</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i220" class="anchor-spacer"></div><h3 class="article-section__title" id="_i220"> Caco-2 Bidirectional Permeability Assay</h3><div class="NLM_p last"><b>26h</b> at 5 μM in Hank’s balanced salt solution (HBSS), final DMSO concentration less than 1%, was placed in 21–28 day confluent monolayer cells in Transwell assay plates. Both apical and basolateral sides were maintained at pH 7.4. When dosed on the apical side, the permeability in the A → B direction was assessed, and when dosed on the basolateral side, the B → A direction was assessed. Both apical and basolateral sides were sampled at 2 h. The concentration of <b>26h</b> was determined by LC/MS using a four-point calibration curve. Atenolol (<i>P</i><sub>app</sub> < 0.5 × 10<sup>–6</sup> cm/s), propranolol (15 × 10<sup>–6</sup> cm/s < <i>P</i><sub>app</sub> < 25 × 10<sup>–6</sup> cm/s), Lucifer yellow (<i>P</i><sub>app</sub> > 0.4 × 10<sup>–6</sup> cm/s), and digoxin (efflux ratio of >3) were used in the quality control of the monolayer batch. The integrity of the monolayer was determined by measuring the pre-experiment TEER (between 450 and 650 Ωcm<sup>2</sup>) and using Lucifer yellow (efflux of ≤0.5%). The efflux ratio was defined as the ratio of <i>P</i><sub>app,B→A</sub> to <i>P</i><sub>app,A→B</sub>.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i221" class="anchor-spacer"></div><h3 class="article-section__title" id="_i221"> In Vitro Plasma Protein Binding</h3><div class="NLM_p last">Equilibrium dialysis was performed in a Micro-Equilibrium Dialyzer (Harvard Apparatus) with a chamber volume of 500 μL (each compartment with a volume of 250 μL). The semipermeable membrane used was rinsed with Milli-Q water and soaked for 10 min in PBS. <b>26h</b> was added to plasma (from mouse, dog, and humans) to obtain a final concentration of 1000 ng/mL. The spiked plasma was vortexed, and 250 μL was aliquoted into one chamber of the dialyzer cell. The other chamber was filled with 250 μL of PBS buffer. The assembled cell was placed into a water bath at 37 °C, and dialysis was performed for 4 h. Following dialysis, 50 μL of PBS dialyzed samples containing free <b>26h</b> was transferred into 2 mL Eppendorf tubes in triplicate for extraction. Samples were extracted with 1500 μL of MTBE (methyl <i>tert</i>-butyl ether) for 30 min using a mixer at motor speed setting 60 with pulsing. After 30 min, the sample tubes were centrifuged at 4 °C for 10 min at 13 000 rpm in a microcentrifuge. The supernatant (1400 μL) was transferred into fresh 2 mL Eppendorf tubes and dried in a SpeedVac at 43 °C for 35 min. The dried samples were reconstituted with 100 μL of methanol/Milli-Q H<sub>2</sub>O (60:40) and analyzed by LC–MS/MS.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i222" class="anchor-spacer"></div><h3 class="article-section__title" id="_i222"> Pharmacokinetics</h3><div class="NLM_p last">Male BALB/c mice (aged ∼10–12 weeks and weighing 17–22 g), male Beagle dogs (∼6–7 months of age, weighing 10–14 kg), and male Wistar rats (aged 6–8 weeks, weighing 239–249 g) were used in this study. All the animal studies were performed as per approved internal protocols for animal care and use. The oral doses for mice, dogs, and rats were 75, 10, and 10 mg/kg, respectively. The doses were administered by gavage as suspensions (0.5% methylcellulose and 0.1% Tween 80) to mice and rats, and as gelatin capsules (12 Torpac) to dogs. Following oral dosing serial blood samples were collected (cardiac puncture in mice, jugular vein in dogs, and superior vena cava in rats) at different time points (0–24 h) in tubes containing K<sub>3</sub>EDTA as anticoagulant, centrifuged, and plasma was separated and stored at −70 °C until analysis. Plasma samples were processed and analyzed by LC–MS/MS. Pharmacokinetic parameters were estimated by noncompartmental methods using WinNonlin (version 5.1, Pharsight, CA).</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i223" class="anchor-spacer"></div><h3 class="article-section__title" id="_i223"> Materials and Methods for HCT-116 and Ramos Studies</h3><div id="sec5_11_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i224" class="anchor-spacer"></div><h4 class="article-section__title" id="_i224">1 Mice/Husbandry</h4><div class="NLM_p last">Female BALB/c nude mice (ARC, West Australia), 10–12 weeks of age, were fed with sterilized tap water (ad libitum water) and irradiated standard rodent diet consisting of 19% protein, 5% fat, and 5% fiber. Mice were housed in individual ventilated cages on a 12 h light cycle at 21–22 °C and 40–60% humidity. The use of animals in the Biological Resource Centre (BRC), Biopolis, Singapore, is compliant with the recommendations of the Guide for Care and Use of Laboratory Animals with respect to restraint, husbandry, surgical procedures, feed and fluid regulation, and veterinary care. The animal care and use program, 050076 at BRC, is Institutional Animal Care and Use Committee (IACUC) accredited.</div></div><div id="sec5_11_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i225" class="anchor-spacer"></div><h4 class="article-section__title" id="_i225">2 Tumor Implantation</h4><div id="sec5_11_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i226" class="anchor-spacer"></div><h5 class="article-section__title" id="_i226">2.1 For HCT-116 Study</h5><div class="NLM_p last">Mice were implanted subcutaneously in the right flank with 5 × 10<sup>6</sup> cells of HCT-116 human colon carcinoma. Each tumor was monitored twice per week and subsequently daily as the neoplasms reached the desired size of approximately 100 mm<sup>3</sup>. At day 8, when the tumors attained a calculated tumor volume between 75 to 144 mm<sup>3</sup>, the animals were pair-matched and distributed randomly into various treatment groups (the mean tumor volume in each group was 105 mm<sup>3</sup>). Estimated tumor volume was calculated using the formula<span class="NLM_disp-formula" id="ueq1"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/jm-2011-01112g_m001.gif" alt="" /></img></span>where <i>w</i> is the width and <i>l</i> is the length in mm of an HCT-116 carcinoma.</div></div><div id="sec5_11_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i227" class="anchor-spacer"></div><h5 class="article-section__title" id="_i227">2.2 For Ramos Study</h5><div class="NLM_p last">Mice were implanted subcutaneously in the right flank with 7 × 10<sup>6</sup> cells of Ramos (ATCC No. CRL-9591) cells (100 μL). The tumor size was monitored twice per week and subsequently daily as the neoplasms reached the desired size, approximately 200 mm<sup>3</sup>. On day 12, when the tumors attained a volume of between 75 and 405 mm<sup>3</sup>, the animal were pair-matched and distributed randomly into various treatment groups (the mean tumor volume in each group was 216 mm<sup>3</sup>). Estimated tumor volume was calculated using the formula<span class="NLM_disp-formula" id="ueq2"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/jm-2011-01112g_m002.gif" alt="" /></img></span>where <i>w</i> is the width and <i>l</i> is the length in mm of a Ramos tumor.</div></div></div><div id="sec5_11_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i228" class="anchor-spacer"></div><h4 class="article-section__title" id="_i228">3 Drug</h4><div class="NLM_p last"><b>26h</b> hydrochloride was synthesized at S*BIO PTE LTD and dissolved in 0.5% methyl cellulose/0.1% Tween 80 (MC/Tween) for oral (po) dosing or in 10% dimethylacetamide (DMA) and 10% Cremophor (DMA/CRE) for ip dosing. Dosing solutions were prepared weekly in a feeding volume of 10 mL per kilogram body weight and stored at 4 °C.</div></div><div id="sec5_11_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i229" class="anchor-spacer"></div><h4 class="article-section__title" id="_i229">4 Treatment Plan</h4><div id="sec5_11_4_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i230" class="anchor-spacer"></div><h5 class="article-section__title" id="_i230">4.1 For HCT-116 Study</h5><div class="NLM_p last">On day 1, HCT-116-bearing nude mice were pair-matched and placed into 3 groups of 9–10 animals each. Treatment with all drugs was initiated on day 1. The test compound, <b>26h</b>, was administered po at the following dosing schedules: 50 and 75 mg/kg × 3 times a week (Monday, Wednesday, and Friday; 3/w). There was a vehicle control group that received vehicle (MC/Tween) on the same schedule. The study was terminated on day 15.</div></div><div id="sec5_11_4_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i231" class="anchor-spacer"></div><h5 class="article-section__title" id="_i231">4.2 For Ramos Study</h5><div class="NLM_p last"><b>26h</b> was administered once daily at doses of 75 mg/kg po q.d. 2d_on–5d_off or 15 mg/kg ip q.d. 5d_on–5d_off. There were two vehicle control groups that received either MC/Tween or DMA/CRE. The treatment groups were compared with the corresponding vehicle control group for the percentage of the tumor growth inhibition (% TGI). The treatment was terminated after 14 days of dosing.</div></div></div><div id="sec5_11_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i232" class="anchor-spacer"></div><h4 class="article-section__title" id="_i232">5 End Points.Tumor Growth Inhibition</h4><div class="NLM_p last">Activity was assessed by the tumor growth inhibition (TGI) method in which treatment-effected decreases in tumor volume on day 15 of various treatment groups were compared to the vehicle group. The percent tumor growth inhibition (% TGI) was calculated as follows:<span class="NLM_disp-formula" id="ueq3"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/jm-2011-01112g_m003.gif" alt="" /></img></span>where Cday_1 is the median tumor volume for control group (vehicle) on day 1, Cday_a is the median tumor volume for control group (vehicle) on day a, and Tday_a is median tumor volume for treatment group on day a.</div></div><div id="sec5_11_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i233" class="anchor-spacer"></div><h4 class="article-section__title" id="_i233">6 Statistics</h4><div id="sec5_11_6_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i234" class="anchor-spacer"></div><h5 class="article-section__title" id="_i234">6.1 For HCT-116 study</h5><div class="NLM_p last">The two-way ANOVA followed by Bonferroni posttests was used to determine the statistical significance of median tumor volume between groups. Statistical analyses were conducted at a <i>p</i> level of 0.05. Prism (GraphPad), version 3, was used for all statistical analyses and graphic presentations.</div></div><div id="sec5_11_6_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i235" class="anchor-spacer"></div><h5 class="article-section__title" id="_i235">6.2 For Ramos study</h5><div class="NLM_p last">The Mann–Whitney <i>U</i> test was used to determine the statistical significance of median tumor volume between a treatment group and the vehicle control group. Statistical analyses were conducted at a <i>p</i> level of 0.05. Prism (GraphPad), version 3, was used for all statistical analyses and graphic presentations.</div></div></div></div><div id="sec6" class="NLM_sec NLM_sec_level_2"><div id="ac_i236" class="anchor-spacer"></div><h3 class="article-section__title" id="_i236"> Computational</h3><div class="NLM_p">The molecules were built using Maestro, version 8.0.308, or converted to 3D structures from the 2D structure using LigPrep, version 2.1.207.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Basic amines were protonated as in aqueous solution at physiological pH. The conformational space was searched using the Monte Carlo multiple minima (MCMM) method as implemented in MacroModel, version 9.5.207.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> All heavy atoms and hydrogens on heteroatoms were included in the test for duplicate conformations. All rotatable single bonds were included in the conformational search. All aliphatic rings were ring-opened, and quaternary atoms were allowed to invert. Each search was continued until the global energy minima were found at least 3 times. The energy minimizations were carried out using the truncated Newton conjugate gradient algorithm (TNCG) and the OPLS-AA force field as implemented in MacroModel.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Default parameters were used. The conformational searches were done for aqueous solution using the generalized Born/solvent accessible surface (GB/SA) continuum solvation model.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a></div><div class="NLM_p last">The CDK2 (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1AQ1">1AQ1</a>),<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> and Flt3 (PDB entry <a href="https://" class="ext-link">1RJB</a>)<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> X-ray structures were downloaded from the Protein Data Bank (PDB<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a>). The protein structures were prepared using the protein preparation wizard in Maestro with standard settings. Grids were generated using Glide, version 4.5.208, following the standard procedure recommended by Schrödinger.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> The conformational ensembles were docked flexibly using Glide with standard settings in both standard and extra precision mode. Only poses with low energy conformations and good hydrogen bond geometries were considered. cLogP values were calculated using QikProp, version 3.0.207, with standard settings.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i237"><a href="/doi/suppl/10.1021/jm201112g">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76613" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76613" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Explanation for the potency of <b>26r</b> against CDK2, structures of the RCM catalysts employed and the iv/po PK of <b>27j</b> in mice. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm201112g/suppl_file/jm201112g_si_001.pdf">jm201112g_si_001.pdf (231.9 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm201112g" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16553" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16553" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anthony D. William</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science Park Road, No. 05-09, The
Capricorn, Singapore Science Park II, 117528, Singapore</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#cdbaaca3b9a5a2a3b4fcfc8db4aca5a2a2e3aea2a0"><span class="__cf_email__" data-cfemail="3f485e514b575051460e0e7f465e575050115c5052">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Angeline C.-H. Lee</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science Park Road, No. 05-09, The
Capricorn, Singapore Science Park II, 117528, Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kee Chuan Goh</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science Park Road, No. 05-09, The
Capricorn, Singapore Science Park II, 117528, Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stéphanie Blanchard</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science Park Road, No. 05-09, The
Capricorn, Singapore Science Park II, 117528, Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anders Poulsen</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science Park Road, No. 05-09, The
Capricorn, Singapore Science Park II, 117528, Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ee Ling Teo</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science Park Road, No. 05-09, The
Capricorn, Singapore Science Park II, 117528, Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Harish Nagaraj</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science Park Road, No. 05-09, The
Capricorn, Singapore Science Park II, 117528, Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chai Ping Lee</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science Park Road, No. 05-09, The
Capricorn, Singapore Science Park II, 117528, Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Haishan Wang</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science Park Road, No. 05-09, The
Capricorn, Singapore Science Park II, 117528, Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Meredith Williams</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science Park Road, No. 05-09, The
Capricorn, Singapore Science Park II, 117528, Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eric T. Sun</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science Park Road, No. 05-09, The
Capricorn, Singapore Science Park II, 117528, Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Changyong Hu</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science Park Road, No. 05-09, The
Capricorn, Singapore Science Park II, 117528, Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ramesh Jayaraman</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science Park Road, No. 05-09, The
Capricorn, Singapore Science Park II, 117528, Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mohammed Khalid Pasha</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science Park Road, No. 05-09, The
Capricorn, Singapore Science Park II, 117528, Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kantharaj Ethirajulu</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science Park Road, No. 05-09, The
Capricorn, Singapore Science Park II, 117528, Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeanette M. Wood</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science Park Road, No. 05-09, The
Capricorn, Singapore Science Park II, 117528, Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brian W. Dymock</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science Park Road, No. 05-09, The
Capricorn, Singapore Science Park II, 117528, Singapore</span></div></li></ul></li><li></li><li></li><li></li></ul></div><div class="ack" id="ACK-d3802e11146-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i238">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81466" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81466" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Bee Kheng Ng and Wai Chung Ong for the biological screening data, Venkatesh Reddy for PK sample analysis, Sam Ramanujulu Murugappan for NMR related work, Zahid Bonday and Miah Kiat for protein preparation work, Veronica Diermayr, Stefan Hart, Tracy Lawhon, and Rob Mansfield for critical review of the manuscript, and Simon Campbell for helpful discussions.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i239" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i239"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i240" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i240"> Abbreviations Used</h2><tr><td class="NLM_term">AML</td><td class="NLM_def"><p class="first last">acute myeloid leukemia</p></td></tr><tr><td class="NLM_term">CDK</td><td class="NLM_def"><p class="first last">cyclin-dependent kinase</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P450</p></td></tr><tr><td class="NLM_term">ERK5</td><td class="NLM_def"><p class="first last">extracellular signal-regulated kinase-5</p></td></tr><tr><td class="NLM_term">ET</td><td class="NLM_def"><p class="first last">essential thrombocythemia</p></td></tr><tr><td class="NLM_term">FLT3</td><td class="NLM_def"><p class="first last">fms-like receptor tyrosine kinase 3</p></td></tr><tr><td class="NLM_term">JAK2</td><td class="NLM_def"><p class="first last">Janus kinase 2</p></td></tr><tr><td class="NLM_term">MF</td><td class="NLM_def"><p class="first last">myelofibrosis</p></td></tr><tr><td class="NLM_term">MPN</td><td class="NLM_def"><p class="first last">myeloproliferative neoplasms</p></td></tr><tr><td class="NLM_term">PV</td><td class="NLM_def"><p class="first last">polycythemia vera</p></td></tr><tr><td class="NLM_term">RCM</td><td class="NLM_def"><p class="first last">ring closing metathesis</p></td></tr><tr><td class="NLM_term">RTKs</td><td class="NLM_def"><p class="first last">receptor tyrosine kinases</p></td></tr><tr><td class="NLM_term">STAT</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription</p></td></tr><tr><td class="NLM_term">TGI</td><td class="NLM_def"><p class="first last">tumor growth inhibition</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i241">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42164" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42164" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 41 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Cantley, L. C. and Baselga, J.</span><span> </span><span class="NLM_article-title">The era of cancer discovery</span>.  <span class="citation_source-journal">Cancer Discovery</span> [Online early access]. DOI: <span class="refDoi"> DOI: 10.1158/2159-8274.CD-11-0049</span> . Published Online: Apr 3,<span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm201112g&amp;key=10.1158%2F2159-8274.CD-11-0049" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=L.+C.+Cantley&author=J.+Baselga&title=The+era+of+cancer+discovery&doi=10.1158%2F2159-8274.CD-11-0049"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1158%2F2159-8274.CD-11-0049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8274.CD-11-0049%26sid%3Dliteratum%253Aachs%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DThe%2520era%2520of%2520cancer%2520discovery%26jtitle%3DCancer%2520Discovery%26doi%3D10.1158%2F2159-8274.CD-11-0049%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Bianco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damiano, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelardi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daniele, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciardiello, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tortora, G.</span><span> </span><span class="NLM_article-title">Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">3358</span><span class="NLM_x">–</span> <span class="NLM_lpage">3367</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm201112g&amp;key=10.2174%2F138161207782360537" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm201112g&amp;key=18045190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm201112g&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVOrs7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=3358-3367&author=R.+Biancoauthor=V.+Damianoauthor=T.+Gelardiauthor=G.+Danieleauthor=F.+Ciardielloauthor=G.+Tortora&title=Rational+combination+of+targeted+therapies+as+a+strategy+to+overcome+the+mechanisms+of+resistance+to+inhibitors+of+EGFR+signaling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling</span></div><div class="casAuthors">Bianco, Roberto; Damiano, Vincenzo; Gelardi, Teresa; Daniele, Gennaro; Ciardiello, Fortunato; Tortora, Giampaolo</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">3358-3367</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The epidermal growth factor receptor (EGFR) has been widely used as a target for novel anticancer agents, such as blocking antibodies and small mol. wt. tyrosine kinase compds.  In spite of recent advances in cancer cell biol., leading to the introduction of clin. active new drugs, such as cetuximab, panitumumab and erlotinib, unfortunately disease control remains unsuccessful due to the presence of constitutive resistance to EGFR inhibitors in most patients and the development of acquired resistance in the responders.  A large no. of mol. abnormalities in tumor cells seem to partly contribute to their resistance to anti-EGFR therapy: increased angiogenesis, constitutive activation of downstream mediators, overexpression of other tyrosine kinase receptors.  Moreover, some mutations in the EGFR receptor kinase domain seem to play a crucial role in detg. the sensitivity of cancer cells to specific inhibitors by altering the conformation of the receptor and its activity.  The development of rational combinations of anticancer agents and EGFR inhibitors, able to exert synergistic cytotoxic interactions, has been widely accepted and used in both preclin. and clin. studies.  Although the failure of large clin. trial based on empirical combination of anti-EGFR and classic chemotherapeutic agents, several preclin. data seems to support the hypothesis that combining EGFR inhibitors and other novel agents could efficiently inhibit tumor growth and overcome intrinsic resistance to a single-agent based therapy.  This review focuses on the role of complementary signaling pathways in the development of resistance to EGFR targeting agents and the rationale to combine novel inhibitors as anticancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqLu7Fv44yMrVg90H21EOLACvtfcHk0lh0S9lnzOphnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVOrs7zK&md5=3af9889204032dcac6b74f1d5ebc673e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.2174%2F138161207782360537&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161207782360537%26sid%3Dliteratum%253Aachs%26aulast%3DBianco%26aufirst%3DR.%26aulast%3DDamiano%26aufirst%3DV.%26aulast%3DGelardi%26aufirst%3DT.%26aulast%3DDaniele%26aufirst%3DG.%26aulast%3DCiardiello%26aufirst%3DF.%26aulast%3DTortora%26aufirst%3DG.%26atitle%3DRational%2520combination%2520of%2520targeted%2520therapies%2520as%2520a%2520strategy%2520to%2520overcome%2520the%2520mechanisms%2520of%2520resistance%2520to%2520inhibitors%2520of%2520EGFR%2520signaling%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2007%26volume%3D13%26spage%3D3358%26epage%3D3367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Mayfield, E.</span><span> </span><span class="NLM_article-title">Combining targeted cancer therapies: much promise, many hurdles</span>.  <span class="citation_source-journal">NCI Cancer Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x"> (</span><span class="NLM_issue">No. 10</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2011&issue=No.+10&author=E.+Mayfield&title=Combining+targeted+cancer+therapies%3A+much+promise%2C+many+hurdles"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMayfield%26aufirst%3DE.%26atitle%3DCombining%2520targeted%2520cancer%2520therapies%253A%2520much%2520promise%252C%2520many%2520hurdles%26jtitle%3DNCI%2520Cancer%2520Bull.%26date%3D2011%26volume%3D8%26issue%3DNo.%252010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Rexer, B. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arteaga, C. L.</span><span> </span><span class="NLM_article-title">Inhibition of PI3K and MEK: It is all about combinations and biomarkers</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">4518</span><span class="NLM_x">–</span> <span class="NLM_lpage">4520</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm201112g&amp;key=10.1158%2F1078-0432.CCR-09-0872" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm201112g&amp;key=19584146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm201112g&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosV2ltrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=4518-4520&author=B.+N.+Rexerauthor=R.+Ghoshauthor=C.+L.+Arteaga&title=Inhibition+of+PI3K+and+MEK%3A+It+is+all+about+combinations+and+biomarkers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of PI3K and MEK: It Is All about Combinations and Biomarkers</span></div><div class="casAuthors">Rexer, Brent N.; Ghosh, Ritwik; Arteaga, Carlos L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4518-4520</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  A small mol. inhibitor of MAP/ERK kinase (MEK) was effective against human breast cancer cells with a basal-like gene expression signature.  Antitumor activity was limited by both feedback upregulation of phosphatidylinositol-3 kinase (PI3K)/AKT upon inhibition of MEK as well as loss of the phosphatase PTEN.  Therefore, MEK inhibitors should preferably be investigated in combination with PI3K inhibitors in basal-like breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGori6Ze0cah3bVg90H21EOLACvtfcHk0lh0S9lnzOphnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosV2ltrc%253D&md5=632a572a8949d9ee2eada07972a8ac65</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-0872&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-0872%26sid%3Dliteratum%253Aachs%26aulast%3DRexer%26aufirst%3DB.%2BN.%26aulast%3DGhosh%26aufirst%3DR.%26aulast%3DArteaga%26aufirst%3DC.%2BL.%26atitle%3DInhibition%2520of%2520PI3K%2520and%2520MEK%253A%2520It%2520is%2520all%2520about%2520combinations%2520and%2520biomarkers%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D4518%26epage%3D4520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Flaherty, K. T.</span><span> </span><span class="NLM_article-title">Sorafenib: delivering a targeted drug to the right targets</span> <span class="citation_source-journal">Expert Rev. Anticancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">617</span><span class="NLM_x">–</span> <span class="NLM_lpage">626</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm201112g&amp;key=10.1586%2F14737140.7.5.617" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm201112g&amp;key=17492926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm201112g&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmvVKqs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=617-626&author=K.+T.+Flaherty&title=Sorafenib%3A+delivering+a+targeted+drug+to+the+right+targets"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Sorafenib: delivering a targeted drug to the right targets</span></div><div class="casAuthors">Flaherty, Keith T.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">617-626</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Future Drugs Ltd.</span>)
        </div><div class="casAbstract">A review.  Approved for the treatment of advanced renal cell carcinoma by the US FDA and other regulatory agencies, sorafenib is an agent with multiple targets that may also prove beneficial in other malignancies.  Phase III trials are underway in melanoma, hepatocellular carcinoma and non-small-cell lung cancer.  Scrutiny of the Phase II data and correlative studies conducted in that context suggests that inhibition of angiogenesis and signaling in tumor cells may play a part in the clin. efficacy of sorafenib.  Although the vascular endothelial growth factor receptor inhibitors are the most populated class of targeted agents in cancer clin. trials, sorafenib may prove to have unique properties that distinguish it.  A detailed discussion of the clin. trials in renal cell carcinoma, melanoma and hepatocellular carcinoma highlights what is known and what has yet to be understood about this agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn28JpeD5ex7Vg90H21EOLACvtfcHk0lj5ugCZGhMYow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmvVKqs70%253D&md5=aaa7fef25f3874c1371b7f8f627a2859</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1586%2F14737140.7.5.617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737140.7.5.617%26sid%3Dliteratum%253Aachs%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26atitle%3DSorafenib%253A%2520delivering%2520a%2520targeted%2520drug%2520to%2520the%2520right%2520targets%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2007%26volume%3D7%26spage%3D617%26epage%3D626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Mena, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pulido, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guillén-Ponce, C.</span><span> </span><span class="NLM_article-title">Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib</span> <span class="citation_source-journal">Anti-Cancer Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">S3</span><span class="NLM_x">–</span> <span class="NLM_lpage">11</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2010&pages=S3-11&issue=Suppl.+1&author=A.+C.+Menaauthor=E.+G.+Pulidoauthor=C.+Guill%C3%A9n-Ponce&title=Understanding+the+molecular-based+mechanism+of+action+of+the+tyrosine+kinase+inhibitor%3A+sunitinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMena%26aufirst%3DA.%2BC.%26aulast%3DPulido%26aufirst%3DE.%2BG.%26aulast%3DGuill%25C3%25A9n-Ponce%26aufirst%3DC.%26atitle%3DUnderstanding%2520the%2520molecular-based%2520mechanism%2520of%2520action%2520of%2520the%2520tyrosine%2520kinase%2520inhibitor%253A%2520sunitinib%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2010%26volume%3D21%26issue%3DSuppl.%25201%26spage%3DS3%26epage%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Lai, C.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atoyan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D.-G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrester, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zifcak, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, G.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DellaRocca, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, H.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munger, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keegan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pepicelli, C. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, C.</span><span> </span><span class="NLM_article-title">CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2 exerts potent anticancer activity</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">3647</span><span class="NLM_x">–</span> <span class="NLM_lpage">3656</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=3647-3656&author=C.-J.+Laiauthor=R.+Baoauthor=X.+Taoauthor=J.+Wangauthor=R.+Atoyanauthor=H.+Quauthor=D.-G.+Wangauthor=L.+Yinauthor=M.+Samsonauthor=J.+Forresterauthor=B.+Zifcakauthor=G.-X.+Xuauthor=S.+DellaRoccaauthor=H.-X.+Zhaiauthor=X.+Caiauthor=W.+E.+Mungerauthor=M.+Keeganauthor=C.+V.+Pepicelliauthor=C.+Qian&title=CUDC-101%2C+a+multitargeted+inhibitor+of+histone+deacetylase%2C+epidermal+growth+factor+receptor%2C+and+human+epidermal+growth+factor+receptor+2+exerts+potent+anticancer+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DC.-J.%26aulast%3DBao%26aufirst%3DR.%26aulast%3DTao%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DAtoyan%26aufirst%3DR.%26aulast%3DQu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DD.-G.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DSamson%26aufirst%3DM.%26aulast%3DForrester%26aufirst%3DJ.%26aulast%3DZifcak%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DG.-X.%26aulast%3DDellaRocca%26aufirst%3DS.%26aulast%3DZhai%26aufirst%3DH.-X.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DMunger%26aufirst%3DW.%2BE.%26aulast%3DKeegan%26aufirst%3DM.%26aulast%3DPepicelli%26aufirst%3DC.%2BV.%26aulast%3DQian%26aufirst%3DC.%26atitle%3DCUDC-101%252C%2520a%2520multitargeted%2520inhibitor%2520of%2520histone%2520deacetylase%252C%2520epidermal%2520growth%2520factor%2520receptor%252C%2520and%2520human%2520epidermal%2520growth%2520factor%2520receptor%25202%2520exerts%2520potent%2520anticancer%2520activity%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D3647%26epage%3D3656" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Knockaert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greengard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meijer, L.</span><span> </span><span class="NLM_article-title">Pharmacological inhibitors of cyclin-dependent kinases</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">417</span><span class="NLM_x">–</span> <span class="NLM_lpage">425</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm201112g&amp;key=10.1016%2FS0165-6147%2802%2902071-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm201112g&amp;key=12237154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm201112g&amp;key=1%3ACAS%3A528%3ADC%252BD38XntVWmsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2002&pages=417-425&author=M.+Knockaertauthor=P.+Greengardauthor=L.+Meijer&title=Pharmacological+inhibitors+of+cyclin-dependent+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological inhibitors of cyclin-dependent kinases</span></div><div class="casAuthors">Knockaert, Marie; Greengard, Paul; Meijer, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">417-425</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Cyclin-dependent kinases (CDKs) regulate the cell division cycle, apoptosis, transcription and differentiation in addn. to functions in the nervous system.  Deregulation of CDKs in various diseases has stimulated an intensive search for selective pharmacol. inhibitors of these kinases.  More than 50 inhibitors have been identified, among which >20 have been co-crystd. with CDK2.  These inhibitors all target the ATP-binding pocket of the catalytic site of the kinase.  The actual selectivity of most known CDK inhibitors, and thus the underlying mechanism of their cellular effects, is poorly known.  Pharmacol. inhibitors of CDKs are currently being evaluated for therapeutic use against cancer, alopecia, neurodegenerative disorders (e.g. Alzheimer's disease, amyotrophic lateral sclerosis and stroke), cardiovascular disorders (e.g. atherosclerosis and restenosis), glomerulonephritis, viral infections (e.g. HCMV, HIV and HSV) and parasitic protozoa (Plasmodium sp. and Leishmania sp.).  Pharmacol. inhibitors of cyclin-dependent kinases are being actively investigated in view of their potential therapeutic use against a large variety of indications such as cancers, Alzheimer's disease and other neurodegenerative disorders, and viral infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokE1X0jvc9GbVg90H21EOLACvtfcHk0lj5ugCZGhMYow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XntVWmsbY%253D&md5=09bb4b161d30cbff71b80f7aae505843</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS0165-6147%2802%2902071-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0165-6147%252802%252902071-0%26sid%3Dliteratum%253Aachs%26aulast%3DKnockaert%26aufirst%3DM.%26aulast%3DGreengard%26aufirst%3DP.%26aulast%3DMeijer%26aufirst%3DL.%26atitle%3DPharmacological%2520inhibitors%2520of%2520cyclin-dependent%2520kinases%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2002%26volume%3D23%26spage%3D417%26epage%3D425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Shapiro, G. I.</span><span> </span><span class="NLM_article-title">Cyclin-dependent kinase pathways as targets for cancer treatment</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1770</span><span class="NLM_x">–</span> <span class="NLM_lpage">1783</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm201112g&amp;key=10.1200%2FJCO.2005.03.7689" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm201112g&amp;key=16603719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm201112g&amp;key=1%3ACAS%3A528%3ADC%252BD28XksVKgtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=1770-1783&author=G.+I.+Shapiro&title=Cyclin-dependent+kinase+pathways+as+targets+for+cancer+treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase pathways as targets for cancer treatment</span></div><div class="casAuthors">Shapiro, Geoffrey I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1770-1783</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  Cyclin-dependent kinases (cdks) are crit. regulators of cell cycle progression and RNA transcription.  A variety of genetic and epigenetic events cause universal overactivity of the cell cycle cdks in human cancer, and their inhibition can lead to both cell cycle arrest and apoptosis.  However, built-in redundancy may limit the effects of highly selective cdk inhibition.  Cdk4/6 inhibition has been shown to induce potent G1 arrest in vitro and tumor regression in vivo; cdk2/1 inhibition has the most potent effects during the S and G2 phases and induces E2F transcription factor-dependent cell death.  Modulation of cdk2 and cdk1 activities also affects survival checkpoint responses after exposure to DNA-damaging and microtubule-stabilizing agents.  The transcriptional cdks phosphorylate the carboxy-terminal domain of RNA polymerase II, facilitating efficient transcriptional initiation and elongation.  Inhibition of these cdks primarily affects the accumulation of transcripts with short half-lives, including those encoding antiapoptosis family members, cell cycle regulators, as well as p53 and nuclear factor-kappa B-responsive gene targets.  These effects may account for apoptosis induced by cdk9 inhibitors, esp. in malignant hematopoietic cells, and may also potentiate cytotoxicity mediated by disruption of a variety of pathways in many transformed cell types.  Current work is focusing on overcoming pharmacokinetic barriers that hindered development of flavopiridol, a pan-cdk inhibitor, as well as assessing novel classes of compds. potently targeting groups of cell cycle cdks (cdk4/6 or cdk2/1) with variable effects on the transcriptional cdks 7 and 9.  These efforts will establish whether the strategy of cdk inhibition is able to produce therapeutic benefit in the majority of human tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYfmCpSfvpTbVg90H21EOLACvtfcHk0lj5ugCZGhMYow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XksVKgtbg%253D&md5=420a31b47f6600625f7d499a4b8a5fc9</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.03.7689&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.03.7689%26sid%3Dliteratum%253Aachs%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26atitle%3DCyclin-dependent%2520kinase%2520pathways%2520as%2520targets%2520for%2520cancer%2520treatment%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2006%26volume%3D24%26spage%3D1770%26epage%3D1783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Cai, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Latham, V. M.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span> </span><span class="NLM_article-title">Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">9270</span><span class="NLM_x">–</span> <span class="NLM_lpage">9280</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=9270-9280&author=D.+Caiauthor=V.+M.+Lathamauthor=X.+Zhangauthor=G.+I.+Shapiro&title=Combined+depletion+of+cell+cycle+and+transcriptional+cyclin-dependent+kinase+activities+induces+apoptosis+in+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DD.%26aulast%3DLatham%26aufirst%3DV.%2BM.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26atitle%3DCombined%2520depletion%2520of%2520cell%2520cycle%2520and%2520transcriptional%2520cyclin-dependent%2520kinase%2520activities%2520induces%2520apoptosis%2520in%2520cancer%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D9270%26epage%3D9280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Jorda, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Havlicek, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNae, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walkinshaw, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voller, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sturc, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navratilova, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuzma, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mistrik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strnad, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krystof, V.</span><span> </span><span class="NLM_article-title">Pyrazolo[4,3-<i>d</i>]pyrimidine bioisostere of roscovitine: evaluation of a novel selective inhibitor of cyclin-dependent kinases with antiproliferative activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">2980</span><span class="NLM_x">–</span> <span class="NLM_lpage">2993</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200064p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2980-2993&author=R.+Jordaauthor=L.+Havlicekauthor=I.+W.+McNaeauthor=M.+D.+Walkinshawauthor=J.+Vollerauthor=A.+Sturcauthor=J.+Navratilovaauthor=M.+Kuzmaauthor=M.+Mistrikauthor=J.+Bartekauthor=M.+Strnadauthor=V.+Krystof&title=Pyrazolo%5B4%2C3-d%5Dpyrimidine+bioisostere+of+roscovitine%3A+evaluation+of+a+novel+selective+inhibitor+of+cyclin-dependent+kinases+with+antiproliferative+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fjm200064p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200064p%26sid%3Dliteratum%253Aachs%26aulast%3DJorda%26aufirst%3DR.%26aulast%3DHavlicek%26aufirst%3DL.%26aulast%3DMcNae%26aufirst%3DI.%2BW.%26aulast%3DWalkinshaw%26aufirst%3DM.%2BD.%26aulast%3DVoller%26aufirst%3DJ.%26aulast%3DSturc%26aufirst%3DA.%26aulast%3DNavratilova%26aufirst%3DJ.%26aulast%3DKuzma%26aufirst%3DM.%26aulast%3DMistrik%26aufirst%3DM.%26aulast%3DBartek%26aufirst%3DJ.%26aulast%3DStrnad%26aufirst%3DM.%26aulast%3DKrystof%26aufirst%3DV.%26atitle%3DPyrazolo%255B4%252C3-d%255Dpyrimidine%2520bioisostere%2520of%2520roscovitine%253A%2520evaluation%2520of%2520a%2520novel%2520selective%2520inhibitor%2520of%2520cyclin-dependent%2520kinases%2520with%2520antiproliferative%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2980%26epage%3D2993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Wyatt, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodhead, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berdini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulstridge, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devine, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Early, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feltell, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMenamin, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navarro, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Reilly, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reule, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saxty, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seavers, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Squires, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trewartha, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woolford, A. J.</span><span> </span><span class="NLM_article-title">Identification of <i>N</i>-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1<i>H</i>-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">4986</span><span class="NLM_x">–</span> <span class="NLM_lpage">4999</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800382h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4986-4999&author=P.+G.+Wyattauthor=A.+J.+Woodheadauthor=V.+Berdiniauthor=J.+A.+Boulstridgeauthor=M.+G.+Carrauthor=D.+M.+Crossauthor=D.+J.+Davisauthor=L.+A.+Devineauthor=T.+R.+Earlyauthor=R.+E.+Feltellauthor=E.+J.+Lewisauthor=R.+L.+McMenaminauthor=E.+F.+Navarroauthor=M.+A.+O%E2%80%99Brienauthor=M.+O%E2%80%99Reillyauthor=M.+Reuleauthor=G.+Saxtyauthor=L.+C.+Seaversauthor=D.+M.+Smithauthor=M.+S.+Squiresauthor=G.+Trewarthaauthor=M.+T.+Walkerauthor=A.+J.+Woolford&title=Identification+of+N-%284-piperidinyl%29-4-%282%2C6-dichlorobenzoylamino%29-1H-pyrazole-3-carboxamide+%28AT7519%29%2C+a+novel+cyclin+dependent+kinase+inhibitor+using+fragment-based+X-ray+crystallography+and+structure+based+drug+design"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm800382h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800382h%26sid%3Dliteratum%253Aachs%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26aulast%3DWoodhead%26aufirst%3DA.%2BJ.%26aulast%3DBerdini%26aufirst%3DV.%26aulast%3DBoulstridge%26aufirst%3DJ.%2BA.%26aulast%3DCarr%26aufirst%3DM.%2BG.%26aulast%3DCross%26aufirst%3DD.%2BM.%26aulast%3DDavis%26aufirst%3DD.%2BJ.%26aulast%3DDevine%26aufirst%3DL.%2BA.%26aulast%3DEarly%26aufirst%3DT.%2BR.%26aulast%3DFeltell%26aufirst%3DR.%2BE.%26aulast%3DLewis%26aufirst%3DE.%2BJ.%26aulast%3DMcMenamin%26aufirst%3DR.%2BL.%26aulast%3DNavarro%26aufirst%3DE.%2BF.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DM.%2BA.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DM.%26aulast%3DReule%26aufirst%3DM.%26aulast%3DSaxty%26aufirst%3DG.%26aulast%3DSeavers%26aufirst%3DL.%2BC.%26aulast%3DSmith%26aufirst%3DD.%2BM.%26aulast%3DSquires%26aufirst%3DM.%2BS.%26aulast%3DTrewartha%26aufirst%3DG.%26aulast%3DWalker%26aufirst%3DM.%2BT.%26aulast%3DWoolford%26aufirst%3DA.%2BJ.%26atitle%3DIdentification%2520of%2520N-%25284-piperidinyl%2529-4-%25282%252C6-dichlorobenzoylamino%2529-1H-pyrazole-3-carboxamide%2520%2528AT7519%2529%252C%2520a%2520novel%2520cyclin%2520dependent%2520kinase%2520inhibitor%2520using%2520fragment-based%2520X-ray%2520crystallography%2520and%2520structure%2520based%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4986%26epage%3D4999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Hughes, A.</span><span> </span><span class="NLM_article-title">CDK inhibitors in 3D: problems with the drugs, their development plans or their linkage to disease?</span> <span class="citation_source-journal">Gene Ther. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span><span class="NLM_x">–</span> <span class="NLM_lpage">54</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2006&pages=41-54&author=A.+Hughes&title=CDK+inhibitors+in+3D%3A+problems+with+the+drugs%2C+their+development+plans+or+their+linkage+to+disease%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DA.%26atitle%3DCDK%2520inhibitors%2520in%25203D%253A%2520problems%2520with%2520the%2520drugs%252C%2520their%2520development%2520plans%2520or%2520their%2520linkage%2520to%2520disease%253F%26jtitle%3DGene%2520Ther.%2520Mol.%2520Biol.%26date%3D2006%26volume%3D10%26spage%3D41%26epage%3D54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Yamaoka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saharinen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holt, V. E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silvennoinen, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Shea, J. J.</span><span> </span><span class="NLM_article-title">The Janus kinases (Jaks)</span> <span class="citation_source-journal">Genome Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">253.1</span><span class="NLM_x">–</span> <span class="NLM_lpage">253.6</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=253.1-253.6&author=K.+Yamaokaauthor=P.+Saharinenauthor=M.+Pesuauthor=V.+E.+T.+Holtauthor=O.+Silvennoinenauthor=J.+J.+O%E2%80%99Shea&title=The+Janus+kinases+%28Jaks%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYamaoka%26aufirst%3DK.%26aulast%3DSaharinen%26aufirst%3DP.%26aulast%3DPesu%26aufirst%3DM.%26aulast%3DHolt%26aufirst%3DV.%2BE.%2BT.%26aulast%3DSilvennoinen%26aufirst%3DO.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520Janus%2520kinases%2520%2528Jaks%2529%26jtitle%3DGenome%2520Biol.%26date%3D2004%26volume%3D5%26spage%3D253.1%26epage%3D253.6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Baxter, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">East, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fourouclas, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swanton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vassiliou, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bench, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyd, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erber, W. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, A. R.</span><span> </span><span class="NLM_article-title">Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">365</span><span class="NLM_x">, </span> <span class="NLM_fpage">1054</span><span class="NLM_x">–</span> <span class="NLM_lpage">1061</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm201112g&amp;key=10.1016%2FS0140-6736%2805%2971142-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm201112g&amp;key=15781101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm201112g&amp;key=1%3ACAS%3A528%3ADC%252BD2MXisFGrs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=2005&pages=1054-1061&author=E.+J.+Baxterauthor=L.+M.+Scottauthor=P.+J.+Campbellauthor=C.+Eastauthor=N.+Fourouclasauthor=S.+Swantonauthor=G.+S.+Vassiliouauthor=A.+J.+Benchauthor=E.+M.+Boydauthor=N.+Curtinauthor=M.+A.+Scottauthor=W.+N.+Erberauthor=A.+R.+Green&title=Acquired+mutation+of+the+tyrosine+kinase+JAK2+in+human+myeloproliferative+disorders"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders</span></div><div class="casAuthors">Baxter, E. Joanna; Scott, Linda M.; Campbell, Peter J.; East, Clare; Fourouclas, Nasios; Swanton, Soheila; Vassiliou, George S.; Bench, Anthony J.; Boyd, Elaine M.; Curtin, Natasha; Scott, Mike A.; Erber, Wendy N.; Green, Anthony R.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">9464</span>),
    <span class="NLM_cas:pages">1054-1061</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Background: Human myeloproliferative disorders form a range of clonal haematol. malignant diseases, the main members of which are polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis.  The mol. pathogenesis of these disorders is unknown, but tyrosine kinases have been implicated in several related disorders.  We investigated the role of the cytoplasmic tyrosine kinase JAK2 in patients with a myeloproliferative disorder.  Methods: We obtained DNA samples from patients with polycythemia vera, essential thrombocythemia, or idiopathic myelofibrosis.  The coding exons of JAK2 were bidirectionally sequenced from peripheral-blood granulocytes, T cells, or both.  Allele-specific PCR, mol. cytogenetic studies, microsatellite PCR, Affymetrix single nucleotide polymorphism array analyses, and colony assays were undertaken on subgroups of patients.  Findings: A single point mutation (Val617Phe) was identified in JAK2 in 71 (97%) of 73 patients with polycythemia vera, 29 (57%) of 51 with essential thrombocythemia, and eight (50%) of 16 with idiopathic myelofibrosis.  The mutation is acquired, is present in a variable proportion of granulocytes, alters a highly conserved valine present in the neg. regulatory JH2 domain, and is predicted to dysregulate kinase activity.  It was heterozygous in most patients, homozygous in a subset as a result of mitotic recombination, and arose in a multipotent progenitor capable of giving rise to erythroid and myeloid cells.  The mutation was present in all erythropoietin-independent erythroid colonies.  Interpretation: A single acquired mutation of JAK2 was noted in more than half of patients with a myeloproliferative disorder.  Its presence in all erythropoietin-independent erythroid colonies demonstrates a link with growth factor hypersensitivity, a key biol. feature of these disorders.  Relevance to practice: Identification of the Val617Phe JAK2 mutation lays the foundation for new approaches to the diagnosis, classification, and treatment of myeloproliferative disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8cc-kg2leZrVg90H21EOLACvtfcHk0liviGlPYGlNdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXisFGrs7g%253D&md5=3c9dc565a1986a47d12e4bccd8c8cc1a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2805%2971142-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252805%252971142-9%26sid%3Dliteratum%253Aachs%26aulast%3DBaxter%26aufirst%3DE.%2BJ.%26aulast%3DScott%26aufirst%3DL.%2BM.%26aulast%3DCampbell%26aufirst%3DP.%2BJ.%26aulast%3DEast%26aufirst%3DC.%26aulast%3DFourouclas%26aufirst%3DN.%26aulast%3DSwanton%26aufirst%3DS.%26aulast%3DVassiliou%26aufirst%3DG.%2BS.%26aulast%3DBench%26aufirst%3DA.%2BJ.%26aulast%3DBoyd%26aufirst%3DE.%2BM.%26aulast%3DCurtin%26aufirst%3DN.%26aulast%3DScott%26aufirst%3DM.%2BA.%26aulast%3DErber%26aufirst%3DW.%2BN.%26aulast%3DGreen%26aufirst%3DA.%2BR.%26atitle%3DAcquired%2520mutation%2520of%2520the%2520tyrosine%2520kinase%2520JAK2%2520in%2520human%2520myeloproliferative%2520disorders%26jtitle%3DLancet%26date%3D2005%26volume%3D365%26spage%3D1054%26epage%3D1061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">James, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ugo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Couedic, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staerk, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delhommeau, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacout, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcon, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raslova, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennaceur-Griscelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villeval, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Constantinescu, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casadevall, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vainchenker, W.</span><span> </span><span class="NLM_article-title">A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">434</span><span class="NLM_x">, </span> <span class="NLM_fpage">1144</span><span class="NLM_x">–</span> <span class="NLM_lpage">1148</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm201112g&amp;key=10.1038%2Fnature03546" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm201112g&amp;key=15793561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm201112g&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjsF2ltbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=434&publication_year=2005&pages=1144-1148&author=C.+Jamesauthor=V.+Ugoauthor=J.+P.+Le+Couedicauthor=J.+Staerkauthor=F.+Delhommeauauthor=C.+Lacoutauthor=L.+Garconauthor=H.+Raslovaauthor=R.+Bergerauthor=A.+Bennaceur-Griscelliauthor=J.+L.+Villevalauthor=S.+N.+Constantinescuauthor=N.+Casadevallauthor=W.+Vainchenker&title=A+unique+clonal+JAK2+mutation+leading+to+constitutive+signalling+causes+polycythaemia+vera"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera</span></div><div class="casAuthors">James, Chloe; Ugo, Valerie; Le Couedic, Jean-Pierre; Staerk, Judith; Delhommeau, Francois; Lacout, Catherine; Garcon, Loic; Raslova, Hana; Berger, Roland; Bennaceur-Griscelli, Annelise; Villeval, Jean Luc; Constantinescu, Stefan N.; Casadevall, Nicole; Vainchenker, William</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">434</span>
        (<span class="NLM_cas:issue">7037</span>),
    <span class="NLM_cas:pages">1144-1148</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Myeloproliferative disorders are clonal hematopoietic stem cell malignancies characterized by independency or hypersensitivity of hematopoietic progenitors to numerous cytokines.  The mol. basis of most myeloproliferative disorders is unknown.  On the basis of the model of chronic myeloid leukemia, it is expected that a constitutive tyrosine kinase activity could be at the origin of these diseases.  Polycythemia vera is an acquired myeloproliferative disorder, characterized by the presence of polycythemia diversely assocd. with thrombocytosis, leukocytosis and splenomegaly.  Polycythemia vera progenitors are hypersensitive to erythropoietin and other cytokines.  Here, the authors describe a clonal and recurrent mutation in the JH2 pseudo-kinase domain of the Janus kinase 2 (JAK2) gene in most (>80%) polycythemia vera patients.  The mutation, a valine-to-phenylalanine substitution at amino acid position 617, leads to constitutive tyrosine phosphorylation activity that promotes cytokine hypersensitivity and induces erythrocytosis in a mouse model.  As this mutation is also found in other myeloproliferative disorders, this unique mutation will permit a new mol. classification of these disorders and novel therapeutical approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqy-6NigTwc97Vg90H21EOLACvtfcHk0liviGlPYGlNdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjsF2ltbk%253D&md5=9e9c223dd4e2da2ebf52d14edda85963</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnature03546&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature03546%26sid%3Dliteratum%253Aachs%26aulast%3DJames%26aufirst%3DC.%26aulast%3DUgo%26aufirst%3DV.%26aulast%3DLe%2BCouedic%26aufirst%3DJ.%2BP.%26aulast%3DStaerk%26aufirst%3DJ.%26aulast%3DDelhommeau%26aufirst%3DF.%26aulast%3DLacout%26aufirst%3DC.%26aulast%3DGarcon%26aufirst%3DL.%26aulast%3DRaslova%26aufirst%3DH.%26aulast%3DBerger%26aufirst%3DR.%26aulast%3DBennaceur-Griscelli%26aufirst%3DA.%26aulast%3DVilleval%26aufirst%3DJ.%2BL.%26aulast%3DConstantinescu%26aufirst%3DS.%2BN.%26aulast%3DCasadevall%26aufirst%3DN.%26aulast%3DVainchenker%26aufirst%3DW.%26atitle%3DA%2520unique%2520clonal%2520JAK2%2520mutation%2520leading%2520to%2520constitutive%2520signalling%2520causes%2520polycythaemia%2520vera%26jtitle%3DNature%26date%3D2005%26volume%3D434%26spage%3D1144%26epage%3D1148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Levine, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loriaux, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huntly, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loh, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beran, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoffregen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willis, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flores, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estey, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gattermann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armstrong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Look, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernard, O. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span> </span><span class="NLM_article-title">The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">3377</span><span class="NLM_x">–</span> <span class="NLM_lpage">3379</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2005&pages=3377-3379&author=R.+L.+Levineauthor=M.+Loriauxauthor=B.+J.+Huntlyauthor=M.+L.+Lohauthor=M.+Beranauthor=E.+Stoffregenauthor=R.+Bergerauthor=J.+J.+Clarkauthor=S.+G.+Willisauthor=K.+T.+Nguyenauthor=N.+J.+Floresauthor=E.+Esteyauthor=N.+Gattermannauthor=S.+Armstrongauthor=A.+T.+Lookauthor=J.+D.+Griffinauthor=O.+A.+Bernardauthor=M.+C.+Heinrichauthor=D.+G.+Gillilandauthor=B.+Drukerauthor=M.+W.+Deininger&title=The+JAK2V617F+activating+mutation+occurs+in+chronic+myelomonocytic+leukemia+and+acute+myeloid+leukemia%2C+but+not+in+acute+lymphoblastic+leukemia+or+chronic+lymphocytic+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLevine%26aufirst%3DR.%2BL.%26aulast%3DLoriaux%26aufirst%3DM.%26aulast%3DHuntly%26aufirst%3DB.%2BJ.%26aulast%3DLoh%26aufirst%3DM.%2BL.%26aulast%3DBeran%26aufirst%3DM.%26aulast%3DStoffregen%26aufirst%3DE.%26aulast%3DBerger%26aufirst%3DR.%26aulast%3DClark%26aufirst%3DJ.%2BJ.%26aulast%3DWillis%26aufirst%3DS.%2BG.%26aulast%3DNguyen%26aufirst%3DK.%2BT.%26aulast%3DFlores%26aufirst%3DN.%2BJ.%26aulast%3DEstey%26aufirst%3DE.%26aulast%3DGattermann%26aufirst%3DN.%26aulast%3DArmstrong%26aufirst%3DS.%26aulast%3DLook%26aufirst%3DA.%2BT.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DBernard%26aufirst%3DO.%2BA.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DDruker%26aufirst%3DB.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26atitle%3DThe%2520JAK2V617F%2520activating%2520mutation%2520occurs%2520in%2520chronic%2520myelomonocytic%2520leukemia%2520and%2520acute%2520myeloid%2520leukemia%252C%2520but%2520not%2520in%2520acute%2520lymphoblastic%2520leukemia%2520or%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DBlood%26date%3D2005%26volume%3D106%26spage%3D3377%26epage%3D3379" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Lin, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meloni, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodgers, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galya, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yue, T. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, J.</span><span> </span><span class="NLM_article-title">Enantioselective synthesis of Janus kinase inhibitor INCB018424 via an organocatalytic aza-Michael reaction</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1999</span><span class="NLM_x">–</span> <span class="NLM_lpage">2002</span></span><div class="citationLinks">[<a href="/doi/10.1021/ol900350k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2009&pages=1999-2002&author=Q.+Linauthor=D.+Meloniauthor=Y.+Panauthor=M.+Xiaauthor=J.+Rodgersauthor=S.+Shepardauthor=M.+Liauthor=L.+Galyaauthor=B.+Metcalfauthor=T.+Y.+Yueauthor=P.+Liuauthor=J.+Zhou&title=Enantioselective+synthesis+of+Janus+kinase+inhibitor+INCB018424+via+an+organocatalytic+aza-Michael+reaction"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fol900350k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol900350k%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DQ.%26aulast%3DMeloni%26aufirst%3DD.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DXia%26aufirst%3DM.%26aulast%3DRodgers%26aufirst%3DJ.%26aulast%3DShepard%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DGalya%26aufirst%3DL.%26aulast%3DMetcalf%26aufirst%3DB.%26aulast%3DYue%26aufirst%3DT.%2BY.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DEnantioselective%2520synthesis%2520of%2520Janus%2520kinase%2520inhibitor%2520INCB018424%2520via%2520an%2520organocatalytic%2520aza-Michael%2520reaction%26jtitle%3DOrg.%2520Lett.%26date%3D2009%26volume%3D11%26spage%3D1999%26epage%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">William, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulsen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teo, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagaraj, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaraman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasha, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ethirajulu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B. W.</span><span> </span><span class="NLM_article-title">Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1. 1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">4638</span><span class="NLM_x">–</span> <span class="NLM_lpage">4658</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200326p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4638-4658&author=A.+D.+Williamauthor=A.+C.+Leeauthor=S.+Blanchardauthor=A.+Poulsenauthor=E.+L.+Teoauthor=H.+Nagarajauthor=E.+Tanauthor=D.+Chenauthor=M.+Williamsauthor=E.+T.+Sunauthor=K.+C.+Gohauthor=W.+C.+Ongauthor=S.+K.+Gohauthor=S.+Hartauthor=R.+Jayaramanauthor=M.+K.+Pashaauthor=K.+Ethirajuluauthor=J.+M.+Woodauthor=B.+W.+Dymock&title=Discovery+of+the+macrocycle+11-%282-pyrrolidin-1-yl-ethoxy%29-14%2C19-dioxa-5%2C7%2C26-triaza-tetracyclo%5B19.3.1.+1%282%2C6%29.1%288%2C12%29%5Dheptacosa-1%2825%29%2C2%2826%29%2C3%2C5%2C8%2C10%2C12%2827%29%2C16%2C21%2C23-decaene+%28SB1518%29%2C+a+potent+Janus+kinase+2%2Ffms-like+tyrosine+kinase-3+%28JAK2%2FFLT3%29+inhibitor+for+the+treatment+of+myelofibrosis+and+lymphoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm200326p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200326p%26sid%3Dliteratum%253Aachs%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DLee%26aufirst%3DA.%2BC.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DTeo%26aufirst%3DE.%2BL.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DE.%2BT.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DOng%26aufirst%3DW.%2BC.%26aulast%3DGoh%26aufirst%3DS.%2BK.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDiscovery%2520of%2520the%2520macrocycle%252011-%25282-pyrrolidin-1-yl-ethoxy%2529-14%252C19-dioxa-5%252C7%252C26-triaza-tetracyclo%255B19.3.1.%25201%25282%252C6%2529.1%25288%252C12%2529%255Dheptacosa-1%252825%2529%252C2%252826%2529%252C3%252C5%252C8%252C10%252C12%252827%2529%252C16%252C21%252C23-decaene%2520%2528SB1518%2529%252C%2520a%2520potent%2520Janus%2520kinase%25202%252Ffms-like%2520tyrosine%2520kinase-3%2520%2528JAK2%252FFLT3%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520myelofibrosis%2520and%2520lymphoma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4638%26epage%3D4658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Verstovsek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deeg, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Odenike, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrov, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, D. A.</span><span> </span><span class="NLM_article-title">Phase 1/2 study of SB1518, a novel JAK2/FLT3 inhibitor, in the treatment of primary myelofibrosis</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">Abstract 3082</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2010&pages=Abstract+3082&author=S.+Verstovsekauthor=H.+J.+Deegauthor=O.+Odenikeauthor=J.+Zhuauthor=H.+M.+Kantarjianauthor=Z.+Estrovauthor=B.+L.+Scottauthor=D.+A.+Thomas&title=Phase+1%2F2+study+of+SB1518%2C+a+novel+JAK2%2FFLT3+inhibitor%2C+in+the+treatment+of+primary+myelofibrosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DDeeg%26aufirst%3DH.%2BJ.%26aulast%3DOdenike%26aufirst%3DO.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26aulast%3DEstrov%26aufirst%3DZ.%26aulast%3DScott%26aufirst%3DB.%2BL.%26aulast%3DThomas%26aufirst%3DD.%2BA.%26atitle%3DPhase%25201%252F2%2520study%2520of%2520SB1518%252C%2520a%2520novel%2520JAK2%252FFLT3%2520inhibitor%252C%2520in%2520the%2520treatment%2520of%2520primary%2520myelofibrosis%26jtitle%3DBlood%26date%3D2010%26volume%3D116%26spage%3DAbstract%25203082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Verstovsek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mesa, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pardanani, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes-Franco, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrov, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridman, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erickson-Viitanen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaddi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tefferi, A.</span><span> </span><span class="NLM_article-title">Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">1117</span><span class="NLM_x">–</span> <span class="NLM_lpage">1127</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm201112g&amp;key=10.1056%2FNEJMoa1002028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm201112g&amp;key=20843246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm201112g&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFOltrjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1117-1127&author=S.+Verstovsekauthor=H.+Kantarjianauthor=R.+A.+Mesaauthor=A.+D.+Pardananiauthor=J.+Cortes-Francoauthor=D.+A.+Thomasauthor=Z.+Estrovauthor=J.+S.+Fridmanauthor=E.+C.+Bradleyauthor=S.+Erickson-Viitanenauthor=K.+Vaddiauthor=R.+Levyauthor=A.+Tefferi&title=Safety+and+efficacy+of+INCB018424%2C+a+JAK1+and+JAK2+inhibitor%2C+in+myelofibrosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis</span></div><div class="casAuthors">Verstovsek, Srdan; Kantarjian, Hagop; Mesa, Ruben A.; Pardanani, Animesh D.; Cortes-Franco, Jorge; Thomas, Deborah A.; Estrov, Zeev; Fridman, Jordan S.; Bradley, Edward C.; Erickson-Viitanen, Susan; Vaddi, Kris; Levy, Richard; Tefferi, Ayalew</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1117-1127</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Myelofibrosis is a Philadelphia chromosome-neg. myeloproliferative neoplasm assocd. with cytopenias, splenomegaly, poor quality of life, and shortened survival.  About half of patients with myelofibrosis carry a gain-of-function mutation in the Janus kinase 2 gene (JAK2 V617F) that contributes to the pathophysiol. of the disease.  INCB018424 is a potent and selective Janus kinase 1 (JAK1) and JAK2 inhibitor.  Methods: We conducted a phase 1-2 trial of INCB018424 in patients with JAK2 V617F-pos. or JAK2 V617F-neg. primary myelofibrosis, post-essential thrombocythemia myelofibrosis, or post-polycythemia vera myelofibrosis.  Results: A total of 153 patients received INCB018424 for a median duration of more than 14.7 mo.  The initial dose-escalation phase established 25 mg twice daily or 100 mg once daily as max. tolerated doses, on the basis of reversible thrombocytopenia.  A dose-dependent suppression of phosphorylated signal transducer and activator of transcription 3 (STAT3), a marker of JAK signaling, was demonstrated in patients with wild-type JAK2 and in patients with the JAK2 V617F mutation.  We studied addnl. doses and established that a 15-mg twice-daily starting dose, followed by individualized dose titrn., was the most effective and safest dosing regimen.  At this dose, 17 of 33 patients (52%) had a rapid objective response (>50% redn. of splenomegaly) lasting for 12 mo or more, and this therapy was assocd. with grade 3 or grade 4 adverse events (mainly myelosuppression) in less than 10% of patients.  Patients with debilitating symptoms, including wt. loss, fatigue, night sweats, and pruritus, had rapid improvement.  Clin. benefits were assocd. with a marked diminution of levels of circulating inflammatory cytokines that are commonly elevated in myelofibrosis.  Conclusions: INCB018424 was assocd. with marked and durable clin. benefits in patients with myelofibrosis for whom no approved therapies existed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUi05ApP1FLrVg90H21EOLACvtfcHk0lhl4Vn9Y_HXrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFOltrjJ&md5=ba6fe766323a10a1508c686fdb3720b1</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1002028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1002028%26sid%3Dliteratum%253Aachs%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DMesa%26aufirst%3DR.%2BA.%26aulast%3DPardanani%26aufirst%3DA.%2BD.%26aulast%3DCortes-Franco%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DD.%2BA.%26aulast%3DEstrov%26aufirst%3DZ.%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DBradley%26aufirst%3DE.%2BC.%26aulast%3DErickson-Viitanen%26aufirst%3DS.%26aulast%3DVaddi%26aufirst%3DK.%26aulast%3DLevy%26aufirst%3DR.%26aulast%3DTefferi%26aufirst%3DA.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520INCB018424%252C%2520a%2520JAK1%2520and%2520JAK2%2520inhibitor%252C%2520in%2520myelofibrosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D1117%26epage%3D1127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Verstovsek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Odenike, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrov, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ethirajulu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deeg, H. J.</span><span> </span><span class="NLM_article-title">Phase I dose escalation trial of SB1518, a novel JAK2-FLT3 inhibitor, in acute and chronic myeloid diseases, including primary or post-ET/post-PV myelofibrosis</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">Abstract 3905</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=Abstract+3905&author=S.+Verstovsekauthor=O.+Odenikeauthor=B.+Scottauthor=Z.+Estrovauthor=J.+Cortesauthor=D.+Thomasauthor=J.+Woodauthor=K.+Ethirajuluauthor=A.+Loweauthor=H.+J.+Zhuauthor=H.+Kantarjianauthor=H.+J.+Deeg&title=Phase+I+dose+escalation+trial+of+SB1518%2C+a+novel+JAK2-FLT3+inhibitor%2C+in+acute+and+chronic+myeloid+diseases%2C+including+primary+or+post-ET%2Fpost-PV+myelofibrosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DOdenike%26aufirst%3DO.%26aulast%3DScott%26aufirst%3DB.%26aulast%3DEstrov%26aufirst%3DZ.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DD.%26aulast%3DWood%26aufirst%3DJ.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DLowe%26aufirst%3DA.%26aulast%3DZhu%26aufirst%3DH.%2BJ.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DDeeg%26aufirst%3DH.%2BJ.%26atitle%3DPhase%2520I%2520dose%2520escalation%2520trial%2520of%2520SB1518%252C%2520a%2520novel%2520JAK2-FLT3%2520inhibitor%252C%2520in%2520acute%2520and%2520chronic%2520myeloid%2520diseases%252C%2520including%2520primary%2520or%2520post-ET%252Fpost-PV%2520myelofibrosis%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26spage%3DAbstract%25203905" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Kindler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipka, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, T.</span><span> </span><span class="NLM_article-title">FLT3 as a therapeutic target in AML: still challenging after all these years</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">5089</span><span class="NLM_x">–</span> <span class="NLM_lpage">5102</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2010&pages=5089-5102&author=T.+Kindlerauthor=D.+B.+Lipkaauthor=T.+Fischer&title=FLT3+as+a+therapeutic+target+in+AML%3A+still+challenging+after+all+these+years"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKindler%26aufirst%3DT.%26aulast%3DLipka%26aufirst%3DD.%2BB.%26aulast%3DFischer%26aufirst%3DT.%26atitle%3DFLT3%2520as%2520a%2520therapeutic%2520target%2520in%2520AML%253A%2520still%2520challenging%2520after%2520all%2520these%2520years%26jtitle%3DBlood%26date%3D2010%26volume%3D116%26spage%3D5089%26epage%3D5102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Gilliland, D. G.</span><span> </span><span class="NLM_article-title">FLT3-activating mutations in acute promyelocytic leukaemia: a rationale for risk-adapted therapy with FLT3 inhibitors</span> <span class="citation_source-journal">Best Prac. Res., Clin. Haematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">409</span><span class="NLM_x">–</span> <span class="NLM_lpage">417</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm201112g&amp;key=10.1016%2FS1521-6926%2803%2900063-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm201112g&amp;key=12935959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm201112g&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmsVCgu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2003&pages=409-417&author=D.+G.+Gilliland&title=FLT3-activating+mutations+in+acute+promyelocytic+leukaemia%3A+a+rationale+for+risk-adapted+therapy+with+FLT3+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3-activating mutations in acute promyelocytic leukaemia: a rationale for risk-adapted therapy with FLT3 inhibitors</span></div><div class="casAuthors">Gilliland, D. Gary</div><div class="citationInfo"><span class="NLM_cas:title">Best Practice & Research, Clinical Haematology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">409-417</span>CODEN:
                <span class="NLM_cas:coden">BPRCA5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  Our understanding of the genetic basis of acute myeloid leukemias has been enhanced through cloning of recurring chromosomal translocation breakpoints.  However, the remarkable observation, more than a decade ago, that all-trans retinoic acid (ATRA) induced remission in patients with t(15;17) acute promyelocytic leukemia (APL) was a driving force in the subsequent cloning and characterization of the PML-RARα fusion that is causally implicated in the pathogenesis of this disease.  Major improvements in treatment and outcome of APL patients have been made since that time by incorporating ATRA in conventional chemotherapy but 30% of APL patients still succumb to complications of their disease or their therapy.  Recent information that the hematopoietic receptor tyrosine kinase FLT3 is mutated in about 30% of APL patients suggests strategies for further improving treatment and outcome in this subset of APL patients using small-mol. inhibitors of FLT3.  The role of FLT3 mutations in APL and other AML is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoo4Lxfsmnh9rVg90H21EOLACvtfcHk0lgnzklFY1ygCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmsVCgu7s%253D&md5=f7b4d39e56a475225ab3fb7cb09e082b</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2FS1521-6926%2803%2900063-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1521-6926%252803%252900063-X%26sid%3Dliteratum%253Aachs%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26atitle%3DFLT3-activating%2520mutations%2520in%2520acute%2520promyelocytic%2520leukaemia%253A%2520a%2520rationale%2520for%2520risk-adapted%2520therapy%2520with%2520FLT3%2520inhibitors%26jtitle%3DBest%2520Prac.%2520Res.%252C%2520Clin.%2520Haematol.%26date%3D2003%26volume%3D16%26spage%3D409%26epage%3D417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Quentmeier, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reinhardt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaborski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drexler, H. G.</span><span> </span><span class="NLM_article-title">FLT3 mutations in acute myeloid leukemia cell lines</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">120</span><span class="NLM_x">–</span> <span class="NLM_lpage">124</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2003&pages=120-124&author=H.+Quentmeierauthor=J.+Reinhardtauthor=M.+Zaborskiauthor=H.+G.+Drexler&title=FLT3+mutations+in+acute+myeloid+leukemia+cell+lines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DQuentmeier%26aufirst%3DH.%26aulast%3DReinhardt%26aufirst%3DJ.%26aulast%3DZaborski%26aufirst%3DM.%26aulast%3DDrexler%26aufirst%3DH.%2BG.%26atitle%3DFLT3%2520mutations%2520in%2520acute%2520myeloid%2520leukemia%2520cell%2520lines%26jtitle%3DLeukemia%26date%3D2003%26volume%3D17%26spage%3D120%26epage%3D124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirazian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuda, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nematalla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sistla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luu, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span> </span><span class="NLM_article-title">Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3<i>Z</i>)-ylidenemethyl]-2,4-dimethyl-1<i>H</i>-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">1116</span><span class="NLM_x">–</span> <span class="NLM_lpage">1119</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0204183" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=1116-1119&author=L.+Sunauthor=C.+Liangauthor=S.+Shirazianauthor=Y.+Zhouauthor=T.+Millerauthor=J.+Cuiauthor=J.+Y.+Fukudaauthor=J.+Y.+Chuauthor=A.+Nematallaauthor=X.+Wangauthor=H.+Chenauthor=A.+Sistlaauthor=T.+C.+Luuauthor=F.+Tangauthor=J.+Weiauthor=C.+Tang&title=Discovery+of+5-%5B5-fluoro-2-oxo-1%2C2-+dihydroindol-%283Z%29-ylidenemethyl%5D-2%2C4-dimethyl-1H-pyrrole-3-carboxylic+acid+%282-diethylaminoethyl%29amide%2C+a+novel+tyrosine+kinase+inhibitor+targeting+vascular+endothelial+and+platelet-derived+growth+factor+receptor+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm0204183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0204183%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DShirazian%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DMiller%26aufirst%3DT.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DFukuda%26aufirst%3DJ.%2BY.%26aulast%3DChu%26aufirst%3DJ.%2BY.%26aulast%3DNematalla%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DSistla%26aufirst%3DA.%26aulast%3DLuu%26aufirst%3DT.%2BC.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DC.%26atitle%3DDiscovery%2520of%25205-%255B5-fluoro-2-oxo-1%252C2-%2520dihydroindol-%25283Z%2529-ylidenemethyl%255D-2%252C4-dimethyl-1H-pyrrole-3-carboxylic%2520acid%2520%25282-diethylaminoethyl%2529amide%252C%2520a%2520novel%2520tyrosine%2520kinase%2520inhibitor%2520targeting%2520vascular%2520endothelial%2520and%2520platelet-derived%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D1116%26epage%3D1119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Bankston, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Natero, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riedl, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monahan, M.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sibley, R.</span><span> </span><span class="NLM_article-title">A scaleable synthesis of BAY 43-9006: a potent raf kinase inhibitor for the treatment of cancer</span> <span class="citation_source-journal">Org. Process Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">777</span><span class="NLM_x">–</span> <span class="NLM_lpage">781</span></span><div class="citationLinks">[<a href="/doi/10.1021/op020205n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm201112g&amp;key=1%3ACAS%3A528%3ADC%252BD38XntFegtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2002&pages=777-781&author=D.+Bankstonauthor=J.+Dumasauthor=R.+Nateroauthor=B.+Riedlauthor=M.-K.+Monahanauthor=R.+Sibley&title=A+scaleable+synthesis+of+BAY+43-9006%3A+a+potent+raf+kinase+inhibitor+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">A Scaleable Synthesis of BAY 43-9006: A Potent Raf Kinase Inhibitor for the Treatment of Cancer</span></div><div class="casAuthors">Bankston, Donald; Dumas, Jacques; Natero, Reina; Riedl, Bernd; Monahan, Mary-Katherine; Sibley, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">777-781</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Urea I (BAY 43-9006), a potent Raf kinase inhibitor, was prepd. in four steps from picolinic acid with an overall yield of 63%.  Significant process research enabled isolation of each intermediate and target without chromatog. purifn., and overall yield increases >50% were obsd. compared to those from previous methods.  This report focuses on improved synthetic strategies for prodn. of scaled quantities of I for preclin., toxicol. studies.  These improvements may be useful to assemble other urea targets as potential therapeutic agents to combat cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxNTMN01nH9LVg90H21EOLACvtfcHk0lgnzklFY1ygCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XntFegtr8%253D&md5=fb46fc9d46416b9fb8250cb87fb18805</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fop020205n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop020205n%26sid%3Dliteratum%253Aachs%26aulast%3DBankston%26aufirst%3DD.%26aulast%3DDumas%26aufirst%3DJ.%26aulast%3DNatero%26aufirst%3DR.%26aulast%3DRiedl%26aufirst%3DB.%26aulast%3DMonahan%26aufirst%3DM.-K.%26aulast%3DSibley%26aufirst%3DR.%26atitle%3DA%2520scaleable%2520synthesis%2520of%2520BAY%252043-9006%253A%2520a%2520potent%2520raf%2520kinase%2520inhibitor%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2002%26volume%3D6%26spage%3D777%26epage%3D781" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">William, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulsen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagaraj, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaraman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasha, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ethirajulu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B. W.</span><span> </span><span class="NLM_article-title">Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/Fms-liketyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">4638</span><span class="NLM_x">–</span> <span class="NLM_lpage">4658</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4638-4658&author=A.+D.+Williamauthor=A.+Leeauthor=S.+Blanchardauthor=A.+Poulsenauthor=E.+Teoauthor=H.+Nagarajauthor=E.+Tanauthor=D.+Chenauthor=M.+Williamsauthor=E.+Sunauthor=K.+C.+Gohauthor=W.+Ongauthor=S.+K.+Gohauthor=S.+Hartauthor=R.+Jayaramanauthor=M.+K.+Pashaauthor=K.+Ethirajuluauthor=J.+Woodauthor=B.+W.+Dymock&title=Discovery+of+the+macrocycle+11-%282-pyrrolidin-1-yl-ethoxy%29-14%2C19-dioxa-5%2C7%2C26-triaza-tetracyclo%5B19.3.1.1%282%2C6%29.1%288%2C12%29%5Dheptacosa-1%2825%29%2C2%2826%29%2C3%2C5%2C8%2C10%2C12%2827%29%2C16%2C21%2C23-decaene+%28SB1518%29%2C+a+potent+Janus+kinase+2%2FFms-liketyrosine+kinase-3+%28JAK2%2FFLT3%29+inhibitor+for+the+treatment+of+myelofibrosis+and+lymphoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DTeo%26aufirst%3DE.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DE.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DOng%26aufirst%3DW.%26aulast%3DGoh%26aufirst%3DS.%2BK.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DJ.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDiscovery%2520of%2520the%2520macrocycle%252011-%25282-pyrrolidin-1-yl-ethoxy%2529-14%252C19-dioxa-5%252C7%252C26-triaza-tetracyclo%255B19.3.1.1%25282%252C6%2529.1%25288%252C12%2529%255Dheptacosa-1%252825%2529%252C2%252826%2529%252C3%252C5%252C8%252C10%252C12%252827%2529%252C16%252C21%252C23-decaene%2520%2528SB1518%2529%252C%2520a%2520potent%2520Janus%2520kinase%25202%252FFms-liketyrosine%2520kinase-3%2520%2528JAK2%252FFLT3%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520myelofibrosis%2520and%2520lymphoma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4638%26epage%3D4658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Driggers, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hale, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terrett, N. K.</span><span> </span><span class="NLM_article-title">The exploration of macrocycles for drug discovery—an underexploited structural class</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">608</span><span class="NLM_x">–</span> <span class="NLM_lpage">624</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=608-624&author=E.+M.+Driggersauthor=S.+P.+Haleauthor=J.+Leeauthor=N.+K.+Terrett&title=The+exploration+of+macrocycles+for+drug+discovery%E2%80%94an+underexploited+structural+class"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDriggers%26aufirst%3DE.%2BM.%26aulast%3DHale%26aufirst%3DS.%2BP.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DTerrett%26aufirst%3DN.%2BK.%26atitle%3DThe%2520exploration%2520of%2520macrocycles%2520for%2520drug%2520discovery%25E2%2580%2594an%2520underexploited%2520structural%2520class%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26spage%3D608%26epage%3D624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Marsault, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, M. L.</span><span> </span><span class="NLM_article-title">Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1961</span><span class="NLM_x">–</span> <span class="NLM_lpage">2004</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm1012374" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm201112g&amp;key=1%3ACAS%3A528%3ADC%252BC3MXivVSjtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1961-2004&author=E.+Marsaultauthor=M.+L.+Peterson&title=Macrocycles+are+great+cycles%3A+applications%2C+opportunities%2C+and+challenges+of+synthetic+macrocycles+in+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Macrocycles Are Great Cycles: Applications, Opportunities, and Challenges of Synthetic Macrocycles in Drug Discovery</span></div><div class="casAuthors">Marsault, Eric; Peterson, Mark L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1961-2004</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Macrocycles occupy a unique segment of chem. space.  In the past decade, their chem. diversity expanded significantly, supported by advances in bioinformatics and synthetic methodol.  As a consequence, this structural type has now been successfully tested on most biol. target classes.  The goal of this article is to put into perspective the current applications, opportunities, and challenges assocd. with synthetic macrocycles in drug discovery.  Accordingly, the first part of this article is dedicated to the drug discovery aspects of macrocycles and highlights salient features of their medicinal chem.  This section is organized by target class, a choice aimed at providing the reader an appreciation of the structural diversity generated for each class.  To give the reader an appreciation of the tools available to construct macrocyclic scaffolds, the site and method of the pivotal macrocyclization step are indicated in the figures.  Readers are referred to the source articles for further details.  In the second part, the technologies and synthetic approaches that already have demonstrated utility or possess a high potential for macrocycle-based drug discovery are discussed.  Finally, a perspective on the future of synthetic macrocycles in medicinal chem. is offered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrygQLE6JraHrVg90H21EOLACvtfcHk0ljlz6ThfFDyfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXivVSjtbo%253D&md5=97c1120896e90a85790a9ac1274259f3</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm1012374&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1012374%26sid%3Dliteratum%253Aachs%26aulast%3DMarsault%26aufirst%3DE.%26aulast%3DPeterson%26aufirst%3DM.%2BL.%26atitle%3DMacrocycles%2520are%2520great%2520cycles%253A%2520applications%252C%2520opportunities%252C%2520and%2520challenges%2520of%2520synthetic%2520macrocycles%2520in%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1961%26epage%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Schmidt, B.</span><span> </span><span class="NLM_article-title">Ruthenium-catalyzed cyclizations: more than just olefin metathesis!</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">4996</span><span class="NLM_x">–</span> <span class="NLM_lpage">4999</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=4996-4999&author=B.+Schmidt&title=Ruthenium-catalyzed+cyclizations%3A+more+than+just+olefin+metathesis%21"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DB.%26atitle%3DRuthenium-catalyzed%2520cyclizations%253A%2520more%2520than%2520just%2520olefin%2520metathesis%2521%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2003%26volume%3D42%26spage%3D4996%26epage%3D4999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Cai, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">You, S.-L.</span><span> </span><span class="NLM_article-title">Asymmetric construction of polycyclic indoles through olefin cross-metathesis/intramolecular Friedel–Crafts alkylation under sequential catalysis</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">7428</span><span class="NLM_x">–</span> <span class="NLM_lpage">7431</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2009&pages=7428-7431&author=Q.+Caiauthor=Z.-A.+Zhaoauthor=S.-L.+You&title=Asymmetric+construction+of+polycyclic+indoles+through+olefin+cross-metathesis%2Fintramolecular+Friedel%E2%80%93Crafts+alkylation+under+sequential+catalysis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DQ.%26aulast%3DZhao%26aufirst%3DZ.-A.%26aulast%3DYou%26aufirst%3DS.-L.%26atitle%3DAsymmetric%2520construction%2520of%2520polycyclic%2520indoles%2520through%2520olefin%2520cross-metathesis%252Fintramolecular%2520Friedel%25E2%2580%2593Crafts%2520alkylation%2520under%2520sequential%2520catalysis%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2009%26volume%3D48%26spage%3D7428%26epage%3D7431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Deiters, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S. F.</span><span> </span><span class="NLM_article-title">Synthesis of oxygen- and nitrogen-containing heterocycles by ring-closing metathesis</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">2199</span><span class="NLM_x">–</span> <span class="NLM_lpage">2238</span></span><div class="citationLinks">[<a href="/doi/10.1021/cr0200872" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm201112g&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsVSltb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2004&pages=2199-2238&author=A.+Deitersauthor=S.+F.+Martin&title=Synthesis+of+oxygen-+and+nitrogen-containing+heterocycles+by+ring-closing+metathesis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of oxygen- and nitrogen-containing heterocycles by ring-closing metathesis</span></div><div class="casAuthors">Deiters, Alexander; Martin, Stephen F.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2199-2238</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review on the synthesis of oxygen- and nitrogen-contg. heterocycles by ring-closing metathesis (RCM).  Applications of olefin and alkyne RCM, enyne RCM, and tandem processes in which these reactions are combined with ring-opening metathesis (ROM) to construct O- and N-heterocycles are presented with a particular emphasis on natural product synthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxORod8gOrIrVg90H21EOLACvtfcHk0li67M6jBJxCFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsVSltb0%253D&md5=93d648a549ce629a402b4849c15c577c</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fcr0200872&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr0200872%26sid%3Dliteratum%253Aachs%26aulast%3DDeiters%26aufirst%3DA.%26aulast%3DMartin%26aufirst%3DS.%2BF.%26atitle%3DSynthesis%2520of%2520oxygen-%2520and%2520nitrogen-containing%2520heterocycles%2520by%2520ring-closing%2520metathesis%26jtitle%3DChem.%2520Rev.%26date%3D2004%26volume%3D104%26spage%3D2199%26epage%3D2238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.-G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, B. M.</span><span> </span><span class="NLM_article-title">Acid-mediated activation of modified ring-closing metathesis catalysts</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">709</span><span class="NLM_x">–</span> <span class="NLM_lpage">713</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2010&pages=709-713&author=S.+Kimauthor=W.+Hwangauthor=I.+S.+Limauthor=S.+H.+Kimauthor=S.-G.+Leeauthor=B.+M.+Kim&title=Acid-mediated+activation+of+modified+ring-closing+metathesis+catalysts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DS.%26aulast%3DHwang%26aufirst%3DW.%26aulast%3DLim%26aufirst%3DI.%2BS.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DLee%26aufirst%3DS.-G.%26aulast%3DKim%26aufirst%3DB.%2BM.%26atitle%3DAcid-mediated%2520activation%2520of%2520modified%2520ring-closing%2520metathesis%2520catalysts%26jtitle%3DTetrahedron%2520Lett.%26date%3D2010%26volume%3D51%26spage%3D709%26epage%3D713" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span> <span class="citation_source-book">Molecular Modeling Platform</span>; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York, NY</span>,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span><a href="http://www.schrodinger.com" class="extLink">http://www.schrodinger.com</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Molecular+Modeling+Platform%3B+Schr%C3%B6dinger%2C+LLC%3A+New+York%2C+NY%2C+2011%3B+http%3A%2F%2Fwww.schrodinger.com."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DMolecular%2520Modeling%2520Platform%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Goh, K. C.; Novotny-Diermayr, V.; Hart, S.; Ong, L. C.; Loh, Y. K.; Cheong, A.; Tan, Y. C.; Hu, C.; Jayaraman, R.; William, A.; Ong, K. H.; Dymock, B. W.; Ethirajulu, K.; Burrows, F.; Wood, J. M.</span><span> </span><span class="NLM_article-title">TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties</span>.  <span class="citation_source-journal">Leukemia</span> [Online early access]. DOI: <span class="refDoi"> DOI: 10.1038/leu.2011.218</span> . Published Online: Aug 23,<span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Fjm201112g&amp;key=10.1038%2Fleu.2011.218" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=K.+C.+Goh&author=V.+Novotny-Diermayr&author=S.+Hart&author=L.+C.+Ong&author=Y.+K.+Loh&author=A.+Cheong&author=Y.+C.+Tan&author=C.+Hu&author=R.+Jayaraman&author=A.+William&author=K.+H.+Ong&author=B.+W.+Dymock&author=K.+Ethirajulu&author=F.+Burrows&author=J.+M.+Wood&title=TG02%2C+a+novel+oral+multi-kinase+inhibitor+of+CDKs%2C+JAK2+and+FLT3+with+potent+anti-leukemic+properties&doi=10.1038%2Fleu.2011.218"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fleu.2011.218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2011.218%26sid%3Dliteratum%253Aachs%26aulast%3DGoh%26aufirst%3DK.%2BC.%26atitle%3DTG02%252C%2520a%2520novel%2520oral%2520multi-kinase%2520inhibitor%2520of%2520CDKs%252C%2520JAK2%2520and%2520FLT3%2520with%2520potent%2520anti-leukemic%2520properties%26jtitle%3DLeukemia%26doi%3D10.1038%2Fleu.2011.218%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Jorgensen, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maxwell, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tirado-Rives, J.</span><span> </span><span class="NLM_article-title">Development and yesting of the OPLS all-atom force field on conformational energetics and properties of organic liquids</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">118</span><span class="NLM_x">, </span> <span class="NLM_fpage">11225</span><span class="NLM_x">–</span> <span class="NLM_lpage">11236</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja9621760" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=1996&pages=11225-11236&author=W.+L.+Jorgensenauthor=D.+S.+Maxwellauthor=J.+Tirado-Rives&title=Development+and+yesting+of+the+OPLS+all-atom+force+field+on+conformational+energetics+and+properties+of+organic+liquids"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fja9621760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja9621760%26sid%3Dliteratum%253Aachs%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26aulast%3DMaxwell%26aufirst%3DD.%2BS.%26aulast%3DTirado-Rives%26aufirst%3DJ.%26atitle%3DDevelopment%2520and%2520yesting%2520of%2520the%2520OPLS%2520all-atom%2520force%2520field%2520on%2520conformational%2520energetics%2520and%2520properties%2520of%2520organic%2520liquids%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1996%26volume%3D118%26spage%3D11225%26epage%3D11236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Hasel, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendrickson, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Still, W. C.</span><span> </span><span class="NLM_article-title">A rapid approximation to the solvent accessible surface areas of atoms</span> <span class="citation_source-journal">Tetrahedron Comput. Methodol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">–</span> <span class="NLM_lpage">116</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm201112g&amp;key=10.1016%2F0898-5529%2888%2990015-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm201112g&amp;key=1%3ACAS%3A528%3ADyaL1MXltFCms7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1988&pages=103-116&author=W.+Haselauthor=T.+F.+Hendricksonauthor=W.+C.+Still&title=A+rapid+approximation+to+the+solvent+accessible+surface+areas+of+atoms"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">A rapid approximation to the solvent-accessible surface areas of atoms</span></div><div class="casAuthors">Hasel, Winnfried; Hendrickson, Thomas F.; Still, W. Clark</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Computer Methodology</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">103-16</span>CODEN:
                <span class="NLM_cas:coden">TCMTE6</span>;
        ISSN:<span class="NLM_cas:issn">0898-5529</span>.
    </div><div class="casAbstract">An anal. expression for approx. at. and mol. van der Waals and solvent accessible surface areas is described.  The treatment is based on the probabilistic method of Wodak and Janin (1980) but with modifications which allow it to be applied to the calcn. of at. surface areas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEtlzGPkwT_7Vg90H21EOLACvtfcHk0li67M6jBJxCFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXltFCms7s%253D&md5=98b3e7fab9432dccb1ff22f726d54fbf</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2F0898-5529%2888%2990015-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0898-5529%252888%252990015-2%26sid%3Dliteratum%253Aachs%26aulast%3DHasel%26aufirst%3DW.%26aulast%3DHendrickson%26aufirst%3DT.%2BF.%26aulast%3DStill%26aufirst%3DW.%2BC.%26atitle%3DA%2520rapid%2520approximation%2520to%2520the%2520solvent%2520accessible%2520surface%2520areas%2520of%2520atoms%26jtitle%3DTetrahedron%2520Comput.%2520Methodol.%26date%3D1988%26volume%3D1%26spage%3D103%26epage%3D116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Lawrie, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noble, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tunnah, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, L. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Endicott, J. A.</span><span> </span><span class="NLM_article-title">Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2</span> <span class="citation_source-journal">Nat. Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">796</span><span class="NLM_x">–</span> <span class="NLM_lpage">801</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1997&pages=796-801&author=A.+M.+Lawrieauthor=M.+E.+Nobleauthor=P.+Tunnahauthor=N.+R.+Brownauthor=L.+N.+Johnsonauthor=J.+A.+Endicott&title=Protein+kinase+inhibition+by+staurosporine+revealed+in+details+of+the+molecular+interaction+with+CDK2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLawrie%26aufirst%3DA.%2BM.%26aulast%3DNoble%26aufirst%3DM.%2BE.%26aulast%3DTunnah%26aufirst%3DP.%26aulast%3DBrown%26aufirst%3DN.%2BR.%26aulast%3DJohnson%26aufirst%3DL.%2BN.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26atitle%3DProtein%2520kinase%2520inhibition%2520by%2520staurosporine%2520revealed%2520in%2520details%2520of%2520the%2520molecular%2520interaction%2520with%2520CDK2%26jtitle%3DNat.%2520Struct.%2520Biol.%26date%3D1997%26volume%3D4%26spage%3D796%26epage%3D801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Griffith, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faerman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swenson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wynn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippke, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saxena, K.</span><span> </span><span class="NLM_article-title">The structural basis for autoinhibition of FLT3 by the juxtamembrane domain</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">178</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm201112g&amp;key=10.1016%2FS1097-2765%2803%2900505-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm201112g&amp;key=14759363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm201112g&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFOiu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2004&pages=169-178&author=J.+Griffithauthor=J.+Blackauthor=C.+Faermanauthor=L.+Swensonauthor=M.+Wynnauthor=F.+Luauthor=J.+Lippkeauthor=K.+Saxena&title=The+structural+basis+for+autoinhibition+of+FLT3+by+the+juxtamembrane+domain"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">The structural basis for autoinhibition of FLT3 by the juxtamembrane domain</span></div><div class="casAuthors">Griffith, James; Black, James; Faerman, Carlos; Swenson, Lora; Wynn, Michael; Lu, Fan; Lippke, Judith; Saxena, Kumkum</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">169-178</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">FLT3 is a type III receptor tyrosine kinase that is thought to play a key role in hematopoiesis.  Certain classes of FLT3 mutations cause constitutively activated forms of the receptor that are found in significant nos. of patients with acute myelogenous leukemia (AML).  The mutations occur either in the activation loop, for example, as point mutations of Asp835 or as internal tandem duplication (ITD) sequences in the juxtamembrane (JM) domain.  To further understand the nature of FLT3 autoinhibition and regulation, we have detd. the crystal structure of the autoinhibited form of FLT3.  This structure shows the autoinhibitory conformation of a complete JM domain in this class of receptor tyrosine kinases.  The detailed inhibitory mechanism of the JM domain is revealed, which is likely utilized by other members of type III receptor tyrosine kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJAabT6TBxpLVg90H21EOLACvtfcHk0liMnggAA4Edeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFOiu7g%253D&md5=d1df4a37aac59f5b59ca242fc8ccd6da</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2FS1097-2765%2803%2900505-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1097-2765%252803%252900505-7%26sid%3Dliteratum%253Aachs%26aulast%3DGriffith%26aufirst%3DJ.%26aulast%3DBlack%26aufirst%3DJ.%26aulast%3DFaerman%26aufirst%3DC.%26aulast%3DSwenson%26aufirst%3DL.%26aulast%3DWynn%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DF.%26aulast%3DLippke%26aufirst%3DJ.%26aulast%3DSaxena%26aufirst%3DK.%26atitle%3DThe%2520structural%2520basis%2520for%2520autoinhibition%2520of%2520FLT3%2520by%2520the%2520juxtamembrane%2520domain%26jtitle%3DMol.%2520Cell%26date%3D2004%26volume%3D13%26spage%3D169%26epage%3D178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span>Protein Data Bank. <a href="http://www.pdb.org" class="extLink">www.pdb.org</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Protein+Data+Bank.+www.pdb.org."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 47 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Jennifer Alisa Amrhein, Stefan Knapp, <span class="NLM_string-name hlFld-ContribAuthor">Thomas Hanke</span>. </span><span class="cited-content_cbyCitation_article-title">Synthetic Opportunities and Challenges for Macrocyclic Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (12)
                                     , 7991-8009. <a href="https://doi.org/10.1021/acs.jmedchem.1c00217" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00217</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00217%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthetic%252BOpportunities%252Band%252BChallenges%252Bfor%252BMacrocyclic%252BKinase%252BInhibitors%26aulast%3DAmrhein%26aufirst%3DJennifer%2BAlisa%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D04022021%26date%3D02062021%26volume%3D64%26issue%3D12%26spage%3D7991%26epage%3D8009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Paula C. Ortet, Samantha N. Muellers, Lauren A. Viarengo-Baker, Kristina Streu, Blair R. Szymczyna, Aaron B. Beeler, Karen N. Allen, <span class="NLM_string-name hlFld-ContribAuthor">Adrian Whitty</span>. </span><span class="cited-content_cbyCitation_article-title">Recapitulating the Binding Affinity of Nrf2 for KEAP1 in a Cyclic Heptapeptide, Guided by NMR, X-ray Crystallography, and Machine Learning. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2021,</strong> <em>143 </em>
                                    (10)
                                     , 3779-3793. <a href="https://doi.org/10.1021/jacs.0c09799" title="DOI URL">https://doi.org/10.1021/jacs.0c09799</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.0c09799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.0c09799%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DRecapitulating%252Bthe%252BBinding%252BAffinity%252Bof%252BNrf2%252Bfor%252BKEAP1%252Bin%252Ba%252BCyclic%252BHeptapeptide%25252C%252BGuided%252Bby%252BNMR%25252C%252BX-ray%252BCrystallography%25252C%252Band%252BMachine%252BLearning%26aulast%3DOrtet%26aufirst%3DPaula%2BC.%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D13092020%26date%3D08032021%26volume%3D143%26issue%3D10%26spage%3D3779%26epage%3D3793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Olga Cruz-López, Carolin Temps, Beatrice Longo, Samuel H. Myers, Francisco Franco-Montalban, <span class="NLM_string-name hlFld-ContribAuthor">Asier Unciti-Broceta</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Characterization of a Click-Assembled 18-Atom Macrocycle That Displays Selective AXL Kinase Inhibitory Activity. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2019,</strong> <em>4 </em>
                                    (25)
                                     , 21620-21626. <a href="https://doi.org/10.1021/acsomega.9b03525" title="DOI URL">https://doi.org/10.1021/acsomega.9b03525</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.9b03525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.9b03525%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DSynthesis%252Band%252BCharacterization%252Bof%252Ba%252BClick-Assembled%252B18-Atom%252BMacrocycle%252BThat%252BDisplays%252BSelective%252BAXL%252BKinase%252BInhibitory%252BActivity%26aulast%3DCruz-L%25C3%25B3pez%26aufirst%3DOlga%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D22102019%26date%3D14112019%26date%3D03122019%26volume%3D4%26issue%3D25%26spage%3D21620%26epage%3D21626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Maxwell D. Cummings, <span class="NLM_string-name hlFld-ContribAuthor">Sivakumar Sekharan</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-Based Macrocycle Design in Small-Molecule Drug Discovery and Simple Metrics To Identify Opportunities for Macrocyclization of Small-Molecule Ligands. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (15)
                                     , 6843-6853. <a href="https://doi.org/10.1021/acs.jmedchem.8b01985" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01985</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01985&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01985%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-Based%252BMacrocycle%252BDesign%252Bin%252BSmall-Molecule%252BDrug%252BDiscovery%252Band%252BSimple%252BMetrics%252BTo%252BIdentify%252BOpportunities%252Bfor%252BMacrocyclization%252Bof%252BSmall-Molecule%252BLigands%26aulast%3DCummings%26aufirst%3DMaxwell%2BD.%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D18122018%26date%3D22032019%26date%3D12032019%26volume%3D62%26issue%3D15%26spage%3D6843%26epage%3D6853" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yahui Huang, Guoqiang Dong, Huanqiu Li, Na Liu, Wannian Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Chunquan Sheng</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (14)
                                     , 6056-6074. <a href="https://doi.org/10.1021/acs.jmedchem.8b00393" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00393</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00393%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BJanus%252BKinase%252B2%252B%252528JAK2%252529%252Band%252BHistone%252BDeacetylase%252B%252528HDAC%252529%252BDual%252BInhibitors%252Bas%252Ba%252BNovel%252BStrategy%252Bfor%252Bthe%252BCombinational%252BTreatment%252Bof%252BLeukemia%252Band%252BInvasive%252BFungal%252BInfections%26aulast%3DHuang%26aufirst%3DYahui%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D10032018%26date%3D14072018%26date%3D25062018%26volume%3D61%26issue%3D14%26spage%3D6056%26epage%3D6074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Priya  Mahajan</span>, <span class="hlFld-ContribAuthor ">Gousia  Chashoo</span>, <span class="hlFld-ContribAuthor ">Monika  Gupta</span>, <span class="hlFld-ContribAuthor ">Amit  Kumar</span>, <span class="hlFld-ContribAuthor ">Parvinder Pal  Singh</span>, and <span class="hlFld-ContribAuthor ">Amit  Nargotra</span>  . </span><span class="cited-content_cbyCitation_article-title">Fusion of Structure and Ligand Based Methods for Identification of Novel CDK2 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2017,</strong> <em>57 </em>
                                    (8)
                                     , 1957-1969. <a href="https://doi.org/10.1021/acs.jcim.7b00293" title="DOI URL">https://doi.org/10.1021/acs.jcim.7b00293</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.7b00293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.7b00293%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DFusion%252Bof%252BStructure%252Band%252BLigand%252BBased%252BMethods%252Bfor%252BIdentification%252Bof%252BNovel%252BCDK2%252BInhibitors%26aulast%3DMahajan%26aufirst%3DPriya%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D22052017%26date%3D03082017%26date%3D28082017%26date%3D19072017%26volume%3D57%26issue%3D8%26spage%3D1957%26epage%3D1969" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Leepakshi  Khurana</span>, <span class="hlFld-ContribAuthor ">Bo-Qiao  Fu</span>, <span class="hlFld-ContribAuthor ">Anantha L.  Duddupudi</span>, <span class="hlFld-ContribAuthor ">Yu-Hsien  Liao</span>, <span class="hlFld-ContribAuthor ">Sri Sujana  Immadi</span>, <span class="hlFld-ContribAuthor ">Debra A.  Kendall</span>, and <span class="hlFld-ContribAuthor ">Dai  Lu</span>  . </span><span class="cited-content_cbyCitation_article-title">Pyrimidinyl Biphenylureas: Identification of New Lead Compounds as Allosteric Modulators of the Cannabinoid Receptor CB1. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (3)
                                     , 1089-1104. <a href="https://doi.org/10.1021/acs.jmedchem.6b01448" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01448</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01448%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPyrimidinyl%252BBiphenylureas%25253A%252BIdentification%252Bof%252BNew%252BLead%252BCompounds%252Bas%252BAllosteric%252BModulators%252Bof%252Bthe%252BCannabinoid%252BReceptor%252BCB1%26aulast%3DKhurana%26aufirst%3DLeepakshi%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D10102016%26date%3D19012017%26date%3D09022017%26date%3D06012017%26volume%3D60%26issue%3D3%26spage%3D1089%26epage%3D1104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Scott E.  Allen</span>, <span class="hlFld-ContribAuthor ">Nikolay V.  Dokholyan</span>, and <span class="hlFld-ContribAuthor ">Albert A.  Bowers</span>  . </span><span class="cited-content_cbyCitation_article-title">Dynamic Docking of Conformationally Constrained Macrocycles: Methods and Applications. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2016,</strong> <em>11 </em>
                                    (1)
                                     , 10-24. <a href="https://doi.org/10.1021/acschembio.5b00663" title="DOI URL">https://doi.org/10.1021/acschembio.5b00663</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschembio.5b00663&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschembio.5b00663%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DDynamic%252BDocking%252Bof%252BConformationally%252BConstrained%252BMacrocycles%25253A%252BMethods%252Band%252BApplications%26aulast%3DAllen%26aufirst%3DScott%2BE.%26date%3D2016%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D19082015%26date%3D17112015%26date%3D04122015%26date%3D15012016%26date%3D17112015%26volume%3D11%26issue%3D1%26spage%3D10%26epage%3D24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gabriella M.  Nepomuceno</span>, <span class="hlFld-ContribAuthor ">Katie M.  Chan</span>, <span class="hlFld-ContribAuthor ">Valerie  Huynh</span>, <span class="hlFld-ContribAuthor ">Kevin S.  Martin</span>, <span class="hlFld-ContribAuthor ">Jared T.  Moore</span>, <span class="hlFld-ContribAuthor ">Terrence E.  O’Brien</span>, <span class="hlFld-ContribAuthor ">Luiz A. E.  Pollo</span>, <span class="hlFld-ContribAuthor ">Francisco J.  Sarabia</span>, <span class="hlFld-ContribAuthor ">Clarissa  Tadeus</span>, <span class="hlFld-ContribAuthor ">Zi  Yao</span>, <span class="hlFld-ContribAuthor ">David E.  Anderson</span>, <span class="hlFld-ContribAuthor ">James B.  Ames</span>, and <span class="hlFld-ContribAuthor ">Jared T.  Shaw</span>  . </span><span class="cited-content_cbyCitation_article-title">Synthesis and Evaluation of Quinazolines as Inhibitors of the Bacterial Cell Division Protein FtsZ. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>6 </em>
                                    (3)
                                     , 308-312. <a href="https://doi.org/10.1021/ml500497s" title="DOI URL">https://doi.org/10.1021/ml500497s</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ml500497s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fml500497s%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSynthesis%252Band%252BEvaluation%252Bof%252BQuinazolines%252Bas%252BInhibitors%252Bof%252Bthe%252BBacterial%252BCell%252BDivision%252BProtein%252BFtsZ%26aulast%3DNepomuceno%26aufirst%3DGabriella%2BM.%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D02122014%26date%3D07012015%26date%3D21012015%26date%3D12032015%26date%3D07012015%26volume%3D6%26issue%3D3%26spage%3D308%26epage%3D312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anthony D.  William</span>, <span class="hlFld-ContribAuthor ">Angeline C.-H.  Lee</span>, <span class="hlFld-ContribAuthor ">Anders  Poulsen</span>, <span class="hlFld-ContribAuthor ">Kee Chuan  Goh</span>, <span class="hlFld-ContribAuthor ">Babita  Madan</span>, <span class="hlFld-ContribAuthor ">Stefan  Hart</span>, <span class="hlFld-ContribAuthor ">Evelyn  Tan</span>, <span class="hlFld-ContribAuthor ">Haishan  Wang</span>, <span class="hlFld-ContribAuthor ">Harish  Nagaraj</span>, <span class="hlFld-ContribAuthor ">Dizhong  Chen</span>, <span class="hlFld-ContribAuthor ">Chai Ping  Lee</span>, <span class="hlFld-ContribAuthor ">Eric T.  Sun</span>, <span class="hlFld-ContribAuthor ">Ramesh  Jayaraman</span>, <span class="hlFld-ContribAuthor ">Mohammad Khalid  Pasha</span>, <span class="hlFld-ContribAuthor ">Kantharaj  Ethirajulu</span>, <span class="hlFld-ContribAuthor ">Jeanette M.  Wood</span>, and <span class="hlFld-ContribAuthor ">Brian W.  Dymock</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of the Macrocycle (9E)-15-(2-(Pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a Potent Inhibitor of Janus Kinase 2/Fms-LikeTyrosine Kinase-3 (JAK2/FLT3) for the Treatment of Rheumatoid Arthritis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2012,</strong> <em>55 </em>
                                    (6)
                                     , 2623-2640. <a href="https://doi.org/10.1021/jm201454n" title="DOI URL">https://doi.org/10.1021/jm201454n</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm201454n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm201454n%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bthe%252BMacrocycle%252B%2525289E%252529-15-%2525282-%252528Pyrrolidin-1-yl%252529ethoxy%252529-7%25252C12%25252C25-trioxa-19%25252C21%25252C24-triaza-tetracyclo%25255B18.3.1.1%2525282%25252C5%252529.1%25252814%25252C18%252529%25255Dhexacosa-1%25252824%252529%25252C2%25252C4%25252C9%25252C14%25252826%252529%25252C15%25252C17%25252C20%25252C22-nonaene%252B%252528SB1578%252529%25252C%252Ba%252BPotent%252BInhibitor%252Bof%252BJanus%252BKinase%252B2%25252FFms-LikeTyrosine%252BKinase-3%252B%252528JAK2%25252FFLT3%252529%252Bfor%252Bthe%252BTreatment%252Bof%252BRheumatoid%252BArthritis%26aulast%3DWilliam%26aufirst%3DAnthony%2BD.%26date%3D2012%26date%3D2012%26date%3D2011%26date%3D27102011%26date%3D06032012%26date%3D22032012%26date%3D17022012%26volume%3D55%26issue%3D6%26spage%3D2623%26epage%3D2640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anna  Richter</span>, <span class="hlFld-ContribAuthor ">Nina  Schoenwaelder</span>, <span class="hlFld-ContribAuthor ">Sina  Sender</span>, <span class="hlFld-ContribAuthor ">Christian  Junghanss</span>, <span class="hlFld-ContribAuthor ">Claudia  Maletzki</span>. </span><span class="cited-content_cbyCitation_article-title">Cyclin-Dependent Kinase Inhibitors in Hematological Malignancies—Current Understanding, (Pre-)Clinical Application and Promising Approaches. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (10)
                                     , 2497. <a href="https://doi.org/10.3390/cancers13102497" title="DOI URL">https://doi.org/10.3390/cancers13102497</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13102497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13102497%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DCyclin-Dependent%252BKinase%252BInhibitors%252Bin%252BHematological%252BMalignancies%2525E2%252580%252594Current%252BUnderstanding%25252C%252B%252528Pre-%252529Clinical%252BApplication%252Band%252BPromising%252BApproaches%26aulast%3DRichter%26aufirst%3DAnna%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D10%26spage%3D2497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rong  Chen</span>, <span class="hlFld-ContribAuthor ">Jennifer  Tsai</span>, <span class="hlFld-ContribAuthor ">Philip A.  Thompson</span>, <span class="hlFld-ContribAuthor ">Yuling  Chen</span>, <span class="hlFld-ContribAuthor ">Ping  Xiong</span>, <span class="hlFld-ContribAuthor ">Chaomei  Liu</span>, <span class="hlFld-ContribAuthor ">Francis  Burrows</span>, <span class="hlFld-ContribAuthor ">Mariela  Sivina</span>, <span class="hlFld-ContribAuthor ">Jan A.  Burger</span>, <span class="hlFld-ContribAuthor ">Michael J.  Keating</span>, <span class="hlFld-ContribAuthor ">William G.  Wierda</span>, <span class="hlFld-ContribAuthor ">William  Plunkett</span>. </span><span class="cited-content_cbyCitation_article-title">The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action. </span><span class="cited-content_cbyCitation_journal-name">Blood Cancer Journal</span><span> <strong>2021,</strong> <em>11 </em>
                                    (3)
                                     <a href="https://doi.org/10.1038/s41408-021-00436-0" title="DOI URL">https://doi.org/10.1038/s41408-021-00436-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41408-021-00436-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41408-021-00436-0%26sid%3Dliteratum%253Aachs%26jtitle%3DBlood%2520Cancer%2520Journal%26atitle%3DThe%252Bmulti-kinase%252Binhibitor%252BTG02%252Binduces%252Bapoptosis%252Band%252Bblocks%252BB-cell%252Breceptor%252Bsignaling%252Bin%252Bchronic%252Blymphocytic%252Bleukemia%252Bthrough%252Bdual%252Bmechanisms%252Bof%252Baction%26aulast%3DChen%26aufirst%3DRong%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hanzhi  Liang</span>, <span class="hlFld-ContribAuthor ">Jintong  Du</span>, <span class="hlFld-ContribAuthor ">Reham M.  Elhassan</span>, <span class="hlFld-ContribAuthor ">Xuben  Hou</span>, <span class="hlFld-ContribAuthor ">Hao  Fang</span>. </span><span class="cited-content_cbyCitation_article-title">Recent progress in development of cyclin-dependent kinase 7 inhibitors for cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Investigational Drugs</span><span> <strong>2021,</strong> <em>30 </em>
                                    (1)
                                     , 61-76. <a href="https://doi.org/10.1080/13543784.2021.1850693" title="DOI URL">https://doi.org/10.1080/13543784.2021.1850693</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543784.2021.1850693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543784.2021.1850693%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Investigational%2520Drugs%26atitle%3DRecent%252Bprogress%252Bin%252Bdevelopment%252Bof%252Bcyclin-dependent%252Bkinase%252B7%252Binhibitors%252Bfor%252Bcancer%252Btherapy%26aulast%3DLiang%26aufirst%3DHanzhi%26date%3D2021%26date%3D2021%26volume%3D30%26issue%3D1%26spage%3D61%26epage%3D76" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jianru  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Zhang</span>, <span class="hlFld-ContribAuthor ">Huidan  Huang</span>, <span class="hlFld-ContribAuthor ">Yimei  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">A review on kinases phosphorylating the carboxyl-terminal domain of RNA polymerase II—Biological functions and inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>104 </em>, 104318. <a href="https://doi.org/10.1016/j.bioorg.2020.104318" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.104318</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.104318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.104318%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DA%252Breview%252Bon%252Bkinases%252Bphosphorylating%252Bthe%252Bcarboxyl-terminal%252Bdomain%252Bof%252BRNA%252Bpolymerase%252BII%2525E2%252580%252594Biological%252Bfunctions%252Band%252Binhibitors%26aulast%3DZhang%26aufirst%3DJianru%26date%3D2020%26volume%3D104%26spage%3D104318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Simon J.  Cook</span>, <span class="hlFld-ContribAuthor ">Julie A.  Tucker</span>, <span class="hlFld-ContribAuthor ">Pamela A.  Lochhead</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecule ERK5 kinase inhibitors paradoxically activate ERK5 signalling: be careful what you wish for…. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Society Transactions</span><span> <strong>2020,</strong> <em>48 </em>
                                    (5)
                                     , 1859-1875. <a href="https://doi.org/10.1042/BST20190338" title="DOI URL">https://doi.org/10.1042/BST20190338</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1042/BST20190338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1042%2FBST20190338%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Society%2520Transactions%26atitle%3DSmall%252Bmolecule%252BERK5%252Bkinase%252Binhibitors%252Bparadoxically%252Bactivate%252BERK5%252Bsignalling%25253A%252Bbe%252Bcareful%252Bwhat%252Byou%252Bwish%252Bfor%2525E2%252580%2525A6%26aulast%3DCook%26aufirst%3DSimon%2BJ.%26date%3D2020%26date%3D2020%26volume%3D48%26issue%3D5%26spage%3D1859%26epage%3D1875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lexian  Tong</span>, <span class="hlFld-ContribAuthor ">Xuemei  Li</span>, <span class="hlFld-ContribAuthor ">Yongzhou  Hu</span>, <span class="hlFld-ContribAuthor ">Tao  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in FLT3 inhibitors for acute myeloid leukemia. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2020,</strong> <em>12 </em>
                                    (10)
                                     , 961-981. <a href="https://doi.org/10.4155/fmc-2019-0365" title="DOI URL">https://doi.org/10.4155/fmc-2019-0365</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2019-0365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2019-0365%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Badvances%252Bin%252BFLT3%252Binhibitors%252Bfor%252Bacute%252Bmyeloid%252Bleukemia%26aulast%3DTong%26aufirst%3DLexian%26date%3D2020%26volume%3D12%26issue%3D10%26spage%3D961%26epage%3D981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiao  Ding</span>, <span class="hlFld-ContribAuthor ">Feng  Ren</span>. </span><span class="cited-content_cbyCitation_article-title">Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-present). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2020,</strong> <em>30 </em>
                                    (4)
                                     , 275-286. <a href="https://doi.org/10.1080/13543776.2020.1729354" title="DOI URL">https://doi.org/10.1080/13543776.2020.1729354</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2020.1729354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2020.1729354%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DLeucine-rich%252Brepeat%252Bkinase%252B2%252Binhibitors%25253A%252Ba%252Bpatent%252Breview%252B%2525282014-present%252529%26aulast%3DDing%26aufirst%3DXiao%26date%3D2020%26date%3D2020%26volume%3D30%26issue%3D4%26spage%3D275%26epage%3D286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pengfei  Xu</span>, <span class="hlFld-ContribAuthor ">Pei  Shen</span>, <span class="hlFld-ContribAuthor ">Bin  Yu</span>, <span class="hlFld-ContribAuthor ">Xi  Xu</span>, <span class="hlFld-ContribAuthor ">Raoling  Ge</span>, <span class="hlFld-ContribAuthor ">Xinying  Cheng</span>, <span class="hlFld-ContribAuthor ">Qiuyu  Chen</span>, <span class="hlFld-ContribAuthor ">Jinlei  Bian</span>, <span class="hlFld-ContribAuthor ">Zhiyu  Li</span>, <span class="hlFld-ContribAuthor ">JuBo  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>192 </em>, 112155. <a href="https://doi.org/10.1016/j.ejmech.2020.112155" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112155</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112155%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DJanus%252Bkinases%252B%252528JAKs%252529%25253A%252BThe%252Befficient%252Btherapeutic%252Btargets%252Bfor%252Bautoimmune%252Bdiseases%252Band%252Bmyeloproliferative%252Bdisorders%26aulast%3DXu%26aufirst%3DPengfei%26date%3D2020%26volume%3D192%26spage%3D112155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alessandro  Tubita</span>, <span class="hlFld-ContribAuthor ">Zoe  Lombardi</span>, <span class="hlFld-ContribAuthor ">Ignazia  Tusa</span>, <span class="hlFld-ContribAuthor ">Persio  Dello Sbarba</span>, <span class="hlFld-ContribAuthor ">Elisabetta  Rovida</span>. </span><span class="cited-content_cbyCitation_article-title">Beyond Kinase Activity: ERK5 Nucleo-Cytoplasmic Shuttling as a Novel Target for Anticancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (3)
                                     , 938. <a href="https://doi.org/10.3390/ijms21030938" title="DOI URL">https://doi.org/10.3390/ijms21030938</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21030938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21030938%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DBeyond%252BKinase%252BActivity%25253A%252BERK5%252BNucleo-Cytoplasmic%252BShuttling%252Bas%252Ba%252BNovel%252BTarget%252Bfor%252BAnticancer%252BTherapy%26aulast%3DTubita%26aufirst%3DAlessandro%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D3%26spage%3D938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lilian  Zsákai</span>, <span class="hlFld-ContribAuthor ">Anna  Sipos</span>, <span class="hlFld-ContribAuthor ">Judit  Dobos</span>, <span class="hlFld-ContribAuthor ">Dániel  Erős</span>, <span class="hlFld-ContribAuthor ">Csaba  Szántai-Kis</span>, <span class="hlFld-ContribAuthor ">Péter  Bánhegyi</span>, <span class="hlFld-ContribAuthor ">János  Pató</span>, <span class="hlFld-ContribAuthor ">László  Őrfi</span>, <span class="hlFld-ContribAuthor ">Zsolt  Matula</span>, <span class="hlFld-ContribAuthor ">Gábor  Mikala</span>, <span class="hlFld-ContribAuthor ">György  Kéri</span>, <span class="hlFld-ContribAuthor ">István  Peták</span>, <span class="hlFld-ContribAuthor ">István  Vályi-Nagy</span>. </span><span class="cited-content_cbyCitation_article-title">Targeted drug combination therapy design based on driver genes. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2019,</strong> <em>10 </em>
                                    (51)
                                     , 5255-5266. <a href="https://doi.org/10.18632/oncotarget.26985" title="DOI URL">https://doi.org/10.18632/oncotarget.26985</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.26985&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.26985%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DTargeted%252Bdrug%252Bcombination%252Btherapy%252Bdesign%252Bbased%252Bon%252Bdriver%252Bgenes%26aulast%3DZs%25C3%25A1kai%26aufirst%3DLilian%26date%3D2019%26date%3D2019%26volume%3D10%26issue%3D51%26spage%3D5255%26epage%3D5266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Reem Fawaz  Abutayeh</span>, <span class="hlFld-ContribAuthor ">Mutasem O.  Taha</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel Flt3 inhibitory chemotypes through extensive ligand-based and new structure-based pharmacophore modelling methods. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Graphics and Modelling</span><span> <strong>2019,</strong> <em>88 </em>, 128-151. <a href="https://doi.org/10.1016/j.jmgm.2019.01.011" title="DOI URL">https://doi.org/10.1016/j.jmgm.2019.01.011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jmgm.2019.01.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jmgm.2019.01.011%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Graphics%2520and%2520Modelling%26atitle%3DDiscovery%252Bof%252Bnovel%252BFlt3%252Binhibitory%252Bchemotypes%252Bthrough%252Bextensive%252Bligand-based%252Band%252Bnew%252Bstructure-based%252Bpharmacophore%252Bmodelling%252Bmethods%26aulast%3DAbutayeh%26aufirst%3DReem%2BFawaz%26date%3D2019%26volume%3D88%26spage%3D128%26epage%3D151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">. </span><span class="cited-content_cbyCitation_article-title">Catalytic Metathesis Reactions: Nobel Prize Catalysis. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 259-290. <a href="https://doi.org/10.1002/9783527807253.ch7" title="DOI URL">https://doi.org/10.1002/9783527807253.ch7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9783527807253.ch7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9783527807253.ch7%26sid%3Dliteratum%253Aachs%26atitle%3DCatalytic%252BMetathesis%252BReactions%25253A%252BNobel%252BPrize%252BCatalysis%26date%3D2018%26date%3D2018%26spage%3D259%26epage%3D290%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26atitle%3DActive%252BPharmaceutical%252BIngredients%252Bin%252BSynthesis%26aulast%3DBurke%26aufirst%3DAnthony%2BJ%26date%3D2018%26volume%3D45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joseph B.  Sweeney</span>, <span class="hlFld-ContribAuthor ">Anthony K.  Ball</span>, <span class="hlFld-ContribAuthor ">Philippa A.  Lawrence</span>, <span class="hlFld-ContribAuthor ">Mackenzie C.  Sinclair</span>, <span class="hlFld-ContribAuthor ">Luke J.  Smith</span>. </span><span class="cited-content_cbyCitation_article-title">A Simple, Broad-Scope Nickel(0) Precatalyst System for the Direct Amination of Allyl Alcohols. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2018,</strong> <em>130 </em>
                                    (32)
                                     , 10359-10363. <a href="https://doi.org/10.1002/ange.201805611" title="DOI URL">https://doi.org/10.1002/ange.201805611</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.201805611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.201805611%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DA%252BSimple%25252C%252BBroad-Scope%252BNickel%2525280%252529%252BPrecatalyst%252BSystem%252Bfor%252Bthe%252BDirect%252BAmination%252Bof%252BAllyl%252BAlcohols%26aulast%3DSweeney%26aufirst%3DJoseph%2BB.%26date%3D2018%26date%3D2018%26volume%3D130%26issue%3D32%26spage%3D10359%26epage%3D10363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joseph B.  Sweeney</span>, <span class="hlFld-ContribAuthor ">Anthony K.  Ball</span>, <span class="hlFld-ContribAuthor ">Philippa A.  Lawrence</span>, <span class="hlFld-ContribAuthor ">Mackenzie C.  Sinclair</span>, <span class="hlFld-ContribAuthor ">Luke J.  Smith</span>. </span><span class="cited-content_cbyCitation_article-title">A Simple, Broad-Scope Nickel(0) Precatalyst System for the Direct Amination of Allyl Alcohols. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2018,</strong> <em>57 </em>
                                    (32)
                                     , 10202-10206. <a href="https://doi.org/10.1002/anie.201805611" title="DOI URL">https://doi.org/10.1002/anie.201805611</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.201805611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.201805611%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DA%252BSimple%25252C%252BBroad-Scope%252BNickel%2525280%252529%252BPrecatalyst%252BSystem%252Bfor%252Bthe%252BDirect%252BAmination%252Bof%252BAllyl%252BAlcohols%26aulast%3DSweeney%26aufirst%3DJoseph%2BB.%26date%3D2018%26date%3D2018%26volume%3D57%26issue%3D32%26spage%3D10202%26epage%3D10206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yesu  Addepalli</span>, <span class="hlFld-ContribAuthor ">Xiaohong  Yang</span>, <span class="hlFld-ContribAuthor ">Minghui  Zhou</span>, <span class="hlFld-ContribAuthor ">D. Prabhakar  Reddy</span>, <span class="hlFld-ContribAuthor ">Shao-Lin  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhen  Wang</span>, <span class="hlFld-ContribAuthor ">Yun  He</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and anticancer activity evaluation of novel azacalix[2]arene[2]pyrimidines. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>151 </em>, 214-225. <a href="https://doi.org/10.1016/j.ejmech.2018.02.079" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.02.079</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.02.079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.02.079%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Banticancer%252Bactivity%252Bevaluation%252Bof%252Bnovel%252Bazacalix%25255B2%25255Darene%25255B2%25255Dpyrimidines%26aulast%3DAddepalli%26aufirst%3DYesu%26date%3D2018%26volume%3D151%26spage%3D214%26epage%3D225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">. </span><span class="cited-content_cbyCitation_article-title">2-Aminopyrimidines. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 237-283. <a href="https://doi.org/10.1002/9781118686263.ch7" title="DOI URL">https://doi.org/10.1002/9781118686263.ch7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781118686263.ch7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781118686263.ch7%26sid%3Dliteratum%253Aachs%26atitle%3D2-Aminopyrimidines%26date%3D2018%26date%3D2018%26spage%3D237%26epage%3D283%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26atitle%3DPrivileged%252BStructures%252Bin%252BDrug%252BDiscovery%26aulast%3DYet%26aufirst%3DLarry%26date%3D2018%26volume%3D57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Steven R.  Whittaker</span>, <span class="hlFld-ContribAuthor ">Aurélie  Mallinger</span>, <span class="hlFld-ContribAuthor ">Paul  Workman</span>, <span class="hlFld-ContribAuthor ">Paul A.  Clarke</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibitors of cyclin-dependent kinases as cancer therapeutics. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology & Therapeutics</span><span> <strong>2017,</strong> <em>173 </em>, 83-105. <a href="https://doi.org/10.1016/j.pharmthera.2017.02.008" title="DOI URL">https://doi.org/10.1016/j.pharmthera.2017.02.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pharmthera.2017.02.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pharmthera.2017.02.008%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520%2526%2520Therapeutics%26atitle%3DInhibitors%252Bof%252Bcyclin-dependent%252Bkinases%252Bas%252Bcancer%252Btherapeutics%26aulast%3DWhittaker%26aufirst%3DSteven%2BR.%26date%3D2017%26volume%3D173%26spage%3D83%26epage%3D105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Van T.  Hoang</span>, <span class="hlFld-ContribAuthor ">Thomas J.  Yan</span>, <span class="hlFld-ContribAuthor ">Jane E.  Cavanaugh</span>, <span class="hlFld-ContribAuthor ">Patrick T.  Flaherty</span>, <span class="hlFld-ContribAuthor ">Barbara S.  Beckman</span>, <span class="hlFld-ContribAuthor ">Matthew E.  Burow</span>. </span><span class="cited-content_cbyCitation_article-title">Oncogenic signaling of MEK5-ERK5. </span><span class="cited-content_cbyCitation_journal-name">Cancer Letters</span><span> <strong>2017,</strong> <em>392 </em>, 51-59. <a href="https://doi.org/10.1016/j.canlet.2017.01.034" title="DOI URL">https://doi.org/10.1016/j.canlet.2017.01.034</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.canlet.2017.01.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.canlet.2017.01.034%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Letters%26atitle%3DOncogenic%252Bsignaling%252Bof%252BMEK5-ERK5%26aulast%3DHoang%26aufirst%3DVan%2BT.%26date%3D2017%26volume%3D392%26spage%3D51%26epage%3D59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrew L.  McIver</span>, <span class="hlFld-ContribAuthor ">Weihe  Zhang</span>, <span class="hlFld-ContribAuthor ">Qingyang  Liu</span>, <span class="hlFld-ContribAuthor ">Xinpeng  Jiang</span>, <span class="hlFld-ContribAuthor ">Michael A.  Stashko</span>, <span class="hlFld-ContribAuthor ">James  Nichols</span>, <span class="hlFld-ContribAuthor ">Michael J.  Miley</span>, <span class="hlFld-ContribAuthor ">Jacqueline  Norris-Drouin</span>, <span class="hlFld-ContribAuthor ">Mischa  Machius</span>, <span class="hlFld-ContribAuthor ">Deborah  DeRyckere</span>, <span class="hlFld-ContribAuthor ">Edgar  Wood</span>, <span class="hlFld-ContribAuthor ">Douglas K.  Graham</span>, <span class="hlFld-ContribAuthor ">H. Shelton  Earp</span>, <span class="hlFld-ContribAuthor ">Dmitri  Kireev</span>, <span class="hlFld-ContribAuthor ">Stephen V.  Frye</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Macrocyclic Pyrimidines as MerTK-Specific Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2017,</strong> <em>12 </em>
                                    (3)
                                     , 207-213. <a href="https://doi.org/10.1002/cmdc.201600589" title="DOI URL">https://doi.org/10.1002/cmdc.201600589</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201600589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201600589%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DDiscovery%252Bof%252BMacrocyclic%252BPyrimidines%252Bas%252BMerTK-Specific%252BInhibitors%26aulast%3DMcIver%26aufirst%3DAndrew%2BL.%26date%3D2017%26date%3D2017%26volume%3D12%26issue%3D3%26spage%3D207%26epage%3D213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fei  Ma</span>, <span class="hlFld-ContribAuthor ">Peng  Liu</span>, <span class="hlFld-ContribAuthor ">Min  Lei</span>, <span class="hlFld-ContribAuthor ">Jian  Liu</span>, <span class="hlFld-ContribAuthor ">Hongtao  Wang</span>, <span class="hlFld-ContribAuthor ">Shaohua  Zhao</span>, <span class="hlFld-ContribAuthor ">Lihong  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of indolin-2-one-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase3 (FLT3). </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>127 </em>, 72-86. <a href="https://doi.org/10.1016/j.ejmech.2016.12.038" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.12.038</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.12.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.12.038%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bindolin-2-one-based%252Bderivatives%252Bas%252Bpotent%25252C%252Bselective%252Band%252Befficacious%252Binhibitors%252Bof%252BFMS-like%252Btyrosine%252Bkinase3%252B%252528FLT3%252529%26aulast%3DMa%26aufirst%3DFei%26date%3D2017%26volume%3D127%26spage%3D72%26epage%3D86" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Diane M.  Pereira</span>, <span class="hlFld-ContribAuthor ">André E. S.  Simões</span>, <span class="hlFld-ContribAuthor ">Sofia E.  Gomes</span>, <span class="hlFld-ContribAuthor ">Rui E.  Castro</span>, <span class="hlFld-ContribAuthor ">Tânia  Carvalho</span>, <span class="hlFld-ContribAuthor ">Cecília M. P.  Rodrigues</span>, <span class="hlFld-ContribAuthor ">Pedro M.  Borralho</span>. </span><span class="cited-content_cbyCitation_article-title">MEK5/ERK5 signaling inhibition increases colon cancer cell sensitivity to 5-fluorouracil through a p53-dependent mechanism. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2016,</strong> <em>7 </em>
                                    (23)
                                     , 34322-34340. <a href="https://doi.org/10.18632/oncotarget.9107" title="DOI URL">https://doi.org/10.18632/oncotarget.9107</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.9107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.9107%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DMEK5%25252FERK5%252Bsignaling%252Binhibition%252Bincreases%252Bcolon%252Bcancer%252Bcell%252Bsensitivity%252Bto%252B5-fluorouracil%252Bthrough%252Ba%252Bp53-dependent%252Bmechanism%26aulast%3DPereira%26aufirst%3DDiane%2BM.%26date%3D2016%26date%3D2016%26volume%3D7%26issue%3D23%26spage%3D34322%26epage%3D34340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoai  Wu</span>, <span class="hlFld-ContribAuthor ">Zhen  Fang</span>, <span class="hlFld-ContribAuthor ">Bo  Yang</span>, <span class="hlFld-ContribAuthor ">Lei  Zhong</span>, <span class="hlFld-ContribAuthor ">Qiuyuan  Yang</span>, <span class="hlFld-ContribAuthor ">Chunhui  Zhang</span>, <span class="hlFld-ContribAuthor ">Shenzhen  Huang</span>, <span class="hlFld-ContribAuthor ">Rong  Xiang</span>, <span class="hlFld-ContribAuthor ">Takayoshi  Suzuki</span>, <span class="hlFld-ContribAuthor ">Lin-Li  Li</span>, <span class="hlFld-ContribAuthor ">Sheng-Yong  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of KDM5A inhibitors: Homology modeling, virtual screening and structure–activity relationship analysis. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>26 </em>
                                    (9)
                                     , 2284-2288. <a href="https://doi.org/10.1016/j.bmcl.2016.03.048" title="DOI URL">https://doi.org/10.1016/j.bmcl.2016.03.048</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2016.03.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2016.03.048%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BKDM5A%252Binhibitors%25253A%252BHomology%252Bmodeling%25252C%252Bvirtual%252Bscreening%252Band%252Bstructure%2525E2%252580%252593activity%252Brelationship%252Banalysis%26aulast%3DWu%26aufirst%3DXiaoai%26date%3D2016%26volume%3D26%26issue%3D9%26spage%3D2284%26epage%3D2288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">James S.  Blachly</span>, <span class="hlFld-ContribAuthor ">John C.  Byrd</span>, <span class="hlFld-ContribAuthor ">Michael  Grever</span>. </span><span class="cited-content_cbyCitation_article-title">Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia. </span><span class="cited-content_cbyCitation_journal-name">Seminars in Oncology</span><span> <strong>2016,</strong> <em>43 </em>
                                    (2)
                                     , 265-273. <a href="https://doi.org/10.1053/j.seminoncol.2016.02.003" title="DOI URL">https://doi.org/10.1053/j.seminoncol.2016.02.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1053/j.seminoncol.2016.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1053%2Fj.seminoncol.2016.02.003%26sid%3Dliteratum%253Aachs%26jtitle%3DSeminars%2520in%2520Oncology%26atitle%3DCyclin-dependent%252Bkinase%252Binhibitors%252Bfor%252Bthe%252Btreatment%252Bof%252Bchronic%252Blymphocytic%252Bleukemia%26aulast%3DBlachly%26aufirst%3DJames%2BS.%26date%3D2016%26volume%3D43%26issue%3D2%26spage%3D265%26epage%3D273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">S  Blondel</span>, <span class="hlFld-ContribAuthor ">A-L  Egesipe</span>, <span class="hlFld-ContribAuthor ">P  Picardi</span>, <span class="hlFld-ContribAuthor ">A-L  Jaskowiak</span>, <span class="hlFld-ContribAuthor ">M  Notarnicola</span>, <span class="hlFld-ContribAuthor ">J  Ragot</span>, <span class="hlFld-ContribAuthor ">J  Tournois</span>, <span class="hlFld-ContribAuthor ">A  Le Corf</span>, <span class="hlFld-ContribAuthor ">B  Brinon</span>, <span class="hlFld-ContribAuthor ">P  Poydenot</span>, <span class="hlFld-ContribAuthor ">P  Georges</span>, <span class="hlFld-ContribAuthor ">C  Navarro</span>, <span class="hlFld-ContribAuthor ">P R  pitrez</span>, <span class="hlFld-ContribAuthor ">L  Ferreira</span>, <span class="hlFld-ContribAuthor ">G  Bollot</span>, <span class="hlFld-ContribAuthor ">C  Bauvais</span>, <span class="hlFld-ContribAuthor ">D  Laustriat</span>, <span class="hlFld-ContribAuthor ">A  Mejat</span>, <span class="hlFld-ContribAuthor ">A  De Sandre-Giovannoli</span>, <span class="hlFld-ContribAuthor ">N  Levy</span>, <span class="hlFld-ContribAuthor ">M  Bifulco</span>, <span class="hlFld-ContribAuthor ">M  Peschanski</span>, <span class="hlFld-ContribAuthor ">X  Nissan</span>. </span><span class="cited-content_cbyCitation_article-title">Drug screening on Hutchinson Gilford progeria pluripotent stem cells reveals aminopyrimidines as new modulators of farnesylation. </span><span class="cited-content_cbyCitation_journal-name">Cell Death & Disease</span><span> <strong>2016,</strong> <em>7 </em>
                                    (2)
                                     , e2105-e2105. <a href="https://doi.org/10.1038/cddis.2015.374" title="DOI URL">https://doi.org/10.1038/cddis.2015.374</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/cddis.2015.374&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fcddis.2015.374%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Death%2520%2526%2520Disease%26atitle%3DDrug%252Bscreening%252Bon%252BHutchinson%252BGilford%252Bprogeria%252Bpluripotent%252Bstem%252Bcells%252Breveals%252Baminopyrimidines%252Bas%252Bnew%252Bmodulators%252Bof%252Bfarnesylation%26aulast%3DBlondel%26aufirst%3DS%26date%3D2016%26date%3D2016%26volume%3D7%26issue%3D2%26spage%3De2105%26epage%3De2105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mohan Reddy  Bodireddy</span>, <span class="hlFld-ContribAuthor ">Ranjeet Singh  Mahla</span>, <span class="hlFld-ContribAuthor ">P. Md.  Khaja Mohinuddin</span>, <span class="hlFld-ContribAuthor ">G. Trivikram  Reddy</span>, <span class="hlFld-ContribAuthor ">D. Vijaya  Raghava Prasad</span>, <span class="hlFld-ContribAuthor ">Himanshu  Kumar</span>, <span class="hlFld-ContribAuthor ">N. C. Gangi  Reddy</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a new class of 16-membered (2Z,11Z)-3,11-di(aryl/naphthyl)-1,13-dioxa-5,9-dithia-2,12-diazacyclohexadeca-2,11-dienes as anti-tumor agents. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2016,</strong> <em>6 </em>
                                    (79)
                                     , 75651-75663. <a href="https://doi.org/10.1039/C6RA15140J" title="DOI URL">https://doi.org/10.1039/C6RA15140J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C6RA15140J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC6RA15140J%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DDiscovery%252Bof%252Ba%252Bnew%252Bclass%252Bof%252B16-membered%252B%2525282Z%25252C11Z%252529-3%25252C11-di%252528aryl%25252Fnaphthyl%252529-1%25252C13-dioxa-5%25252C9-dithia-2%25252C12-diazacyclohexadeca-2%25252C11-dienes%252Bas%252Banti-tumor%252Bagents%26aulast%3DBodireddy%26aufirst%3DMohan%2BReddy%26date%3D2016%26date%3D2016%26volume%3D6%26issue%3D79%26spage%3D75651%26epage%3D75663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cheng-Qing  Ning</span>, <span class="hlFld-ContribAuthor ">Cheng  Lu</span>, <span class="hlFld-ContribAuthor ">Liang  Hu</span>, <span class="hlFld-ContribAuthor ">Yan-Jing  Bi</span>, <span class="hlFld-ContribAuthor ">Lei  Yao</span>, <span class="hlFld-ContribAuthor ">Yu-Jun  He</span>, <span class="hlFld-ContribAuthor ">Li-Fei  Liu</span>, <span class="hlFld-ContribAuthor ">Xiao-Yu  Liu</span>, <span class="hlFld-ContribAuthor ">Nie-Fang  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">Macrocyclic compounds as anti-cancer agents: Design and synthesis of multi-acting inhibitors against HDAC, FLT3 and JAK2. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>95 </em>, 104-115. <a href="https://doi.org/10.1016/j.ejmech.2015.03.034" title="DOI URL">https://doi.org/10.1016/j.ejmech.2015.03.034</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2015.03.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2015.03.034%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMacrocyclic%252Bcompounds%252Bas%252Banti-cancer%252Bagents%25253A%252BDesign%252Band%252Bsynthesis%252Bof%252Bmulti-acting%252Binhibitors%252Bagainst%252BHDAC%25252C%252BFLT3%252Band%252BJAK2%26aulast%3DNing%26aufirst%3DCheng-Qing%26date%3D2015%26volume%3D95%26spage%3D104%26epage%3D115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Philippe  Compain</span>, <span class="hlFld-ContribAuthor ">Damien  Hazelard</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Amine-Containing Heterocycles by Metathesis Reactions: Recent Advances and Opportunities. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2014,</strong>,, 111-153. <a href="https://doi.org/10.1007/7081_2014_139" title="DOI URL">https://doi.org/10.1007/7081_2014_139</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7081_2014_139&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7081_2014_139%26sid%3Dliteratum%253Aachs%26atitle%3DSynthesis%252Bof%252BAmine-Containing%252BHeterocycles%252Bby%252BMetathesis%252BReactions%25253A%252BRecent%252BAdvances%252Band%252BOpportunities%26aulast%3DCompain%26aufirst%3DPhilippe%26date%3D2014%26date%3D2015%26spage%3D111%26epage%3D153%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DSynthesis%252Bof%252BHeterocycles%252Bby%252BMetathesis%252BReactions%26aulast%3DPrunet%26aufirst%3DJo%25C3%25ABlle%26date%3D2017%26volume%3D47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A.  Mortlock</span>, <span class="hlFld-ContribAuthor ">K.  Foote</span>, <span class="hlFld-ContribAuthor ">J.  Kettle</span>, <span class="hlFld-ContribAuthor ">B.  Aquila</span>. </span><span class="cited-content_cbyCitation_article-title">Kinase Inhibitors in Cancer. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2014,</strong>,<a href="https://doi.org/10.1016/B978-0-12-409547-2.11033-9" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.11033-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.11033-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.11033-9%26sid%3Dliteratum%253Aachs%26atitle%3DKinase%252BInhibitors%252Bin%252BCancer%26aulast%3DMortlock%26aufirst%3DA.%26date%3D2014%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BChemistry%25252C%252BMolecular%252BSciences%252Band%252BChemical%252BEngineering%26date%3D2014%26volume%3D409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kh. Dhanachandra  Singh</span>, <span class="hlFld-ContribAuthor ">Queen  Naveena</span>, <span class="hlFld-ContribAuthor ">Muthusamy  Karthikeyan</span>. </span><span class="cited-content_cbyCitation_article-title">Jak2 inhibitor – a jackpot for pharmaceutical industries: a comprehensive computational method in the discovery of new potent Jak2 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Mol. BioSyst.</span><span> <strong>2014,</strong> <em>10 </em>
                                    (8)
                                     , 2146-2159. <a href="https://doi.org/10.1039/C4MB00071D" title="DOI URL">https://doi.org/10.1039/C4MB00071D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C4MB00071D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC4MB00071D%26sid%3Dliteratum%253Aachs%26jtitle%3DMol.%2520BioSyst.%26atitle%3DJak2%252Binhibitor%252B%2525E2%252580%252593%252Ba%252Bjackpot%252Bfor%252Bpharmaceutical%252Bindustries%25253A%252Ba%252Bcomprehensive%252Bcomputational%252Bmethod%252Bin%252Bthe%252Bdiscovery%252Bof%252Bnew%252Bpotent%252BJak2%252Binhibitors%26aulast%3DSingh%26aufirst%3DKh.%2BDhanachandra%26date%3D2014%26date%3D2014%26volume%3D10%26issue%3D8%26spage%3D2146%26epage%3D2159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Altaf  Hussain</span>, <span class="hlFld-ContribAuthor ">S. K.  Yousuf</span>, <span class="hlFld-ContribAuthor ">Debaraj  Mukherjee</span>. </span><span class="cited-content_cbyCitation_article-title">Importance and synthesis of benzannulated medium-sized and macrocyclic rings (BMRs). </span><span class="cited-content_cbyCitation_journal-name">RSC Adv.</span><span> <strong>2014,</strong> <em>4 </em>
                                    (81)
                                     , 43241-43257. <a href="https://doi.org/10.1039/C4RA07434C" title="DOI URL">https://doi.org/10.1039/C4RA07434C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C4RA07434C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC4RA07434C%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Adv.%26atitle%3DImportance%252Band%252Bsynthesis%252Bof%252Bbenzannulated%252Bmedium-sized%252Band%252Bmacrocyclic%252Brings%252B%252528BMRs%252529%26aulast%3DHussain%26aufirst%3DAltaf%26date%3D2014%26date%3D2014%26volume%3D4%26issue%3D81%26spage%3D43241%26epage%3D43257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stela  Álvarez-Fernández</span>, <span class="hlFld-ContribAuthor ">María Jesús  Ortiz-Ruiz</span>, <span class="hlFld-ContribAuthor ">Tracy  Parrott</span>, <span class="hlFld-ContribAuthor ">Sara  Zaknoen</span>, <span class="hlFld-ContribAuthor ">Enrique M.  Ocio</span>, <span class="hlFld-ContribAuthor ">Jesús  San Miguel</span>, <span class="hlFld-ContribAuthor ">Francis J.  Burrows</span>, <span class="hlFld-ContribAuthor ">Azucena  Esparís-Ogando</span>, <span class="hlFld-ContribAuthor ">Atanasio  Pandiella</span>. </span><span class="cited-content_cbyCitation_article-title">Potent Antimyeloma Activity of a Novel ERK5/CDK Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Clinical Cancer Research</span><span> <strong>2013,</strong> <em>19 </em>
                                    (10)
                                     , 2677-2687. <a href="https://doi.org/10.1158/1078-0432.CCR-12-2118" title="DOI URL">https://doi.org/10.1158/1078-0432.CCR-12-2118</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1078-0432.CCR-12-2118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1078-0432.CCR-12-2118%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Cancer%2520Research%26atitle%3DPotent%252BAntimyeloma%252BActivity%252Bof%252Ba%252BNovel%252BERK5%25252FCDK%252BInhibitor%26aulast%3D%25C3%2581lvarez-Fern%25C3%25A1ndez%26aufirst%3DStela%26date%3D2013%26date%3D2013%26volume%3D19%26issue%3D10%26spage%3D2677%26epage%3D2687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brian W  Dymock</span>, <span class="hlFld-ContribAuthor ">Cheng Shang  See</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 – 2012. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2013,</strong> <em>23 </em>
                                    (4)
                                     , 449-501. <a href="https://doi.org/10.1517/13543776.2013.765862" title="DOI URL">https://doi.org/10.1517/13543776.2013.765862</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/13543776.2013.765862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F13543776.2013.765862%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DInhibitors%252Bof%252BJAK2%252Band%252BJAK3%25253A%252Ban%252Bupdate%252Bon%252Bthe%252Bpatent%252Bliterature%252B2010%252B%2525E2%252580%252593%252B2012%26aulast%3DDymock%26aufirst%3DBrian%2BW%26date%3D2013%26date%3D2013%26volume%3D23%26issue%3D4%26spage%3D449%26epage%3D501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anders  Poulsen</span>, <span class="hlFld-ContribAuthor ">Anthony  William</span>, <span class="hlFld-ContribAuthor ">Stéphanie  Blanchard</span>, <span class="hlFld-ContribAuthor ">Harish  Nagaraj</span>, <span class="hlFld-ContribAuthor ">Meredith  Williams</span>, <span class="hlFld-ContribAuthor ">Haishan  Wang</span>, <span class="hlFld-ContribAuthor ">Angeline  Lee</span>, <span class="hlFld-ContribAuthor ">Eric  Sun</span>, <span class="hlFld-ContribAuthor ">Ee-Ling  Teo</span>, <span class="hlFld-ContribAuthor ">Evelyn  Tan</span>, <span class="hlFld-ContribAuthor ">Kee Chuan  Goh</span>, <span class="hlFld-ContribAuthor ">Brian  Dymock</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-based design of nitrogen-linked macrocyclic kinase inhibitors leading to the clinical candidate SB1317/TG02, a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3). </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Modeling</span><span> <strong>2013,</strong> <em>19 </em>
                                    (1)
                                     , 119-130. <a href="https://doi.org/10.1007/s00894-012-1528-7" title="DOI URL">https://doi.org/10.1007/s00894-012-1528-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00894-012-1528-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00894-012-1528-7%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Modeling%26atitle%3DStructure-based%252Bdesign%252Bof%252Bnitrogen-linked%252Bmacrocyclic%252Bkinase%252Binhibitors%252Bleading%252Bto%252Bthe%252Bclinical%252Bcandidate%252BSB1317%25252FTG02%25252C%252Ba%252Bpotent%252Binhibitor%252Bof%252Bcyclin%252Bdependant%252Bkinases%252B%252528CDKs%252529%25252C%252BJanus%252Bkinase%252B2%252B%252528JAK2%252529%25252C%252Band%252BFms-like%252Btyrosine%252Bkinase-3%252B%252528FLT3%252529%26aulast%3DPoulsen%26aufirst%3DAnders%26date%3D2013%26date%3D2012%26volume%3D19%26issue%3D1%26spage%3D119%26epage%3D130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sandrine  Vendeville</span>, <span class="hlFld-ContribAuthor ">Maxwell D.  Cummings</span>. </span><span class="cited-content_cbyCitation_article-title">Synthetic Macrocycles in Small-Molecule Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2013,</strong>,, 371-386. <a href="https://doi.org/10.1016/B978-0-12-417150-3.00023-5" title="DOI URL">https://doi.org/10.1016/B978-0-12-417150-3.00023-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-417150-3.00023-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-417150-3.00023-5%26sid%3Dliteratum%253Aachs%26atitle%3DSynthetic%252BMacrocycles%252Bin%252BSmall-Molecule%252BDrug%252BDiscovery%26aulast%3DVendeville%26aufirst%3DSandrine%26date%3D2013%26spage%3D371%26epage%3D386%26pub%3DElsevier%26date%3D2013%26volume%3D48" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Raoul  Tibes</span>, <span class="hlFld-ContribAuthor ">James M  Bogenberger</span>, <span class="hlFld-ContribAuthor ">Holly L  Geyer</span>, <span class="hlFld-ContribAuthor ">Ruben A  Mesa</span>. </span><span class="cited-content_cbyCitation_article-title">JAK2 inhibitors in the treatment of myeloproliferative neoplasms. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Investigational Drugs</span><span> <strong>2012,</strong> <em>21 </em>
                                    (12)
                                     , 1755-1774. <a href="https://doi.org/10.1517/13543784.2012.721352" title="DOI URL">https://doi.org/10.1517/13543784.2012.721352</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/13543784.2012.721352&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F13543784.2012.721352%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Investigational%2520Drugs%26atitle%3DJAK2%252Binhibitors%252Bin%252Bthe%252Btreatment%252Bof%252Bmyeloproliferative%252Bneoplasms%26aulast%3DTibes%26aufirst%3DRaoul%26date%3D2012%26date%3D2012%26volume%3D21%26issue%3D12%26spage%3D1755%26epage%3D1774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jamie  Mallinson</span>, <span class="hlFld-ContribAuthor ">Ian  Collins</span>. </span><span class="cited-content_cbyCitation_article-title">Macrocycles in new drug discovery. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2012,</strong> <em>4 </em>
                                    (11)
                                     , 1409-1438. <a href="https://doi.org/10.4155/fmc.12.93" title="DOI URL">https://doi.org/10.4155/fmc.12.93</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc.12.93&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc.12.93%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DMacrocycles%252Bin%252Bnew%252Bdrug%252Bdiscovery%26aulast%3DMallinson%26aufirst%3DJamie%26date%3D2012%26volume%3D4%26issue%3D11%26spage%3D1409%26epage%3D1438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">M. Montserrat  Martínez</span>, <span class="hlFld-ContribAuthor ">Cristina  Pérez-Caaveiro</span>, <span class="hlFld-ContribAuthor ">Miguel  Peña-López</span>, <span class="hlFld-ContribAuthor ">Luis A.  Sarandeses</span>, <span class="hlFld-ContribAuthor ">José  Pérez Sestelo</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of 4,6-disubstituted 2-(4-morpholinyl)pyrimidines by cross-coupling reactions using triorganoindium compounds. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2012,</strong> <em>10 </em>
                                    (45)
                                     , 9045. <a href="https://doi.org/10.1039/c2ob26398j" title="DOI URL">https://doi.org/10.1039/c2ob26398j</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/c2ob26398j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2Fc2ob26398j%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DSynthesis%252Bof%252B4%25252C6-disubstituted%252B2-%2525284-morpholinyl%252529pyrimidines%252Bby%252Bcross-coupling%252Breactions%252Busing%252Btriorganoindium%252Bcompounds%26aulast%3DMart%25C3%25ADnez%26aufirst%3DM.%2BMontserrat%26date%3D2012%26volume%3D10%26issue%3D45%26spage%3D9045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/medium/jm-2011-01112g_0025.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201112g&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/medium/jm-2011-01112g_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0018.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Advanced CDK, JAK2, and FLT3 kinase inhibitors in clinical trials.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201112g&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/medium/jm-2011-01112g_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0019.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Evolution of CDK inhibitor motif by modulating the macrocycle linking moiety.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201112g&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/medium/jm-2011-01112g_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201112g&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reactions and conditions: (a) tetrakis(triphenylphosphine)palladium(0), Na<sub>2</sub>CO<sub>3</sub>, 1,2-dimethoxyethane, water, 80 °C, 53–91%; (b) SnCl<sub>2</sub>·H<sub>2</sub>O, CH<sub>2</sub>Cl<sub>2</sub>/MeOH (1:1), room temp, 56–98%; (c) <b>12a</b> or <b>12b</b>, allyl bromide, KOH, TBAHSO<sub>4</sub>, CH<sub>2</sub>Cl<sub>2</sub>, room temp, 55–59%; (d) <b>12d</b>, vinylacetic acid, HOBt, EDCI, CH<sub>2</sub>Cl<sub>2</sub>, room temp, 77%; (e) <b>12e</b>, allylamine, HOBt, EDCI, CH<sub>2</sub>Cl<sub>2</sub>, room temp, 59%. (f) <b>12a</b>, 4-bromobut-1-ene, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 40 °C, 75%; (g) <b>12f</b>, <i>N</i>-allylmethylamine or allylamine, Na(OAc)<sub>3</sub>BH, CH<sub>2</sub>Cl<sub>2</sub>, room temp, 88–95%.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/medium/jm-2011-01112g_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201112g&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reactions and conditions: (a) <b>16a</b>, 4-pentenoic acid, HOBt, EDCI, CH<sub>2</sub>Cl<sub>2</sub>, room temp, 58%; (b) SnCl<sub>2</sub>·H<sub>2</sub>O, CH<sub>2</sub>Cl<sub>2</sub>/MeOH (1:1), room temp, 56–98%; (c) <b>16b</b>, <i>N</i>-allylmethylamine or allylamine, Na(OAc)<sub>3</sub>BH, CH<sub>2</sub>Cl<sub>2</sub>, room temp, 88–95%; (d) (CF<sub>3</sub>CO)<sub>2</sub>O, Et<sub>3</sub>N, THF, room temp, 99%; (e) <b>16a</b>, allyl bromide, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, room temp, 66%; (f) (Boc)<sub>2</sub>O, NaOH, THF, room temp, 86%; (g)<b>16c</b>, allyl bromide, KOH, TBAHSO<sub>4</sub>, CH<sub>2</sub>Cl<sub>2</sub>, room temp, 78%; (h) 4 M HCl, <i>n</i>-butanol, 80–100 °C, 59–92%; (i) Grubbs second generation catalyst, TFA, CH<sub>2</sub>Cl<sub>2</sub>, 40–45 °C, 64–89%; (j) 4 M HCl, MeOH/CH<sub>2</sub>Cl<sub>2</sub>, 40 °C, 79%.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/medium/jm-2011-01112g_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201112g&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reactions and conditions: (a) <i>N</i>-allylmethylamine, Na(OAc)<sub>3</sub>BH, CH<sub>2</sub>Cl<sub>2</sub>, room temp, 75%, quantitative; (b) Fe powder, NH<sub>4</sub>Cl, EtOH, water, 80 °C, 81–93% or SnCl<sub>2</sub>·H<sub>2</sub>O, CH<sub>2</sub>Cl<sub>2</sub>/MeOH (1:1), room temp, 52–97%; (c) <b>16h</b> or <b>16c</b>, 1,2-dichloroethane, K<sub>2</sub>CO<sub>3</sub>, DMF, 100 °C, 64–72%; (d) amine, Na(OAc)<sub>3</sub>BH<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, room temp, 68–88%; (e) allyl bromide, K<sub>2</sub>CO<sub>3</sub>, DMF, 70 °C, 48–91%; (f) amine, DMA, 90 °C, 75–90%; (g) morpholine, ACN, room temp, 83%; (h) NH<sub>4</sub>Cl, MeOH, 60 °C, 95%; (i) ethanethiol, K<sub>2</sub>CO<sub>3</sub>, DMF, 70 °C, 86–97%; (j) MCPBA, CH<sub>2</sub>Cl<sub>2</sub>, room temp, 46%; (k) TFA/H<sub>2</sub>O (1:1), CH<sub>2</sub>Cl<sub>2</sub>, room temp, quantitative; (l) conc HNO<sub>3</sub>, conc H<sub>2</sub>SO<sub>4</sub>, 0 °C, 80%.</p></p></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/medium/jm-2011-01112g_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201112g&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reactions and conditions: (a) <i>N</i>-allylmethylamine, Na(OAc)<sub>3</sub>BH, CH<sub>2</sub>Cl<sub>2</sub>, room temp, 75%, quantitative; (b) Fe powder, NH<sub>4</sub>Cl, EtOH, water, 80 °C, 81–93% or SnCl<sub>2</sub>·H<sub>2</sub>O, CH<sub>2</sub>Cl<sub>2</sub>/MeOH (1:1), room temp, 52–97%; (c) <b>16h</b> or <b>16c</b>, 1,2-dichloroethane, K<sub>2</sub>CO<sub>3</sub>, DMF, 100 °C, 64–72%; (d) amine, DMA, 90 °C, 75–90%; (e) 2-bromoethyl methyl ether, K<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, 86%; (f) methyl bromoacetate, K<sub>2</sub>CO<sub>3</sub>, ACN, room temp, 87%; (g) LiOH, THF/H<sub>2</sub>O (1:1), room temp, quantitative; (h) pyrrolidine, HOBt, EDCI, CH<sub>2</sub>Cl<sub>2</sub>, room temp, quantitative; (i) (CF<sub>3</sub>CO)<sub>2</sub>O, Et<sub>3</sub>N, THF, room temp, quantitative; (j) DIBAL, CH<sub>2</sub>Cl<sub>2</sub>, −78 °C, 48%.</p></p></figure><figure data-id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/medium/jm-2011-01112g_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 5. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201112g&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reactions and conditions: (a) 4 M HCl, <i>n</i>-butanol, 80–100 °C, 49–97%; (b) Grubbs second generation catalyst, TFA, CH<sub>2</sub>Cl<sub>2</sub>, 40–45 °C, 42–89%; (c) K<sub>2</sub>CO<sub>3</sub>, H<sub>2</sub>O, MeOH, room temp, 48–58%; (d) (i) bromoacetyl bromide, CH<sub>2</sub>Cl<sub>2</sub>, room temp; (ii) isopropylamine, DIEA, CH<sub>2</sub>Cl<sub>2</sub>, room temp, two steps 39%; (e) ethanesulfonyl chloride, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, room temp, 40%; (f) 4-morpholinecarbonyl chloride, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, room temp, 48%.</p></p></figure><figure data-id="fig3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/medium/jm-2011-01112g_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0020.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Macrocycles docked into CDK2. The CDK2 ATP-binding site is shown in thin tube with gray carbon. Inhibitors are shown in thick tube with green carbon. (A) In addition to the hydrogen bonds to the hinge residue Leu83, <b>26h</b> is forming a salt bridge to Asp86. (B) <b>26i</b> is also forming a salt bridge to Asp86, but the ether oxygen is clashing with the backbone carbonyl of Gln131, resulting in a lower IC<sub>50</sub>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201112g&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/medium/jm-2011-01112g_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0021.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) <b>26h</b> docked into FLT3. The predicted bioactive conformation of the macrocycle is different from that docked into CDK2. However, the interactions with the protein are conserved with two hydrogen bonds formed to the hinge backbone and a salt bridge to Asp698. (B) <b>26h</b> docked into JAK2. The conformation of the macrocycle is different from that docked into CDK2 and FLT3. The two hydrogen bonds formed to the hinge backbone are conserved, but instead of the salt bridge interaction there is a hydrogen bond to Ser936.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201112g&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/medium/jm-2011-01112g_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0022.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. <b>26h</b> docked into CDK2 which is shown with an electrostatic surface. The methyl substituent on the basic nitrogen is just the right size. A slightly larger substituent like cyclopropyl may be accommodated but will clash slightly with the protein. Larger or more bulky substituents cannot be docked without compromising the salt bridge to Asp86.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201112g&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/medium/jm-2011-01112g_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0023.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. <b>27s</b> docked into CDK2. The aniline nitrogen is forming an additional hydrogen bond to the backbone carbonyl of His84 at the end of the kinase hinge region. This is probably not a strong hydrogen bond as evident from the increase in activity of only 2-fold over <b>26h</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201112g&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/medium/jm-2011-01112g_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0024.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) <b>28c</b> docked into CDK2. In the putative bioactive conformation, the methyl group interacts favorably with Phe80. However, the methyl group induces a twist in the A and C rings, so they are less coplanar, shifting the A-ring slightly away from Phe80 and thus preventing the A-ring from interacting with Phe80. (B) <b>28e</b> docked into CDK2. The orange-black dashed lines indicate clashes between protein and ligand atoms. The methoxy substituent clashes with the side chains of Lys33 and Asp145. These are flexible residues and may move to accommodate the substituents. However, this is energetically unfavorable, as it will break the salt bridge between the two residues.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201112g&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/medium/jm-2011-01112g_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0001.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. HCT-116 cells were treated separately with the indicated concentrations of <b>26h</b> for 24 h prior to denaturing lysis. An amount of 30 μg of lysate from each treatment was resolved on 10% SDS–PAGE, transferred onto PVDF membrane, and probed with antibodies against phospho-Rb and β-actin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201112g&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/medium/jm-2011-01112g_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0002.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. <b>26h</b> is efficacious in a murine sc xenograft model of human colon cancer (HCT-116). Tumors were established in female BALB/c nude mice by sc implantation of 5 × 10<sup>6</sup> HCT-116 tumor cells. Tumor burden (volume, mm<sup>3</sup>) was measured twice a week by (<i>w</i><sup>2</sup><i>l</i>)/2, where <i>w</i> is the width and <i>l</i> is the length in mm of an HCT-116 carcinoma. Treatment started on day 1 when the group mean tumor volume reached 105 mm<sup>3</sup> and treatment ended on day 15. </p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201112g&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/medium/jm-2011-01112g_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0003.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. <b>26h</b> is efficacious in a sc xenograft model of human B-cell lymphoma (Ramos). Ramos tumors were established in female BALB/c nude mice by sc implantation of 7 × 10<sup>6</sup> Ramos cells. Treatment with <b>26h</b> and vehicle (MC/Tween for po or DMA/CRE for ip) was initiated on day 1 and continued until day 15. The tumor volumes from the 15 mg/kg ip group was significantly different compared to the ip vehicle control group on day 15. Sample size, <i>n</i> = 8–10 mice per group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201112g/production/images/large/jm-2011-01112g_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201112g&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i241">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81666" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81666" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 41 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Cantley, L. C. and Baselga, J.</span><span> </span><span class="NLM_article-title">The era of cancer discovery</span>.  <span class="citation_source-journal">Cancer Discovery</span> [Online early access]. DOI: <span class="refDoi"> DOI: 10.1158/2159-8274.CD-11-0049</span> . Published Online: Apr 3,<span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm201112g&amp;key=10.1158%2F2159-8274.CD-11-0049" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=L.+C.+Cantley&author=J.+Baselga&title=The+era+of+cancer+discovery&doi=10.1158%2F2159-8274.CD-11-0049"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1158%2F2159-8274.CD-11-0049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8274.CD-11-0049%26sid%3Dliteratum%253Aachs%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DThe%2520era%2520of%2520cancer%2520discovery%26jtitle%3DCancer%2520Discovery%26doi%3D10.1158%2F2159-8274.CD-11-0049%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Bianco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damiano, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelardi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daniele, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciardiello, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tortora, G.</span><span> </span><span class="NLM_article-title">Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">3358</span><span class="NLM_x">–</span> <span class="NLM_lpage">3367</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm201112g&amp;key=10.2174%2F138161207782360537" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm201112g&amp;key=18045190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm201112g&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVOrs7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=3358-3367&author=R.+Biancoauthor=V.+Damianoauthor=T.+Gelardiauthor=G.+Danieleauthor=F.+Ciardielloauthor=G.+Tortora&title=Rational+combination+of+targeted+therapies+as+a+strategy+to+overcome+the+mechanisms+of+resistance+to+inhibitors+of+EGFR+signaling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling</span></div><div class="casAuthors">Bianco, Roberto; Damiano, Vincenzo; Gelardi, Teresa; Daniele, Gennaro; Ciardiello, Fortunato; Tortora, Giampaolo</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">3358-3367</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The epidermal growth factor receptor (EGFR) has been widely used as a target for novel anticancer agents, such as blocking antibodies and small mol. wt. tyrosine kinase compds.  In spite of recent advances in cancer cell biol., leading to the introduction of clin. active new drugs, such as cetuximab, panitumumab and erlotinib, unfortunately disease control remains unsuccessful due to the presence of constitutive resistance to EGFR inhibitors in most patients and the development of acquired resistance in the responders.  A large no. of mol. abnormalities in tumor cells seem to partly contribute to their resistance to anti-EGFR therapy: increased angiogenesis, constitutive activation of downstream mediators, overexpression of other tyrosine kinase receptors.  Moreover, some mutations in the EGFR receptor kinase domain seem to play a crucial role in detg. the sensitivity of cancer cells to specific inhibitors by altering the conformation of the receptor and its activity.  The development of rational combinations of anticancer agents and EGFR inhibitors, able to exert synergistic cytotoxic interactions, has been widely accepted and used in both preclin. and clin. studies.  Although the failure of large clin. trial based on empirical combination of anti-EGFR and classic chemotherapeutic agents, several preclin. data seems to support the hypothesis that combining EGFR inhibitors and other novel agents could efficiently inhibit tumor growth and overcome intrinsic resistance to a single-agent based therapy.  This review focuses on the role of complementary signaling pathways in the development of resistance to EGFR targeting agents and the rationale to combine novel inhibitors as anticancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqLu7Fv44yMrVg90H21EOLACvtfcHk0lj3Ba45qC3r0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVOrs7zK&md5=3af9889204032dcac6b74f1d5ebc673e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.2174%2F138161207782360537&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161207782360537%26sid%3Dliteratum%253Aachs%26aulast%3DBianco%26aufirst%3DR.%26aulast%3DDamiano%26aufirst%3DV.%26aulast%3DGelardi%26aufirst%3DT.%26aulast%3DDaniele%26aufirst%3DG.%26aulast%3DCiardiello%26aufirst%3DF.%26aulast%3DTortora%26aufirst%3DG.%26atitle%3DRational%2520combination%2520of%2520targeted%2520therapies%2520as%2520a%2520strategy%2520to%2520overcome%2520the%2520mechanisms%2520of%2520resistance%2520to%2520inhibitors%2520of%2520EGFR%2520signaling%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2007%26volume%3D13%26spage%3D3358%26epage%3D3367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Mayfield, E.</span><span> </span><span class="NLM_article-title">Combining targeted cancer therapies: much promise, many hurdles</span>.  <span class="citation_source-journal">NCI Cancer Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x"> (</span><span class="NLM_issue">No. 10</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2011&issue=No.+10&author=E.+Mayfield&title=Combining+targeted+cancer+therapies%3A+much+promise%2C+many+hurdles"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMayfield%26aufirst%3DE.%26atitle%3DCombining%2520targeted%2520cancer%2520therapies%253A%2520much%2520promise%252C%2520many%2520hurdles%26jtitle%3DNCI%2520Cancer%2520Bull.%26date%3D2011%26volume%3D8%26issue%3DNo.%252010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Rexer, B. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arteaga, C. L.</span><span> </span><span class="NLM_article-title">Inhibition of PI3K and MEK: It is all about combinations and biomarkers</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">4518</span><span class="NLM_x">–</span> <span class="NLM_lpage">4520</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm201112g&amp;key=10.1158%2F1078-0432.CCR-09-0872" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm201112g&amp;key=19584146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm201112g&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosV2ltrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=4518-4520&author=B.+N.+Rexerauthor=R.+Ghoshauthor=C.+L.+Arteaga&title=Inhibition+of+PI3K+and+MEK%3A+It+is+all+about+combinations+and+biomarkers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of PI3K and MEK: It Is All about Combinations and Biomarkers</span></div><div class="casAuthors">Rexer, Brent N.; Ghosh, Ritwik; Arteaga, Carlos L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4518-4520</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  A small mol. inhibitor of MAP/ERK kinase (MEK) was effective against human breast cancer cells with a basal-like gene expression signature.  Antitumor activity was limited by both feedback upregulation of phosphatidylinositol-3 kinase (PI3K)/AKT upon inhibition of MEK as well as loss of the phosphatase PTEN.  Therefore, MEK inhibitors should preferably be investigated in combination with PI3K inhibitors in basal-like breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGori6Ze0cah3bVg90H21EOLACvtfcHk0lj3Ba45qC3r0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosV2ltrc%253D&md5=632a572a8949d9ee2eada07972a8ac65</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-0872&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-0872%26sid%3Dliteratum%253Aachs%26aulast%3DRexer%26aufirst%3DB.%2BN.%26aulast%3DGhosh%26aufirst%3DR.%26aulast%3DArteaga%26aufirst%3DC.%2BL.%26atitle%3DInhibition%2520of%2520PI3K%2520and%2520MEK%253A%2520It%2520is%2520all%2520about%2520combinations%2520and%2520biomarkers%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D4518%26epage%3D4520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Flaherty, K. T.</span><span> </span><span class="NLM_article-title">Sorafenib: delivering a targeted drug to the right targets</span> <span class="citation_source-journal">Expert Rev. Anticancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">617</span><span class="NLM_x">–</span> <span class="NLM_lpage">626</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm201112g&amp;key=10.1586%2F14737140.7.5.617" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm201112g&amp;key=17492926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm201112g&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmvVKqs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=617-626&author=K.+T.+Flaherty&title=Sorafenib%3A+delivering+a+targeted+drug+to+the+right+targets"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Sorafenib: delivering a targeted drug to the right targets</span></div><div class="casAuthors">Flaherty, Keith T.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">617-626</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Future Drugs Ltd.</span>)
        </div><div class="casAbstract">A review.  Approved for the treatment of advanced renal cell carcinoma by the US FDA and other regulatory agencies, sorafenib is an agent with multiple targets that may also prove beneficial in other malignancies.  Phase III trials are underway in melanoma, hepatocellular carcinoma and non-small-cell lung cancer.  Scrutiny of the Phase II data and correlative studies conducted in that context suggests that inhibition of angiogenesis and signaling in tumor cells may play a part in the clin. efficacy of sorafenib.  Although the vascular endothelial growth factor receptor inhibitors are the most populated class of targeted agents in cancer clin. trials, sorafenib may prove to have unique properties that distinguish it.  A detailed discussion of the clin. trials in renal cell carcinoma, melanoma and hepatocellular carcinoma highlights what is known and what has yet to be understood about this agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn28JpeD5ex7Vg90H21EOLACvtfcHk0lj3Ba45qC3r0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmvVKqs70%253D&md5=aaa7fef25f3874c1371b7f8f627a2859</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1586%2F14737140.7.5.617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737140.7.5.617%26sid%3Dliteratum%253Aachs%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26atitle%3DSorafenib%253A%2520delivering%2520a%2520targeted%2520drug%2520to%2520the%2520right%2520targets%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2007%26volume%3D7%26spage%3D617%26epage%3D626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Mena, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pulido, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guillén-Ponce, C.</span><span> </span><span class="NLM_article-title">Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib</span> <span class="citation_source-journal">Anti-Cancer Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">S3</span><span class="NLM_x">–</span> <span class="NLM_lpage">11</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2010&pages=S3-11&issue=Suppl.+1&author=A.+C.+Menaauthor=E.+G.+Pulidoauthor=C.+Guill%C3%A9n-Ponce&title=Understanding+the+molecular-based+mechanism+of+action+of+the+tyrosine+kinase+inhibitor%3A+sunitinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMena%26aufirst%3DA.%2BC.%26aulast%3DPulido%26aufirst%3DE.%2BG.%26aulast%3DGuill%25C3%25A9n-Ponce%26aufirst%3DC.%26atitle%3DUnderstanding%2520the%2520molecular-based%2520mechanism%2520of%2520action%2520of%2520the%2520tyrosine%2520kinase%2520inhibitor%253A%2520sunitinib%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2010%26volume%3D21%26issue%3DSuppl.%25201%26spage%3DS3%26epage%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Lai, C.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atoyan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D.-G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrester, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zifcak, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, G.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DellaRocca, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, H.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munger, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keegan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pepicelli, C. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, C.</span><span> </span><span class="NLM_article-title">CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2 exerts potent anticancer activity</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">3647</span><span class="NLM_x">–</span> <span class="NLM_lpage">3656</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=3647-3656&author=C.-J.+Laiauthor=R.+Baoauthor=X.+Taoauthor=J.+Wangauthor=R.+Atoyanauthor=H.+Quauthor=D.-G.+Wangauthor=L.+Yinauthor=M.+Samsonauthor=J.+Forresterauthor=B.+Zifcakauthor=G.-X.+Xuauthor=S.+DellaRoccaauthor=H.-X.+Zhaiauthor=X.+Caiauthor=W.+E.+Mungerauthor=M.+Keeganauthor=C.+V.+Pepicelliauthor=C.+Qian&title=CUDC-101%2C+a+multitargeted+inhibitor+of+histone+deacetylase%2C+epidermal+growth+factor+receptor%2C+and+human+epidermal+growth+factor+receptor+2+exerts+potent+anticancer+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DC.-J.%26aulast%3DBao%26aufirst%3DR.%26aulast%3DTao%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DAtoyan%26aufirst%3DR.%26aulast%3DQu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DD.-G.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DSamson%26aufirst%3DM.%26aulast%3DForrester%26aufirst%3DJ.%26aulast%3DZifcak%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DG.-X.%26aulast%3DDellaRocca%26aufirst%3DS.%26aulast%3DZhai%26aufirst%3DH.-X.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DMunger%26aufirst%3DW.%2BE.%26aulast%3DKeegan%26aufirst%3DM.%26aulast%3DPepicelli%26aufirst%3DC.%2BV.%26aulast%3DQian%26aufirst%3DC.%26atitle%3DCUDC-101%252C%2520a%2520multitargeted%2520inhibitor%2520of%2520histone%2520deacetylase%252C%2520epidermal%2520growth%2520factor%2520receptor%252C%2520and%2520human%2520epidermal%2520growth%2520factor%2520receptor%25202%2520exerts%2520potent%2520anticancer%2520activity%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D3647%26epage%3D3656" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Knockaert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greengard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meijer, L.</span><span> </span><span class="NLM_article-title">Pharmacological inhibitors of cyclin-dependent kinases</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">417</span><span class="NLM_x">–</span> <span class="NLM_lpage">425</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm201112g&amp;key=10.1016%2FS0165-6147%2802%2902071-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm201112g&amp;key=12237154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm201112g&amp;key=1%3ACAS%3A528%3ADC%252BD38XntVWmsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2002&pages=417-425&author=M.+Knockaertauthor=P.+Greengardauthor=L.+Meijer&title=Pharmacological+inhibitors+of+cyclin-dependent+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological inhibitors of cyclin-dependent kinases</span></div><div class="casAuthors">Knockaert, Marie; Greengard, Paul; Meijer, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">417-425</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Cyclin-dependent kinases (CDKs) regulate the cell division cycle, apoptosis, transcription and differentiation in addn. to functions in the nervous system.  Deregulation of CDKs in various diseases has stimulated an intensive search for selective pharmacol. inhibitors of these kinases.  More than 50 inhibitors have been identified, among which >20 have been co-crystd. with CDK2.  These inhibitors all target the ATP-binding pocket of the catalytic site of the kinase.  The actual selectivity of most known CDK inhibitors, and thus the underlying mechanism of their cellular effects, is poorly known.  Pharmacol. inhibitors of CDKs are currently being evaluated for therapeutic use against cancer, alopecia, neurodegenerative disorders (e.g. Alzheimer's disease, amyotrophic lateral sclerosis and stroke), cardiovascular disorders (e.g. atherosclerosis and restenosis), glomerulonephritis, viral infections (e.g. HCMV, HIV and HSV) and parasitic protozoa (Plasmodium sp. and Leishmania sp.).  Pharmacol. inhibitors of cyclin-dependent kinases are being actively investigated in view of their potential therapeutic use against a large variety of indications such as cancers, Alzheimer's disease and other neurodegenerative disorders, and viral infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokE1X0jvc9GbVg90H21EOLACvtfcHk0lifVmQKEh7Zxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XntVWmsbY%253D&md5=09bb4b161d30cbff71b80f7aae505843</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS0165-6147%2802%2902071-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0165-6147%252802%252902071-0%26sid%3Dliteratum%253Aachs%26aulast%3DKnockaert%26aufirst%3DM.%26aulast%3DGreengard%26aufirst%3DP.%26aulast%3DMeijer%26aufirst%3DL.%26atitle%3DPharmacological%2520inhibitors%2520of%2520cyclin-dependent%2520kinases%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2002%26volume%3D23%26spage%3D417%26epage%3D425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Shapiro, G. I.</span><span> </span><span class="NLM_article-title">Cyclin-dependent kinase pathways as targets for cancer treatment</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1770</span><span class="NLM_x">–</span> <span class="NLM_lpage">1783</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm201112g&amp;key=10.1200%2FJCO.2005.03.7689" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm201112g&amp;key=16603719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm201112g&amp;key=1%3ACAS%3A528%3ADC%252BD28XksVKgtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=1770-1783&author=G.+I.+Shapiro&title=Cyclin-dependent+kinase+pathways+as+targets+for+cancer+treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase pathways as targets for cancer treatment</span></div><div class="casAuthors">Shapiro, Geoffrey I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1770-1783</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  Cyclin-dependent kinases (cdks) are crit. regulators of cell cycle progression and RNA transcription.  A variety of genetic and epigenetic events cause universal overactivity of the cell cycle cdks in human cancer, and their inhibition can lead to both cell cycle arrest and apoptosis.  However, built-in redundancy may limit the effects of highly selective cdk inhibition.  Cdk4/6 inhibition has been shown to induce potent G1 arrest in vitro and tumor regression in vivo; cdk2/1 inhibition has the most potent effects during the S and G2 phases and induces E2F transcription factor-dependent cell death.  Modulation of cdk2 and cdk1 activities also affects survival checkpoint responses after exposure to DNA-damaging and microtubule-stabilizing agents.  The transcriptional cdks phosphorylate the carboxy-terminal domain of RNA polymerase II, facilitating efficient transcriptional initiation and elongation.  Inhibition of these cdks primarily affects the accumulation of transcripts with short half-lives, including those encoding antiapoptosis family members, cell cycle regulators, as well as p53 and nuclear factor-kappa B-responsive gene targets.  These effects may account for apoptosis induced by cdk9 inhibitors, esp. in malignant hematopoietic cells, and may also potentiate cytotoxicity mediated by disruption of a variety of pathways in many transformed cell types.  Current work is focusing on overcoming pharmacokinetic barriers that hindered development of flavopiridol, a pan-cdk inhibitor, as well as assessing novel classes of compds. potently targeting groups of cell cycle cdks (cdk4/6 or cdk2/1) with variable effects on the transcriptional cdks 7 and 9.  These efforts will establish whether the strategy of cdk inhibition is able to produce therapeutic benefit in the majority of human tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYfmCpSfvpTbVg90H21EOLACvtfcHk0lifVmQKEh7Zxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XksVKgtbg%253D&md5=420a31b47f6600625f7d499a4b8a5fc9</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.03.7689&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.03.7689%26sid%3Dliteratum%253Aachs%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26atitle%3DCyclin-dependent%2520kinase%2520pathways%2520as%2520targets%2520for%2520cancer%2520treatment%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2006%26volume%3D24%26spage%3D1770%26epage%3D1783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Cai, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Latham, V. M.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span> </span><span class="NLM_article-title">Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">9270</span><span class="NLM_x">–</span> <span class="NLM_lpage">9280</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=9270-9280&author=D.+Caiauthor=V.+M.+Lathamauthor=X.+Zhangauthor=G.+I.+Shapiro&title=Combined+depletion+of+cell+cycle+and+transcriptional+cyclin-dependent+kinase+activities+induces+apoptosis+in+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DD.%26aulast%3DLatham%26aufirst%3DV.%2BM.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26atitle%3DCombined%2520depletion%2520of%2520cell%2520cycle%2520and%2520transcriptional%2520cyclin-dependent%2520kinase%2520activities%2520induces%2520apoptosis%2520in%2520cancer%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D9270%26epage%3D9280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Jorda, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Havlicek, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNae, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walkinshaw, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voller, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sturc, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navratilova, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuzma, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mistrik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strnad, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krystof, V.</span><span> </span><span class="NLM_article-title">Pyrazolo[4,3-<i>d</i>]pyrimidine bioisostere of roscovitine: evaluation of a novel selective inhibitor of cyclin-dependent kinases with antiproliferative activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">2980</span><span class="NLM_x">–</span> <span class="NLM_lpage">2993</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200064p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2980-2993&author=R.+Jordaauthor=L.+Havlicekauthor=I.+W.+McNaeauthor=M.+D.+Walkinshawauthor=J.+Vollerauthor=A.+Sturcauthor=J.+Navratilovaauthor=M.+Kuzmaauthor=M.+Mistrikauthor=J.+Bartekauthor=M.+Strnadauthor=V.+Krystof&title=Pyrazolo%5B4%2C3-d%5Dpyrimidine+bioisostere+of+roscovitine%3A+evaluation+of+a+novel+selective+inhibitor+of+cyclin-dependent+kinases+with+antiproliferative+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fjm200064p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200064p%26sid%3Dliteratum%253Aachs%26aulast%3DJorda%26aufirst%3DR.%26aulast%3DHavlicek%26aufirst%3DL.%26aulast%3DMcNae%26aufirst%3DI.%2BW.%26aulast%3DWalkinshaw%26aufirst%3DM.%2BD.%26aulast%3DVoller%26aufirst%3DJ.%26aulast%3DSturc%26aufirst%3DA.%26aulast%3DNavratilova%26aufirst%3DJ.%26aulast%3DKuzma%26aufirst%3DM.%26aulast%3DMistrik%26aufirst%3DM.%26aulast%3DBartek%26aufirst%3DJ.%26aulast%3DStrnad%26aufirst%3DM.%26aulast%3DKrystof%26aufirst%3DV.%26atitle%3DPyrazolo%255B4%252C3-d%255Dpyrimidine%2520bioisostere%2520of%2520roscovitine%253A%2520evaluation%2520of%2520a%2520novel%2520selective%2520inhibitor%2520of%2520cyclin-dependent%2520kinases%2520with%2520antiproliferative%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2980%26epage%3D2993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Wyatt, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodhead, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berdini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulstridge, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devine, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Early, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feltell, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMenamin, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navarro, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Reilly, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reule, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saxty, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seavers, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Squires, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trewartha, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woolford, A. J.</span><span> </span><span class="NLM_article-title">Identification of <i>N</i>-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1<i>H</i>-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">4986</span><span class="NLM_x">–</span> <span class="NLM_lpage">4999</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800382h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4986-4999&author=P.+G.+Wyattauthor=A.+J.+Woodheadauthor=V.+Berdiniauthor=J.+A.+Boulstridgeauthor=M.+G.+Carrauthor=D.+M.+Crossauthor=D.+J.+Davisauthor=L.+A.+Devineauthor=T.+R.+Earlyauthor=R.+E.+Feltellauthor=E.+J.+Lewisauthor=R.+L.+McMenaminauthor=E.+F.+Navarroauthor=M.+A.+O%E2%80%99Brienauthor=M.+O%E2%80%99Reillyauthor=M.+Reuleauthor=G.+Saxtyauthor=L.+C.+Seaversauthor=D.+M.+Smithauthor=M.+S.+Squiresauthor=G.+Trewarthaauthor=M.+T.+Walkerauthor=A.+J.+Woolford&title=Identification+of+N-%284-piperidinyl%29-4-%282%2C6-dichlorobenzoylamino%29-1H-pyrazole-3-carboxamide+%28AT7519%29%2C+a+novel+cyclin+dependent+kinase+inhibitor+using+fragment-based+X-ray+crystallography+and+structure+based+drug+design"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm800382h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800382h%26sid%3Dliteratum%253Aachs%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26aulast%3DWoodhead%26aufirst%3DA.%2BJ.%26aulast%3DBerdini%26aufirst%3DV.%26aulast%3DBoulstridge%26aufirst%3DJ.%2BA.%26aulast%3DCarr%26aufirst%3DM.%2BG.%26aulast%3DCross%26aufirst%3DD.%2BM.%26aulast%3DDavis%26aufirst%3DD.%2BJ.%26aulast%3DDevine%26aufirst%3DL.%2BA.%26aulast%3DEarly%26aufirst%3DT.%2BR.%26aulast%3DFeltell%26aufirst%3DR.%2BE.%26aulast%3DLewis%26aufirst%3DE.%2BJ.%26aulast%3DMcMenamin%26aufirst%3DR.%2BL.%26aulast%3DNavarro%26aufirst%3DE.%2BF.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DM.%2BA.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DM.%26aulast%3DReule%26aufirst%3DM.%26aulast%3DSaxty%26aufirst%3DG.%26aulast%3DSeavers%26aufirst%3DL.%2BC.%26aulast%3DSmith%26aufirst%3DD.%2BM.%26aulast%3DSquires%26aufirst%3DM.%2BS.%26aulast%3DTrewartha%26aufirst%3DG.%26aulast%3DWalker%26aufirst%3DM.%2BT.%26aulast%3DWoolford%26aufirst%3DA.%2BJ.%26atitle%3DIdentification%2520of%2520N-%25284-piperidinyl%2529-4-%25282%252C6-dichlorobenzoylamino%2529-1H-pyrazole-3-carboxamide%2520%2528AT7519%2529%252C%2520a%2520novel%2520cyclin%2520dependent%2520kinase%2520inhibitor%2520using%2520fragment-based%2520X-ray%2520crystallography%2520and%2520structure%2520based%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4986%26epage%3D4999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Hughes, A.</span><span> </span><span class="NLM_article-title">CDK inhibitors in 3D: problems with the drugs, their development plans or their linkage to disease?</span> <span class="citation_source-journal">Gene Ther. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span><span class="NLM_x">–</span> <span class="NLM_lpage">54</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2006&pages=41-54&author=A.+Hughes&title=CDK+inhibitors+in+3D%3A+problems+with+the+drugs%2C+their+development+plans+or+their+linkage+to+disease%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DA.%26atitle%3DCDK%2520inhibitors%2520in%25203D%253A%2520problems%2520with%2520the%2520drugs%252C%2520their%2520development%2520plans%2520or%2520their%2520linkage%2520to%2520disease%253F%26jtitle%3DGene%2520Ther.%2520Mol.%2520Biol.%26date%3D2006%26volume%3D10%26spage%3D41%26epage%3D54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Yamaoka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saharinen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holt, V. E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silvennoinen, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Shea, J. J.</span><span> </span><span class="NLM_article-title">The Janus kinases (Jaks)</span> <span class="citation_source-journal">Genome Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">253.1</span><span class="NLM_x">–</span> <span class="NLM_lpage">253.6</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=253.1-253.6&author=K.+Yamaokaauthor=P.+Saharinenauthor=M.+Pesuauthor=V.+E.+T.+Holtauthor=O.+Silvennoinenauthor=J.+J.+O%E2%80%99Shea&title=The+Janus+kinases+%28Jaks%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYamaoka%26aufirst%3DK.%26aulast%3DSaharinen%26aufirst%3DP.%26aulast%3DPesu%26aufirst%3DM.%26aulast%3DHolt%26aufirst%3DV.%2BE.%2BT.%26aulast%3DSilvennoinen%26aufirst%3DO.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520Janus%2520kinases%2520%2528Jaks%2529%26jtitle%3DGenome%2520Biol.%26date%3D2004%26volume%3D5%26spage%3D253.1%26epage%3D253.6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Baxter, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">East, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fourouclas, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swanton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vassiliou, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bench, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyd, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erber, W. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, A. R.</span><span> </span><span class="NLM_article-title">Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">365</span><span class="NLM_x">, </span> <span class="NLM_fpage">1054</span><span class="NLM_x">–</span> <span class="NLM_lpage">1061</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm201112g&amp;key=10.1016%2FS0140-6736%2805%2971142-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm201112g&amp;key=15781101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm201112g&amp;key=1%3ACAS%3A528%3ADC%252BD2MXisFGrs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=2005&pages=1054-1061&author=E.+J.+Baxterauthor=L.+M.+Scottauthor=P.+J.+Campbellauthor=C.+Eastauthor=N.+Fourouclasauthor=S.+Swantonauthor=G.+S.+Vassiliouauthor=A.+J.+Benchauthor=E.+M.+Boydauthor=N.+Curtinauthor=M.+A.+Scottauthor=W.+N.+Erberauthor=A.+R.+Green&title=Acquired+mutation+of+the+tyrosine+kinase+JAK2+in+human+myeloproliferative+disorders"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders</span></div><div class="casAuthors">Baxter, E. Joanna; Scott, Linda M.; Campbell, Peter J.; East, Clare; Fourouclas, Nasios; Swanton, Soheila; Vassiliou, George S.; Bench, Anthony J.; Boyd, Elaine M.; Curtin, Natasha; Scott, Mike A.; Erber, Wendy N.; Green, Anthony R.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">9464</span>),
    <span class="NLM_cas:pages">1054-1061</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Background: Human myeloproliferative disorders form a range of clonal haematol. malignant diseases, the main members of which are polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis.  The mol. pathogenesis of these disorders is unknown, but tyrosine kinases have been implicated in several related disorders.  We investigated the role of the cytoplasmic tyrosine kinase JAK2 in patients with a myeloproliferative disorder.  Methods: We obtained DNA samples from patients with polycythemia vera, essential thrombocythemia, or idiopathic myelofibrosis.  The coding exons of JAK2 were bidirectionally sequenced from peripheral-blood granulocytes, T cells, or both.  Allele-specific PCR, mol. cytogenetic studies, microsatellite PCR, Affymetrix single nucleotide polymorphism array analyses, and colony assays were undertaken on subgroups of patients.  Findings: A single point mutation (Val617Phe) was identified in JAK2 in 71 (97%) of 73 patients with polycythemia vera, 29 (57%) of 51 with essential thrombocythemia, and eight (50%) of 16 with idiopathic myelofibrosis.  The mutation is acquired, is present in a variable proportion of granulocytes, alters a highly conserved valine present in the neg. regulatory JH2 domain, and is predicted to dysregulate kinase activity.  It was heterozygous in most patients, homozygous in a subset as a result of mitotic recombination, and arose in a multipotent progenitor capable of giving rise to erythroid and myeloid cells.  The mutation was present in all erythropoietin-independent erythroid colonies.  Interpretation: A single acquired mutation of JAK2 was noted in more than half of patients with a myeloproliferative disorder.  Its presence in all erythropoietin-independent erythroid colonies demonstrates a link with growth factor hypersensitivity, a key biol. feature of these disorders.  Relevance to practice: Identification of the Val617Phe JAK2 mutation lays the foundation for new approaches to the diagnosis, classification, and treatment of myeloproliferative disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8cc-kg2leZrVg90H21EOLACvtfcHk0lhYslmJxRMHUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXisFGrs7g%253D&md5=3c9dc565a1986a47d12e4bccd8c8cc1a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2805%2971142-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252805%252971142-9%26sid%3Dliteratum%253Aachs%26aulast%3DBaxter%26aufirst%3DE.%2BJ.%26aulast%3DScott%26aufirst%3DL.%2BM.%26aulast%3DCampbell%26aufirst%3DP.%2BJ.%26aulast%3DEast%26aufirst%3DC.%26aulast%3DFourouclas%26aufirst%3DN.%26aulast%3DSwanton%26aufirst%3DS.%26aulast%3DVassiliou%26aufirst%3DG.%2BS.%26aulast%3DBench%26aufirst%3DA.%2BJ.%26aulast%3DBoyd%26aufirst%3DE.%2BM.%26aulast%3DCurtin%26aufirst%3DN.%26aulast%3DScott%26aufirst%3DM.%2BA.%26aulast%3DErber%26aufirst%3DW.%2BN.%26aulast%3DGreen%26aufirst%3DA.%2BR.%26atitle%3DAcquired%2520mutation%2520of%2520the%2520tyrosine%2520kinase%2520JAK2%2520in%2520human%2520myeloproliferative%2520disorders%26jtitle%3DLancet%26date%3D2005%26volume%3D365%26spage%3D1054%26epage%3D1061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">James, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ugo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Couedic, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staerk, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delhommeau, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacout, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcon, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raslova, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennaceur-Griscelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villeval, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Constantinescu, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casadevall, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vainchenker, W.</span><span> </span><span class="NLM_article-title">A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">434</span><span class="NLM_x">, </span> <span class="NLM_fpage">1144</span><span class="NLM_x">–</span> <span class="NLM_lpage">1148</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm201112g&amp;key=10.1038%2Fnature03546" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm201112g&amp;key=15793561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm201112g&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjsF2ltbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=434&publication_year=2005&pages=1144-1148&author=C.+Jamesauthor=V.+Ugoauthor=J.+P.+Le+Couedicauthor=J.+Staerkauthor=F.+Delhommeauauthor=C.+Lacoutauthor=L.+Garconauthor=H.+Raslovaauthor=R.+Bergerauthor=A.+Bennaceur-Griscelliauthor=J.+L.+Villevalauthor=S.+N.+Constantinescuauthor=N.+Casadevallauthor=W.+Vainchenker&title=A+unique+clonal+JAK2+mutation+leading+to+constitutive+signalling+causes+polycythaemia+vera"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera</span></div><div class="casAuthors">James, Chloe; Ugo, Valerie; Le Couedic, Jean-Pierre; Staerk, Judith; Delhommeau, Francois; Lacout, Catherine; Garcon, Loic; Raslova, Hana; Berger, Roland; Bennaceur-Griscelli, Annelise; Villeval, Jean Luc; Constantinescu, Stefan N.; Casadevall, Nicole; Vainchenker, William</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">434</span>
        (<span class="NLM_cas:issue">7037</span>),
    <span class="NLM_cas:pages">1144-1148</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Myeloproliferative disorders are clonal hematopoietic stem cell malignancies characterized by independency or hypersensitivity of hematopoietic progenitors to numerous cytokines.  The mol. basis of most myeloproliferative disorders is unknown.  On the basis of the model of chronic myeloid leukemia, it is expected that a constitutive tyrosine kinase activity could be at the origin of these diseases.  Polycythemia vera is an acquired myeloproliferative disorder, characterized by the presence of polycythemia diversely assocd. with thrombocytosis, leukocytosis and splenomegaly.  Polycythemia vera progenitors are hypersensitive to erythropoietin and other cytokines.  Here, the authors describe a clonal and recurrent mutation in the JH2 pseudo-kinase domain of the Janus kinase 2 (JAK2) gene in most (>80%) polycythemia vera patients.  The mutation, a valine-to-phenylalanine substitution at amino acid position 617, leads to constitutive tyrosine phosphorylation activity that promotes cytokine hypersensitivity and induces erythrocytosis in a mouse model.  As this mutation is also found in other myeloproliferative disorders, this unique mutation will permit a new mol. classification of these disorders and novel therapeutical approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqy-6NigTwc97Vg90H21EOLACvtfcHk0li-hyBPWZLivw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjsF2ltbk%253D&md5=9e9c223dd4e2da2ebf52d14edda85963</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnature03546&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature03546%26sid%3Dliteratum%253Aachs%26aulast%3DJames%26aufirst%3DC.%26aulast%3DUgo%26aufirst%3DV.%26aulast%3DLe%2BCouedic%26aufirst%3DJ.%2BP.%26aulast%3DStaerk%26aufirst%3DJ.%26aulast%3DDelhommeau%26aufirst%3DF.%26aulast%3DLacout%26aufirst%3DC.%26aulast%3DGarcon%26aufirst%3DL.%26aulast%3DRaslova%26aufirst%3DH.%26aulast%3DBerger%26aufirst%3DR.%26aulast%3DBennaceur-Griscelli%26aufirst%3DA.%26aulast%3DVilleval%26aufirst%3DJ.%2BL.%26aulast%3DConstantinescu%26aufirst%3DS.%2BN.%26aulast%3DCasadevall%26aufirst%3DN.%26aulast%3DVainchenker%26aufirst%3DW.%26atitle%3DA%2520unique%2520clonal%2520JAK2%2520mutation%2520leading%2520to%2520constitutive%2520signalling%2520causes%2520polycythaemia%2520vera%26jtitle%3DNature%26date%3D2005%26volume%3D434%26spage%3D1144%26epage%3D1148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Levine, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loriaux, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huntly, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loh, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beran, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoffregen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willis, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flores, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estey, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gattermann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armstrong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Look, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernard, O. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span> </span><span class="NLM_article-title">The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">3377</span><span class="NLM_x">–</span> <span class="NLM_lpage">3379</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2005&pages=3377-3379&author=R.+L.+Levineauthor=M.+Loriauxauthor=B.+J.+Huntlyauthor=M.+L.+Lohauthor=M.+Beranauthor=E.+Stoffregenauthor=R.+Bergerauthor=J.+J.+Clarkauthor=S.+G.+Willisauthor=K.+T.+Nguyenauthor=N.+J.+Floresauthor=E.+Esteyauthor=N.+Gattermannauthor=S.+Armstrongauthor=A.+T.+Lookauthor=J.+D.+Griffinauthor=O.+A.+Bernardauthor=M.+C.+Heinrichauthor=D.+G.+Gillilandauthor=B.+Drukerauthor=M.+W.+Deininger&title=The+JAK2V617F+activating+mutation+occurs+in+chronic+myelomonocytic+leukemia+and+acute+myeloid+leukemia%2C+but+not+in+acute+lymphoblastic+leukemia+or+chronic+lymphocytic+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLevine%26aufirst%3DR.%2BL.%26aulast%3DLoriaux%26aufirst%3DM.%26aulast%3DHuntly%26aufirst%3DB.%2BJ.%26aulast%3DLoh%26aufirst%3DM.%2BL.%26aulast%3DBeran%26aufirst%3DM.%26aulast%3DStoffregen%26aufirst%3DE.%26aulast%3DBerger%26aufirst%3DR.%26aulast%3DClark%26aufirst%3DJ.%2BJ.%26aulast%3DWillis%26aufirst%3DS.%2BG.%26aulast%3DNguyen%26aufirst%3DK.%2BT.%26aulast%3DFlores%26aufirst%3DN.%2BJ.%26aulast%3DEstey%26aufirst%3DE.%26aulast%3DGattermann%26aufirst%3DN.%26aulast%3DArmstrong%26aufirst%3DS.%26aulast%3DLook%26aufirst%3DA.%2BT.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DBernard%26aufirst%3DO.%2BA.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DDruker%26aufirst%3DB.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26atitle%3DThe%2520JAK2V617F%2520activating%2520mutation%2520occurs%2520in%2520chronic%2520myelomonocytic%2520leukemia%2520and%2520acute%2520myeloid%2520leukemia%252C%2520but%2520not%2520in%2520acute%2520lymphoblastic%2520leukemia%2520or%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DBlood%26date%3D2005%26volume%3D106%26spage%3D3377%26epage%3D3379" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Lin, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meloni, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodgers, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galya, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yue, T. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, J.</span><span> </span><span class="NLM_article-title">Enantioselective synthesis of Janus kinase inhibitor INCB018424 via an organocatalytic aza-Michael reaction</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1999</span><span class="NLM_x">–</span> <span class="NLM_lpage">2002</span></span><div class="citationLinks">[<a href="/doi/10.1021/ol900350k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2009&pages=1999-2002&author=Q.+Linauthor=D.+Meloniauthor=Y.+Panauthor=M.+Xiaauthor=J.+Rodgersauthor=S.+Shepardauthor=M.+Liauthor=L.+Galyaauthor=B.+Metcalfauthor=T.+Y.+Yueauthor=P.+Liuauthor=J.+Zhou&title=Enantioselective+synthesis+of+Janus+kinase+inhibitor+INCB018424+via+an+organocatalytic+aza-Michael+reaction"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fol900350k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol900350k%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DQ.%26aulast%3DMeloni%26aufirst%3DD.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DXia%26aufirst%3DM.%26aulast%3DRodgers%26aufirst%3DJ.%26aulast%3DShepard%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DGalya%26aufirst%3DL.%26aulast%3DMetcalf%26aufirst%3DB.%26aulast%3DYue%26aufirst%3DT.%2BY.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DEnantioselective%2520synthesis%2520of%2520Janus%2520kinase%2520inhibitor%2520INCB018424%2520via%2520an%2520organocatalytic%2520aza-Michael%2520reaction%26jtitle%3DOrg.%2520Lett.%26date%3D2009%26volume%3D11%26spage%3D1999%26epage%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">William, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulsen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teo, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagaraj, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaraman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasha, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ethirajulu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B. W.</span><span> </span><span class="NLM_article-title">Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1. 1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">4638</span><span class="NLM_x">–</span> <span class="NLM_lpage">4658</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200326p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4638-4658&author=A.+D.+Williamauthor=A.+C.+Leeauthor=S.+Blanchardauthor=A.+Poulsenauthor=E.+L.+Teoauthor=H.+Nagarajauthor=E.+Tanauthor=D.+Chenauthor=M.+Williamsauthor=E.+T.+Sunauthor=K.+C.+Gohauthor=W.+C.+Ongauthor=S.+K.+Gohauthor=S.+Hartauthor=R.+Jayaramanauthor=M.+K.+Pashaauthor=K.+Ethirajuluauthor=J.+M.+Woodauthor=B.+W.+Dymock&title=Discovery+of+the+macrocycle+11-%282-pyrrolidin-1-yl-ethoxy%29-14%2C19-dioxa-5%2C7%2C26-triaza-tetracyclo%5B19.3.1.+1%282%2C6%29.1%288%2C12%29%5Dheptacosa-1%2825%29%2C2%2826%29%2C3%2C5%2C8%2C10%2C12%2827%29%2C16%2C21%2C23-decaene+%28SB1518%29%2C+a+potent+Janus+kinase+2%2Ffms-like+tyrosine+kinase-3+%28JAK2%2FFLT3%29+inhibitor+for+the+treatment+of+myelofibrosis+and+lymphoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm200326p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200326p%26sid%3Dliteratum%253Aachs%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DLee%26aufirst%3DA.%2BC.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DTeo%26aufirst%3DE.%2BL.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DE.%2BT.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DOng%26aufirst%3DW.%2BC.%26aulast%3DGoh%26aufirst%3DS.%2BK.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDiscovery%2520of%2520the%2520macrocycle%252011-%25282-pyrrolidin-1-yl-ethoxy%2529-14%252C19-dioxa-5%252C7%252C26-triaza-tetracyclo%255B19.3.1.%25201%25282%252C6%2529.1%25288%252C12%2529%255Dheptacosa-1%252825%2529%252C2%252826%2529%252C3%252C5%252C8%252C10%252C12%252827%2529%252C16%252C21%252C23-decaene%2520%2528SB1518%2529%252C%2520a%2520potent%2520Janus%2520kinase%25202%252Ffms-like%2520tyrosine%2520kinase-3%2520%2528JAK2%252FFLT3%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520myelofibrosis%2520and%2520lymphoma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4638%26epage%3D4658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Verstovsek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deeg, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Odenike, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrov, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, D. A.</span><span> </span><span class="NLM_article-title">Phase 1/2 study of SB1518, a novel JAK2/FLT3 inhibitor, in the treatment of primary myelofibrosis</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">Abstract 3082</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2010&pages=Abstract+3082&author=S.+Verstovsekauthor=H.+J.+Deegauthor=O.+Odenikeauthor=J.+Zhuauthor=H.+M.+Kantarjianauthor=Z.+Estrovauthor=B.+L.+Scottauthor=D.+A.+Thomas&title=Phase+1%2F2+study+of+SB1518%2C+a+novel+JAK2%2FFLT3+inhibitor%2C+in+the+treatment+of+primary+myelofibrosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DDeeg%26aufirst%3DH.%2BJ.%26aulast%3DOdenike%26aufirst%3DO.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26aulast%3DEstrov%26aufirst%3DZ.%26aulast%3DScott%26aufirst%3DB.%2BL.%26aulast%3DThomas%26aufirst%3DD.%2BA.%26atitle%3DPhase%25201%252F2%2520study%2520of%2520SB1518%252C%2520a%2520novel%2520JAK2%252FFLT3%2520inhibitor%252C%2520in%2520the%2520treatment%2520of%2520primary%2520myelofibrosis%26jtitle%3DBlood%26date%3D2010%26volume%3D116%26spage%3DAbstract%25203082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Verstovsek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mesa, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pardanani, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes-Franco, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrov, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridman, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erickson-Viitanen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaddi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tefferi, A.</span><span> </span><span class="NLM_article-title">Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">1117</span><span class="NLM_x">–</span> <span class="NLM_lpage">1127</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm201112g&amp;key=10.1056%2FNEJMoa1002028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm201112g&amp;key=20843246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm201112g&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFOltrjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1117-1127&author=S.+Verstovsekauthor=H.+Kantarjianauthor=R.+A.+Mesaauthor=A.+D.+Pardananiauthor=J.+Cortes-Francoauthor=D.+A.+Thomasauthor=Z.+Estrovauthor=J.+S.+Fridmanauthor=E.+C.+Bradleyauthor=S.+Erickson-Viitanenauthor=K.+Vaddiauthor=R.+Levyauthor=A.+Tefferi&title=Safety+and+efficacy+of+INCB018424%2C+a+JAK1+and+JAK2+inhibitor%2C+in+myelofibrosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis</span></div><div class="casAuthors">Verstovsek, Srdan; Kantarjian, Hagop; Mesa, Ruben A.; Pardanani, Animesh D.; Cortes-Franco, Jorge; Thomas, Deborah A.; Estrov, Zeev; Fridman, Jordan S.; Bradley, Edward C.; Erickson-Viitanen, Susan; Vaddi, Kris; Levy, Richard; Tefferi, Ayalew</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1117-1127</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Myelofibrosis is a Philadelphia chromosome-neg. myeloproliferative neoplasm assocd. with cytopenias, splenomegaly, poor quality of life, and shortened survival.  About half of patients with myelofibrosis carry a gain-of-function mutation in the Janus kinase 2 gene (JAK2 V617F) that contributes to the pathophysiol. of the disease.  INCB018424 is a potent and selective Janus kinase 1 (JAK1) and JAK2 inhibitor.  Methods: We conducted a phase 1-2 trial of INCB018424 in patients with JAK2 V617F-pos. or JAK2 V617F-neg. primary myelofibrosis, post-essential thrombocythemia myelofibrosis, or post-polycythemia vera myelofibrosis.  Results: A total of 153 patients received INCB018424 for a median duration of more than 14.7 mo.  The initial dose-escalation phase established 25 mg twice daily or 100 mg once daily as max. tolerated doses, on the basis of reversible thrombocytopenia.  A dose-dependent suppression of phosphorylated signal transducer and activator of transcription 3 (STAT3), a marker of JAK signaling, was demonstrated in patients with wild-type JAK2 and in patients with the JAK2 V617F mutation.  We studied addnl. doses and established that a 15-mg twice-daily starting dose, followed by individualized dose titrn., was the most effective and safest dosing regimen.  At this dose, 17 of 33 patients (52%) had a rapid objective response (>50% redn. of splenomegaly) lasting for 12 mo or more, and this therapy was assocd. with grade 3 or grade 4 adverse events (mainly myelosuppression) in less than 10% of patients.  Patients with debilitating symptoms, including wt. loss, fatigue, night sweats, and pruritus, had rapid improvement.  Clin. benefits were assocd. with a marked diminution of levels of circulating inflammatory cytokines that are commonly elevated in myelofibrosis.  Conclusions: INCB018424 was assocd. with marked and durable clin. benefits in patients with myelofibrosis for whom no approved therapies existed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUi05ApP1FLrVg90H21EOLACvtfcHk0linaOdkJ0UeXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFOltrjJ&md5=ba6fe766323a10a1508c686fdb3720b1</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1002028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1002028%26sid%3Dliteratum%253Aachs%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DMesa%26aufirst%3DR.%2BA.%26aulast%3DPardanani%26aufirst%3DA.%2BD.%26aulast%3DCortes-Franco%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DD.%2BA.%26aulast%3DEstrov%26aufirst%3DZ.%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DBradley%26aufirst%3DE.%2BC.%26aulast%3DErickson-Viitanen%26aufirst%3DS.%26aulast%3DVaddi%26aufirst%3DK.%26aulast%3DLevy%26aufirst%3DR.%26aulast%3DTefferi%26aufirst%3DA.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520INCB018424%252C%2520a%2520JAK1%2520and%2520JAK2%2520inhibitor%252C%2520in%2520myelofibrosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D1117%26epage%3D1127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Verstovsek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Odenike, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrov, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ethirajulu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deeg, H. J.</span><span> </span><span class="NLM_article-title">Phase I dose escalation trial of SB1518, a novel JAK2-FLT3 inhibitor, in acute and chronic myeloid diseases, including primary or post-ET/post-PV myelofibrosis</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">Abstract 3905</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=Abstract+3905&author=S.+Verstovsekauthor=O.+Odenikeauthor=B.+Scottauthor=Z.+Estrovauthor=J.+Cortesauthor=D.+Thomasauthor=J.+Woodauthor=K.+Ethirajuluauthor=A.+Loweauthor=H.+J.+Zhuauthor=H.+Kantarjianauthor=H.+J.+Deeg&title=Phase+I+dose+escalation+trial+of+SB1518%2C+a+novel+JAK2-FLT3+inhibitor%2C+in+acute+and+chronic+myeloid+diseases%2C+including+primary+or+post-ET%2Fpost-PV+myelofibrosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DOdenike%26aufirst%3DO.%26aulast%3DScott%26aufirst%3DB.%26aulast%3DEstrov%26aufirst%3DZ.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DD.%26aulast%3DWood%26aufirst%3DJ.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DLowe%26aufirst%3DA.%26aulast%3DZhu%26aufirst%3DH.%2BJ.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DDeeg%26aufirst%3DH.%2BJ.%26atitle%3DPhase%2520I%2520dose%2520escalation%2520trial%2520of%2520SB1518%252C%2520a%2520novel%2520JAK2-FLT3%2520inhibitor%252C%2520in%2520acute%2520and%2520chronic%2520myeloid%2520diseases%252C%2520including%2520primary%2520or%2520post-ET%252Fpost-PV%2520myelofibrosis%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26spage%3DAbstract%25203905" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Kindler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipka, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, T.</span><span> </span><span class="NLM_article-title">FLT3 as a therapeutic target in AML: still challenging after all these years</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">5089</span><span class="NLM_x">–</span> <span class="NLM_lpage">5102</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2010&pages=5089-5102&author=T.+Kindlerauthor=D.+B.+Lipkaauthor=T.+Fischer&title=FLT3+as+a+therapeutic+target+in+AML%3A+still+challenging+after+all+these+years"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKindler%26aufirst%3DT.%26aulast%3DLipka%26aufirst%3DD.%2BB.%26aulast%3DFischer%26aufirst%3DT.%26atitle%3DFLT3%2520as%2520a%2520therapeutic%2520target%2520in%2520AML%253A%2520still%2520challenging%2520after%2520all%2520these%2520years%26jtitle%3DBlood%26date%3D2010%26volume%3D116%26spage%3D5089%26epage%3D5102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Gilliland, D. G.</span><span> </span><span class="NLM_article-title">FLT3-activating mutations in acute promyelocytic leukaemia: a rationale for risk-adapted therapy with FLT3 inhibitors</span> <span class="citation_source-journal">Best Prac. Res., Clin. Haematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">409</span><span class="NLM_x">–</span> <span class="NLM_lpage">417</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm201112g&amp;key=10.1016%2FS1521-6926%2803%2900063-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm201112g&amp;key=12935959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm201112g&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmsVCgu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2003&pages=409-417&author=D.+G.+Gilliland&title=FLT3-activating+mutations+in+acute+promyelocytic+leukaemia%3A+a+rationale+for+risk-adapted+therapy+with+FLT3+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3-activating mutations in acute promyelocytic leukaemia: a rationale for risk-adapted therapy with FLT3 inhibitors</span></div><div class="casAuthors">Gilliland, D. Gary</div><div class="citationInfo"><span class="NLM_cas:title">Best Practice & Research, Clinical Haematology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">409-417</span>CODEN:
                <span class="NLM_cas:coden">BPRCA5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  Our understanding of the genetic basis of acute myeloid leukemias has been enhanced through cloning of recurring chromosomal translocation breakpoints.  However, the remarkable observation, more than a decade ago, that all-trans retinoic acid (ATRA) induced remission in patients with t(15;17) acute promyelocytic leukemia (APL) was a driving force in the subsequent cloning and characterization of the PML-RARα fusion that is causally implicated in the pathogenesis of this disease.  Major improvements in treatment and outcome of APL patients have been made since that time by incorporating ATRA in conventional chemotherapy but 30% of APL patients still succumb to complications of their disease or their therapy.  Recent information that the hematopoietic receptor tyrosine kinase FLT3 is mutated in about 30% of APL patients suggests strategies for further improving treatment and outcome in this subset of APL patients using small-mol. inhibitors of FLT3.  The role of FLT3 mutations in APL and other AML is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoo4Lxfsmnh9rVg90H21EOLACvtfcHk0linaOdkJ0UeXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmsVCgu7s%253D&md5=f7b4d39e56a475225ab3fb7cb09e082b</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2FS1521-6926%2803%2900063-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1521-6926%252803%252900063-X%26sid%3Dliteratum%253Aachs%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26atitle%3DFLT3-activating%2520mutations%2520in%2520acute%2520promyelocytic%2520leukaemia%253A%2520a%2520rationale%2520for%2520risk-adapted%2520therapy%2520with%2520FLT3%2520inhibitors%26jtitle%3DBest%2520Prac.%2520Res.%252C%2520Clin.%2520Haematol.%26date%3D2003%26volume%3D16%26spage%3D409%26epage%3D417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Quentmeier, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reinhardt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaborski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drexler, H. G.</span><span> </span><span class="NLM_article-title">FLT3 mutations in acute myeloid leukemia cell lines</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">120</span><span class="NLM_x">–</span> <span class="NLM_lpage">124</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2003&pages=120-124&author=H.+Quentmeierauthor=J.+Reinhardtauthor=M.+Zaborskiauthor=H.+G.+Drexler&title=FLT3+mutations+in+acute+myeloid+leukemia+cell+lines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DQuentmeier%26aufirst%3DH.%26aulast%3DReinhardt%26aufirst%3DJ.%26aulast%3DZaborski%26aufirst%3DM.%26aulast%3DDrexler%26aufirst%3DH.%2BG.%26atitle%3DFLT3%2520mutations%2520in%2520acute%2520myeloid%2520leukemia%2520cell%2520lines%26jtitle%3DLeukemia%26date%3D2003%26volume%3D17%26spage%3D120%26epage%3D124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirazian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuda, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nematalla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sistla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luu, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span> </span><span class="NLM_article-title">Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3<i>Z</i>)-ylidenemethyl]-2,4-dimethyl-1<i>H</i>-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">1116</span><span class="NLM_x">–</span> <span class="NLM_lpage">1119</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0204183" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=1116-1119&author=L.+Sunauthor=C.+Liangauthor=S.+Shirazianauthor=Y.+Zhouauthor=T.+Millerauthor=J.+Cuiauthor=J.+Y.+Fukudaauthor=J.+Y.+Chuauthor=A.+Nematallaauthor=X.+Wangauthor=H.+Chenauthor=A.+Sistlaauthor=T.+C.+Luuauthor=F.+Tangauthor=J.+Weiauthor=C.+Tang&title=Discovery+of+5-%5B5-fluoro-2-oxo-1%2C2-+dihydroindol-%283Z%29-ylidenemethyl%5D-2%2C4-dimethyl-1H-pyrrole-3-carboxylic+acid+%282-diethylaminoethyl%29amide%2C+a+novel+tyrosine+kinase+inhibitor+targeting+vascular+endothelial+and+platelet-derived+growth+factor+receptor+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm0204183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0204183%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DShirazian%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DMiller%26aufirst%3DT.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DFukuda%26aufirst%3DJ.%2BY.%26aulast%3DChu%26aufirst%3DJ.%2BY.%26aulast%3DNematalla%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DSistla%26aufirst%3DA.%26aulast%3DLuu%26aufirst%3DT.%2BC.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DC.%26atitle%3DDiscovery%2520of%25205-%255B5-fluoro-2-oxo-1%252C2-%2520dihydroindol-%25283Z%2529-ylidenemethyl%255D-2%252C4-dimethyl-1H-pyrrole-3-carboxylic%2520acid%2520%25282-diethylaminoethyl%2529amide%252C%2520a%2520novel%2520tyrosine%2520kinase%2520inhibitor%2520targeting%2520vascular%2520endothelial%2520and%2520platelet-derived%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D1116%26epage%3D1119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Bankston, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Natero, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riedl, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monahan, M.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sibley, R.</span><span> </span><span class="NLM_article-title">A scaleable synthesis of BAY 43-9006: a potent raf kinase inhibitor for the treatment of cancer</span> <span class="citation_source-journal">Org. Process Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">777</span><span class="NLM_x">–</span> <span class="NLM_lpage">781</span></span><div class="citationLinks">[<a href="/doi/10.1021/op020205n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm201112g&amp;key=1%3ACAS%3A528%3ADC%252BD38XntFegtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2002&pages=777-781&author=D.+Bankstonauthor=J.+Dumasauthor=R.+Nateroauthor=B.+Riedlauthor=M.-K.+Monahanauthor=R.+Sibley&title=A+scaleable+synthesis+of+BAY+43-9006%3A+a+potent+raf+kinase+inhibitor+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">A Scaleable Synthesis of BAY 43-9006: A Potent Raf Kinase Inhibitor for the Treatment of Cancer</span></div><div class="casAuthors">Bankston, Donald; Dumas, Jacques; Natero, Reina; Riedl, Bernd; Monahan, Mary-Katherine; Sibley, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">777-781</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Urea I (BAY 43-9006), a potent Raf kinase inhibitor, was prepd. in four steps from picolinic acid with an overall yield of 63%.  Significant process research enabled isolation of each intermediate and target without chromatog. purifn., and overall yield increases >50% were obsd. compared to those from previous methods.  This report focuses on improved synthetic strategies for prodn. of scaled quantities of I for preclin., toxicol. studies.  These improvements may be useful to assemble other urea targets as potential therapeutic agents to combat cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxNTMN01nH9LVg90H21EOLACvtfcHk0lgWHL5dZEYivg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XntFegtr8%253D&md5=fb46fc9d46416b9fb8250cb87fb18805</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fop020205n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop020205n%26sid%3Dliteratum%253Aachs%26aulast%3DBankston%26aufirst%3DD.%26aulast%3DDumas%26aufirst%3DJ.%26aulast%3DNatero%26aufirst%3DR.%26aulast%3DRiedl%26aufirst%3DB.%26aulast%3DMonahan%26aufirst%3DM.-K.%26aulast%3DSibley%26aufirst%3DR.%26atitle%3DA%2520scaleable%2520synthesis%2520of%2520BAY%252043-9006%253A%2520a%2520potent%2520raf%2520kinase%2520inhibitor%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2002%26volume%3D6%26spage%3D777%26epage%3D781" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">William, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulsen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagaraj, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaraman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasha, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ethirajulu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B. W.</span><span> </span><span class="NLM_article-title">Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/Fms-liketyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">4638</span><span class="NLM_x">–</span> <span class="NLM_lpage">4658</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4638-4658&author=A.+D.+Williamauthor=A.+Leeauthor=S.+Blanchardauthor=A.+Poulsenauthor=E.+Teoauthor=H.+Nagarajauthor=E.+Tanauthor=D.+Chenauthor=M.+Williamsauthor=E.+Sunauthor=K.+C.+Gohauthor=W.+Ongauthor=S.+K.+Gohauthor=S.+Hartauthor=R.+Jayaramanauthor=M.+K.+Pashaauthor=K.+Ethirajuluauthor=J.+Woodauthor=B.+W.+Dymock&title=Discovery+of+the+macrocycle+11-%282-pyrrolidin-1-yl-ethoxy%29-14%2C19-dioxa-5%2C7%2C26-triaza-tetracyclo%5B19.3.1.1%282%2C6%29.1%288%2C12%29%5Dheptacosa-1%2825%29%2C2%2826%29%2C3%2C5%2C8%2C10%2C12%2827%29%2C16%2C21%2C23-decaene+%28SB1518%29%2C+a+potent+Janus+kinase+2%2FFms-liketyrosine+kinase-3+%28JAK2%2FFLT3%29+inhibitor+for+the+treatment+of+myelofibrosis+and+lymphoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DTeo%26aufirst%3DE.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DE.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DOng%26aufirst%3DW.%26aulast%3DGoh%26aufirst%3DS.%2BK.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DJ.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDiscovery%2520of%2520the%2520macrocycle%252011-%25282-pyrrolidin-1-yl-ethoxy%2529-14%252C19-dioxa-5%252C7%252C26-triaza-tetracyclo%255B19.3.1.1%25282%252C6%2529.1%25288%252C12%2529%255Dheptacosa-1%252825%2529%252C2%252826%2529%252C3%252C5%252C8%252C10%252C12%252827%2529%252C16%252C21%252C23-decaene%2520%2528SB1518%2529%252C%2520a%2520potent%2520Janus%2520kinase%25202%252FFms-liketyrosine%2520kinase-3%2520%2528JAK2%252FFLT3%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520myelofibrosis%2520and%2520lymphoma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4638%26epage%3D4658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Driggers, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hale, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terrett, N. K.</span><span> </span><span class="NLM_article-title">The exploration of macrocycles for drug discovery—an underexploited structural class</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">608</span><span class="NLM_x">–</span> <span class="NLM_lpage">624</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=608-624&author=E.+M.+Driggersauthor=S.+P.+Haleauthor=J.+Leeauthor=N.+K.+Terrett&title=The+exploration+of+macrocycles+for+drug+discovery%E2%80%94an+underexploited+structural+class"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDriggers%26aufirst%3DE.%2BM.%26aulast%3DHale%26aufirst%3DS.%2BP.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DTerrett%26aufirst%3DN.%2BK.%26atitle%3DThe%2520exploration%2520of%2520macrocycles%2520for%2520drug%2520discovery%25E2%2580%2594an%2520underexploited%2520structural%2520class%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26spage%3D608%26epage%3D624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Marsault, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, M. L.</span><span> </span><span class="NLM_article-title">Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1961</span><span class="NLM_x">–</span> <span class="NLM_lpage">2004</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm1012374" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm201112g&amp;key=1%3ACAS%3A528%3ADC%252BC3MXivVSjtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1961-2004&author=E.+Marsaultauthor=M.+L.+Peterson&title=Macrocycles+are+great+cycles%3A+applications%2C+opportunities%2C+and+challenges+of+synthetic+macrocycles+in+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Macrocycles Are Great Cycles: Applications, Opportunities, and Challenges of Synthetic Macrocycles in Drug Discovery</span></div><div class="casAuthors">Marsault, Eric; Peterson, Mark L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1961-2004</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Macrocycles occupy a unique segment of chem. space.  In the past decade, their chem. diversity expanded significantly, supported by advances in bioinformatics and synthetic methodol.  As a consequence, this structural type has now been successfully tested on most biol. target classes.  The goal of this article is to put into perspective the current applications, opportunities, and challenges assocd. with synthetic macrocycles in drug discovery.  Accordingly, the first part of this article is dedicated to the drug discovery aspects of macrocycles and highlights salient features of their medicinal chem.  This section is organized by target class, a choice aimed at providing the reader an appreciation of the structural diversity generated for each class.  To give the reader an appreciation of the tools available to construct macrocyclic scaffolds, the site and method of the pivotal macrocyclization step are indicated in the figures.  Readers are referred to the source articles for further details.  In the second part, the technologies and synthetic approaches that already have demonstrated utility or possess a high potential for macrocycle-based drug discovery are discussed.  Finally, a perspective on the future of synthetic macrocycles in medicinal chem. is offered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrygQLE6JraHrVg90H21EOLACvtfcHk0lgm6uRDoklSxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXivVSjtbo%253D&md5=97c1120896e90a85790a9ac1274259f3</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm1012374&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1012374%26sid%3Dliteratum%253Aachs%26aulast%3DMarsault%26aufirst%3DE.%26aulast%3DPeterson%26aufirst%3DM.%2BL.%26atitle%3DMacrocycles%2520are%2520great%2520cycles%253A%2520applications%252C%2520opportunities%252C%2520and%2520challenges%2520of%2520synthetic%2520macrocycles%2520in%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1961%26epage%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Schmidt, B.</span><span> </span><span class="NLM_article-title">Ruthenium-catalyzed cyclizations: more than just olefin metathesis!</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">4996</span><span class="NLM_x">–</span> <span class="NLM_lpage">4999</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=4996-4999&author=B.+Schmidt&title=Ruthenium-catalyzed+cyclizations%3A+more+than+just+olefin+metathesis%21"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DB.%26atitle%3DRuthenium-catalyzed%2520cyclizations%253A%2520more%2520than%2520just%2520olefin%2520metathesis%2521%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2003%26volume%3D42%26spage%3D4996%26epage%3D4999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Cai, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">You, S.-L.</span><span> </span><span class="NLM_article-title">Asymmetric construction of polycyclic indoles through olefin cross-metathesis/intramolecular Friedel–Crafts alkylation under sequential catalysis</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">7428</span><span class="NLM_x">–</span> <span class="NLM_lpage">7431</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2009&pages=7428-7431&author=Q.+Caiauthor=Z.-A.+Zhaoauthor=S.-L.+You&title=Asymmetric+construction+of+polycyclic+indoles+through+olefin+cross-metathesis%2Fintramolecular+Friedel%E2%80%93Crafts+alkylation+under+sequential+catalysis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DQ.%26aulast%3DZhao%26aufirst%3DZ.-A.%26aulast%3DYou%26aufirst%3DS.-L.%26atitle%3DAsymmetric%2520construction%2520of%2520polycyclic%2520indoles%2520through%2520olefin%2520cross-metathesis%252Fintramolecular%2520Friedel%25E2%2580%2593Crafts%2520alkylation%2520under%2520sequential%2520catalysis%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2009%26volume%3D48%26spage%3D7428%26epage%3D7431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Deiters, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S. F.</span><span> </span><span class="NLM_article-title">Synthesis of oxygen- and nitrogen-containing heterocycles by ring-closing metathesis</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">2199</span><span class="NLM_x">–</span> <span class="NLM_lpage">2238</span></span><div class="citationLinks">[<a href="/doi/10.1021/cr0200872" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm201112g&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsVSltb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2004&pages=2199-2238&author=A.+Deitersauthor=S.+F.+Martin&title=Synthesis+of+oxygen-+and+nitrogen-containing+heterocycles+by+ring-closing+metathesis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of oxygen- and nitrogen-containing heterocycles by ring-closing metathesis</span></div><div class="casAuthors">Deiters, Alexander; Martin, Stephen F.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2199-2238</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review on the synthesis of oxygen- and nitrogen-contg. heterocycles by ring-closing metathesis (RCM).  Applications of olefin and alkyne RCM, enyne RCM, and tandem processes in which these reactions are combined with ring-opening metathesis (ROM) to construct O- and N-heterocycles are presented with a particular emphasis on natural product synthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxORod8gOrIrVg90H21EOLACvtfcHk0lgm6uRDoklSxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsVSltb0%253D&md5=93d648a549ce629a402b4849c15c577c</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fcr0200872&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr0200872%26sid%3Dliteratum%253Aachs%26aulast%3DDeiters%26aufirst%3DA.%26aulast%3DMartin%26aufirst%3DS.%2BF.%26atitle%3DSynthesis%2520of%2520oxygen-%2520and%2520nitrogen-containing%2520heterocycles%2520by%2520ring-closing%2520metathesis%26jtitle%3DChem.%2520Rev.%26date%3D2004%26volume%3D104%26spage%3D2199%26epage%3D2238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.-G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, B. M.</span><span> </span><span class="NLM_article-title">Acid-mediated activation of modified ring-closing metathesis catalysts</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">709</span><span class="NLM_x">–</span> <span class="NLM_lpage">713</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2010&pages=709-713&author=S.+Kimauthor=W.+Hwangauthor=I.+S.+Limauthor=S.+H.+Kimauthor=S.-G.+Leeauthor=B.+M.+Kim&title=Acid-mediated+activation+of+modified+ring-closing+metathesis+catalysts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DS.%26aulast%3DHwang%26aufirst%3DW.%26aulast%3DLim%26aufirst%3DI.%2BS.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DLee%26aufirst%3DS.-G.%26aulast%3DKim%26aufirst%3DB.%2BM.%26atitle%3DAcid-mediated%2520activation%2520of%2520modified%2520ring-closing%2520metathesis%2520catalysts%26jtitle%3DTetrahedron%2520Lett.%26date%3D2010%26volume%3D51%26spage%3D709%26epage%3D713" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span> <span class="citation_source-book">Molecular Modeling Platform</span>; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York, NY</span>,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span><a href="http://www.schrodinger.com" class="extLink">http://www.schrodinger.com</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Molecular+Modeling+Platform%3B+Schr%C3%B6dinger%2C+LLC%3A+New+York%2C+NY%2C+2011%3B+http%3A%2F%2Fwww.schrodinger.com."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DMolecular%2520Modeling%2520Platform%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Goh, K. C.; Novotny-Diermayr, V.; Hart, S.; Ong, L. C.; Loh, Y. K.; Cheong, A.; Tan, Y. C.; Hu, C.; Jayaraman, R.; William, A.; Ong, K. H.; Dymock, B. W.; Ethirajulu, K.; Burrows, F.; Wood, J. M.</span><span> </span><span class="NLM_article-title">TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties</span>.  <span class="citation_source-journal">Leukemia</span> [Online early access]. DOI: <span class="refDoi"> DOI: 10.1038/leu.2011.218</span> . Published Online: Aug 23,<span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Fjm201112g&amp;key=10.1038%2Fleu.2011.218" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=K.+C.+Goh&author=V.+Novotny-Diermayr&author=S.+Hart&author=L.+C.+Ong&author=Y.+K.+Loh&author=A.+Cheong&author=Y.+C.+Tan&author=C.+Hu&author=R.+Jayaraman&author=A.+William&author=K.+H.+Ong&author=B.+W.+Dymock&author=K.+Ethirajulu&author=F.+Burrows&author=J.+M.+Wood&title=TG02%2C+a+novel+oral+multi-kinase+inhibitor+of+CDKs%2C+JAK2+and+FLT3+with+potent+anti-leukemic+properties&doi=10.1038%2Fleu.2011.218"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fleu.2011.218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2011.218%26sid%3Dliteratum%253Aachs%26aulast%3DGoh%26aufirst%3DK.%2BC.%26atitle%3DTG02%252C%2520a%2520novel%2520oral%2520multi-kinase%2520inhibitor%2520of%2520CDKs%252C%2520JAK2%2520and%2520FLT3%2520with%2520potent%2520anti-leukemic%2520properties%26jtitle%3DLeukemia%26doi%3D10.1038%2Fleu.2011.218%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Jorgensen, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maxwell, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tirado-Rives, J.</span><span> </span><span class="NLM_article-title">Development and yesting of the OPLS all-atom force field on conformational energetics and properties of organic liquids</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">118</span><span class="NLM_x">, </span> <span class="NLM_fpage">11225</span><span class="NLM_x">–</span> <span class="NLM_lpage">11236</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja9621760" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=1996&pages=11225-11236&author=W.+L.+Jorgensenauthor=D.+S.+Maxwellauthor=J.+Tirado-Rives&title=Development+and+yesting+of+the+OPLS+all-atom+force+field+on+conformational+energetics+and+properties+of+organic+liquids"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fja9621760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja9621760%26sid%3Dliteratum%253Aachs%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26aulast%3DMaxwell%26aufirst%3DD.%2BS.%26aulast%3DTirado-Rives%26aufirst%3DJ.%26atitle%3DDevelopment%2520and%2520yesting%2520of%2520the%2520OPLS%2520all-atom%2520force%2520field%2520on%2520conformational%2520energetics%2520and%2520properties%2520of%2520organic%2520liquids%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1996%26volume%3D118%26spage%3D11225%26epage%3D11236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Hasel, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendrickson, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Still, W. C.</span><span> </span><span class="NLM_article-title">A rapid approximation to the solvent accessible surface areas of atoms</span> <span class="citation_source-journal">Tetrahedron Comput. Methodol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">–</span> <span class="NLM_lpage">116</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm201112g&amp;key=10.1016%2F0898-5529%2888%2990015-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm201112g&amp;key=1%3ACAS%3A528%3ADyaL1MXltFCms7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1988&pages=103-116&author=W.+Haselauthor=T.+F.+Hendricksonauthor=W.+C.+Still&title=A+rapid+approximation+to+the+solvent+accessible+surface+areas+of+atoms"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">A rapid approximation to the solvent-accessible surface areas of atoms</span></div><div class="casAuthors">Hasel, Winnfried; Hendrickson, Thomas F.; Still, W. Clark</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Computer Methodology</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">103-16</span>CODEN:
                <span class="NLM_cas:coden">TCMTE6</span>;
        ISSN:<span class="NLM_cas:issn">0898-5529</span>.
    </div><div class="casAbstract">An anal. expression for approx. at. and mol. van der Waals and solvent accessible surface areas is described.  The treatment is based on the probabilistic method of Wodak and Janin (1980) but with modifications which allow it to be applied to the calcn. of at. surface areas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEtlzGPkwT_7Vg90H21EOLACvtfcHk0lh9KoWuS0_qUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXltFCms7s%253D&md5=98b3e7fab9432dccb1ff22f726d54fbf</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2F0898-5529%2888%2990015-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0898-5529%252888%252990015-2%26sid%3Dliteratum%253Aachs%26aulast%3DHasel%26aufirst%3DW.%26aulast%3DHendrickson%26aufirst%3DT.%2BF.%26aulast%3DStill%26aufirst%3DW.%2BC.%26atitle%3DA%2520rapid%2520approximation%2520to%2520the%2520solvent%2520accessible%2520surface%2520areas%2520of%2520atoms%26jtitle%3DTetrahedron%2520Comput.%2520Methodol.%26date%3D1988%26volume%3D1%26spage%3D103%26epage%3D116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Lawrie, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noble, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tunnah, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, L. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Endicott, J. A.</span><span> </span><span class="NLM_article-title">Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2</span> <span class="citation_source-journal">Nat. Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">796</span><span class="NLM_x">–</span> <span class="NLM_lpage">801</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1997&pages=796-801&author=A.+M.+Lawrieauthor=M.+E.+Nobleauthor=P.+Tunnahauthor=N.+R.+Brownauthor=L.+N.+Johnsonauthor=J.+A.+Endicott&title=Protein+kinase+inhibition+by+staurosporine+revealed+in+details+of+the+molecular+interaction+with+CDK2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLawrie%26aufirst%3DA.%2BM.%26aulast%3DNoble%26aufirst%3DM.%2BE.%26aulast%3DTunnah%26aufirst%3DP.%26aulast%3DBrown%26aufirst%3DN.%2BR.%26aulast%3DJohnson%26aufirst%3DL.%2BN.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26atitle%3DProtein%2520kinase%2520inhibition%2520by%2520staurosporine%2520revealed%2520in%2520details%2520of%2520the%2520molecular%2520interaction%2520with%2520CDK2%26jtitle%3DNat.%2520Struct.%2520Biol.%26date%3D1997%26volume%3D4%26spage%3D796%26epage%3D801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Griffith, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faerman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swenson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wynn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippke, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saxena, K.</span><span> </span><span class="NLM_article-title">The structural basis for autoinhibition of FLT3 by the juxtamembrane domain</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">178</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm201112g&amp;key=10.1016%2FS1097-2765%2803%2900505-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm201112g&amp;key=14759363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm201112g&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFOiu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2004&pages=169-178&author=J.+Griffithauthor=J.+Blackauthor=C.+Faermanauthor=L.+Swensonauthor=M.+Wynnauthor=F.+Luauthor=J.+Lippkeauthor=K.+Saxena&title=The+structural+basis+for+autoinhibition+of+FLT3+by+the+juxtamembrane+domain"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">The structural basis for autoinhibition of FLT3 by the juxtamembrane domain</span></div><div class="casAuthors">Griffith, James; Black, James; Faerman, Carlos; Swenson, Lora; Wynn, Michael; Lu, Fan; Lippke, Judith; Saxena, Kumkum</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">169-178</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">FLT3 is a type III receptor tyrosine kinase that is thought to play a key role in hematopoiesis.  Certain classes of FLT3 mutations cause constitutively activated forms of the receptor that are found in significant nos. of patients with acute myelogenous leukemia (AML).  The mutations occur either in the activation loop, for example, as point mutations of Asp835 or as internal tandem duplication (ITD) sequences in the juxtamembrane (JM) domain.  To further understand the nature of FLT3 autoinhibition and regulation, we have detd. the crystal structure of the autoinhibited form of FLT3.  This structure shows the autoinhibitory conformation of a complete JM domain in this class of receptor tyrosine kinases.  The detailed inhibitory mechanism of the JM domain is revealed, which is likely utilized by other members of type III receptor tyrosine kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJAabT6TBxpLVg90H21EOLACvtfcHk0lh9KoWuS0_qUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFOiu7g%253D&md5=d1df4a37aac59f5b59ca242fc8ccd6da</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2FS1097-2765%2803%2900505-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1097-2765%252803%252900505-7%26sid%3Dliteratum%253Aachs%26aulast%3DGriffith%26aufirst%3DJ.%26aulast%3DBlack%26aufirst%3DJ.%26aulast%3DFaerman%26aufirst%3DC.%26aulast%3DSwenson%26aufirst%3DL.%26aulast%3DWynn%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DF.%26aulast%3DLippke%26aufirst%3DJ.%26aulast%3DSaxena%26aufirst%3DK.%26atitle%3DThe%2520structural%2520basis%2520for%2520autoinhibition%2520of%2520FLT3%2520by%2520the%2520juxtamembrane%2520domain%26jtitle%3DMol.%2520Cell%26date%3D2004%26volume%3D13%26spage%3D169%26epage%3D178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span>Protein Data Bank. <a href="http://www.pdb.org" class="extLink">www.pdb.org</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Protein+Data+Bank.+www.pdb.org."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1AQ1" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1AQ1','PDB','1AQ1'); return false;">PDB: 1AQ1</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i237"><a href="/doi/suppl/10.1021/jm201112g">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_13616"></div></div></div></div></div><hr /></hr><p class="last">Explanation for the potency of <b>26r</b> against CDK2, structures of the RCM catalysts employed and the iv/po PK of <b>27j</b> in mice. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm201112g/suppl_file/jm201112g_si_001.pdf">jm201112g_si_001.pdf (231.9 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm201112g&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Fjm201112g%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2012.55.issue-1%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm201112g" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66797aae3ab632b5","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
